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Summary 
Atopic dermatitis (AD) is a chronic, inflammatory skin rash which affects approximately 15-
30% of children and 2-10% of adults. The presentation of AD can vary but common 
symptoms include severe itching, redness and dryness of the skin, weeping or scarring and 
lichenification. While rarely fatal, the itch-scratch cycle can lead to disfiguration, sleep 
disturbances, and subsequent lack of self-confidence and low work productivity. Patients 
and families are further burdened by the economic costs for disease managements. 
Medication and other forms of management are targeted at symptomatic relief of AD. The 
mainstay therapies include topical corticosteroids, topical calcineurin inhibitors and 
emollient therapy. However, extended use of these therapies can lead to local and systemic 
adverse events and the development of drug tolerance. 
Traditional Chinese medicine (TCM) has been used to treat various conditions, including 
dermatological diseases. Treatment of AD via TCM syndrome differentiation is said to be 
able to regulate the allergy or atopy-prone constitution and has shown promising effects in 
relieving signs and symptoms, preventing recurrence, maintaining remission and improving 
quality of life. Recent studies have shown that Chinese herbs possess pharmacological 
properties, including anti-inflammatory, anti-bacterial, anti-fungal, and immuno-suppressive 
functions, which are useful in the management of AD. Several studies have also evaluated 
the clinical benefits of TCM treatments for AD. However, systematic reviews (SRs) have 
deemed the overall studies to be of “poor quality”, resulting in insufficient evidence for valid 
conclusions. Furthermore, there are still concerns regarding the safety of TCM treatments.  
The scope of this thesis is focused on the Chinese medicine treatments in the management 
of AD. The objectives of this project were to: 1)  evaluate the efficacy and safety of TCM 
treatments for AD and identify the current state of evidence and limitations by 
systematically reviewing the classical and modern literature; and, 2) design a randomised 
controlled trial (RCT) that would suit the paediatric population (who are more prone to AD) 
and address methodological problems identified from the SRs, to evaluate the efficacy and 
safety of a newly-formulated Chinese herbal medicine (CHM) formula for the management 
of AD. 
2 
 
There were 2 parts involved in addressing Objective 1 – the evaluation of the TCM classical 
literature of TCM treatments of AD through a TCM database software, Zhong Hua Yi Dian; 
and the evaluation of available RCTs on TCM treatments of AD from the modern literature. 
The SR of the classical literature was conducted using a similar protocol for a previous study 
which evaluated the classical literature for Chinese herbs used in the treatment of dementia. 
A total of 999 citations were identified from the search, with 738 remaining citations after 
the exclusion of duplicates and oddities. None of the TCM dermatological diseases from the 
classical literature fully matched the presentation of AD; Si Wan Feng (四弯风) and Nai Xuan 
(奶癣) had the most similar presentations. When evaluating treatments, there were 2 
citations which included acupuncture treatment, 7 citations which mentioned moxibustion, 
10 citations which mentioned bloodletting and over 600 citations with CHM. Twenty-seven 
individual herbs, 290 externally-used CHM formulae and 36 systemic CHM formulae were 
identified for the treatment of AD-like conditions. The common externally-used herbs could 
be categorised into minerals, emollients, plant- and animal-based herbs, most of which 
contain toxicity; the commonly-used systemic herbs were mostly plant-based. Externally-
used herbs consisted mostly of herbs which expel pathogenic factors while systemic herbs 
included herbs which tonify the Spleen, Qi, Blood and Yin. The SR of the classical literature 
showed that TCM treatments recorded in the classics for AD-like conditions were similar to 
current clinical practice. However, it should be noted that there were many inconsistencies 
between citations and much of the data was subject to individual interpretations. 
To evaluate the modern literature, a comprehensive review of RCTs involving any form of 
TCM treatments for AD (or infantile/childhood eczema) was conducted using search 
strategies guided by the Cochrane Handbook for Systematic Reviews and Interventions. 
Major English and Chinese databases were searched and studies were selected based on 
pre-defined criteria. A total of 191 studies were included in the comprehensive review, 
involving CHM, acupuncture, acupressure, Tuina, acupoint injection or bloodletting, alone or 
in combination with other treatments, as the trial intervention. Fifty-five studies referenced 
validated diagnostic criteria for AD; 50 studies failed to reference any diagnostic criteria. Six 
CHM studies and 2 acupuncture studies involved placebo controls, with the remainder of the 
studies using active control interventions. The English studies were more in accordance with 
the scientific method of conducting explanatory trials, while the Chinese studies tended to 
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be more pragmatic, with approximately one fifth of the studies allowing modification of 
interventions according to the disease presentation or syndrome differentiation. The most 
frequently-used outcome measure was the “self-defined global response”, which was used 
in 176 Chinese studies and in 1 English study. Seventy-seven studies used disease/symptom 
severity scoring system, out of which 33 studies failed to report the scores obtained from 
the study or had incomplete reporting. Forty-six studies used validated outcome measure 
instruments; however, 5 studies used PASI, which is a validated instrument for the 
evaluation of psoriasis rather than AD. Only 5 studies evaluated quality of life. 
From the studies obtained from the comprehensive review, a SR of oral CHM treatment and 
another SR of acupuncture treatment for AD were conducted with reference to the 
Cochrane Handbook. The SR of oral CHM included 6 studies; the meta-analysis supported 
the use of integrated oral CHM with WM in the treatment of AD when compared to WM 
alone (MD -2.56, 95% CI -3.46 to -1.66). The meta-analysis also supported the use of oral 
CHM to reduce symptom severity (erythema: SMD -0.84, 95% CI -1.21 to -0.48; surface 
damage: SMD -1.14, 95% CI -2.06 to -0.22; pruritus: MD -1.10, 95% CI -1.59 to -0.61; sleep 
disturbance: MD -0.80, 95% CI -1.12 to -0.48), improve quality of life (MD -2.50, 95% CI -4.77 
to -0.23) and reduce the need for concurrent Western medication (MD -24.50. 95% CI -27.92 
to -21.08) when compared to placebo; however, there was conflicting evidence with regard 
to the use of oral CHM to reduce overall disease severity when compared to placebo. 
Nevertheless, the number of studies included in the SR was small and the overall quality of 
studies was poor, preventing valid conclusions from being made.  
The SR of acupuncture for AD included 3 studies and supported the use of acupuncture for 
the reduction of AD itch intensity when compared to placebo acupuncture (preventive 
effect: MD -2.64, 95% CI -4.39 to -0.89; direct effect: MD -4.56, 95% CI -6.28 to -2.84) and no 
treatment (preventive effect: MD -8.77, 95% CI -10.66 to -6.88; direct effect: MD -12.85, 95% 
CI -14.68 to -11.02). There were conflicting findings with regard to the effects of acupuncture 
in reducing itch perception, and wheal and flare size; and there was insufficient data to 
conduct meta-analysis comparing acupuncture to Western medication. The SR showed that 
the overall quality of studies was poor and warranted more rigorous RCTs on acupuncture 
for AD.  
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To address Objective 2, a new CHM formula, RCM-106, was formulated based on the 
findings of the reviews and a protocol for a clinical study was designed to evaluate the 
efficacy and safety of RCM-106 in the management of AD. The protocol is for a double-blind, 
placebo-controlled RCT specifically for the paediatric population with AD. Its study design 
addresses methodological problems identified from the above-mentioned reviews, as well as 
several issues relating to the clinical study of CHM involving the paediatric population. The 
protocol conforms to the Declaration of Helsinki, Good Clinical Practice guidelines and 
relevant regulations by the World Health Organisation, Food and Drug Administration and 
Therapeutic Goods Administration. It has been approved and finalized and the RCT will be 
conducted in the near future.  
The RCT for which the protocol was designed will utilise validated diagnostic criteria and 
outcome measure instruments for AD, including the evaluation of quality of life, and. Upon 
completion of this RCT, its reporting will be guided by the Consolidated Standards of 
Reporting Trials statement and its relevant extension of herbal intervention.  
The RCT will employ the reverse pharmacology paradigm for traditional medicine, whereby 
the trial intervention and its use is according to traditional practice is well-supported by 
historical/empirical evidence and the literature, to allow a Phase II study prior to Phase I and 
pre-clinical studies. The dosing regimen for the study was determined based on the dosages 
from the Chinese Pharmacopoeia and Materia Medica; and treatment frequency and 
duration was determined based on the SRs. The calculation for paediatric doses was based 
on the age-to-dose guidelines as published by the Nanjing College of Traditional Chinese 
Medicine as well as the Conversion Table of Von Harnack, which is used in Japan.  
For ease of dosing and to support blinding and patient compliance, the interventions will be 
administered in the form of small capsules. The literature has shown that children as young 
as 6 years old were able to swallow solid forms of medication. As safety precautions, the RCT 
includes a swallow-test during participant screening to include only participants who are 
able to swallow capsules. To prevent the excessive loss of participants due to inability to 
swallow capsules, there is an optional capsule-swallowing training programme, whereby 
patients will be able to participate upon gaining the ability to swallow capsules after 
completion of the training programme. Due to the vulnerability of the target paediatric 
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population of the study, aside from informed consent from the legal representative of 
participants not of legal age, written or verbal assent from the participant in the presence of 
a witness not directly involved in the trial will be sought. Additional safety precautions of the 
RCT include the involvement of a registered medical practitioner to assist with participant 
evaluation and monitoring, the evaluation of laboratory parameters (full blood count, renal 
function and liver function) before and after the study, the exclusion of participants with 
contraindications towards the intervention or with abnormal lab test results, the use of a 
daily diary to record the use of therapies and the occurrence of any adverse events, the 
measurement of vital signs (temperature, blood pressure, and heart rate) during 
participants’ fortnightly visits and the provision of the contact number of the investigators, 
which will be made available 24 hours a day, to allow participants to contact in cases of 
emergencies or adverse events.  
The results of this RCT will provide clinical data on the efficacy and safety of RCM-106 in 
reducing the severity of AD and improving the quality of life of AD patients and potentially 
lead to a better form of management of AD. Overall, this protocol will lead to a high quality 
RCT and act as a guide for future oral CHM studies and paediatric studies.  
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 General Introduction Chapter 1
1.1 Background 
Dermatitis, or eczema, is a type of chronic, pruritic skin rash. The term dermatitis refers to 
an inflammation of the skin whereas the term eczema originated from the Greek language, 
meaning “to break or boil over” (Burge & Wallis, 2010). Dermatitis usually presents with 
characteristic clinical features, namely itching and lesions that are not clearly demarcated. In 
the acute phase, erythema, swelling, blistering, and weeping are generally present; while 
dryness, scaling and lichenification can be seen in the long-term (Weller, Hunter, Savin, & 
Dahl, 2008).  
Dermatitis can be classified into exogenous or endogenous (Table 1-1) (Buxton & Morris-
Jones, 2009). Exogenous dermatitis refers to dermatitis caused by an external stimulus while 
endogenous dermatitis refers to a constitutional aetiology (Graham-Brown & Burns, 2007).  
 
Table 1-1: Classification of dermatitis (Buxton & Morris-Jones, 2009) 
Endogenous (Constitutional) 
dermatitis 
Exogenous (Contact) 
dermatitis 
Secondary Changes 
Atopic  Irritant Lichen simplex 
(Neurodermatitis) 
Discoid Allergic Asteatotic 
Pompholyx Photodermatitis Pompholyx 
Varicose  Infection 
Seborrhoeic   
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Dermatitis can be further classified according to its aetiology, appearance, distribution or 
age of onset (Weller et al., 2008). However, Graham-Brown and Burns (2007) emphasised 
that the current classification of dermatitis is limited by the incomplete understanding of the 
disease and often cases overlap between classifications. By revising the nomenclature of 
allergy published by the European Allergology and Clinical Immunology (EAACI), the World 
Allergy Organisation (WAO) has recommended the terminology and subgroups for dermatitis 
as illustrated in Figure 1-1, stating that certain patients might be affected by a combination 
of subgroup types (Johansson et al., 2004). The report by the WAO also defined several key 
terms, as listed in Table 1-2. 
 
 
Figure 1-1: Subgroups of dermatitis by the World Allergy Organisation (Adapted from 
Johansson et al., 2004) 
 
 
  
Dermatitis 
Eczema 
Atopic Non-atopic 
Contact 
Dermatitis 
Allergic Non-allergic† 
Other types of 
dermatitis* 
*Includes nummular (discoid) eczema, photosensitive dermatitis and seborrhoeic 
dermatitis 
†Non-allergic contact dermatitis is also known as irritant contact dermatitis 
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Table 1-2: Definition of Key Terms by the WAO (Johansson et al., 2004) 
Term Definition 
Hypersensitivity Objectively reproducible symptoms or signs initiated by exposure 
to a defined stimulus at a dose tolerated by normal persons 
Allergy A hypersensitivity reaction initiated by specific immunologic 
mechanisms 
Atopy A personal and/or familial tendency, usually in childhood or 
adolescence, to become sensitised and produce IgE antibodies in 
response to ordinary exposures to allergens, usually proteins. As a 
consequence, these persons can develop typical symptoms of 
asthma, rhinoconjunctivitis, or eczema. 
 
According to the definitions proposed by the WAO, the term eczema has replaced the 
provisional term, atopic eczema/dermatitis syndrome, which was previously used by the 
EAACI, and should be used when the immunological mechanism of the rash remains unclear 
(Johansson et al., 2004).   
The scope of this thesis is focused on atopic dermatitis (AD), which is also known as atopic 
eczema (AE) as proposed in the current WAO nomenclature. The term “atopy” originated 
from the Greek term “atopos”, which meant “out of the way” or “uncommon”. It was first 
used by Coca and Cooke (1923) to describe an unusual type of hypersensitivity. Based on the 
definitions of the WAO, AD refers to dermatitis seen in people with an atopic constitution, 
whereby there is an underlying IgE (Immunoglobulin E) antibody-associated reaction 
(Johansson et al., 2004), and is therefore related to a family history of other atopic diseases 
such as asthma or allergic rhinitis (Feingold, Huang, Kristal, Kalish, & Clark, 1998). However, 
up to two-thirds of diagnosed patients have no associated allergen-specific IgE-antibody 
sensitisation (Flohr, Johansson, Wahlgren, & Williams, 2004). 
The debate with regard to the nomenclature, classification and diagnosis of AD is ongoing 
(Hanifin, 2012; Schmitt, Flohr, & Williams, 2012). Due to the earlier nomenclature proposed 
by the EAACI, there have been variant terms such as “nonallergic AD” (Novak & Bieber, 
2003), “intrinsic AD” (Tokura, 2010), and “atopiform AD” (Brenninkmeijer, Spuls, et al., 2008) 
to describe AD that does not present with IgE-mediated allergy. Regardless of whether there 
is associated “atopy”, the diagnosis of AD should be based on a combination of clinical 
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features and disease history (Williams et al., 1994) and should not require IgE testing 
(Hanifin, 2012). However, there is currently no gold standard for the diagnosis of AD. 
Researchers are continuously striving to unify terminologies, diagnostic criteria and outcome 
measures in relation to AD (Schmitt & Williams, 2010). 
In accordance with the 2 main diagnostic criteria, the Hanifin and Rajka Diagnostic Criteria 
(Hanifin & Rajka, 1980) and the United Kingdom (UK) Diagnostic Criteria (Williams et al., 
1994), the disease shall be referred as AD throughout this thesis, except where there is 
specific discussion related to the other nomenclatures. The diagnosis of AD will be further 
discussed in Chapter 1.4. 
 
1.2 Epidemiology of Atopic Dermatitis  
1.2.1 Prevalence 
AD is said to be the most common inflammatory skin disease among children (W. Zhang et 
al., 2009). According to the International Study of Asthma and Allergies in Childhood (ISAAC) 
Phase Three survey studies (Williams, Stewart, von Mutius, Cookson, & Anderson, 2008), the 
lifetime-reported “eczema” prevalence in children aged 6-7 years ranged from 1.2% in both 
Panevezyz, Lithuania and Cuernavaca, Mexico to 38.6% in Linköping, Sweden; in those aged 
13-14 years, the prevalence ranged from 0.8% in Ciudad Victoria, Mexico to 48.3% in 
Linköping, Sweden. The breakdown of prevalence in the 2 age groups according to region is 
illustrated in Figure 1-2. The Australian arm of the study which was conducted in 1998 
showed that 10.9% of children aged 6-7 years old and 9.7% of the 13-14 year olds were 
affected by eczema (Robertson et al., 1998). 
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Figure 1-2: Prevalence of AD in children aged 6-7 years and 13-14 years (Adapted from 
Williams, et al., 2008) 
 
Reports have shown an increase in prevalence of AD over the last few decades, especially in 
industrialised countries (Buys, 2007; Möhrenschlager, Darsow, Schnopp, & Ring, 2006). 
However, the reasons for its increase remain unidentified (Möhrenschlager et al., 2006). 
Nevertheless, this finding of increasing incidence was consistent when the results from the 
ISAAC Phase Three studies were compared to those of the Phase One studies (Williams et al., 
2008).   
Although it has been reported that around 60% of childhood AD tend to resolve in early 
childhood, more than half of them would experience recurrences (Sandstrom Falk & 
Faergemann, 2006; Vickers, Rees, Zollman, Smith, & Ellis, 1999). The prevalence of AD in 
adults remains unclear, with the literature quoting between 1-2% (Herd, Tidman, Prescott, & 
Hunter, 1996b) and 2-10% (Baron, Cohen, & Archer, 2012). Bannister and Freeman (2000) 
reported that up to 20% of the total patients attending a contact dermatitis clinic were 
diagnosed with pure AD (i.e. without relevant contact dermatitis factors); 9% were 
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diagnosed with adult-onset AD (i.e. patients whose first onset of AD was at the age of 20 
years or older). Many of the adult patients were diagnosed with “probable AD” as they 
presented with clinical distribution, personal/familial history of atopy, and multiple positive 
prick tests, but failed to satisfy the diagnostic criteria which include an “onset of diseases at 
less than 2 years of age” (Bannister & Freeman, 2000). 
There is an increased incidence of AD seen in smaller families and families of higher social-
economic brackets (Ring, Przybilla, & Ruzicka, 2006; Williams, 2000, 2013). Epidemiology 
studies also showed that there were increased risks among the children of East Asian 
ethnicities in Melbourne, Australia (Martin et al., 2013), among Chinese migrants in Hawaii 
and among black Caribbean children who were born in London (Williams, 1995). 
1.2.2 Impact of Atopic Dermatitis 
While rarely fatal, the insatiable itch of AD can cause unbearable frustration, reduced quality 
of life (QoL) and inconveniences to families. The characteristic symptoms of AD include skin 
dryness and itching; patients, therefore, fall victim to the itch-scratch-itch cycle.  
1.2.2.1 Health Impact 
The itching in AD, which is usually exacerbated at night (Yosipovitch et al., 2002), has been 
widely reported to result in sleep disturbances and related consequences among AD patients 
and their families (Lawson, Lewis-Jones, Finlay, Reid, & Owens, 1998; Moore, David, Murray, 
Child, & Arkwright, 2006). Apart from health concerns related to total sleep deprivation, 
recurrent partial sleep disturbance can also lead to mood disturbances and neurocognitive 
impairment (Brown & Reynolds, 2006; Dahl, Bernhisel-Broadbent, Scanlon-Holdford, 
Sampson, & Lupo, 1995; Lawson et al., 1998).  
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AD patients often feel guilty for scratching and are often embarrassed about their 
appearances due to the presence of rash, scarring or scratch marks (Brown & Reynolds, 
2006). They may also be shunned by their peers due to the condition and have low self-
esteem as a result (Hoare, Li Wan Po, & Williams, 2000; W. Zhang, Leonard, et al., 2010). The 
frustration with the condition may lead to further stress and psychological burden, which in 
turn, worsens the condition (Arck & Paus, 2006; Arndt, Smith, & Tausk, 2008; Tran et al., 
2010; Wright et al., 2004). 
There is also an increased risk of superinfections by Staphylococcus aureus and Herpes 
simplex virus in AD patients (Ring et al., 2006). Furthermore, AD is said to be the beginning of 
the “atopic march”, preceding the development of other atopic diseases – asthma and 
allergic rhinitis. Studies have shown that 30% of children with AD will develop asthma and 
35% will develop allergic rhinitis (Baron et al., 2012). 
1.2.2.2 Quality of Life Impact 
AD patients are often subjected to restricted diets and activities, special bedding or clothing, 
application of greasy emollients and doctor visits (Hoare et al., 2000), which subsequently 
affect their daily life. The sleep disturbances caused by the condition can also lead to lower 
school or work productivity in patients and their caretakers (Brown & Reynolds, 2006; Dahl 
et al., 1995; Lawson et al., 1998). 
A study comparing QoL impairment in children due to dermatological conditions and other 
childhood chronic diseases showed that generalised AD rated second, after cerebral palsy, 
but surpassed more severe diseases such as cystic fibrosis, epilepsy and diabetes (Figure 1-3). 
The social, emotional and financial impact on families caring for a child with moderate to 
severe AD is said to be higher than that of families caring for a child with type-1 diabetes 
(Kemp, 1999).  
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Figure 1-3: Quality of Life (QoL) impairment in children with dermatological and other 
chronic diseases (Adapted from Beattie & Lewis-Jones, 2006) 
 
1.2.2.3 Economic Impact 
Patients and families are further burdened by the economic costs of disease management 
(Hoare et al., 2000). The yearly management costs for AD can amount to several hundred 
millions of dollars (Hoare et al., 2000; Mancini, Kaulback, & Chamlin, 2008). In the UK, the 
total annual expenditure on AD was estimated at £465 million (Herd, Tidman, Prescott, & 
Hunter, 1996a); in the United States, the estimated national direct costs ranged from 
USD$364 million to USD$3.8 billion (Mancini et al., 2008). In Australia, the annual personal 
financial costs for the management of AD ranged from AUD$330 to AUD$1255, and is said to 
be greater than the management costs for asthma and diabetes (excluding dietary expenses 
in children (Figure 1-4) (Su, Kemp, Varigos, & Nolan, 1997).  
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Figure 1-4: Comparison of management costs for AD, asthma and diabetes in Australia 
(Adapted from Su, Kemp, Varigos, & Nolan, 1997) 
*Data on indirect costs for asthma not available; **Allow a further AUD$1000 for dietary 
expenses for the management of diabetes 
 
1.3 Aetiology and Pathophysiology of Atopic Dermatitis 
The aetiology and pathogenesis of AD has not been completely understood. However, it has 
been hypothesised that there are genetic and environmental factors involved, as well as 
immune dysregulation and permeability barrier defects of the skin (Feingold et al., 1998). AD 
can be aggravated by irritants (e.g. detergents, fabrics), allergens (e.g. dust mites, foods), 
infection, stress or hormonal changes (Feingold et al., 1998). Previously, AD was thought to 
be mainly an immunologic disease, whereby the T helper type 2 (Th2) inflammatory 
response to allergens invoked skin barrier function impairment (inside-outside hypothesis) 
(De & Handa, 2012). However, recent studies, especially the discovery of filaggrin gene (FLG) 
mutations, have shifted the views towards an outside-inside hypothesis, wherein the Th2 
inflammatory response seen in AD is said to be due to constant insults through the impaired 
skin barrier (De & Handa, 2012).  
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1.3.1 Genetic Factors 
Twin studies have shown that monozygotic twins have a 0.86 risk of concordant AD 
compared to dizygotic twins, who have a risk of 0.21 which is equivalent to the risk among 
regular siblings (Schultz Larsen, Holm, & Henningsen, 1986). There are also increased risks of 
AD development in children whose parents have AD compared to children whose parents 
have asthma or allergic rhinitis (Dold, Wjst, Von Mutius, Reitmeir, & Stiepel, 1992), 
suggesting that there are specific skin genes that result in the eczema phenotype (Brown & 
Reynolds, 2006). Hoffjan and Epplen (2005) have identified that there are AD regions in 
chromosomes overlapping with psoriasis and asthma regions, respectively.  
Studies on genome-wide screens followed by positional cloning are used to identify genes 
influencing AD susceptibility while candidate gene-association studies are focused on 
comparing dissimilarities between genes whose functions contribute to the pathophysiology 
of AD patients and non-AD controls (Hoffjan & Epplen, 2005). Nevertheless, the role of many 
AD-related genes remains unclear due to conflicting evidence or failure to reproduce 
findings (Weidinger et al., 2006). However, genetic studies seemed to be in agreement that 
there are 2 components in AD – immunological, where there is IgE-mediated sensitisation 
and Th2-tilted immune dysregulation; and skin, which accounts for the skin barrier 
dysfunctions (Hoffjan & Epplen, 2005; Paternoster et al., 2012; Saito, 2005).  
1.3.1.1 Skin Barrier Function 
Skin barrier function prevents water loss and penetration by allergens and microbes through 
the skin (Figure 1-5). In AD, there is a defect in terminal differentiation of the keratinocytes 
in the stratum corneum (SC), leading to decreased ceramides, anti-microbial peptides and 
filaggrin (filament aggregating protein) production in the skin (D. Y. M. Leung, 2013). 
Filaggrin plays an important role in the formation of cornified envelope in the SC and 
terminal differentiation of the skin keratinocytes (De & Handa, 2012).  Furthermore, its 
metabolites contribute to the formation of natural moisturising factor and increase in acidity 
of the SC (D. Y. M. Leung, 2013). The loss-of-function mutations in the FLG leading to 
reduced filaggrin production and disrupted skin barrier function has been shown to be the 
most significant genetic cause of AD. Decreased filaggrin metabolites raise the pH of the SC, 
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causing reduced ceramide synthesis (De & Handa, 2012) and increased barrier breakdown 
via the activation of several serine proteases (D. Y. M. Leung, 2013). There is also an increase 
in percutaneous immune response and expression of interleukin (IL)-1 as a result of FLG 
mutations (D. Y. M. Leung, 2013).  
The outside-inside hypothesis advocates that the immune dysfunction in AD, which will be 
discussed next, is a result of enhanced allergen penetration though the damaged skin barrier 
(Jung & Stingl, 2008).   
 
 
Figure 1-5: Normal and atopic skin barrier (Adapted from Rahman, Collins, Williams and 
Ma, 2011) 
 
1.3.1.2 Immune Dysfunction 
As mentioned previously, genome-wide screens have identified several genes related to 
immune dysregulation. However, replication of positive findings has been scarce (Hoffjan & 
Epplen, 2005).  
The inflammation of AD is biphasic, whereby acute AD involves Th2 inflammation, while the 
chronic stage involves T helper type 1 (Th1) inflammation (Terui, 2009). When an allergen or 
microbe penetrates the skin barrier, it triggers the body’s innate immune response. Toll-like 
receptors (TLRs) are innate immune receptors which, upon stimulation by microbes or tissue 
damage, release anti-microbial peptides, cytokines, chemokines and enhance the strength of 
tight junctions in the stratum granulosum to limit penetration (D. Y. M. Leung, 2013). 
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However, there is diminished TLR function in AD patients, leading to enhanced intrusion 
from the environment.  
Dendritic cells in AD have increased expression of high affinity IgE receptors (Bieber, 2008). 
There are 2 types of dendritic cells – Langerhans cells which are present in normal skin and 
inflammatory dendritic epidermal cells which are found in inflamed skin. When the allergen 
or microbe penetrates through the initial barriers, it gets taken up by Langerhans cells, which 
in turn binds to naïve T cells to trigger the adaptive immune response (Bieber, 2008). The 
elevated thymic stromal lymphopoietin (TSLP) expressed on AD epidermal keratinocytes 
enhances dendritic cell driven Th2 cell differentiation (D. Y. M. Leung, 2013). IL-25 and IL-33 
are two other pro-Th2 cytokines present in acute AD (Brandt & Umasundari, 2011) that 
activate eosinophils and mast cells as well (D. Y. M. Leung, 2013). The release of TSLP, IL-25 
and IL-33 can be boosted by mechanical trauma, allergen exposure and infections (D. Y. M. 
Leung, 2013). Cutaneous lymphocyte-associated antigen expressed on memory T helper cells 
increases the production of Th2 cytokines, including IL-4, IL5 and IL-13 and decreases 
interferon-gamma (IFN-γ) (Saito, 2005). IL-4 and IL-13 are involved in IgE synthesis and IL-5 is 
involved in eosinophil maturation; whereas IFN-γ is a Th1 cytokine which impedes Th2 
function. Another Th2 cytokine is IL-31, which inhibits epidermal differentiation, contributing 
to severe pruritus (D. Y. M. Leung, 2013). As AD progresses into chronicity, allergens and 
microbes get taken up by the inflammatory dendritic epidermal cells, which produce IL-12, 
IL-18 and pro-inflammatory cytokines, leading to Th1 polarisation (Figure 1-6).  
The inside-outside hypothesis debates that a primary immunological defect is the cause of 
skin barrier dysfunction. This is because Th2 cytokines can disrupt skin barrier function by 
reducing epidermal keratinocyte differentiation and subsequently decreasing the production 
of ceramides, filaggrin and anti-microbial peptides (Elias, Sun, Eder, Wakefield, & Man, 2013; 
D. Y. M. Leung, 2013). As this remains true, the outside-inside hypothesis may be referred to 
as “outside-to-inside-back-to-outside” (Elias et al., 2013). 
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Figure 1-6: Biphasic inflammation in AD (D. Y. M. Leung, 2013; Saito, 2005) 
 
1.3.2 Environmental Factors 
The increase seen in AD prevalence cannot be attributed to genetic changes. Furthermore, 
the increased prevalence seen in those of higher socio-economic status, small families and 
ethnic groups who migrated to countries of higher AD prevalence strongly suggests the 
involvement of environmental factors.   
The shift towards a more “Western” lifestyle or the influence of urbanisation factors (which 
may have led to an increase in aeroallergens or dietary allergens), or changes in the physical 
environment, was proposed as a possible environmental factor (Williams, 1995, 2000). 
Recently, Silverberg et al. (2013) reported that there was an increased prevalence of AD in 
locations of low humidity, low ultraviolet (UV) exposure, low outdoor temperature, indoor 
heating (therefore low indoor humidity) and increased precipitation. While these findings 
were in agreement with those of earlier studies, the authors highlighted the lack of 
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specificity in the definition of eczema as a limitation of their study. Flohr et al. (2009) 
commented that the questionnaire might have referred to “eczema or other kinds of skin 
allergy”. 
Another possible environmental factor contributing to the increase in AD prevalence is 
known as the “hygiene hypothesis”, first proposed by Strachan (1989) in relation to hay 
fever and allergic diseases. The hygiene hypothesis suggested that infection in early 
childhood protects against atopy. This hypothesis was supported by the decreased 
prevalence of atopic diseases among children of families with larger number of older 
siblings, and therefore increased exposure to pathogens. The hypothesis was further 
strengthened when it was proven that natural immunity against infections induced Th1 
response and suppressed Th2 inflammation (Strachan, 2000). Thus, better overall hygiene, 
as seen in those of higher socio-economic status, resulted in a lack of exposure to microbial 
stimulation during early childhood, subsequently leading to the failure of inducing the Th1 
polarised inflammatory response and increasing the likelihood of Th2 polarised diseases, 
such as AD.  
A systematic review (SR) by Flohr and Yeo (2011) explored the relation of AD and the 
hygiene hypothesis by examining basic hygiene, day care attendance, anthroposophic 
lifestyle and living on a farm or with pets. The study concluded that there was a negative 
relation between helminthic infections and AD but not other pathogens, that there were 
possible protective effects through the exposure to non-pathogenic microbes from early day 
care, endotoxins, unpasteurised farm milk and animals, and that there was increased risk of 
AD related to the use of broad-spectrum antibiotics. However, it should be noted that there 
were inconsistent findings with regard to the hygiene hypothesis (Williams, 2013), with 
several studies reporting a lack of supporting evidence for the hygiene hypothesis (Cramer et 
al., 2012; Zutavern et al., 2005). One study failed to show “a protective sibling effect” and 
countered that the presence of elder siblings increased chances of filaggrin deficiency 
(Cramer et al., 2010). Flohr and Yeo’s review (2011) also failed to find supporting evidence of 
the protective sibling effect.  
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1.3.3 Dietary Factors 
It is known that certain food allergens may aggravate AD (Ring et al., 2006), with 33-63% of 
children with AD affected by food hypersensitivity (Werfel et al., 2007). A study on the 
effects of diet on asthma and allergic diseases concluded that diet is associated with wheeze 
and asthma but not allergic sensitisation (Nagel et al., 2010). Two Cochrane SRs were 
conducted with regard to dietary interventions for AD – 1 on dietary exclusion and 1 on 
dietary supplements, respectively (Bath-Hextall, Delamere, & Williams, 2009; J., Jenkinson, 
Humphreys, & Williams, 2012). Both SRs concluded that there was a lack of convincing 
evidence of the benefits of dietary exclusion or supplements for AD. With regard to the 
preventative effects of exclusive breastfeeding, hydrolysed protein formulae, soy formulae, 
maternal dietary antigen avoidance, omega-3 or -6 fatty acid supplementation, probiotics or 
prebiotics, an overview of Cochrane and non-Cochrane reviews showed no clear evidence of 
either intervention (Foisy, Boyle, Chalmers, Simpson, & Williams, 2011). Nevertheless, 
Saadeh et al. (2013) insisted that the relation between diet and allergic diseases exists, 
despite contradictory or barely significant findings. Saadeh et al. (2013) pointed out that a 
person’s diet was not based on a single food but a mixture of nutrients, in which food 
interactions should be accounted for. The study concluded that an increased intake of 
antioxidants and omega-3 fatty acids by the mother prenatally or by the child during 
childhood might reduce the occurrence of atopic diseases.  
1.3.4 Psychological Factors 
Psychological factors play a part in the aggravation of AD. Stress and emotional factors are 
said to cause exacerbations, trigger immune activation and aggravate pruritus and scratching 
(Schneider et al., 2013). This aggravation, in turn, leads to further stress, anxiety and other 
psychological disturbance, as shown by QoL studies (Absolon, Cottrell, Eldridge, & Glover, 
1997; Hashiro & Okumura, 1997; Ricci, Bellini, Dondi, Patrizi, & Pession, 2012), creating a 
vicious cycle between stress-aggravated AD and AD-induced stress.  
The mechanism behind psychological factors affecting AD remains unknown but may be 
related to neuro-immune regulation (Brown & Reynolds, 2006). The Th2-tilted inflammatory 
response in AD may have been brought upon by early-life stress, as the immuno-suppressive 
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effects of stress hormones mainly affect Th1 cells (Arndt et al., 2008). Stress can lead to the 
degranulation of mast cells and there is an increase in mast cell-nerve fibre contacts in AD, 
which may account for its neurogenic inflammation (Arndt et al., 2008). Furthermore, stress 
causes a disruption in the homeostasis of the skin barrier permeability and further damages 
skin integrity and cohesion (Arndt et al., 2008).  
1.3.5 Other Factors 
The itching nature of AD results in scratching, which in turn, aggravates itching by damaging 
the skin barrier. This endless cycle is known as the itch-scratch cycle. Defects in skin barrier 
function result in AD skin being more sensitive towards irritants, including various materials 
such as wool, or chemicals and detergents, which could further disrupt skin barrier function 
(Brown & Reynolds, 2006). Scratching also causes an increased risk of secondary infections 
(Brown & Reynolds, 2006) and triggers pro-inflammatory cytokines to be released by 
keratinocytes (Bieber, 2008).  
Secondary infections are a concern as the Staphylococcus aureus bacteria is found in more 
than 90% of AD patients, on both eczematous lesions and uninvolved skin. The overgrowth 
of Staphylococcus aureus is due to the suppressed innate immune system and decreased 
anti-microbial peptide in AD (Bieber, 2008) and contributes to the recurrent nature of AD 
(Brown & Reynolds, 2006).  
Furthermore, along with chronic inflammation of the skin in AD, scratching may lead to the 
development of an autoimmune form of the disease, where the body produces IgE 
autoantibodies against self-proteins (Bieber, Cork, & Reitamo, 2012; S. Rahman, Collins, 
Williams, & Ma, 2011). Autoimmunity is said to be present in up to 25% of AD patients 
(Bieber, 2008).  
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1.4 Diagnosis of Atopic Dermatitis 
AD is often known as the “itch that rashes”. Its onset can appear in babies younger than 3 
months old and can lead to a greater tendency to develop irritant and contact dermatitis 
(Van Onselen, 2012).  AD can be classified into acute, subacute and chronic stages (Table 
1-3). Some dermatological textbooks have also classified AD into infant, childhood and adult 
phases (Habif, 2009). 
 
Table 1-3: Clinical and pathological features of the different phases of AD (MacKie, 2003) 
Presentation Acute Subacute Chronic 
Clinical  Redness, swelling, 
oozing; formation of 
small blisters; pain, 
heat, tenderness 
Redness, swelling, 
crusting; scaling, 
secondary infection; 
itch (may be severe) 
Scaling; thickening of 
the skin and increase 
in skin markings 
(lichenification); itch 
Pathological Dermal and 
epidermal oedema 
(spongiosis); dilated 
and congested 
dermal capillaries; 
dermal infiltrate very 
early leukocytes and 
later lymphocytes 
Crusting and 
parakeratosis; early 
acanthosis; oedema; 
perivascular 
lymphocytic dermal 
infiltrate; few 
lymphocytes in 
dermis 
Scaling, 
parakeratosis; 
marked acanthosis 
(epidermal 
thickening); 
coarsening of 
papillary dermal 
collagen 
 
The diagnosis of AD is mainly based on clinical features and patient history. Despite the lack 
of concrete evidence, it has been acknowledged that there are ethnic differences in the 
presentation of AD (NICE, 2007; Van Onselen, 2012). In children of black African, black 
Caribbean or Asian backgrounds, AD may occur on the extensors as well as the flexures and 
there is an increased possibility of lichenification, lumpy or papular skin and pigmentation 
changes (NICE, 2007; Van Onselen, 2012). Inflammation appears to be milder in these ethnic 
groups but they are more likely to present with discoid eczema (Van Onselen, 2012). Due to 
the variability of AD presentation and terminology, there are still disagreements with regard 
to its definition and methods of diagnosis.  
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Johansson et al. (2004) advocated that a skin test or an IgE-antibody determination test is 
essential for diagnosis, as the term “atopy” refers to a predisposition to have IgE-mediated 
allergies. However, Hanifin (2012) rebutted that the criterion of IgE testing is unwarranted 
and would increase avoidable health-care costs. Furthermore, it has been shown that up to 
two-thirds of AD patients do not present with any identifiable specific IgE-antibody 
sensitisation (Flohr et al., 2004). The management guidelines by the National Institute for 
Health and Clinical Excellence (NICE) (2007) stated that there are currently no laboratory 
markers or definitive tests for the diagnosis of AD.  
1.4.1 Diagnostic Criteria for Atopic Dermatitis 
At present, there are a number of diagnostic criteria (Table 1-4); however, they lack in 
uniformity (Brenninkmeijer, Schram, Leeflang, Bos, & Spuls, 2008). Comparisons between 
the minor accompanying symptoms of AD in the various diagnostic criteria and research 
studies failed to show conclusive evidence due to the discrepancies in results 
(Brenninkmeijer, Schram, et al., 2008; Kang & Tian, 1989; Rothe & Grant-Kels, 1996; Schram, 
Leeflang, Den Ottolander, Spuls, & Bos, 2011; Svensson, Edman, & Moller, 1985). A 
commentary by Rothe and Grant-Kels (1996) stated that variability of minor symptoms 
might be related to variation in the age and ethnicity of patients.  
 
Table 1-4: List of AD Diagnostic Criteria 
Diagnostic criteria 
Hanifin and Rajka Diagnostic Criteria (Hanifin & Rajka, 1980) 
Kang & Tian Diagnostic Criteria (Kang & Tian, 1989) 
Schultz-Larsen Criteria (Larsen & Hanifin, 1992) 
UK Diagnostic Criteria (Williams et al., 1994) 
ISAAC Questionnaire (Asher et al., 1995) 
Criteria of Diepgen (Diepgen, Sauerbrei, & Fartasch, 1996) 
Millennium Criteria (Bos, Van Leent, & Sillevis Smitt, 1998) 
Lillehammer Criteria (Bieber & Leung, 2002) 
Japanese Dermatology Association Criteria (Tada, 2002) 
Danish Allergy Research Centre (DARC) (Johnke et al., 2005) 
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Out of the 10 listed diagnostic criteria, a SR showed that only 6 had been validated 
(Brenninkmeijer, Schram, et al., 2008). The Hanifin and Rajka Diagnostic Criteria is 
considered the “landmark diagnostic criteria” (Flohr, 2011); however, it includes 4 major and 
23 minor criteria, based on the consensus among experienced dermatologist, without 
objective clinical validation (Brenninkmeijer, Schram, et al., 2008). Its extensiveness and lack 
of validity deems it impractical for population-based studies (Larsen & Hanifin, 1992; 
Svensson et al., 1985). The UK Diagnostic Criteria is a refined version of the Hanifin and Rajka 
Diagnostic Criteria by the UK Working Party (Williams et al., 1994). It is the most widely-
validated diagnostic criteria and its use has been recommended for future intervention 
studies (Brenninkmeijer, Schram, et al., 2008).  
The NICE guidelines for AD in children stated that the high specificity of the UK Diagnostic 
Criteria in validation studies suggested low false-positive diagnosis and optimised 
consultation time in clinical practice. However, it was also emphasised that patients’ clinical 
and drug histories and the differences in atopic patterns of certain ethnic groups should not 
be neglected (NICE, 2007). The NICE guidelines proposed a modified version of the UK 
Diagnostic Criteria (Table 1-5) 
This thesis will mainly refer to the UK Diagnostic Criteria for AD. However, the Hanifin and 
Rajka Criteria will be referred to when discussing the minor signs/symptoms of AD. 
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Table 1-5: UK Diagnostic Criteria (Williams et al., 1994) and Diagnostic Criteria proposed by 
NICE (NICE, 2007) 
Must have:  
An itchy skin condition  
Plus three or more of the following: 
UK Diagnostic Criteria NICE Diagnostic Criteria 
 Visible flexural eczema (or eczema 
involving the cheeks/forehead and outer 
limbs in children under 4 years)  
 Visible flexural dermatitis involving skin 
creases (or visible dermatitis on the 
cheeks and/or extensor area in children 
18 months or under  
 A history of involvement of the skin 
creases such as folds of elbows, behind 
the knees, fronts of ankles or around the 
neck (including cheeks in children under 
10 years)  
 A personal history of flexural dermatitis 
(or dermatitis on the cheeks and/or 
extensor area in children 18 months or 
under 
 A history of general dry skin in the last 
year 
 A personal history of dry skin in the last 
12 months 
 A personal history of asthma or hay 
fever (or a history of atopic diseases in a 
first-degree relative for children aged 
under four years) 
 A personal history of asthma or allergic 
rhinitis (or a history of atopic disease in 
a first-degree relative of children under 
four years) 
 Onset under the age of two (not used if 
the child is under 4 years) 
 Onset under the age of two years (this 
criterion should not be used in children 
aged under four) 
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1.4.2 Differential Diagnosis 
The differential diagnosis of AD includes other forms of dermatitis, such as seborrhoeic 
dermatitis with greasy yellow scaling; juvenile plantar dermatosis (foot dermatitis); 
pompholyx (dyshidrotic eczema); allergic or irritant contact dermatitis; and discoid eczema 
(Van Onselen, 2012; White, 2013). Other dermatological diseases that are differential 
diagnoses of AD include fungal infections (tinea), which may also be confused with discoid 
eczema lesions; psoriasis which presents with silver scaling; infestations by head lice or 
scabies; keratosis pilaris, which is a disorder of hair follicle keratinisation that does not 
present with itching; and ichthyoses (Archer, 2013; Van Onselen, 2012). However, 
keratinosis pilaris and ichthyosis vulgaris are often associated with AD and are listed as 
minor criteria in the Hanifin and Rajka Criteria (Archer, 2013; Hanifin & Rajka, 1980). 
 
1.5 Management of Atopic Dermatitis  
Currently, there is no cure for AD; medication and other forms of management available are 
targeted at symptomatic relief (W. Zhang et al., 2009). The main treatment aim is to 
recognise and remove triggering factors, maintain skin hydration and reduce itching and 
inflammation (Feingold et al., 1998; Ring et al., 2012a). However, relapse of AD is very 
common.  
There are several evidence-based international guidelines on the management of AD (Akdis 
et al., 2006; Baron et al., 2012; Darsow et al., 2010; Katayama et al., 2011; T. N. H. Leung et 
al., 2013; NICE, 2007; Ring et al., 2012a, 2012b; Rubel et al., 2013; Saeki et al., 2009). The 
objective of AD managements is said to assist patients to reach a state where there would 
be either no symptoms or only minor symptoms which do not disrupt daily life and do not 
require much medication; if slight or mild symptoms persist, it should be in a state where 
exacerbations are rarely acute, intense or protracted (T. N. H. Leung et al., 2013; Saeki et al., 
2009). Seven out of these 10 guidelines suggested a stepwise management of AD depending 
on severity (Table 1-6). 
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Table 1-6: Stepwise management of AD (Adapted from Akdis et al., 2006; Darsow et al., 
2010; Katayama et al., 2011; T. N. H. Leung et al., 2013; NICE, 2007; Rubel et al., 2013; 
Saeki et al., 2009) 
Severity Signs and Symptoms Impact on Quality of Life Treatment 
Clear/Dry 
skin only 
No active lesions None Basic treatment: skin 
hydration, emollients, 
avoidance of irritants and 
addressing specific 
trigger factors 
Mild Areas of dry skin with 
infrequent itching 
(with or without small 
areas of redness) 
Little impact on everyday 
activities, sleep and 
psychosocial well-being 
Mild to moderate potent 
(low-mid potency) topical 
corticosteroid  
Moderate Areas of dry skin with 
frequent itching and 
redness (with or 
without excoriation 
and localised skin 
thickening) 
Moderate impact on 
everyday activities and 
psychosocial well-being, 
frequently disturbed 
sleep 
Moderate to potent 
(mid-high potency) 
topical corticosteroid or 
topical calcineurin 
inhibitors* 
Severe Widespread areas of 
dry skin, incessant 
itching and redness 
(with or without 
excoriation, extensive 
skin thickening, 
bleeding, oozing, 
cracking and 
alteration of 
pigmentation 
Severe limitation of 
everyday activities and 
psychosocial functioning, 
nightly loss of sleep 
Potent to very potent 
TCS, systemic therapy 
(e.g. 
Immunosuppressants, 
ciclosporine A), 
phototherapy. 
*Topical calcineurin inhibitors are not recommended as first-line treatments for AD of any 
severity. It is recommended, within its licensed indications, as an option for the second-line 
treatment of moderate to severe AD in those over the age of 2 years that have failed to 
respond to topical corticosteroid use or have a risk of adverse effects from further topical 
corticosteroid use. 
28 
 
1.5.1 Identification and Avoidance of Trigger Factors 
Many factors have been known to aggravate AD; these can range from allergens and 
irritants, climatic and other environmental factors, to psychological distress from the 
condition itself or daily life. Medical interventions following the stepwise approach may be 
effective. However, in many cases, the existence of trigger factors results in the failure to 
achieve management goals. While it is important to eliminate any identified trigger factors 
where possible, it should be noted that this removal does not guarantee the cure of the 
disease as AD is multifactorial (Saeki et al., 2009).  
Currently, there are no tests to evaluate AD reactions to climatic, psychological or 
environmental trigger factors, but there are tests evaluating reactions to aeroallergens and 
food allergens. The atopy patch test allows more specific results to identify aeroallergens 
(mainly dust mites, cat hair and grass pollen) compared to the prick test or specific IgE test 
(Nosbaum, Hennino, Berard, & Nicolas, 2010); while the double-blind, placebo-controlled 
food challenge is considered the gold standard for identifying food sensitivity (NICE, 2007).  
The general advice given to AD patients is to avoid clothing made of occluding, irritating, 
synthetic or woollen materials and also to avoid other trigger factors such as certain soaps, 
detergents, smoke, stress, humidity and extreme temperatures (T. N. H. Leung et al., 2013; 
NICE, 2007). AD patients are also advised to reduce contact with water, especially hot water 
as it can further aggravate the condition; and use mild syndets (synthetic detergents) with a 
pH value of 5.5-6.0 to maintain the acidic pH of the skin (Akdis et al., 2006). 
Common food allergens related to AD exacerbation include milk, eggs, peanuts, soy and 
wheat. As mentioned previously, the evidence supporting dietary exclusions is limited (Bath-
Hextall et al., 2009). Specific food exclusion diets should only be recommended where the 
specific food trigger has been identified (Werfel et al., 2007). For bottle-fed infants under 
the age of 6 months with uncontrolled moderate to severe AD, the NICE guidelines 
suggested a 6-8 week trial of replacing cow’s milk formula with extensively hydrolysed or 
amino acid formula (NICE, 2007). The NICE guidelines also recommended specialist dietary 
advice to children following a cow’s milk-free diet for longer than 8 weeks (NICE, 2007). 
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1.5.2 Skin Hydration 
As discussed previously, skin barrier disruption leads to an increase in transepidermal water 
loss and decrease in natural moisturising factor and ceramides in the skin, leading to 
dryness. Emollients (or moisturisers) are required to maintain skin hydration and are 
considered the mainstay treatment of AD. Their efficacy has been shown to reduce the need 
for topical steroids by half (Brown & Reynolds, 2006).  
Emollients function by acting as a protective layer over the skin, thereby preventing water 
loss or pathogen invasion; some also directly add moisture to the outer layers of the skin 
(NICE, 2007). The NICE guidelines (2007) recommended an essential emollient therapy 
package consisting of a topical emollient and a wash product, which should be used regularly 
and copiously, especially after washing or bathing; guidelines by Saeki et al (2009) 
recommended a standard of twice-a-day applications during acute exacerbations and once-
a-day when there is no recurrence.  
There are several preparations of moisturisers and emollients (Table 1-7 & Table 1-8) (NICE, 
2007; Varothai, Nitayavardhana, & Kulthanan, 2013). Akdis et al. (2006) emphasised that the 
correct emollient be chosen based on the individual skin status, seasonal or climatic 
conditions and time of day for optimal effects. The NICE guidelines (NICE, 2007) 
recommended a “trial and error” approach to finding the right emollient(s) for patients and 
discouraged the repeated use of the same emollients over long periods. 
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Table 1-7: Classification of moisturisers (Adapted from Varothai et al. 2013) 
Classification Mechanism of action Similarity to normal 
skin components 
Examples 
Occlusives Form a hydrophobic 
film to prevent 
transepidermal water 
loss 
Intracellular lipid 
bilayers (ceramide, 
cholesterol, free fatty 
acids) 
Beeswax, carnuba, 
lanolin, mineral oils, 
paraffin, petrolatum, 
propylene glycol, 
silicones, squalene 
Humectants Attract and bind 
water from deeper 
epidermis to stratum 
corneum 
Natural moisturising 
factor in cornerocytes 
Alpha hydroxyl acids, 
glycerine, hyarulonic 
acid, propylene glycol, 
pyrrolidone, carboxylic 
acid, sorbitol, sugars, 
urea 
Emollients Smoothen skin by 
filling cracks between 
desquamation of 
corneocytes 
Natural lipids in skin 
and sebum 
Lauric acid, linoleic 
acid, linolenic acid, 
oleic acid, stearic acid 
 
Table 1-8: Types of emollient products (Adapted from NICE guidelines, 2007) 
Types Description 
Emollient creams 
and ointments 
Designed to be left on skin; Creams are absorbed by the skin faster 
than ointments and contain preservatives to protect against 
microbial growth in the presence of water; Ointments are greasy in 
nature 
Emollient soap 
substitutes 
Contain emollient ingredients with very mild emulsifiers and are used 
in replacement of soaps or other detergents 
Emollient semi-
dispersing bath oils 
Contain oils and emulsifiers that disperse oil in water; has a cleansing 
effect if gently rubbed over skin 
Non-dispersing 
emollient bath oils 
Contain oil with no emulsifying agent – the oil forms a layer on the 
water surface and is deposited on the skin when leaving the bath 
Adjuvant emollient 
products 
Contain additional ingredients, such as anti-pruritics and antiseptics 
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Despite the insistence of emollients as a mainstay therapy for AD, NICE reported that there 
was a lack of controlled studies investigating its effectiveness (NICE, 2007). While the lack of 
evidence makes it impossible to quantify the benefits or harms of emollients in the 
treatment of AD, rare side-effects such as contact dermatitis, occlusion folliculitis and skin 
irritation have been reported (T. N. H. Leung et al., 2013). 
1.5.3 Pharmacotherapy 
1.5.3.1 Topical Corticosteroids (TCS) 
Topical corticosteroids (TCS) are part of the mainstay therapies of AD and its evidence is well 
documented (Brown & Reynolds, 2006). Other therapies are usually compared to TCS as the 
standard of care (Hanifin et al., 2004). TCS are derived from natural hydrocortisone secreted 
by the adrenal cortex. Its anti-inflammatory effects are exerted via an up-regulation of 
transcription of anti-inflammatory genes and down-regulation of inflammatory transcription 
genes; while its immuno-suppressive effects occur via the suppression of maturation and 
differentiation of immune cells (Uva et al., 2012) (Figure 1-7).  
 
 
Figure 1-7: Mechanism of action of topical corticosteroids (Modified from Uva et al, 2012) 
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The potency of TCS may vary. In the UK, they are categorised according to their 
vasoconstrictive properties into 4 groups: mild, moderate, potent and very potent (Table 
1-9) (NICE, 2007; Uva et al., 2012). The severity of AD should dictate the choice of TCS 
potency to be used. It is also important to select appropriate bases (ointment, cream, lotion) 
of TCS according to the condition and location of lesions (Saeki et al., 2009).  
 
Table 1-9: Potency of topical corticosteroids (NICE, 2007) 
Topical corticosteroid Potency 
Desonide 0.05% Mild 
Hydrocortisone acetate 0.1-2.5% Mild 
Alclometasome dipropionate 0.05% Moderately potent 
Betamethasone valerate 0.025% Moderately potent 
Clobetasone butyrate 0.05% Moderately potent 
Fludroxycortide 0.0125% Moderately potent 
Fluocinolone acetonide 0.00625% Moderately potent 
Flucortine butylester 0.75% Moderately potent 
Fluocortolone Moderately potent 
Hydrocortisone valerate 0.2% Moderately potent 
Prednicarbate 0.25% Moderately potent 
Beclometasone dipropionate 0.025% Potent 
Betamethasone dipropionate 0.05% Potent 
Betamethasone valerate 0.1% Potent 
Diflucortolone acetonide 0.025% Potent 
Fluocinolone acetonide 0.025% Potent 
Fluocinonide 0.05% Potent 
Fluticasone propionate 0.05% Potent 
Hydrocortisone butyrate 0.1% Potent 
Mometasone furoate 0.1% Potent 
Triamcinolone acetonide 0.1% Potent 
Clobetasol propionate 0.05% Very potent 
Diflucortolone valerate 0.3% Very potent 
Halcinonide 0.1% Very potent 
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TCS have been proven in trials to be effective and safe for flare-ups of AD when used for up 
to 4 weeks (Buys, 2007). Studies have reported greater response rates to TCS compared to 
vehicle (NICE, 2007). However, TCS do not cure AD and long-term use may result in local and 
systemic adverse effects such as skin atrophy and primary hypothalamic-pituitary-adrenal 
axis suppression (Buys, 2007). Overuse of TCS can result in complications such as secondary 
bacterial infections and eczema herpeticum (infection of herpes simplex virus) (Brown & 
Reynolds, 2006). The NICE guidelines found that there was no statistically significant 
suppression of adrenal function with the short-term use of TCS of any potency but noted a 
possibility of such adversity with potent TCS (NICE, 2007). Other adverse effects seen with 
TCS include stinging sensation upon application, hypertrichosis, telangiectasia on the cheeks, 
acne, folliculitis and steroid-induced or contact dermatitis.  
These complications are the reasons for AD patients and their caretakers being hesitant 
towards the use of TCS. However, the NICE guidelines emphasised that withholding TCS 
treatment might exacerbate AD and further decrease QoL (NICE, 2007). The risk of adverse 
effects is related to the surface area in contact with TCS, thickness of the skin, potency and 
duration of use. The finger-tip unit is a validated method to apply TCS in safe quantities 
(NICE, 2007), where 1 unit is about 0.5g and refers to a squeeze of TCS cream/ointment from 
the tip to the first finger joint of the index finger for the surface area of 2 adult hands. With 
regard to frequency of application, once-daily or twice-daily applications have been found to 
be effective and should be applied to only affected areas. For AD with frequent, recurrent 
exacerbations, it is recommended to apply TCS for 2 consecutive days each week (also 
known as weekend therapy) to prevent further flares (NICE, 2007). 
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1.5.3.2 Topical Calcineurin Inhibitors (TCI) 
Tacrolimus and pimecrolimus are 2 topical calcineurin inhibitors (TCI) introduced in the 
clinical management of AD. Topical tacrolimus is available in 0.03% and 0.1% ointment while 
pimecrolimus is available in 1% cream. Only tacrolimus 0.03% and pimecrolimus 1% have 
been licensed for the use in children above the age of 2 years old. TCI inhibit the 
transcription of cytokines and chemokines in keratinocytes, T cells and mast cells of the skin 
(Frieden, Gilliam, & Richardson, 2006). TCI bind to cytosolic immunophilins and block 
calcineurin from dephosphorylating the inactive cytosolic form of nuclear factor of activated 
T cells, thereby preventing the transcription of pro-inflammatory cytokine genes for T cell 
activation (Figure 1-8). 
 
 
Figure 1-8: Mechanism of action of topical calcineurin inhibitors (Adapted Frieden, et al., 
2006) 
(cNF-AT: cytosolic form of nuclear factor of activated T cells; NF-AT: nuclear factor of 
activated T cells)  
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Short-term studies have shown that TCI were more effective than vehicle alone in treating 
AD (NICE, 2007). There is a lack of data comparing the efficacy of TCI and TCS, but the main 
benefit of using TCI is that there are no adverse effects such as skin atrophy, and it can be 
used on thin skin (NICE, 2007). However, there have been reports of transient burning 
sensations upon application (Saeki et al., 2009). The effectiveness of TCI depends on its 
absorbency, which is related to the region of application and skin barrier status (Saeki et al., 
2009).  
The long term safety profile of TCI remains unclear. There were reports of associated 
malignancy risks with the use of TCI (NICE, 2007). However, a Europe-wide safety review 
failed to identify the causal link. Nevertheless, the United States Food and Drug 
Administration (FDA) has issued and maintained that a boxed warning be affixed on the 
labels of both tacrolimus and pimecrolimus (FDA, 2011). Due to this uncertainty of the 
safety, TCI are recommended as second-line of treatment and only for short-term or 
occasional use in patients with AD above the age of 2 years old who have been unresponsive 
to conventional treatments (Brown & Reynolds, 2006; NICE, 2007). Recently, several 
researchers, including the Canadian Society of Allergy and Clinical Immunology, have made a 
stand that the malignancy risks are negligible and that TCI should be considered when 
treating AD (Carr, 2013; Segal, Ellis, & Kim, 2013; Siegfried, Jaworski, & Hebert, 2013).  
1.5.3.3 Systemic Treatments 
There are a number of systemic treatments which have been used as part of the 
management of AD. These include, but are not limited to, antihistamines, antibiotics, 
antimycotics, antivirals, immuno-suppressive agents and biological agents.  
Antihistamines exert their action by blocking histamine receptors, thus inhibiting histamine 
from binding for a normal histamine response. They have been indicated to relieve pruritus 
in AD for decades (Ring et al., 2012a), though the NICE guidelines (2007) stated that the 
indications for antihistamine treatment were not always clear. Furthermore, studies have 
shown little or no effect of antihistamines in reducing pruritus (Ring et al., 2012a). The NICE 
guidelines noted that antihistamine could be useful, especially the use of sedating 
antihistamines when there is severe sleep disturbance, or associated urticaria with AD (NICE, 
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2007). However, long-term use is not encouraged as there may be associated alteration in 
mood and cognitive function. 
Oral antibiotics, antimycotics and antivirals are indicated in infected cases of AD. These 
interventions do not specifically benefit the skin condition unless there is substantial 
superinfection (Ring et al., 2012a). Moreover, repeated or long-term use of antibiotics 
should be avoided to prevent the development of resistance (NICE, 2007). However, upon 
the suspicion of viral infections, such as herpes simplex virus and eczema herpeticum, 
systemic aciclovir treatment should commence immediately to control the infection (NICE, 
2007). 
Systemic immuno-suppressive therapies such as systemic corticosteroids, ciclosporine, 
antimetabolites (methotrexate), azathioprine, IFN-γ, and intravenous immunoglobulins; or 
biological agents such as omalizumab, rituximab, alefacept should be introduced only if 
patients fail to respond to other therapies (NICE, 2007; Plotz & Ring, 2010). The effects of 
these treatments remain unclear with some having either conflicting or no supporting 
evidence for its use in the management of AD (Buys, 2007). Furthermore, most of these 
therapies have associated adverse effects. For example, ciclosporin may cause 
nephrotoxicity, immuno-suppression, and malignancy risks; while azathioprine is related to 
dose-dependent nausea, bone marrow toxicity and liver toxicity (Brown & Reynolds, 2006).  
While the potential effects of systemic treatments are appealing, the possibility of severe 
adverse effects discounts them as ideal forms of treatment. 
1.5.4 Other Therapies 
1.5.4.1 Coal Tar 
Coal tar has a long history in the treatment of skin diseases, including AD. While its exact 
mechanism of action remains unclear, coal tar is said to restore the expression of skin barrier 
proteins and reduce inflammation by intercepting the Th2 cytokine signalling cascade in 
keratinocytes (Varothai et al., 2013). There is, however, limited evidence of the benefits of 
coal tar for the treatment of AD and its use during acute inflammation is not recommended 
as it may induce further skin irritation (Schneider et al., 2013). 
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1.5.4.2 Dry bandages and Medicated Dressings  
A number of dressings are used in the management of AD (Table 1-10). These dressings help 
skin barrier recovery by improving the absorption of topical preparations and preventing 
further skin damage from scratching, leading to quicker healing (Schneider et al., 2013). 
 
Table 1-10: Types of dressing used in the management of AD (NICE, 2007) 
Type of dressing Description 
Dry wrap dressing Open-weave tubular bandage or crepe bandage used as a 
protective dressing to keep greasy moisturisers in place 
Wet wrapping Two layers of open-weave tubular bandage applied over topical 
preparations – the bottom layer is soaked in warm water, squeezed 
out, and then put onto skin over topical preparation; the top layer is 
dry. They can be worn under clothes. Wet wraps are available in 
bandage form or garments 
Occlusive/semi-
occlusive dressings 
Vapour-permeable films or membranes or hydrocolloid dressings. 
They can be used over topical preparations. Nappies, sleep suits 
and pyjamas may also have occlusive effects and enhance skin 
penetration of topical preparations 
Medicated bandage Cotton bandages impregnated with a variety of therapeutic 
substances such as tar or ichthammol. The bandages are usually 
applied over topical preparations in a spiralling and pleated fashion 
in the direction of venous return. A layer of self-gripping, 
elasticised, non-adhesive bandage is usually needed over the 
bandage to keep it in place. These can only be used on the limbs, 
not on the trunk or face, as they may tighten as they dry. 
 
While existing studies evaluating the effectiveness of wet wrap therapies were of poor 
quality, there have yet to be studies evaluating the effectiveness of dry, occlusive or 
medicated dressings in the management of AD (NICE, 2007). While there was no clear 
evidence of its superiority over conventional treatment, the NICE guidelines noted that wet 
wrap therapy might be beneficial in severe, uncontrolled AD accompanied by very dry skin 
which had been badly affected by scratching. However, when used over TCS, its duration 
should be limited to no more than 2 weeks, due to the increased risks of systemic adverse 
effects as a result of increased absorption. 
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1.5.4.3 Phototherapy 
Phototherapy refers to treatment using artificial UV light, such as UVA or UVB rays. The 
complete mechanism of action is still being investigated. However, it is known that 
phototherapy results in immune suppression via inducing apoptosis of inflammatory cells, 
inhibiting Langerhans cells and altering cytokine production (Ring et al., 2012b). UV radiation 
also has anti-microbial effects, anti-inflammatory effects and can help improve skin barrier.  
Generally, phototherapy is indicated in chronic, pruritic, lichenified forms of severe AD (Ring 
et al., 2012b). The NICE guidelines recommended the use of phototherapy prior to 
introducing systemic therapies, unless there are contraindications such as very fair skin or a 
family history of skin cancer (NICE, 2007). It should be noted that with all UV treatments, 
there is a long-term risk of developing skin malignancies. 
1.5.4.4 Behavioural Therapy 
Behavioural therapy can be in the form of psychological interventions or educational 
programmes. While psychological interventions are targeted at relieving the psychological or 
emotional aspects which develop a vicious cycle with AD aggravation, educational 
programmes aim to increase patient understanding of the disease to assist with coping 
behaviours, treatment adherence and compliance, as well as itch-scratching cognition (Ring 
et al., 2012b). Ring et al. (2012b) recommended that psychological and educational 
interventions be adjuvant treatments in the management of AD. 
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1.5.4.5 Complementary and Alternative Medicine 
Complementary and alternative medicine refer to a broad range of non-proven or traditional 
therapies, including homeopathy, phytotherapy, Chinese herbal medicine (CHM), 
acupuncture, massage, hypnotherapy, aromatherapy, essential fatty acids and others. 
Despite the potential benefits from some of these therapies, there is an overall lack of 
evidence to recommend their use in the management of AD. Moreover, there are 
uncertainties with regard to the safety aspects of these therapies. The NICE guidelines 
emphasised that “natural” did not equal “safe” and that further research in these therapies 
was needed (NICE, 2007). 
 
1.6 Atopic Dermatitis in Chinese Medicine 
Traditional Chinese Medicine (TCM) has been practised for thousands of years, with the 
earliest Chinese medical treatise dating back to 2698BC (Kayne, 2009).  TCM consists of 
many different therapies including CHM, acupuncture (including body, scalp, ear, hand-foot, 
and wrist-ankle, laser, magnetic and electro-acupuncture), moxibustion, cupping, 
spooning/coining (Guasha), and Chinese massage (Tuina). Furthermore, there are exercise 
therapies such as Taiji and Qigong, and also the Chinese medicine diet which focuses on the 
Yin-Yang balance of the body.  
TCM has its own unique and holistic approach to diagnosis and treatment. It takes into 
account the patient’s overall health condition, lifestyle and environment. TCM aims to treat 
the underlying cause of the disease and is also used as prevention of a disease. The use of 
TCM has been increasing worldwide for various conditions, including dermatological 
conditions (Bedi & Shenefelt, 2002).  Salameh et al. (2008) stated that “failure of 
conventional therapy” was the main reason patients turned to complementary medicine. In 
a study on the use of complementary medicine at a tertiary children’s hospital in Australia, 
up to 55% of children have tried some form of complementary medicine – of which 12% was 
herbal medicine (not including homeopathy, naturopathy and the herb, Echinacea) and 9% 
was for eczema and skin conditions (Lim, Cranswick, Skull, & South, 2005).  
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1.6.1 Aetiology and Pathogenesis 
According to TCM, AD patients have a congenitally weak constitution, resulting in a 
predisposition towards “atopic” diseases and susceptibility towards the attack of external 
pathogenic factors, such as wind, dampness and heat (D. Chen & Lu, 2007). AD can also be 
due to internal pathogenic factors – such as wind and heat generated by emotional 
disturbances; damp and heat due to either irregular diet or Spleen and Stomach deficiency – 
being lodged in the skin (D. Chen & Lu, 2007). The recurrent and chronic nature of the 
disease can injure Yin and Blood, and generate wind and dryness (D. Chen & Lu, 2007). 
Figure 1-9 summarises the possible aetiologies and pathogeneses of AD according to TCM. 
According to Yao (2008), the TCM treatment of AD via syndrome differentiation can regulate 
the allergy or atopy-prone constitution and has shown promising effects in relieving signs 
and symptoms, preventing recurrence, maintaining remission and improving QoL. 
 
 
Figure 1-9: TCM Aetiology and pathogenesis of AD (D. Chen & Lu, 2007) 
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1.6.2 Diagnosis and Treatment Principles 
The diagnosis of “atopic dermatitis” did not exist in the classical literature of TCM. According 
to the Criteria of Diagnosis and Therapeutic Effect of Diseases and Syndromes in Traditional 
Chinese Medicine published by the State Administration of Traditional Chinese Medicine of 
the People’s Republic of China (1994), the diagnosis of Si Wan Feng (四弯风) in TCM has 
been deemed equivalent to AD due to matching clinical features. 
The clinical diagnosis of Si Wan Feng (四弯风) includes extreme pruritus and skin lesions 
which are dry, rough, thickened or lichenified, with a possibility of acute or subacute 
exacerbations (State Administration of Traditional Chinese Medicine of the People's Republic 
of China, 1994). Lesions are said to occur mainly around the elbow or knee joints, but may 
occur on the calves, face and neck or around the mouth. There may be associated history of 
infantile eczema and the disease may be stubborn and recurrent. There is also a genetic 
predisposition, with a family history of asthma or urticaria. An increase in IgE and eosinophil 
levels is usually observed in patients.  
According to this set of diagnostic criteria, Si Wan Feng (四弯风) can be further 
differentiated into 2 syndromes – blood deficiency with wind dryness and wind-damp 
pathogens lodged in the skin (State Administration of Traditional Chinese Medicine of the 
People's Republic of China, 1994). The former refers to AD with dry, lichenified skin with 
itching, excoriations and blood scabs, accompanied by a bloating sensation after meals, 
constipation or loose stools, dull, swollen tongue with white coating and slippery pulse. The 
latter points to AD with erythema, intense itching, exudation and ulceration upon scratching, 
accompanied by fatigue, loose stools, dull tongue a thin greasy coating and a slippery, taut 
pulse. 
However, according to other TCM texts, there is a variation in the diagnosis and syndrome 
differentiation of AD. Other terms which may also be interpreted as AD include Shi Zhen (湿
疹/溼疹), Jin Yin Chuang (浸淫疮), Shi Chuang (湿疮), Shi Lian (湿敛), Gan Lian (干敛), Ru 
Xuan (乳癣), Nai Xuan (奶癣), Tai Xuan (胎癣) and Tai Lian Chuang (胎敛疮) (L. Li & Zhao, 
1991; L. Lin, 1995). Other syndrome differentiations of AD include damp-heat stagnation, 
Spleen and Stomach deficiency, dampness due to Spleen deficiency, foetal heat, Heart fire, 
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Heart fire with dampness, Lung heat, Spleen deficiency with dryness, wind-damp 
accumulation, wind-dryness, Yin deficiency with damp stagnation, Yin deficiency and blood 
dryness (D. Chen & Lu, 2007; L. Li & Zhao, 1991; L. Lin, 1995; Shen, Wu, & Wang, 1995).  
Apart from relieving pruritus, the TCM treatment principles of AD also correlate with the 
syndrome differentiation of the diagnosis. Generally, stagnations are removed, pathogens 
(wind, dampness, heat/fire) are expelled, deficiencies are tonified, and dryness is moistened.  
1.6.3 Treatment by Traditional Chinese Medicine 
Traditionally, the treatment of AD would include a combination of dietary and lifestyle 
advice, CHM with or without acupuncture, cupping and moxibustion. The advice and choice 
of CHM formula and acupuncture points to be applied would depend on the presentation 
and syndrome of the condition. There are several historically-used formulae for AD, with or 
without modifications, including Xiao Feng San, Long Dan Xie Gan Tang, Bi Xie Sheng Shi 
Tang, Dang Gui Yin Zi, Chu Shi Wei Ling Tang and Dao Chi San (D. Chen & Lu, 2007; L. Li & 
Zhao, 1991; L. Lin, 1995; Shen et al., 1995).   
Studies have shown that Chinese herbs possess various pharmacological properties, 
including anti-inflammatory, anti-bacterial, anti-fungal, and immuno-suppressive functions 
(Bedi & Shenefelt, 2002). Some also function as smooth muscle relaxants or inhibitors of 
platelet activating factors (Bedi & Shenefelt, 2002). Studies involving CHM for AD patients 
showed that there was decreased expression of low affinity IgE receptor (CD23) (Bedi & 
Shenefelt, 2002) and down-regulation of AD-related inflammatory mediators (T. F. Leung et 
al., 2008). One study showed that a topical Chinese herbal extract improved epidermal 
barrier function (Man et al., 2011). Studies have also shown the anti-pruritic effects of 
acupuncture treatment on histamine-induced itch (Belgrade, Solomon, & Lichter, 1984; 
Carlsson, Sundler, & Wallengren, 2006; Kesting et al., 2006; Lundeberg, Bondesson, & 
Thomas, 1987), which might be beneficial in the management of AD. 
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1.7 Research Questions 
TCM is expected to have beneficial prospects in the treatment of AD as it has its own form of 
diagnosis to enable targeted treatment. Over the years, along with its increasing popularity, 
regulations have been planned or implemented to ensure its safety (Kayne, 2010). Clinical 
and laboratory studies on Chinese medicine as stated above have highlighted the potential 
of TCM treatment. Studies have shown positive outcomes from the use of TCM in the 
treatment of AD (Harper, 1994).  
Despite the promising results, TCM has not gained the recognition it deserves. Studies have 
been deemed to be of “poor quality” and lacking evidence (Armstrong & Ernst, 1999; Hoare 
et al., 2000; Kayne, 2010). With regard to clinical trials, there were often methodological 
issues, inadequate sample sizes and low compliance with treatment. While no severe 
adverse effects were reported in most studies, there are still concerns regarding the safety 
of TCM treatments due to occasional reports of adverse events such as contact dermatitis, 
arsenic or mercury poisoning, liver toxicity and other diseases (Boneberger, Rupec, & 
Ruzicka, 2010).  
As the current state of evidence of TCM treatment of AD remains unknown, the scope of this 
thesis is focused on the Chinese medicine treatment in the management of AD. This thesis 
aims to systematically review the available modern and classical literature to evaluate the 
efficacy and safety of the TCM treatment of AD in the general population. These reviews 
contribute to a complete understanding of the current situation and provide direction for 
future studies. Using the information from the reviews, this thesis includes the development 
of a new CHM formula for the treatment of AD and a protocol for a rigorous randomised 
controlled trial (RCT) to evaluate the efficacy and safety of the new formula in the treatment 
of AD in the paediatric population.  
  
44 
 
All in all, this thesis aims to answer the following research questions: 
1. What is the existing evidence (from the modern and classical literature) of TCM as a 
potential treatment of AD? 
2. What does the classical literature of TCM say about AD? How does it compare with 
the modern literature? 
3. Is TCM a safe and efficacious form of treatment of AD? 
4. What is involved in the preparation of a rigorous RCT evaluating the efficacy and 
safety of a CHM formula in the management of AD in the paediatric population? 
5. What are the challenges and potential solutions of conducting an RCT involving CHM 
and the paediatric population? 
In order to answer these research questions, this thesis includes the following chapters: 
Chapter 1 provides a complete literature review of the background of AD, including its 
epidemiological and prevalence, impact, diagnosis, aetiology and pathogenesis. This chapter 
also briefly describes the current AD managements, and AD according to TCM. 
Chapter 2 provides the general methodology of the comprehensive and SRs of the classical 
and modern literature. The subsections include search strategies, criteria for identifying 
studies, quality assessment and data analysis methods. 
Chapters 3, 4, 5 and 6 present the results of the SR of the TCM classical literature on the 
TCM nomenclature and treatments of AD-like conditions, the comprehensive review of TCM 
treatments of AD, the SR of CHM treatment of AD, and the SR of acupuncture treatment of 
AD, respectively. 
Chapter 7 presents a protocol for a rigorous RCT to evaluate the safety and efficacy of a 
newly-developed CHM formula in the management of AD in the paediatric population. The 
chapter includes the development of a new CHM formula, and other details of the RCT such 
as sample size calculation, trial design procedures, human ethics application, and budget 
calculations.  
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Chapter 8 focuses on the challenges that were encountered during the preparation of the 
RCT and how they were overcome. The challenges and limitations highlighted in this chapter 
provide direction for future studies. 
Chapter 9, the final chapter, discusses the strengths and limitations of the overall project. It 
summarises the findings of the project and provides recommendations for future research 
and clinical practice.  
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 General Methodology of Systematic Reviews Chapter 2
2.1 Introduction 
Systematic reviews critically evaluate and summarise the vast available research evidence 
within the scope of a particular research question by applying systematic methods to select 
studies which suit a pre-determined eligibility criteria. Assessments to appraise data validity 
and reduce bias of the data and results of included studies are carried out to provide more 
reliable findings and conclusions in relation to the research question (Higgins & Green, 
2011).  SRs of high-quality RCTs are essential to evidence-based healthcare.  
Since its establishment in 1993, the Cochrane collaboration – the world leader in evidence-
based healthcare, has strived to assist in making well-informed healthcare decisions via 
Cochrane reviews. Cochrane reviews are currently considered the highest quality SRs of the 
best available research evidence. Aside from gathering evidence to enable making informed 
healthcare decisions, SRs outlines the overall quality of current research and highlights flaws 
in the literature to enable improvements to be made in future studies. 
In this thesis, SRs of the TCM classical literature as well as a comprehensive review of the 
modern literature on the Chinese medicine treatments of AD were conducted. In addition, 
two SRs – 1 evaluating the efficacy and safety of orally-administered CHM in the 
management of AD and the other evaluating acupuncture as the treatment intervention – 
were also included.  
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The aims of the comprehensive review and SRs were: 
1. To identify the available historical and current evidence of TCM treatments of AD 
2. To enable comparison between historical and current evidence of TCM treatments of 
AD 
3. To identify the limitations of the available evidence, especially in relation to 
published RCTs of TCM managements of AD 
4. To assist the formulation and RCT design of a new Chinese medicine formula in the 
management of AD 
5. To evaluate the efficacy and safety of: 
a. Orally-administered CHM in comparison to control interventions (placebo 
and/or non-TCM treatments) or no treatment 
b. Acupuncture in comparison to control interventions (placebo acupuncture 
and/or non-TCM treatments) or no treatment 
 
2.2 Systematic Review of Classical Literature 
For the SR of classical literature, the methodology applied was adapted from a study that 
evaluated the TCM classical literature for herbal treatment of age-related dementia and 
memory impairment by May and colleagues (2012). 
2.2.1 Search Strategies 
The search of the TCM classical literature was carried out through a TCM classical literature 
database software known as Zhong Hua Yi Dian (ZHYD) (中华医典) (Figure 2-1) 
([Encyclopedia of Traditional Chinese Medicine], 2000). As the terminologies used in the 
classical literature differed from the naming of diseases used today, it was incumbent to 
identify the terminologies used in the classical literature which could possibly refer to the 
disease AD. All identified search terms were run in the search engine of ZHYD. As the ZHYD 
search engine allowed a basic search with only one term at a time, there would be no 
discrepancies in search results and so only one researcher conducted the search.  
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Figure 2-1: Zhong Hua Yi Dian database software ([Encyclopedia of Traditional Chinese 
Medicine], 2000) 
 
2.2.1.1 Identification of Search Terms 
Current TCM dermatology textbooks, bilingual TCM dermatology textbooks and Chinese 
language dictionaries were searched for disease names and descriptions. The TCM 
dermatology textbooks that were used as sources included: 
 The English-Chinese encyclopaedia of practical traditional Chinese medicine (Xu, 
1991) 
 Practical Traditional Chinese Dermatology (L. Lin, 1995) 
 Manual of Dermatology in Chinese Medicine (Shen et al., 1995) 
 Western Names for Chinese Disease Classes (Hsu, 1990) 
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The Chinese language dictionaries that were searched included: 
 "Explaining Simple and Analysing Compound Characters" (Shuo Wen Jie Zi 说文解字) 
 Encyclopaedia Dictionary (Ci Hai 辞海) 
 Chinese Medical Dictionary (Zhong Yi Zi Dian 中医字典) 
 Comprehensive Chinese Medical Dictionary (Zhong Yi Da Ci Dian 中医大辞典)  
The above-listed TCM dermatology textbooks were first examined. TCM dermatological 
disease names and their respective characteristics were extracted into a spread sheet on 
Microsoft Excel. Disease names which matched the description of AD presentation as 
described in the Hanifin and Rajka Criteria (Hanifin & Rajka, 1980) or UK Diagnostic Criteria 
(Williams et al., 1994) and ambiguous terms (e.g. various Chinese characters referring to 
“rash”) were checked in the above-listed dictionaries to confirm their actual meaning and 
subsequent inclusion/exclusion as a search term. Disease characteristics extracted from the 
textbooks were used to assist in the identification of distinct AD and non-AD characteristics. 
Terms which matched the following inclusion criteria were used as search terms: 
 Terms which were disease names that have been directly translated as 
eczema/dermatitis 
 Terms which referred to diseases of an itchy rash  
However, terms were excluded if they had one or more of the following exclusion criteria: 
 Terms which were disease names that have been distinctly translated as a disease 
other than AD (e.g. acne, herpes simplex) 
 Terms which referred to a TCM syndrome 
 Terms which referred to a particular sign or symptom 
 Terms which referred to diseases that are due to a particular cause (e.g. parasites) or 
affecting only a particular part of the body (e.g. hand dermatitis) 
 Terms which referred to diseases with identifying characteristics of diseases other 
than AD (e.g. wheals, neuralgia, sebum plug) 
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2.2.2 Data Extraction and Management 
From the search in ZHYD, citations containing the search terms in their title or body text 
were extracted into a Microsoft Excel spread sheet, together with the source book title, 
chapter, year and dynasty. Duplicates were identified using the filter function in Microsoft 
Excel.  
After the removal of duplicates, each citation was screened and oddities were excluded. 
Oddities referred to citations which only had a passing mention of the search term or 
citations in which the search term was a coincident grouping of the same Chinese characters 
that did not refer to a dermatological lesion/disease. Data of disease pathogeneses, signs 
and symptoms, treatment principles and treatments from the remaining citations were 
extracted into separate columns on the Excel sheet. A coding system was established for 
book source, dynasty, treatment type and individual herb and a scoring system was 
developed for each sign and symptom to enable data analysis. A code was also assigned to 
other reasons for exclusion. Extraction and coding was conducted by one reviewer (HYT) and 
a random sample of the included citations was then checked by a second reviewer (JT) to 
ensure that the data extraction and coding was accurate and appropriate. 
2.2.2.1 Data coding and scoring system 
The presence of the coding system enabled analysis to be conducted using the Statistical 
Package for the Social Sciences (SPSS) software, Windows Version 21.0. Each search term, 
book title, chapter, year and dynasty, treatment type and herb was assigned a unique code. 
As for the scoring system of signs and symptoms, a column in the Excel sheet was created for 
each AD characteristic. As mentioned in Chapter 1.4.1, there is a lack of uniformity among 
the diagnosis criteria of AD. Therefore, a wide list of diagnostic criteria (refer to Table 1-4) 
was consulted during the formation of the coding system for the data of this study. The 
scoring system of signs and symptoms focused on clinical signs and symptoms only. Criteria 
involving investigative tests were not considered as they would not have been mentioned in 
the classical literature. Subsequent new columns were added for each additional sign or 
symptom mentioned in the citations. Generally, each sign or symptom was given a score of 
“0” if it was not mentioned in the disease description in the citation; “1” if it was not a 
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characteristic of the disease; and “2” if it was a positive characteristic of the disease. When 
necessary, the scoring for particular signs/symptoms was modified depending on the 
reported details.  
2.2.3 Data Analysis 
After data extraction, coding and scoring was completed on the Excel sheet, a transcript 
sheet was made to enable the transfer of data into SPSS for analysis. In SPSS, an initial 
frequency analysis of all data was conducted to double-check accuracy of data entry and 
identified mistakes were corrected. Analysis was conducted with regard to 2 main aspects: 
1) description of the search term diseases; and 2) TCM treatment for the search term 
diseases. Frequency analysis of disease characteristics was used to pinpoint filters to be 
applied to identify citations which were most likely referring to the treatment of AD or AD-
like rash. 
2.2.3.1 Description of Search Term  
The timeline of appearance of search terms and, where possible, the earliest recorded 
description of each search term and any discrepancies in later descriptions were tabulated 
for qualitative analysis. For each included citation, the major signs or symptoms of AD and 
distinct non-AD characteristics were analysed for frequency of appearance. Crosstab analysis 
was then conducted between these characteristics and each search term. The results of the 
crosstab analysis, combined with the qualitative analysis of search terms, were used to 
identify the likelihood of the search terms referring to AD. 
2.2.3.2 TCM Treatment 
All forms of TCM treatments for the AD-like conditions were included for analysis. Filters 
were then applied against the data set to identify TCM treatments which were used for AD 
or AD-like conditions. 
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2.3 Systematic Reviews of Modern Literature 
The methodology for the comprehensive and SRs was guided by the Cochrane Handbook for 
Systematic Reviews and Interventions (Higgins & Green, 2011). Its reporting was with 
reference to the Preferred Reporting Items for Systematic Reviews and Meta-analyses 
(PRISMA) statement (Liberati et al., 2009). 
2.3.1 Search Strategies for Identification of Studies 
Studies to be reviewed were identified via electronic searching of online databases. “Atopic 
dermatitis” or “atopic eczema”, “human studies”, “Chinese herbal medicine”, 
“acupuncture”, “acupressure”, “cutaneous needling”, “moxibustion”, “cupping”, 
“bloodletting”, “Taiji”, “Tuina”, “Guasha” and “Chinese diet” were used as search terms. 
Separate searches were conducted for each of the TCM treatment modality listed above. All 
databases were searched from their inception until October 2013. The searches were carried 
out by 2 researchers (HYT and JT) using the same protocol on 8 major databases (6 English 
databases; 2 Chinese databases (Table 2-1). Hits returned from the electronic searching were 
exported and combined into one EndNote X6 file. The “Find Duplicates” command in 
EndNote X6 was used to remove identical references; identical references which were not 
picked out through this command were removed during further screening processes. Titles 
and abstracts (where available) were screened by 2 independent researchers (HYT and JK) to 
identify studies which met the inclusion criteria. Any discrepancies between the two 
researchers were resolved via discussion. Full articles of included references were then 
screened to be assessed for eligibility to be included for qualitative and quantitative analysis.  
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Table 2-1: List of databases for SR Searching 
Language of Database Database 
English Database PubMed  
Embase  
Cochrane Library 
Cumulative Index to Nursing and Allied Health Literature (CINAHL) 
Web of Science 
Allied and Complementary Medicine Database (AMED) 
Chinese Database VIP Database for Chinese Technical Periodicals (CQVIP) 
China National Knowledge Infrastructure  (CNKI) 
 
2.3.2 Criteria for Considering Studies for Reviews 
2.3.2.1 Language of Studies 
Studies published in English, Chinese, Japanese, French and Spanish were included in the 
reviews. 
2.3.2.2 Types of Studies 
All RCTs – regardless of blinding – using any TCM treatment for AD on humans were included 
in the comprehensive review. RCTs that were of oral CHM or acupuncture were marked to 
be included in their respective SRs. Studies which involved only animals or laboratory studies 
were excluded. 
2.3.2.3 Types of Participants 
All participants diagnosed with AD or AE were included in the comprehensive review. There 
was no limit to age, gender or ethnicity of participants. Studies which used the general term 
“eczema” – including “acute eczema”, “subacute eczema”, or “chronic eczema” – were 
accepted only when referring to paediatric cases. Studies on adults which did not specify 
eczema or dermatitis of atopic type or studies which encompassed location-specific 
dermatitis (e.g. nipple dermatitis, hand eczema) or other forms of dermatitis/eczema (e.g. 
neurodermatitis, nummular/discoid dermatitis) were excluded. For both SRs, only 
participants diagnosed with validated diagnostic criteria, such as the Hanifin and Rajka 
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definition or the UK refinement, or other referenced diagnostic criteria (in cases of 
paediatric eczema) were included. 
2.3.2.4 Interventions 
For the comprehensive review, studies involving any form of TCM treatment, including 
topical or oral CHM, acupuncture, acupressure, cutaneous needling, moxibustion, cupping, 
bloodletting, Taiji, Tuina, Guasha, or Chinese medicine diet therapy, alone or in combination 
with other treatments, were included. Treatments with specific compounds of a Chinese 
herb (e.g. injection of glycyrrhizin, a compound of Gan Cao) were not considered as a form 
of TCM treatment and were excluded from the reviews. 
Studies involving oral CHM or acupuncture were included in the respective SRs. Co-
interventions and concurrent treatments were included in the SRs only if they were non-
TCM interventions and were applied to all treatment groups.  
All forms of control intervention were accepted for studies included in the comprehensive 
review. However, only studies which used placebo, non-TCM treatments or no treatment as 
control interventions were included in both SRs. 
2.3.2.5 Outcome Measures 
Any clinically-relevant outcome measure was accepted for the comprehensive review; 
however, only scoring systems for disease/symptom severity or QoL were accepted for the 
two SRs. Concurrent therapies, adverse events and safety profiles were recorded as 
secondary outcome measures in both SRs. Studies with incomplete reporting of scores or 
studies which reported only physiological or laboratory parameters as outcome measures 
were excluded from the SRs.  
2.3.3 Data Extraction 
Information on participants, study design, interventions, outcome measures and results 
were extracted. One reviewer (HYT) extracted the data of included studies onto the 
Cochrane Skin Group data extraction form; a second reviewer (JT) checked the extraction. 
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Any discrepancies between the 2 reviewers were resolved via discussion. Extracted data 
were presented in separate tables. 
2.3.4 Quality Assessment  
Quality assessment was conducted only in the two SRs. The quality of included studies was 
evaluated using the Cochrane Collaboration’s tool for assessing risk of bias (Higgins & Green, 
2011) which rated a low, high or unclear risk in 6 domains – random sequence generation, 
allocation concealment, blinding of participants and personnel, blinding of outcome 
assessment, incomplete outcome data and selective reporting. Evaluation of the quality of 
reporting was conducted using the Consolidated Standards of Reporting Trials (CONSORT) 
2010 statement (Schulz, Altman, & Moher, 2010), along with the relative extensions for 
herbal interventions (Gagnier et al., 2006) and the Standards for Reporting Interventions in 
Clinical Trials of Acupuncture (STRICTA) (MacPherson et al., 2010) for each of the respective 
SRs. The CONSORT 2010 statement consists of a 25-item checklist used to appraise the 
quality of reporting and to enable the assessment of the validity of the results of a RCT. The 
quality of acupuncture administered in the included studies of the SR for acupuncture was 
also evaluated using an instrument developed via the Delphi consensus process (Smith et al., 
2011). 
2.3.5 Data Analysis 
Meta-analysis was conducted only in the two SRs, where possible, using the Cochrane’s 
software, Review Manager 5.2 (RevMan 5.2). Where there were missing data, authors of the 
studies were contacted via email to request for the raw data. With regard to meta-analysis, 
when there were multiple intervention groups, relevant groups were combined using the 
formulae for combining groups (Table 2-2) in the Cochrane Handbook to create a single pair-
wise comparison (Higgins & Green, 2011).  
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Table 2-2: Formulae for combining groups (Higgins & Green, 2011) 
  Group 1 Group 2 Combined groups 
Sample size N1 N2 N1 + N2 
Mean M1 M2 
 
Standard 
deviation 
(SD) 
SD1 SD2 
 
  
A random-effects model was used if there was significant heterogeneity among the trials, as 
detected by the I2 statistic (I2 ≥ 50%); a fixed-effects model was used when heterogeneity 
was less than 50% (I2 ≤ 50%). For continuous data, the mean difference (MD) was calculated 
when the same scale was used for one outcome measure; while the standard mean 
difference (SMD) was calculated if different numerical scales were calculated. The results of 
meta-analyses were presented in forest plots. While meta-analysis is not required when 
there is only one study involved, results will still be presented in forest plots for ease of 
comprehension.  
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 Systematic Review of Classical Literature of Atopic Dermatitis Chapter 3
3.1 Introduction 
Traditional Chinese medicine had its origins in early as 100BC when the first definitive 
version of Chinese medical Treatise, Huang Di Nei Jing, appeared (Kayne, 2009). Since then, 
its principles and theoretical systems have developed over the various dynasties (B. Zhu & 
Wang, 2011). SRs have been concentrated on “research-based evidence” to answer specific 
research questions (Higgins & Green, 2011). However, when the research questions involved 
historical medical systems such as TCM, the historical aspects should also be considered. The 
classical literature of TCM contains invaluable information on principles and treatment 
methods which have been tested over time. Although lacking in scientific or research-based 
evidence, the experiences of the experts who developed the system and contributed to the 
survival of TCM over the years were well recorded in these classics. Previously, there had 
been 1 review of the classical literature on the TCM treatments of AD (C. Huang, Cai, et al., 
2011). However, it was published only in the Chinese literature and its scope was limited to 
particular classical books from ZHYD which were considered by experts to be of clinical 
importance to AD. For a more complete evaluation, as well as to assist in the formulation of 
a new CHM formula for AD, this SR, which included all books in ZHYD, was conducted.  
 
3.2 Objectives 
Through reviewing the classical literature for TCM treatments of AD, this review aimed to: 
1. Identify historical evidence of TCM treatments for AD or conditions with similar 
descriptions to AD; 
2. Analyse the herbal components of formulae used and their principles of application 
3. Allow the comparison between historical and current Chinese medicine treatments 
for AD or conditions with similar descriptions to AD; 
4. Combine results from the SR of classical literature review with those of the modern 
literature to assist in the formulation of a herbal formula for AD. 
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3.3 Methods  
The methodology utilised for this review is described in Chapter 2.2. 
3.3.1 Search Terms for Identification of Citations 
From the TCM dermatology textbooks and Chinese language dictionaries, a total of 17 terms 
were used as search terms for the identification of citations in ZHYD. The search terms and 
their literal translations are listed in Table 3-1. 
3.3.2 Data Codes and Scoring of Search Term Characteristics 
Codes were given for the following details for each citation: 
 Citation identification code 
 Other reasons for exclusion 
o Duplicate herb in the same formula 
o Search term was part of a TCM syndrome  
o Search term was part of another disease name 
o Search term was describing rash of another disease 
o Search term was describing a location-specific rash  
 Dynasty of book source 
 Treatment type 
 Chinese herb 
 Search term used to identify the citation 
With regard to the scoring of characteristics, the complete decision log for the scoring of 
signs and symptoms is listed in Appendix 1. 
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Table 3-1: Classical literature review search terms 
Search term Chinese characters 
of search term 
Literal translations Reason for inclusion 
Shi Zhen  湿疹 Damp papule Current Chinese term equivalent to “eczema” 
Jin Yin Chuang 浸淫疮 Immersed sore Noted to be synonymous with “eczema” 
Shi Chuang 湿疮 Damp sore Noted to be synonymous with “eczema” 
Si Wan Feng 四弯风 Four bend wind Noted to be synonymous with “eczema” or “atopic dermatitis”  
Te Ying Xing Pi Yan 特应性皮炎 Atopic dermatitis Current Chinese term for “atopic dermatitis” 
Te Ying Xing Shi Zhen 特应性湿疹 Atopic eczema Current Chinese term for “atopic eczema” 
Shi Du Chuang 湿毒疮 Damp toxin sore Noted to be synonymous with “eczema (on the lower limbs)”  
Shi Qi Chuang 湿气疮 Damp Qi sore Noted to be synonymous with “eczema (on the lower limbs)” 
Tai Lian Chuang 胎敛疮 Foetal accumulation sore Synonym of Nai Xuan(奶癣) 
Nai Xuan 奶癣 Milk tinea/ dry ulcer Noted to be synonymous with “infantile eczema”; may refer to nipple 
dermatitis 
Shi Lian 湿敛 Damp accumulation May refer to a syndrome differentiation of Nai Xuan (奶癣); may also be 
synonymous with Tai Lian Chuang (胎敛疮) 
Gan Lian 干敛 Dry accumulation May refer to a syndrome differentiation of Nai Xuan (奶癣); may also be 
synonymous with Tai Lian Chuang (胎敛疮) 
Shi Zhen 溼疹 Damp papule Same as Shi Zhen (湿疹) (in traditional Chinese characters) 
Shi Xuan 湿癣 Damp tinea/dry ulcer Noted to be synonymous with “acute eczema” 
Tai Xuan 胎癣 Foetal tinea/dry ulcer Noted to be synonymous with Nai Xuan (奶癣) or “infantile eczema” 
Ru Xuan 乳癣 Milk/Nipple tinea/dry 
ulcer 
Noted to be synonymous with Nai Xuan (奶癣) or “infantile eczema”; may 
refer to nipple dermatitis 
Gan Xuan 干癣 Dry tinea/dry ulcer Noted to be synonymous with “chronic eczema” or “neurodermatitis”; 
current Chinese term equivalent to “psoriasis” or “tinea” 
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3.4 Results 
3.4.1 Identification of Citations 
A total of 999 citations were retrieved from the searches. One hundred and ninety-three 
overlapping duplicates and 68 oddities were excluded from analysis. The search terms, Te 
Ying Xing Pi Yan (特应性皮炎), Te Ying Xing Shi Zhen (特应性湿疹), Tai Lian Chuang (胎敛疮
) and Shi Zhen (溼疹), which yielded no citations, were excluded from further analysis. The 
former 2 terms are modern-day translations of AD and AE, respectively, and were unlikely to 
be found in ZHYD. However, they were included as search terms for the sake of confirmation. 
The term Tai Lian Chuang (胎敛疮) had been noted to be synonymous with infantile eczema; 
while Shi Zhen (溼疹) were the traditional Chinese characters used in the Encyclopaedia 
Dictionary (Ci Hai 辞海) instead of Shi Zhen (湿疹). 
From the remaining 738 citations, there were none for the search term, Gan Lian (干敛), and 
so the term was also excluded from further analysis. With regard to TCM treatment, 86 
citations identified a total of 27 individual herbs being used in the treatment of the AD-like 
skin diseases while 601 citations mentioned the use of various CHM formulae treatments. 
There were also 2 citations mentioning acupuncture treatment, 12 citations of moxibustion 
treatment and 7 citations with treatments by bloodletting. The breakdown of identified 
citations according to search term is presented in Table 3-2.   
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Table 3-2: Overview of citations from search terms 
Search term Citations 
identified 
from 
search 
Citations 
after removal 
of duplicates 
and oddities 
Citations with 
individual herb 
Citations with 
CHM 
formula(e) 
Citations with other treatments  
 
     Acupuncture Moxibustion Bloodletting 
Shi Zhen 湿疹 5 2 0 1 0 0 0 
Jin Yin Chuang 浸淫疮 163 140 8 106 0 0 0 
Shi Chuang 湿疮 403 350 43 300 2 4 0 
Si Wan Feng 四弯风 12 7 0 7 0 0 0 
Te Ying Xing Pi Yan特应性皮炎 0 0 0 0 0 0 0 
Te  Ying Xing Shi Zhen 特应性湿疹 0 0 0 0 0 0 0 
Shi Du Chuang 湿毒疮 24 18 2 16 0 0 0 
Shi Qi Chuang 湿气疮 2 2 0 2 0 0 0 
Tai Lian Chuang 胎敛疮 0 0 0 0 0 0 0 
Nai Xuan 奶癣 36 31 0 25 0 1 0 
Shi Lian 湿敛 6 1 1 0 0 0 0 
Gan Lian 干敛 6 0 0 0 0 0 0 
Shi Zhen 溼疹 0 0 0 0 0 0 0 
Shi Xuan 湿癣 230 212 31 167 0 3 7 
Tai Xuan 胎癣 8 7 1 5 0 0 0 
Ru Xuan 乳癣 26 24 0 24 0 0 0 
Gan Xuan 干癣 78 71 2 73 0 4 0 
Total  999 865* 88* 726* 2 12* 7 
*One citation may contain more than one search term – the actual number of citations after removal of duplicates and oddities is 738 and the 
number of citations with individual herbs, CHM formula and moxibustion, is 86, 601 and 10, respectively.
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3.5 Data Analysis 
Frequency analysis of search term characteristics was conducted for all 738 citations which 
were transferred to SPSS. All signs and symptoms which had frequency percentages of more 
than 0% are presented in Figure 3-1. From the initial frequency analysis, it was shown that a 
total of 52 characteristics were mentioned from the 738 citations. Among the 52 
characteristics, 21 characteristics (11 AD characteristics and 10 non-AD characteristics) could 
be used to assist the differential diagnosis of AD.  
As mentioned in Chapter 2.2.3, the frequency analysis of characteristics guided the choice of 
filters to be applied in order to identify citations which were most likely referring to the 
treatment of AD. As the general frequency percentages of characteristics were low, only 
“itching” was used as a filter.  
3.5.1 Search Terms 
As mentioned above, 5 search terms were excluded, leaving a total of 12 search terms 
included for analysis. Table 3-3 summarises the dynasties of use and descriptions of each 
search term. 
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Figure 3-1: Frequency analysis of search term characteristics 
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Table 3-3: Dynasties and descriptions of search terms 
Search term 
(Chinese 
character) 
Dynasty (Year) Description  
Shi Zhen (湿疹) Qing (1644-1911) “Shi Zhen is white without red spots” (Yi Shu 医述, 1817). Limited description as a condition; the term in citations 
were mostly passing mention in the prevention of Mei Du (梅毒), which may be translated as syphilis. 
Jin Yin Chuang 
(浸淫疮) 
Pre-Tang (before 
618) – Min Guo 
(1912-1949)  
“Jin Yin Chuang that occurs from the mouth spreading to the limbs can be treated. But if it occurs from the limbs 
spreading to the mouth, it is untreatable. May cause fatality if the disease enters the body” (Jin Gui Yao Lue Fang 
Lun 金匮要略方论, 206). Fatality or severe pain was mentioned in most descriptions of Jin Yin Chuang. Some 
descriptions also mentioned that the lesions “circles around the body”.  
Shi Chuang 
(湿疮) 
Pre-Tang (before 
618) – Modern 
(after 1949) 
No good description of Shi Chuang as a disease. The term usually refers to general exudative rash, exudative 
lesions of other dermatological conditions or lesions due to dampness (Shi 湿) and other pathogens according to 
TCM theory. Earliest citation with the term was from Zhu Bing Yuan Hou Lun (诸病源候论), 610. However, the 
term in the citation was referring to Gan Shi Chuang (疳湿疮) which mentioned rashes related to weakness and 
parasites in the stomach/intestines. 
Si Wan Feng 
(四弯风) 
Qing (1644-1911) 
– Min Guo (1912-
1949) 
“Itchy rash that occurs in the creases of the legs (knees and ankles)” (Wai Ke Da Cheng 外科大成, 1665). 
Shi Du Chuang 
(湿毒疮) 
Ming (1368-1644) 
– Min Guo (1912-
1949) 
“Shi Du Chuang, also known as Xia Zhu Chuang (下注疮), are chronic and exudative lesions that occur around the 
knee creases” (Zheng Zhi Zhun Sheng: Yang Yi 证治准绳·疡医, 1602). 
“Lesions that are caused by damp toxins and occurs around the shins, heels, ankles and feet” (Wai Ke Qi Xuan 外
科启玄, 1604) 
Shi Qi Chuang 
(湿气疮) 
 
 
Qing (1644-1911) No description of Shi Qi Chuang as a disease. The term in the citation was referring to “wind-cold-damp lesions” 
(Feng Han Shi Qi Chuang 风寒湿气疮). 
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Nai Xuan (奶癣) Song-Jin (960-
1279) – Min Guo 
(1912-1949) 
In Sheng Ji Zong Lu (圣济总录，1117) Nai Xuan was said to be caused by “wind-heat in the children’s body, 
combined with weak Spleen and Lung function or damp pathogens in the skin, causing stagnation of Qi and 
Blood and the skin to thicken to appear as Xuan. The lesion may be bevelled or round, gradually growing. The 
rash reduces in the cold but itches with warmth; yellow exudation is present upon scratching. It can occur on the 
face, with scabbing or dry skin. The condition is due to drinking (breast) milk and lesions grow on areas which 
come in contact with breast milk. Treat by washing with breast milk” 
In Wai Ke Qi Xuan (外科启玄),1604, the term in the citation referred to Shi Nai Xuan (湿奶癣), which was 
described as a type of Bai Ke Chuang (白壳疮, literally translates as “white shelled ulcer”) caused by the 
consumption of “damp milk” (Shi Nai 湿奶) and can lead to parasitic growth in chronic phases. 
 “Nai Xuan is an itchy, bleeding, exudative, painful rash that occurs in infants/children” (Wai Ke Zheng Zong 外科
正宗, 1617). Wu Shi Yi Fang (吴氏医方), 1823, adds that it is due to foetal heat acquired from parents.  
Yang Yi Da Quan (疡医大全), 1760, had two descriptions – one stating that the rash “starts at the extremities 
and spreads to the back, and is chronic and recurrent” and another stating that the rash “occurs on the vertex or 
eyebrow edges with white scaling upon scratching”. 
Shi Lian (湿敛) Qing (1644-1911) No description of Shi Lian as a disease.  
Shi Xuan (湿癣) Pre-Tang (before 
618) – Min Guo 
(1912-1949) 
Earliest description found in Zhu Bing Yuan Hou Lun (诸病源候论), 610. Shi Xuan and Gan Xuan respectively 
referred to exudative or dry Xuan. Xuan was described to be related to the presence of insects/parasites. Lesions 
have been described to have distinct margins and be coin-shaped or have the appearance of insects crawling. 
Tai Xuan 
(胎癣) 
Song-Jin (960-
1279) – Qing 
(1644-1911) 
“Tai Xuan are childhood rash caused by wind stagnation in Lung, due to parents, Lung disharmony, or failure to 
avoid wind-cold attack” (You You Xin Shu 幼幼新书, 1150). No description of rash presentation.  
“Rash which occurs on the heads of children and spreads upon scratching” (Pu Ji Fang 普济方, 1406) 
“More commonly known as Nai Xuan. Itching and exudative rash which occurs on the head and face; or at the 
eyebrow edges of babies and may spread to the whole body.” (Wai Ke Zheng Zhi Quan Shu 外科证治全书, 1831) 
Ru Xuan 
(乳癣) 
Pre-Tang (before 
618) – Min Guo 
(1912-1949) 
Records from 610 up to 1902 mostly indicated that Ru Xuan is a form on infantile eczema due to breast milk 
contact with skin. However, records from Wen Tang Ji Yan Fang (文堂集验方), 1775, Ji Jiu Guang Sheng Ji (急救
广生集), 1803, Chen Shen Tian Wai Ke Fang An (陈莘田外科方案), 1892 and Wai Ke Fang Wai Qi Fang (外科方
外奇方), 1893, described Ru Xuan as “nipple eczema”. Records from 1911 and 1917 mentioned Ru Xuan without 
disease descriptions, making it unclear if it was referring to infantile or nipple eczema. 
Gan Xuan 
(干癣) 
Pre-Tang (before 
618) – Min Guo 
(1912-1949) 
Earliest description found in Zhu Bing Yuan Hou Lun (诸病源候论), 610. Shi Xuan and Gan Xuan respectively 
referred to exudative or dry Xuan. Xuan was described to be related to the presence of insects/parasites. Lesions 
have been described to have “white crust” and have the appearance of insects crawling. 
66 
 
As mentioned above, 21 out of the 52 characteristics could be used in the differential 
diagnosis of AD and were therefore applied in the crosstab analyses of each search term. 
The crosstab analyses showed that there were no disease characteristics mentioned for Shi 
Zhen (湿疹), Shi Qi Chuang (湿气疮) and Shi Lian (湿敛). Considering that there were only 1 
or 2 citations identified for each of these 3 search terms with minimal or no description, it is 
unlikely that they were used in the classical literature to refer to AD-like conditions. 
The analyses of characteristics of Jin Yin Chuang (浸淫疮), Shi Chuang (湿疮), Si Wan Feng 
(四弯风), Shi Du Chuang (湿毒疮), Nai Xuan (奶癣), Shi Xuan (湿癣), Tai Xuan (胎癣), Ru 
Xuan (乳癣) and Gan Xuan (干癣) are discussed in the following subsections. 
3.5.1.1 Jin Yin Chuang (浸淫疮) 
The term Jin Yin Chuang (浸淫疮) literally translates as “spreading sore” (L. Lin, 1995) and 
has been used since the pre-Tang Dynasty (before 618). In current textbooks, the term can 
still be found to describe general eczema (L. Li & Zhao, 1991; L. Lin, 1995). The term, 
however, is not found in the Criteria of Diagnosis and Therapeutic Effect of Diseases and 
Syndromes in Traditional Chinese Medicine (State Administration of Traditional Chinese 
Medicine of the People's Republic of China, 1994). 
The crosstab analysis of the characteristics of Jin Yin Chuang (浸淫疮) (Figure 3-2) showed a 
fairly high relation to the AD characteristics of itching, chronicity or recurrence, and 
childhood onset, with a very small percentage describing the presence of a history of rash. 
However, there was also a fairly high relation to pain and fever, which were not 
characteristic of AD.  
The description of lesion distribution along the limbs and mouth with fever proposed the 
possibility of the term referring to hand, foot and mouth disease; while the description of 
the lesions circling the body, with severe pain, suggested the possibility of the term referring 
to herpes zoster (Burge & Wallis, 2010).  
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Figure 3-2: Crosstab analysis of the characteristics of Jin Yin Chuang (浸淫疮) 
 
3.5.1.2 Shi Chuang (湿疮) 
The term Shi Chuang (湿疮) literally translates as “wet sores”. The term has been used since 
the pre-Tang Dynasty (before 618) and is still used today. In the Criteria of Diagnosis and 
Therapeutic Effect of Diseases and Syndromes in Traditional Chinese Medicine (State 
Administration of Traditional Chinese Medicine of the People's Republic of China, 1994), the 
term is said to be synonymous with Shi Zhen (湿疹), the modern Chinese term for eczema. 
However, it is not said to be synonymous with the modern Chinese term for AD, Te Ying Xing 
Pi Yan (特应性皮炎).  
The crosstab analysis of Shi Chuang (湿疮) (Figure 3-3) showed that while there were several 
AD-like characteristics describing the term, there were also a number of non-AD-like 
characteristics, with pain being the characteristic that stood out.  
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From the descriptions of Shi Chuang (湿疮) in the citations, more often than not, the term 
referred to its literal meaning of exudative lesions, on its own or under the heading of 
another dermatological condition; on occasion, the term was also used in combination with 
other Chinese terms as a name of another condition or to describe the TCM syndrome of 
lesions. It is probable that the term had always been used to describe general exudative 
lesions, which eventually led to its current status as a synonym of the term for “eczema”.  
 
 
Figure 3-3: Crosstab analysis of the characteristics of Shi Chuang (湿疮) 
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3.5.1.3 Si Wan Feng (四弯风) 
The term Si Wan Feng (四弯风) literally translates as “four bend wind” and is relatively new, 
with the earliest records dating back to the Qing Dynasty (1644-1911). According to the 
description in Wai Ke Da Cheng (外科大成), 1665, the term referred to an itchy rash which 
occurs in the “four bends” – the folds of the knees and ankles. Although the distribution 
mentioned the involvement of only the lower limbs, this was the only term which mentioned 
specific distribution around joint creases, matching one of the key diagnostic criteria for AD. 
As mentioned in chapter 1.6.2, Si Wan Feng (四弯风) is noted to be synonymous with AD in 
the Criteria of Diagnosis and Therapeutic Effect of Diseases and Syndromes in Traditional 
Chinese Medicine (State Administration of Traditional Chinese Medicine of the People's 
Republic of China, 1994). 
According to the crosstab analysis of the characteristics of Si Wan Feng (四弯风) (Figure 3.4), 
the term was related to the characteristics of itching, chronicity and related hand/foot 
dermatitis. It should be noted that the relation to hand/foot dermatitis in the frequency 
analysis was due to its description of distribution about the bends of the ankles, and that 
there was no specific mention of hand dermatitis. Also, the null percentage of other 
characteristics in Figure 3-4 did not mean that they were not present in Si Wan Feng (四弯
风); rather, none of those characteristics were mentioned in the citations. Furthermore, 
there were only 7 citations which were identified with the search term, Si Wan Feng (四弯
风), from which the limited information was extracted.  
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Figure 3-4: Crosstab analysis of the characteristics of Si Wan Feng (四弯风) 
 
3.5.1.4 Shi Du Chuang (湿毒疮) 
The term Shi Du Chuang (湿毒疮) literally translates as “damp toxin sores”. The term has 
been used since the Ming Dynasty (1368-1644) and can still be found in modern texts, 
usually referring to “eczema of the leg” (L. Lin, 1995). The term, however, is not found in the 
Criteria of Diagnosis and Therapeutic Effect of Diseases and Syndromes in Traditional 
Chinese Medicine (State Administration of Traditional Chinese Medicine of the People's 
Republic of China, 1994). 
According to the crosstab analysis of the characteristics of Shi Du Chuang (湿毒疮) (Figure 3-
5), the term was usually attributed to an itchy and chronic/recurrent condition; with a small 
percentage of descriptions mentioning non-AD characteristics such as pain, spreading 
(contagious), presence of parasites and chills and fever. The minor descriptions seemed to 
suggest the possibility of the condition being related to an infection of some sort.  
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The description of lesion distribution mentioned that the rash occurred on the lower limbs. 
Apart from the minor non-AD characteristics, its distribution differed slightly from Si Wan 
Feng (四弯风) as the rash did not seem to be localised around the joint creases only, 
identifying itself as a separate disease from Si Wan Feng (四弯风). 
 
 
Figure 3-5: Crosstab analysis of the characteristics of Shi Du Chuang (湿毒疮) 
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3.5.1.5 Nai Xuan (奶癣) 
The Chinese character Nai (奶) may be translated as “milk” or “breast”, and the character 
Xuan (癣) may refer to “tinea” or “dry ulcer”. According to the Comprehensive Chinese 
Medical Dictionary (Zhong Yi Da Ci Dian 中医大辞典), the term Nai Xuan (奶癣) may refer to 
a type of infantile eczema or nipple dermatitis. The term has been used since the Song-Jin 
Dynasties (960-1279). In current Chinese medicine textbooks, the term can still be found to 
describe infantile eczema (L. Lin, 1995). The term, however, is not found in the Criteria of 
Diagnosis and Therapeutic Effect of Diseases and Syndromes in Traditional Chinese Medicine 
(State Administration of Traditional Chinese Medicine of the People's Republic of China, 
1994). 
From the crosstab analysis of the characteristics of Nai Xuan (奶癣) (Figure 3-6), it is shown 
that the term always referred to an itchy, paediatric rash. There was also a high relation to 
scaling, but no mention of nipple dermatitis.  
When looking at the various descriptions of the lesions, none mentioned nipple dermatitis. 
Although all descriptions described Nai Xuan (奶癣) as a paediatric rash, there was no 
mention of the rash persisting till adulthood. Two descriptions mentioned that the lesions 
were due to skin contact with breast milk; while another 2 mentioned the presence of white 
scaling. The distribution of the lesions was stated to be around the face (mouth or edges of 
eyebrows), head, or extremities and back. In one description, it was stated that there was 
involvement of parasites.  
As far as it is known, in modern medicine, there is no dermatological condition said to be 
caused by skin contact with breast milk. However, it has been an ongoing debate as to 
whether breastfeeding affects AD (Sampson, 2003). Nevertheless, there is a possibility of 
food allergens being transferred via breast milk, causing allergic reactions, including rash 
outbreaks, in children which food allergies (Brill, 2008; Sampson, 2003). Pertaining to the 
presence of white scaling and parasites, the term might refer to a form of tinea or ringworm 
in children, matching the common translation of the Chinese word Xuan (癣). 
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Figure 3-6: Crosstab analysis of the characteristics of Nai Xuan (奶癣) 
 
3.5.1.6 Shi Xuan (湿癣) 
The term Shi Xuan (湿癣) literally translates as “damp tinea” and has been used since the 
pre-Tang Dynasty (before 618) till the Min Guo era (1912-1949). The term, however, is not 
commonly found in current textbooks and is not recorded in the Criteria of Diagnosis and 
Therapeutic Effect of Diseases and Syndromes in Traditional Chinese Medicine (State 
Administration of Traditional Chinese Medicine of the People's Republic of China, 1994). 
According to the crosstab analysis of the characteristics of Shi Xuan (湿癣) (Figure 3-7), there 
was a fairly high relation to the AD characteristics of itching, chronicity or recurrence, and 
childhood onset. However, its lesions seemed to usually present with distinct margins, 
scaling, pain and presence of parasites, which were not AD characteristics.  
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The description of lesion seemed to imply that Shi Xuan (湿癣) and Gan Xuan (干癣) were 
the same disease with the main difference being the presence or lack of exudation. The 
presence of lesions with distinct margins and parasites in both, the description and crosstab 
analysis of the characteristics of Shi Xuan (湿癣), suggested that the term refers to a form of 
tinea or ringworm. The description of coin-shaped lesions, however, also implied the 
possibility of the term referring to nummular eczema (Burge & Wallis, 2010; Buxton & 
Morris-Jones, 2009; Habif, 2009; Weller et al., 2008).  
 
 
Figure 3-7: Crosstab analysis of the characteristics of Shi Xuan (湿癣) 
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3.5.1.7 Tai Xuan (胎癣) 
The term Tai Xuan (胎癣) literally translates as “foetal tinea”. The term has been used since 
the Song-Jin Dynasties (960-1279), with its last record from the Qing Dynasty (1644-1911). 
While rarely found in current books, it is noted as a synonym of Nai Xuan (奶癣) in the 
Comprehensive Chinese Medical Dictionary (Zhong Yi Da Ci Dian 中医大辞典). 
From the crosstab analysis of the characteristics of Tai Xuan (胎癣) (Figure 3-8), like Nai 
Xuan (奶癣), the term always referred to a form of itchy, paediatric dermatological condition. 
The only difference was that Tai Xuan (胎癣) seemed to be contagious.   
There were 3 descriptions of Tai Xuan (胎癣). The first stated the TCM syndrome of the 
condition, with no further elaboration of its clinical presentation apart from it being a 
paediatric rash. The second stated that Tai Xuan (胎癣) referred to rashes that occur on the 
heads of children and could spread with scratching. The third stated that Tai Xuan (胎癣) 
was an alternative name for Nai Xuan (奶癣), followed by a description which matched that 
of Nai Xuan (奶癣), but with an additional line stating that the lesions might spread 
throughout the body.  As the disease presentation seemed to be related to contagious 
rashes on the heads of children, it is possible that the term Tai Xuan (胎癣), just as Nai Xuan 
(奶癣), was referring to a form of tinea (Burge & Wallis, 2010; Buxton & Morris-Jones, 2009; 
Habif, 2009; Weller et al., 2008). The distribution around the head suggested that it was 
more likely referring to tinea capitis.  
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Figure 3-8: Crosstab analysis of the characteristics of Tai Xuan (胎癣) 
 
3.5.1.8 Ru Xuan (乳癣) 
The term Ru Xuan (乳癣) literally translates as “milk tinea” or “nipple tinea”. The term has 
been used since the pre-Tang Dynasty (before 618). While its records lasted till the Min Guo 
era (1912-1949), it is rarely found in the modern literature. The Comprehensive Chinese 
Medical Dictionary (Zhong Yi Da Ci Dian 中医大辞典) noted that the term is synonymous 
with Nai Xuan (奶癣). 
According to the crosstab analysis of the characteristics of Ru Xuan (乳癣) (Figure 3-9), the 
term was fairly highly related to the AD characteristics of itching, chronicity or recurrence, 
and childhood onset, as well as with the presentation of hand/foot or nipple dermatitis. 
However, the high frequency of nipple dermatitis noted in the crosstab analysis was due to 
Ru Xuan (乳癣) literally referring to nipple dermatitis as a condition, rather than a symptom 
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of the rash. There were only small percentages of non-AD characteristics, most of which 
were tinea-like such as distinct lesion margins, contagiousness and presence of parasites. 
There were 2 main descriptions of Ru Xuan (乳癣) – one being a paediatric dermatological 
condition that mirrored the description of Nai Xuan (奶癣); and the other referring to nipple 
eczema. The former description was found in records in the period of pre-Tang Dynasty 
(before 618) till the Qing Dynasty (1644-1911). The latter was found from only Qing Dynasty 
(1644-1911) records. The 2 most recent citations, which were from Ding Gan Ren Xian Sheng 
Jia Chuan Zhen Fang (丁甘仁先生家传珍方), 1911 and Yang Ke Gang Yao (疡科纲要), 1917, 
did not provide elaboration on the term Ru Xuan (乳癣), and it was therefore unclear if they 
were referring to a paediatric or nipple rash. It is more likely that the term originally referred 
to a paediatric rash which was similar to that of Nai Xuan (奶癣), as its reference to nipple 
rash was identified only in the Qing Dynasty (1644-1911). Considering that the term was 
found in records much earlier than Nai Xuan (奶癣), Ru Xuan (乳癣) might have been the 
original term which had been displaced by Nai Xuan (奶癣). 
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Figure 3-9: Crosstab analysis of the characteristics of Ru Xuan (乳癣) 
 
3.5.1.9 Gan Xuan (干癣) 
The term Gan Xuan (干癣) literally translates as “dry tinea” and has been used since the pre-
Tang Dynasty (before 618) till the Min Guo era (1912-1949). The term, however, is not 
commonly found in current textbooks and is not recorded in the Criteria of Diagnosis and 
Therapeutic Effect of Diseases and Syndromes in Traditional Chinese Medicine (State 
Administration of Traditional Chinese Medicine of the People's Republic of China, 1994). 
According to TCM, the term is occasionally translated as “psoriasis” (Hsu, 1990). 
The crosstab analysis of the characteristics of Gan Xuan (干癣) (Figure 3-10) showed that 
there was a fairly high relation to the AD characteristics of itching, chronicity or recurrence, 
childhood onset and aggravation by gloomy weather. However, the term was also highly 
related to tinea-like characteristics such as distinct lesion margins, scaling, pain and presence 
of parasites.  
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As mentioned above, the descriptions suggested that Shi Xuan (湿癣) and Gan Xuan (干癣) 
be the same disease, apart from the fact that the former being an exudative form and the 
latter being a dry form. The description and crosstab analysis of Gan Xuan (干癣) 
characteristics supported the possibility of the term referring to a form of tinea or ringworm 
as well. Its description of the presence of “white crusts” may be interpreted as the presence 
of silver scaling, which explained why the term might be translated as “psoriasis” (Burge & 
Wallis, 2010; Buxton & Morris-Jones, 2009; Habif, 2009; Weller et al., 2008).   
 
 
Figure 3-10: Crosstab analysis of the characteristics of Gan Xuan (干癣) 
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3.5.2 TCM Treatment of AD or AD-like Conditions 
The TCM treatments identified from the citations included acupuncture, moxibustion, 
bloodletting and CHM for AD-like conditions. As there were only a small number of 
acupuncture, moxibustion and bloodletting treatments, there was no requirement for 
further analysis. The respective treatment details are summarised in the next 3 subsections.  
With regard to CHM treatments, filters were applied to identify the most frequently-used 
topical and systemic CHM formulae, respectively. Analysis of the formulae ingredients were 
also conducted to identify the most frequently used herbs in the treatment of AD or AD-like 
conditions. 
3.5.2.1 Acupuncture treatment 
As mentioned above, there were 2 citations which mentioned the use of acupuncture 
treatment. However, both these citations were from the books, Zhen Jiu Zi Sheng Jing (针灸
资生经), 1220, and Pu Ji Fang (普济方), 1406, recorded under the chapters regarding Kou 
Chi Gan Chuang (口齿疳疮) [mouth and teeth malnutrition sores]. The acupuncture 
treatments in these citations were for the condition Xiao Er Gan Shi Chuang (小儿疳湿疮) 
[paediatric malnutrition eczema]. According to the definition of Gan Shi Chuang (疳湿疮) 
[malnutrition eczema] recorded in Zhu Bing Yuan Hou Lun (诸病源候论), 610, the disease 
referred to lesions related to weakness or parasites in the stomach/intestines, which 
differentiated it from AD.  
3.5.2.2 Moxibustion treatment 
A total of 10 citations mentioned the use of moxibustion treatment. Of these 10, 4 citations 
were excluded as they were not referring to the search term as the disease of interest – 1 
citation was referring to the treatment of Han Shi Chuang Du (寒湿疮毒), which may 
translate as cold-damp lesion toxins while the other 3 citations were for the treatment for 
Xiao Er Gan Shi Chuang (小儿疳湿疮) [paediatric malnutrition eczema]. Among the 
remaining 6 citations, 1 mentioned the treatment of Nai Xuan (奶癣) and poor eyesight by 
applying moxibustion on the acupuncture point, Jianzhong (SI 15). Four citations mentioned 
the treatment of Gan Xuan (干癣) by applying moxibustion on the papular lesions. Three 
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citations (2 of which were the same citations which mentioned Gan Xuan (干癣)) mentioned 
the application of moxibustion following the topical application of the herbs, She Chuang Zi 
and Zhu Zhi (Lard) for the treatment of Shi Xuan (湿癣). 
3.5.2.3 Bloodletting treatment 
Seven citations mentioned the use of bloodletting to treat Shi Xuan (湿癣). However, upon 
screening, it was shown that all 7 citations were citing the treatment of the same case, 
whereby a young girl had Shi Xuan (湿癣) between her thighs with accompanying pain, 
itching and exudation. The treatment was bloodletting – pricking the areas of the itching 
with a needle, followed by washing with salt decoction. Only 1 citation differed by 
mentioning the use of the oral decoction, Fu Ping San, for diaphoresis when the condition 
improved after 3 bleeds.  
3.5.2.4 CHM treatment 
The majority of the citations mentioned the use of CHM treatment. As mentioned above, 86 
citations mentioned 27 individual herbs (Table 3-4) being used in the treatment of the 
search term diseases. As these citations did not contain any information on how the herbs 
were used in treatment, they were excluded from the subsequent analysis of topical and 
systemic CHM treatment of AD or AD-like conditions. 
 
Table 3-4: Frequency analysis of individual herbs from the classical literature 
Herbs Frequency 
She Chuang Zi 15 
Wu Bei Zi 12 
Song Ye; Xi Xian 9 
Lu Hui 8 
Fang Feng 4 
Qu Mai; Bian Xu; Dong Bi Tu 3 
Mu Jing Ye; Yan Wo 2 
He Shou Wu; Che Qian Zi; Shi Hu; Bai Xian Pi; Ci Ji Li; Zhang Nao; Qing Fen; 
Lang Du; Yin Chen Hao; Zhe Bei Mu; Ma Bo; Qian Fen; Peng Qi; Tong Lu; 
Sang Du Chong Fen; Cao Shi Can 
1 
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Prior to further analysis of CHM treatment, citations coded with other reasons for exclusion 
were excluded and the filter for “itching” was applied. From the remaining citations, 
frequency analysis of CHM was conducted for external and systemic treatments, respectively. 
External CHM treatments referred to topical preparations such as creams, ointments, 
powders, washes, soaks or steams; while systemic treatments referred to orally-
administered CHM. 
A total of 290 external CHM formulae were accounted for – 162 formulae had no quoted 
names while 82 formula names were identified from the remaining 128 formulae (Table 3-5). 
It should be noted that formulae with the same names were not always made of the same 
herbal ingredients; and in some instances, different names were used for formulae 
containing the same ingredients. Therefore, frequency analysis was conducted on the 
formulae ingredients to identify the most commonly-used Chinese herbs in the external 
treatment of AD or AD-like conditions (Table 3-6). 
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Table 3-5: Frequency analysis of external CHM formulae for AD identified from the classical 
literature 
Formula Names Frequency 
No Name 162 
Run Ji Gao 7 
San Miao San; Wu Yun Gao 5 
Bi Xiao Fang; Hu Fen San Fang; Huang Lian San Fang; Ji Guan Xue Tu Fang; Luo Ke 
San; Qing Ge San; Yi Mo San; Zhi Shi Xuan Fang 
3 
Bai Fan Tu Fang; Cong Bai Gan Cao Tang; Cong Jiao Tang; Er Shen Gao; Fan Du Yu 
Si Fang; Fu Zi San; Huang Bai San; Jiang Can San; Jing Jie San Fang; Ku Lian San; Lu 
Hui San Fang; Ma Chi Xian Gao; Niu Shi Zhi Tu Fang; Pi Zhi San; Qu Shi San; Rong 
Yan Tu Fu Fang; Wen Ge San; Ying Fen San Fang; Zhi Yu Tu Fang 
2 
Ba Bao San; Chen Xiang Li; Chen Xiang Li Fang; Cong Lian Gao; Cui Yun San; Ding 
Fen Gao; Ding Fen Gao Fang; Du Lian Liu; Ge Fen San; Hu Fen Gao; Hu Fen Gao 
Fang; Hu Fen San; Hu Yan Ke Fu Fang; Huang Bai San Fang; Huang Lian Hu Fen San; 
Ji Yu Tu Fu Fang; Jie Du Dan; Jie Du Xiong Huang San; Jing Jie San; Jing Shu San; Jiu 
Cai Tang; Ku Hu San; Ku Hu San Tu Fu Fang; Ku Lian Fu Fang; Ku Shen Zhi; Li Lu 
Gao; Lian Shi Xi Fang; Lian Shi Xuan Fang; Liu Huang San; Liu Huang San Fang; Long 
Nao Gao; Long Nao Gao Fang; Mei Shi Gao; Mei Shi Gao Fang; Qian Jin Fang; Qing 
Fen San; Qing Jin San; Ru Sheng San; Ru Sheng San Fang; She Chuang Zi San Fang; 
Shi Xuan Fang; Shui Chen Gao; Shui Yin Gao; Tian Ma Cao Tang; Wu Mei Jian; Xiao 
Du Gao; Xuan San Fang; Yang Bu Zhi Fang; Yang Ti San; Yi Sao Guang; Shi Gan Shi 
Xuan Yang Tong Bu Ke Ren Fang; Zhi Xuan Fang 
1 
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Table 3-6: Frequency analysis of Chinese herbs used in external CHM treatment for AD 
identified from the classical literature 
 Herb Names Frequency 
Qing Fen 49 
Ma You 41 
Qian Dan 36 
Cu 34 
Zhu Zhi 33 
Huang Lian; Huang Bai 29 
Ban Mao 25 
Yang Ti 23 
Shi Liu Huang 22 
She Chuang Zi 17 
Bai Fan 15 
Shi Yan 14 
Feng Mi; Lang Du 13 
Wu Tou 12 
Gan Cao; Ji Yu 11 
Xiong Huang 10 
Song Xiang; Qing Dai 9 
Shi Gao; Lu Ru; Mian You 8 
Dang Gui; Ku Shen; Zao Jia; Lu Hui; Ji Guan Xue; Ba Dou; Zi Cao; Wen Jiang Shui 7 
Zhen Su; Long Nao; Chuan Jia; Bing Lang; Wu Yi; Yan Wo; Liang Shang Chen 6 
Huang La; She Xiang; Wu Mei; Da Huang; Cang Zhu; Li Lu; Dan Dou Chi; Da Mai; Da 
Suan; Shi 
5 
Cong Bai; Lu Feng Fang; Ge Li Fen; Ji Zi Huang; Hu Cong; Jin Tuo; Fa Hui; Chen Jiu; Ku 
Hu Lu; She Tui; Ma Chi Xian; Luo Ke 
4 
Jing Jie; Tian Nan Xing; Su He You; Da Ma Ren; Quan Xie; Wu Zhu Yu; Rong Yan; Bai 
Lian; Hua Shi; Yu; Da Feng Zi; Tong You; Wu Chen; La Yin Zhi; Yan Jiao; Mi Gan; Kou 
Zhi; You Dian; Cai You 
3 
Sheng Jiang; Dan Shen; Bai You; Chen Xiang; Ru Xiang; Gui Jia; Bai Ji; Zhi Shi; Xian He 
Cao; Ku Lian; Chu Pi Zhi Ye; Chuan Lian Zi; Jiang Can; Can Sha; Hei Zhi Ma; Song Bai 
Jie; Long Dan Cao; Bo He; Da Fu Pi; Wu Bei Zi; Xue Jie; Di Yu; Qing Xiang Zi; Fu Shen 
Mu; Mang Cao; Ku Lian Gen; Feng Wei Cao; Jiang Shui; Zhu Dan Zhi; Mi; Hao Er Cha; 
Ling Xiao Teng; Ling Xiao Ye; Tong Lv; Zhu Gu; Hu Pi; Di Juan Pi; Shi Hui; Dian Fen; 
Jian Sui You Fa; Yan Jiang Shui; Ying Fen; Ma Chang Gen; Shan Jie; Tuo Zhi; Fei Dan; 
Chun Ye; Yang Ru 
2 
Tian Ma Cao; He Ye; Chi Shao; Long Gu; Xuan Shen; Huang Qin; Xing Ren; Xi Xin; Jiu 
Zi; Jiu Cai Gen; Bing Pian; Ci Huang; Ci Ji Li; Mo Yao; Bai Zhi; Han Shui Shi; Zhang Nao; 
Chi Lian; Hu Jiao; Huang Da Dou; Mu Bie Zi; Hai Ge Ke; Tao Jing Bai Pi; Da Ji; Fu Long 
Gan; Qu Mai; Xue Yu; Shi Shu Pi; Liang Shui; Wen Tang; Xin Shui; Yu Shi; Bi Ma Zi; Hai 
Tong Pi; Bai Yao Jian; Zhu Rou; Yin Zhu; Peng Qi; Diao Yang Chen; Mu Jin; Jian Bing; 
Wu Yu Gu; Jiang Qing; Jiang Ban; Wu Jiu You; You La; Lian Ye; Lian Nen Zhi; Bang Ke 
Hui; Gu Yang Lao; Lv Mu Cao; Xiang Li; Niu Lao; Jing Shu Pi  
1 
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A total of 182 Chinese herbs were identified from the external CHM formulae. The most 
commonly-used herbs can be divided into several categories – minerals, emollients, plants 
and insects/animals (Table 3-7).  
 
Table 3-7: Categories of the commonly used herbs in the external CHM treatment for AD 
identified from the classical literature 
Minerals Emollients Plants Insects/Animals 
Qing Fen 
Qian Dan 
Shi Liu Huang 
Bai Fan 
Shi Yan 
Xiong Huang 
Ma You 
Cu 
Zhu Zhi 
Feng Mi 
Huang Lian 
Huang Bai 
Yang Ti 
She Chuang Zi 
Lang Du 
Wu Tou 
Gan Cao 
Ban Mao 
Ji Yu 
 
With regard to systemic CHM treatment, a total of 39 formulae were identified, out of which 
18 classical CHM formulae names were recognised. The most frequently-cited formula was 
Xiao Feng Dao Chi San (Table 3-8). A total of 92 Chinese herbs were identified from the 
ingredients of the systemic formulae (Table 3-9) 
 
Table 3-8: Frequency analysis of systemic CHM formulae for AD identified from the 
classical literature 
 Formula Names Frequency 
Xiao Feng Dao Chi Tang 5 
Dang Gui Nian Tong Tang; No Name; Sheng Ma Xiao Du Yin; Wu Fu Hua Du 
Dan; Xiao Feng San; Sheng Ma Tang 
3 
Bo He Tang; Jun Chuan San; Liang Ge San; Zhou Che Wan 2 
Bai Lian San; Dang Gui Yin Zi; Fang Feng Pai Du Yin; Fu Ping San; Li Xiao Wan; 
San Feng Ku Shen Wan; San Wei Wu She San Fang; Wu She San 
1 
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Table 3-9: Frequency analysis of Chinese herbs used in systemic CHM treatment for AD 
identified from the classical literature 
 Herb Names Frequency 
Gan Cao 22 
Dang Gui 13 
Huang Lian 12 
Fang Feng; Niu Bang Zi 11 
Di Huang; Da Huang; Bo He 10 
Sheng Ma; Ku Shen; Cang Zhu; Mang Xiao 9 
Jie Geng; Huang Qin; Jin Yin Hua 8 
Fu Ling; Mu Tong 7 
Ren Shen; Zhi Zi; Jing Jie; Qiang Huo; Zhi Shi 6 
Zhi Mu; Chi Shao; Mu Xiang; Bai Xian Pi; Lian Qiao 5 
Gan Cao Shao; Bai Shao; Feng Mi; Xuan Shen; Zhu Ye; Qian Niu Zi; Chan Tui; Gan Sui; 
Chen Jiu 
4 
Bai Zhu; Ze Xie; Shi Gao; Hong Hua; Zhu Sha; Deng Xin Cao; Ge Gen; Hei Zhi Ma; Bing 
Pian; Long Dan Cao; Qing Dai; Zhu Ling; Bai Zhi 
3 
Chuan Xiong; He Ye; Chen Pi; Yu Li Ren; Qing Pi; Bai Hua She; Yin Chen Hao; Yuan 
Hua; Jing Da Ji 
2 
Huang Qi; He Shou Wu; Fu Ling Pi; Mu Dan Pi; Yu Zhu; Ju Hua; Sheng Jiang; Da Zao; 
Ru Xiang; Jin Bo; Du Huo; Xi Jiao; Ling Yang Jiao; Tian Nan Xing; Xiong Huang; Cong 
Bai; Quan Xie; Ye Can; Man Jing Zi; Lv Dou; Ci Huang; Ma Huang; Bai Fan; Wu Tou; Ci 
Ji Li; Mo Yao; Hua Shi; Ba Dou; Dan Dou Chi; Ma You; Yan Wo; Fu Ping; Fu She; Xie 
Ke 
1 
 
Unlike the commonly-used herbs in external CHM treatment, the commonly-used Chinese 
herbs in systemic CHM treatment were mostly plant-based. Gan Cao was identified as the 
most commonly-used Chinese herb systemically. It should be noted that Gan Cao has been 
commonly added in CHM formulae to harmonise the herbal ingredients and to reduce 
toxicity. It was possibly due to its formula-harmonising action, rather than therapeutic 
benefit in the treatment of AD or AD-like rash, that put it at the top of the list. However, in 
the modern literature, Gan Cao (Glycyrrhiza sp.) has been widely studied for its 
pharmacological effects, including anti-inflammatory and immuno-modulating effects 
(Nassiri Asl & Hosseinzadeh, 2008; Saeedi, Morteza-Semnani, & Ghoreishi, 2003), which may 
be beneficial in the management of AD. Out of the 9 herbs with a frequency analysis of 10 
and above, 4 herbs (Gan Cao, Niu Bang Zi, Di Huang, Bo He) were ingredients of Xiao Feng 
Dao Chi Tang, while 5 herbs (Gan Cao, Dang Gui, Fang Feng, Niu Bang Zi, Di Huang) were 
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ingredients of Xiao Feng San. Both Xiao Feng Dao Chi San and Xiao Feng San were among the 
top commonly-used systemic formulae for AD-like rash. 
When comparing the TCM actions of the commonly-used external and systemic Chinese 
herbs, most of the herbs clear heat, toxins, dampness and/or wind pathogens. With the 
externally-used herbs, almost all were listed under the category of “substances for topical 
application” in the Materia Medica (Bensky, Clavey, & Stoger, 2004). Most of these 
externally-used herbs, especially the mineral-based herbs, are said to be toxic or cause side-
effects, which possibly explained why they were not identified among the commonly-used 
systemic CHM in the classical literature. Also, emollient herbs, except Feng Mi (honey), were 
not identified among the systemic herbs, possibly because they acted topically as a 
treatment vehicle or as a local moisturising agent. Among the systemic herbs, it could be 
observed that there were herbs which focused more on treating the root of the disease or 
underlying deficiencies, such as Dang Gui to tonify Blood, Sheng Di to tonify the Yin, Ren 
Shen to tonify the Qi and Bai Zhu to tonify the Spleen.  
 
3.6 Discussion 
The analysis of search terms showed that there was a lack of information to determine the 
term for AD in the TCM classical literature. Furthermore, there were many inconsistencies in 
the descriptions of the search terms.  
While the term Si Wan Feng (四弯风) seemed to be describing a condition most similar to 
the presentation of AD, the fact that it was described as a condition which affected the joint 
creases of only the lower limbs suggested that it might have been a different disease 
altogether. However, looking at it the other way, there is no particular skin rash which 
affects only the knee and ankle joints in modern dermatology (Burge & Wallis, 2010; Buxton 
& Morris-Jones, 2009; Graham-Brown & Burns, 2007; Habif, 2009; MacKie, 2003; Weller et 
al., 2008). Considering that the concept of atopy was introduced only in 1923 (Coca & Cooke, 
1923), and the fact that the prevalence of AD has been increasing (Ring et al., 2006; Williams, 
2000, 2013), the disease that is AD might not have existed or been prominent enough to be 
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mentioned in the TCM classical literature; or it could have evolved from one of the skin 
conditions in the past to what it is today.  
While there were no exact matches between the search term characteristics and AD, 
identifying skin conditions similar to AD, and subsequently similar TCM diagnosis, will be 
beneficial in formulating the TCM treatment for AD.  
From the analysis of treatment, CHM treatment was the most commonly-used form of 
treatment for AD-like conditions. There were a large number of external CHM formulae 
identified, with the top 3 being Run Ji Gao, San Miao San and Wu Yun Gao. The herbal 
ingredients commonly used in the externally-applied treatments included the use of toxic 
herbs such as mineral-based herbs, as well as the use of emollient herbs. However, external 
CHM treatments seemed to be focused on clearing external pathogenic factors.   
With regard to the systemic CHM treatment, the most frequently-used formula identified 
was Xiao Feng Dao Chi Tang. However, when looking at the most commonly-used systemic 
herbs, out of the 9 herbs with a frequency analysis of 10 and above, 4 herbs were 
ingredients of Xiao Feng Dao Chi Tang, and 5 herbs were ingredients of Xiao Feng San. Both 
Xiao Feng Dao Chi Tang and Xiao Feng San were of the top-ranking frequently-used systemic 
CHM formulae. Most of the systemic Chinese herbs were plant-based herbs. There were also 
more tonifying herbs, which suggested that systemic CHM treatments tended to address the 
underlying cause of the disease.  
3.6.1 Strengths of this Review 
As mentioned previously, a review of the TCM classical literature among the Chinese 
literature had been conducted (C. Huang, Cai, et al., 2011). However, based on the database 
searches for the comprehensive review (Chapter 4), no such review was identified among 
the English literature. This SR allows the access of data on AD-like conditions from the TCM 
classical literature to the non-Chinese literate community. The results from this SR provide 
an understanding of the different TCM nomenclature of AD-like rashes and their treatments 
according to the classical literature. While none of the search terms matched the 
presentation of AD, this review is a source of historical evidence which can provide guidance 
in the TCM diagnosis and treatment of conditions similar to AD. 
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3.6.2 Limitations of this Review 
The main limitations of this review were the lack of or inconsistencies in information in the 
citations and also, certain parts of the citations were subject to different interpretation. This 
meant that it is difficult to make definitive conclusions. Many citations cited the same 
sources but had variations in information. One of the main reasons for this was the fact that 
Chinese classical literature was originally written without the use of any punctuation 
(Minford & Lau, 2000; Pollard, 2000). In this review, there were citations without 
punctuation that were subject to the reviewers’ interpretation; but the same citation could 
be repeated with punctuations which had been added in more recent times, resulting in a 
variation in interpretations. Another source of confusion was the use of different Chinese 
characters with similar form or pronunciation, resulting in a different meaning or treatment 
(especially in relation to herb names) or rendering the phrase/sentence meaningless.  
3.6.3 Comparison with Other Reviews of the TCM Classical Literature  
When compared to the previous Chinese review, this review included a complete search of 
the ZHYD with no limitations to the types of classical books or treatment.  Furthermore, the 
search terms for this review were chosen by reviewing various TCM and Western medicine 
(WM) dermatology textbooks and bilingual dictionaries to ensure all possible terms were 
included, with as little loss in translation as possible. In the previous review, the various 
Chinese search terms were presumed to be the same disease that is AD, whereas in this 
review, the possibility of the search terms representing AD or other conditions was 
evaluated. Nevertheless, it is in agreement that Si Wan Feng (四弯风) had the closest 
description to AD.  As this review only included citations with signs and symptoms that 
matched AD, there was insufficient data to analyse syndrome differentiation. 
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3.6 Conclusion 
From the TCM classical literature, the term Si Wan Feng (四弯风) had the closest description 
to AD. This is in agreement with the previous Chinese review as well as the Criteria of 
Diagnosis and Therapeutic Effect of Diseases and Syndromes in Traditional Chinese Medicine 
(State Administration of Traditional Chinese Medicine of the People's Republic of China, 
1994), which stated that the term is synonymous with the current Chinese term for AD, Te 
Ying Xing Pi Yan (特应性皮炎). With regard to treatment, TCM dermatology texts have 
mentioned the use of Xiao Feng Dao Chi San, Xiao Feng San, Dang Gui Yin Zi, which were 
among the commonly-used systemic CHM formulae identified from the classical literature. 
When looking into the type of herbs identified from both the external and systemic CHM 
treatments, their actions are in line with treatment principles for the syndromes involved in 
the pathogenesis of AD (Figure 1-9). 
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 Comprehensive Review of Traditional Chinese Medicine Chapter 4
Treatments in the Management of Atopic Dermatitis 
4.1 Introduction 
There has yet to be a comprehensive review of the current evidence of the major forms of 
TCM treatments for AD. While a general review (Hon, Chan, & Leung, 2011) and several SRs 
(Armstrong & Ernst, 1999; Gu et al., 2013; W. Zhang, Leonard, et al., 2010) of CHM 
treatment have been conducted, the general quality of studies has been poor, preventing 
valid conclusions from being made. Furthermore, aside from CHM, the current state of 
evidence of other forms of TCM treatment of AD remains unknown. In order to illustrate the 
current evidence of the efficacy and safety of the various forms of TCM treatment, this 
comprehensive review was conducted to give an overview of RCTs involving any form of 
TCM treatment of AD among the general population and to outline the limitations of the 
currently available RCTs to provide guidance for future studies. 
 
4.2 Objectives 
The comprehensive review of TCM treatments of AD aimed to: 
1. Identify TCM treatments of AD which have been evaluated in RCTs from the modern 
literature; 
2. Identify limitations of the currently-available studies on TCM treatments of AD; 
3. Allow the comparison between historical and current Chinese medicine treatments 
of AD. 
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4.3 Methods 
There were a total of 11 TCM modalities which were included in this review. The 11 
modalities included acupressure, acupuncture, bloodletting, CHM, Chinese medicine diet 
therapy, cutaneous needling, cupping, Guasha, moxibustion, Taiji and Tuina. A separate 
search was conducted for each modality in the English databases. 
The search terms for each modality which were used in PubMed are listed in Appendix 2. 
Due to the difference in database searching methods between the English and Chinese 
databases, only 1 search encompassing all modalities was conducted in each of the 2 
Chinese databases (Appendix 3). 
The methodology utilised for this review is described in Chapter 2.3. 
 
4.4 Results 
4.4.1 Identification of Studies 
A total of 19,041 studies were found through the electronic searches, from which 4098 
duplicates were excluded. After the screening of titles and abstracts, a further 13,788 studies 
were excluded for being a non-RCT, non-human, non-TCM, and/or non-AD related study. 
From the screening of the full articles of the remaining 1,155 studies, 2 studies were 
excluded as their full articles could not be retrieved and another 962 articles were also 
excluded – 435 studies were not RCTs, 492 studies were not on AD, 32 studies were 
duplicate studies, 2 studies were not using TCM treatments, and 1 study was published in 
Mongolian. A total of 191 studies were included in this comprehensive review of 
methodological analysis. The study selection process is illustrated in the PRISMA flow 
diagram (Figure 4-1). 
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Figure 4-1: PRISMA flow diagram illustrating the study selection process for the 
comprehensive review of TCM treatments in the management of AD 
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4.4.2 Description of Studies 
A total of 191 studies were included in this review – 12 were published in English (one of 
which was a translated Chinese study) and 179 were published in Chinese. There were 180 
studies from China, 3 studies from Germany, 2 studies each from the UK and Hong Kong, and 
1 study each from the United States, Taiwan, Japan and Korea. The included studies had one 
or more of the following diagnoses: AD, eczema in the paediatric population, Si Wan Feng 
(四弯风) and/or Nai Xuan (奶癣).  
The types of TCM treatments as experimental trial interventions identified included oral 
CHM, topical CHM, CHM enema, acupuncture, acupressure, Tuina, acupoint injection and 
bloodletting via cupping and plum-blossom needling. Eighty-six studies involved a 
combination of one or more TCM interventions, with or without other non-TCM therapies.  
For control interventions, there were 6 placebo-controlled studies among the RCTs on CHM.  
Two out of 3 acupuncture studies involved placebo acupuncture as one of the control 
interventions. Five studies (3 were multiple-armed trials) had “no treatment” as a control 
intervention, with the remaining studies using one or more active interventions as the 
control intervention(s). These active interventions included WM, CHM, emollients, water 
baths and saline wet wraps. 
4.4.3 Diagnostic Criteria 
Out of the 191 studies, 74 were on AD, 1 was on Si Wan Feng (四弯风), 105 were on infantile 
or childhood eczema, 5 were on Nai Xuan (奶癣), 3 utilised diagnostic criteria for both AD 
and Si Wan Feng (四弯风), while another 3 utilised diagnostic criteria for both AD and 
eczema.  
Studies which were on Si Wan Feng (四弯风) or Nai Xuan (奶癣) utilised Zhong Yi Bing Zheng 
Zhen Duan Liao Xiao Biao Zhun (中医病症诊断疗效标准) as the diagnostic criteria. 
However, there were a number of different diagnostic criteria cited between the remaining 
studies; the most frequently-used criteria for AD was the UK diagnosis, while the most 
frequently-used criteria for eczema (in the paediatric population) was Lin Chuang Pi Fu Bing 
Xue (临床皮肤病学). Table 4-1 lists the diagnoses used in the included studies. 
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Table 4-1: Diagnostic criteria of studies included in the comprehensive review of TCM treatments of AD 
Condition for diagnosis Diagnostic Criteria cited Studies 
Atopic dermatitis Hanifin and Rajka Diagnostic Criteria 11 studies (An, Zhang, & Cai, 1996; H. M. 
Cheng, Chiang, Jan, Chen, & Li, 2011; Chi, 
2012; I. H. Choi, Kim, Kim, & Yun, 2012; 
Fung, Look, Chong, But, & Wong, 1999; Y. 
Guo & Ye, 2011; Hon et al., 2007; Lang, 
2011; Sheehan et al., 1992; J. Sun & Xu, 
2006; S. Sun, Lin, & Xiao, 2009) 
UK Diagnostic Criteria 27 studies (Cai, 2012; Cao, 2009; B. Chen 
& Zhang, 2011; Y. Chen, Lin, Huang, & 
Gao, 2006; Z. Fu & Fu, 2012; X. Guan, 
2009; H. Han, Guo, & Liu, 2013; Y. Huang, 
Chen, & Mo, 2004; Z. Huang, Chen, & Wei, 
2010; X. Li, 2004; S. Lin, 2011; H. Liu, 2006; 
J. Liu & Ma, 2008; W. Luo, 2010b; Y. Ma, 
Sun, Wang, Zhang, & Cai, 2010; Ou, Liu, & 
Wang, 2006; Peng et al., 2013; Y. Shi, 
Zhang, & Ma, 2008; Weng, 2013; Y. Yang, 
Sun, Feng, Yang, & Wang, 2007; Yao et al., 
2007; Q. Zhang, 2005; T. Zhang, 2013a; X. 
Zhang, Yang, Yang, Wu, & Li, 2012; Y. 
Zheng, Xie, Chen, & Zhang, 2012; F. Zhou, 
Li, Qin, & Wang, 2012; H. Zhou, 2000) 
Criteria for Atopic Dermatitis by the American Academy of 
Dermatology 
6 studies (Z. Fu, 2013; Y. Huang & Song, 
2013; H. Li, 2010a; Y. Tian, 2011; Y. Zhang, 
Ling, & Guo, 2010; Z. Zhu, 2008) 
Japanese Dermatology Association Criteria 1 study (H. Kobayashi et al., 2010) 
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Condition for diagnosis Diagnostic Criteria cited Studies 
Scoring Atopic Dermatitis (SCORAD) 3 studies (Pfab et al., 2011; Pfab et al., 
2010; Pfab et al., 2012) 
Kang & Tian Diagnostic Criteria 4 studies (J. Chen et al., 2012; X. Gong, 
Guo, & Liu, 2010; M. Xiao, 2008; Z. Zhao, 
Lao, Xia, & Wu, 2010) 
Lin Chuang Pi Fu Bing Xue (临床皮肤病学) [Clinical Dermatology] 2 studies (J. Guan & Dong, 2009; L. Yang, 
Zheng, & Yang, 2012) 
Zhong Yi Bing Zheng Zhen Duan Liao Xiao Biao Zhun (中医病症诊断
疗效标准) [Chinese Medicine Diagnosis and Treatment Efficacy 
Criteria of Diseases] 
1 study (Bu & Li, 2003) 
Shi Yong Pi Fu Ke Xue (实用皮肤科学) [Practical Dermatology]  1 study (N. Zhang, 2012b) 
Xiao Er Pi Fu Bing Xue (小儿皮肤病学) [Paediatric Dermatology] 1 study (H. Fu & Xu, 2000) 
Pi Fu Xing Bing Xue (皮肤性病学) [Dermatology and Venereology] 1 study (W. Li, 2006) 
Xian Dai Pi Fu Bing Xue (现代皮肤病学) [Modern Dermatology] 3 studies (K. Chen, 2004; L. Wang & Zhou, 
2002; W. Zhong, 2002)  
Chang Jian Ji Bing De Zhen Duan Yu Liao Xiao Pan Ding Biao Zhun (常
见疾病的诊断与疗效判定标准) [The Diagnostic and Clinical Efficacy 
Criteria of Common Diseases] 
1 study (S. Yang & Yan, 2012) 
Zhong Guo Te Ying Xing Pi Yan Zhen Duan He Zhi Liao Zhi Nan (中国
特应性皮炎诊断和治疗指南) [Atopic Dermatitis Diagnosis and 
Treatment Guideline of China] 
1 study (Qu, Cai, Li, Liu, & Hu, 2010) 
Hu Xi Xi Tong Bian Tai Fan Ying Ji Bing Zhen Duan Zhi Liao Xue (呼吸
系统变态反应疾病诊断治疗学) [Diagnosis and Treatment of 
Respiratory and Allergic Diseases] 
1 study (L. Guan & Li, 2006) 
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Condition for diagnosis Diagnostic Criteria cited Studies 
Not stated 10 studies (Lee et al., 2012; H. Lin, 2006a; 
H. Liu & Li, 2007; Lu, 2002; Sheehan & 
Atherton, 1992; J. Shi, Diao, & Li, 2012; 
Xia, 1995; Xie & Sun, 2013; L. Yang, Zhang, 
et al., 2012; M. Zhou, 2007) 
Si Wan Feng (四弯风) Zhong Yi Bing Zheng Zhen Duan Liao Xiao Biao Zhun (中医病症诊断
疗效标准) [Chinese Medicine Diagnosis and Treatment Efficacy 
Criteria of Diseases] 
1 study (J. Zhang, 2012a) 
1) AD 
2) Si Wan Feng (四弯风) 
1) Hanifin and Rajka Diagnostic Criteria 
2) Zhong Yi Bing Zheng Zhen Duan Liao Xiao Biao Zhun (中医病症诊
断疗效标准) [Chinese Medicine Diagnosis and Treatment Efficacy 
Criteria of Diseases] 
2 studies (Y. Zhao, 2011, 2013) 
1) AD 
2) Si Wan Feng (四弯风) 
1) UK Diagnostic Criteria 
2) Zhong Yi Bing Zheng Zhen Duan Liao Xiao Biao Zhun (中医病症诊
断疗效标准) [Chinese Medicine Diagnosis and Treatment Efficacy 
Criteria of Diseases] 
1 study (Bao, 2009) 
1) AD 
2) Acute eczema  
1) Hanifin and Rajka Diagnostic Criteria  
2) Lin Chuang Pi Fu Bing Xue (临床皮肤病学) [Clinical Dermatology] 
1 study (Lu & Zhao, 2010) 
1) AD 
2) Acute eczema  
 
1) UK Diagnostic Criteria 
2) Zhong Yi Bing Zheng Zhen Duan Liao Xiao Biao Zhun (中医病症诊
断疗效标准) [Chinese Medicine Diagnosis and Treatment Efficacy 
Criteria of Diseases] 
1 study (Zou & Xie, 2011) 
1) AD 
2) Eczema  
1) UK Diagnostic Criteria 
2) Zhong Yi Bing Zheng Zhen Duan Liao Xiao Biao Zhun (中医病症诊
断疗效标准) [Chinese Medicine Diagnosis and Treatment Efficacy 
Criteria of Diseases] 
1 study (Y. Zhou, 2011) 
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Condition for diagnosis Diagnostic Criteria cited Studies 
Infantile or Childhood 
Eczema (Shi Zhen 湿疹) 
Zhong Yi Bing Zheng Zhen Duan Liao Xiao Biao Zhun (中医病症诊断
疗效标准) [Chinese Medicine Diagnosis and Treatment Efficacy 
Criteria of Diseases] 
8 studies (H. S. Chen, 2008a; Z. Gong & 
Zhou, 2007; H. Huang & Wang, 2009; J. 
Huang, Fu, Wu, & Zheng, 2011; C. Liu et 
al., 2009; C. Xiao, Yin, & Y., 2013; W. Zhang 
& Luo, 2012; Y. Zhao & Tang, 2002) 
Lin Chuang Pi Fu Bing Xue (临床皮肤病学) [Clinical Dermatology] 19 studies (Chao, 2003; L. Chen, 2008b; 
Du, 2012; J. Gong, Wei, & Liu, 2012; S. 
Huang, 2010; N. Jiang, 2008; Z. Li & Di, 
2007; Mo, 2007; Qiao, 2008; L. Tan, 2011; 
J. Tian, 2002; Tong, 2010; P. Wang, Cai, & 
Xu, 2008; Wei & Liu, 2011; J. Zhang, Chen, 
& Gu, 2010; F. Zheng & Gu, 2013; L. 
Zheng, Ren, & Zhou, 2010; R. Zhong, 2008; 
X. Zhou, Wang, & Shi, 2007) 
Zhong Yao Xin Yao Lin Chuang Yan Jiu Zhi Dao Yuan Ze (中药新药临
床研究指导原则) [Clinical Research Guidelines for Chinese Medicine 
and New Drugs] 
2 studies (X. Huang, 2011; Zhuo et al., 
2010) 
Shi Yong Pi Fu Ke Xue (实用皮肤科学) [Practical Dermatology] 4 studies (J. Chen & Zhang, 2010; X. Cheng 
& Yue, 2012; Lu, 2011; H. Wang, Yuan, Lin, 
& Liu, 2013) 
Pi Fu Xing Bing Xue (Editor: Zhang Xuejun) (皮肤性病学, 张学军主
编) [Dermatology and Venereology] 
4 studies (Z. Li, 2010b; Qin & Zhang, 2011; 
Rao, Wang, Lin, Wu, & Chen, 2012; Tang & 
Zhu, 2007) 
Pi Fu Xing Bing Xue (Editor: Wu Zhihua) (皮肤性病学, 吴志华主编) 
[Dermatology and Venereology] 
1 study (X. Zhang, 2010b) 
Pi Fu Xing Bing Xue (Editor: Chen Hongduo) (皮肤性病学, 陈洪铎主
编) [Dermatology and Venereology] 
1 study (W. Huang, 2001) 
Zhong Yi Er Ke Xue (中医儿科学) [Chinese Medicine Paediatrics] 1 study (He & Wang, 2009) 
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Condition for diagnosis Diagnostic Criteria cited Studies 
Zhong Yi Pi Fu Ke Bing Zheng Zhen Duan Liao Xiao Biao Zhun (中医皮
肤科病症诊断疗效标准) [Chinese Medicine Diagnosis and 
Treatment Efficacy Criteria of Dermatological Conditions] 
1 study (S. Lin et al., 2002) 
Shi Yong Er Ke Xue (实用儿科学) [Practical Paediatrics] 2 studies (X. Han, 2011; X. M. Qian, Ren, 
He, & Deng, 2005) 
Pi Fu Bing Xing Bing Zhen Liao Zhi Nan (皮肤病性病诊疗指南) 
[Clinical Guidelines of Dermatological and Venereological 
Conditions] 
1 study (J. Wang, 2004) 
Pi Fu Bing Xue (皮肤病学) [Dermatology] 1 study (J. Qian, 2006) 
Bian Tai Fan Ying Bing Zhen Duan Zhi Liao Xue (变态反应病诊断治
疗学) [Diagnosis and Treatment of Allergic Diseases] 
1 study (Xuan, 2008) 
Shi Yong Pi Fu Bing Zhen Liao Xue (实用皮肤病诊疗学) [Practical 
Diagnosis and Treatment of Dermatological Conditions] 
1 study (P. Fan, 2012) 
Zhu Fu Tang Shi Yong Er Ke Xue (诸福棠实用儿科学) [Zhu Fu Tang’s 
Practical Paediatrics] 
1 study (S. Wang, Ma, Li, Liu, & Wen, 
2013) 
Ying Er Shi Zhen Zhen Duan He Zhi Liao (婴儿湿疹诊断和治疗) 
[Diagnosis and Treatment of Infantile Eczema] 
1 study (X. Zhu, 2013) 
Study by Liu et al. (Y. Liu, Liu, & Dong, 2005) 1 study (S. Yuan, 2008) 
1) Pi Fu Bing Xue (皮肤病学) [Dermatology] 
2) Shi Yong Pi Fu Bing Xue (实用皮肤病学) [Practical Dermatology] 
3) Zhong Yi Wai Ke Xue (中医外科学) [Chinese Medicine Surgery] 
1 study (He, Li, & Ding, 2000) 
1) Lin Chuang Pi Fu Bing Xue (临床皮肤病学) [Clinical Dermatology] 
2) Zhong Yi Wai Ke Xue (中医外科学) [Chinese Medicine Surgery] 
1 study (X. Guan, 2010) 
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Condition for diagnosis Diagnostic Criteria cited Studies 
1) Lin Chuang Pi Fu Xing Bing Xue (临床皮肤性病学) [Clinical 
Dermatology and Venereology] 
2) Zhong Yi Pi Fu Ke Bing Zheng Zhen Duan Liao Xiao Biao Zhun (中医
皮肤科病症诊断疗效标准) [Chinese Medicine Diagnosis and 
Treatment Efficacy Criteria of Dermatological Conditions] 
1 study (Song, 2008) 
1) Shi Yong Zhong Yi Er Ke Xue (实用中医儿科学) [Practical Chinese 
Medicine Paediatrics] 
2) Zhong Yi Pi Fu Ke Xue (中医皮肤科学) [Chinese Medicine 
Dermatology] 
3) Yang Guo Liang Pi Fu Bing Xue (杨国亮皮肤病学) [Yang Guo 
Liang’s Dermatology] 
1 study (Z. Wu & Li, 2010) 
1) Zhong Yi Nei Ke Xue (中医内科学) [Chinese Internal Medicine] 
2) Zhong Yao Yao Li Yu Ling Chuang (中药药理与临床) [Clinical 
Chinese Medicine and Pharmacology] 
1 study (M. Fu & Zhang, 2005) 
1) Shi Yong Zhong Yi Wai Ke Xue (实用中医外科学) [Practical 
Chinese Medicine Surgery] 
2) Zhong Yi Wai Ke Xue (中医外科学) [Chinese Medicine Surgery] 
3) Shi Yong Zhong Yi Jie He Pi Fu Bing Xue (实用中医结合皮肤病学) 
[Practical Integrative Chinese Medicine Dermatology] 
1 study (X. Guo, 2013) 
1) Shi Yong Pi Fu Ke Xue (实用皮肤科学) [Practical Dermatology] 
2) Zhuang Yi Yao Xian Dian Jiu Xue (壮医药线点灸学) [Zhuang Folk 
Medicine’s Thread Moxibustion] 
1 study (J. Zhong, 2010) 
1) Zhong Guo Lin Chuang Pi Fu Bing Xue (中国临床皮肤病学) 
[Clinical Dermatology of China] 
2) Zhong Yi Pi Fu Xing Bing Xue (中医皮肤性病学) [Chinese Medicine 
Dermatology and Venereology] 
1 study (J. Li, Huang, & Li, 2013) 
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Condition for diagnosis Diagnostic Criteria cited Studies 
Not stated 38 studies (G. Chen, 2013; Chu, 2005; C. 
Deng, 2009; Gao, 2006; L. Ji, 2005; L. Jiang, 
1998; Lan, 2013; Lei, 2005; C. Li, 2012; H. 
Li, 2005; H. Li, Yin, Sun, & Feng, 2007; Liao, 
2012; K. Lin, 2006b; T. Lin & Xu, 2003; G. 
Liu & Zhang, 2004; N. Liu & Zhang, 2012; 
W. Liu, 2002; Nie, 2002; Qie, Wang, Xie, & 
Lian, 2013; Qin & Zhang, 2011; Ren & Lu, 
2002; Shao & Niu, 2004; Sheng & He, 
1996; H. Wang, Guan, & Li, 2008; Q. Wang 
& Zhang, 2010; Z. Wu, 2013; H. Xiao, 1996; 
Xu & Guo, 2012; Xue, 2010; S. Yang, 2007; 
Ye, 2006; A. Zhang, Zhang, & Sun, 2006; H. 
Zhang, 2010a; X. Zhang & Li, 2011; X. 
Zhang & Zhang, 1994; Y. Zhang, 2013c; Y. 
Zhang & Li, 2009; X. Zhao & Li, 2004) 
Acute eczema Pi Fu Bing Xue Yu Xing Bing Xue (皮肤病学与性病学) [Dermatology 
and Venereology] 
1 study (Gan & Gong, 2011) 
1) Chang Jian Ji Bing De Zhen Duan Yu Liao Xiao Pan Duan Biao Zhun 
(常见疾病的诊断与疗效判断标准) [The Diagnostic and Clinical 
Efficacy Criteria of Common Diseases] 
2) Lin Chuang Ji Bing Zhen Duan Yi Ju Zhi Yu Hao Zhuan Biao Zhun (临
床疾病诊断依据治愈好转标准) [Standard of Clinical Diagnosis and 
Clinical Efficacy] 
1 study (H. Yu, Wang, Liu, & Su, 2007) 
Not stated 1 study (Yin, 2005) 
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Condition for diagnosis Diagnostic Criteria cited Studies 
Acute/subacute eczema Zhong Yi Bing Zheng Zhen Duan Liao Xiao Biao Zhun (中医病症诊断
疗效标准) [Chinese Medicine Diagnosis and Treatment Efficacy 
Criteria of Diseases] 
1 study (Cai, 2011b) 
Chronic eczema Kou Qiang, Pi Fu Ke Ji Bing Zhen Duan Biao Zhun (口腔、皮肤科疾病
诊断标准) [Diagnostic Criteria of Mouth and Skin Disease] 
1 study (Y. Zhang, 2013b) 
Pi Fu Xing Bing Xue (Editor: Zhang Xuejun) (皮肤性病学, 张学军主
编) [Dermatology and Venereology] 
1 study (Dai & Wang, 2007) 
Acute eczema or chronic 
eczema with acute 
exacerbation 
Zhong Yao Xin Yao Lin Chuang Yan Jiu Zhi Dao Yuan Ze (中药新药临
床研究指导原则) [Clinical Research Guidelines for Chinese Medicine 
and New Drugs] 
1 study (He, Kang, & Liu, 2009) 
Acute exudative eczema Lin Chuang Pi Fu Bing Xue (临床皮肤病学) [Clinical Dermatology] 1 study (Tao, 2010) 
Exudative eczema Not stated 1 study (R. Liu, Yong, Liao, Wang, & Ding, 
2005) 
Nai Xuan (奶癣) Zhong Yi Bing Zheng Zhen Duan Liao Xiao Biao Zhun (中医病症诊断
疗效标准) [Chinese Medicine Diagnosis and Treatment Efficacy 
Criteria of Diseases] 
5 studies (Cai, 2011a; L. Deng & Mao, 
2012; X. Huang & Deng, 2010; S. Tan, 
Wang, Deng, Feng, & Liang, 2008; M. 
Zhou, Tong, Zhou, & Zhang, 2012)  
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4.4.4 Interventions 
Among the TCM modalities, studies were identified for CHM (internal and external 
application), acupuncture, acupressure, Tuina, acupoint injection and bloodletting (via 
cupping and plum-blossom needling) (Table 4-2).  
 
Table 4-2: Identified TCM treatments as experimental trial interventions 
Experimental trial interventions Number of studies identified 
Oral CHM alone 30 
Oral CHM + WM 18 
Oral CHM + Topical CHM 22 
Oral CHM + Topical CHM + WM 3 
CHM enema 1 
Topical CHM alone 65 
Topical CHM + WM 34 
Topical CHM + Emollient 3 
Topical CHM + Saline wet wrap 1 
Topical CHM + Semiconductor laser 1 
Topical CHM + Acupressure 2 
Topical CHM + Tuina 1 
Topical CHM + Tuina + Swimming Therapy 1 
Acupuncture alone 3 
Acupressure alone 1 
Tuina alone 2 
Acupoint injection 2 
Bloodletting (Cupping + plum-blossom needling) 1 
Total 191 
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4.4.4.1 Chinese Herbal Medicine 
A total of 30 studies utilised oral CHM alone as the experimental trial intervention. Six of 
these studies, all from the English literature, were placebo-controlled; 20 studies utilised 
WM as control intervention; 3 used a different oral CHM formula as control intervention; 
and 1 study was a three-armed, comparing oral CHM to 1) WM alone and 2) no treatment 
(Table 4-3). Eighteen studies used a combination of oral CHM and WM, with 13 of the 
studies comparing to the same WM alone; 4 studies comparing to different WM; and 1 study 
was a three-armed trial comparing combined oral CHM and WM to 1) TCM alone and 2) WM 
alone (Table 4-4). 
Twenty-two studies utilised a combination of oral and topical CHM, with 16 studies 
comparing to WM alone; 2 studies comparing to the same oral CHM alone; 2 studies 
comparing to the same topical CHM alone; and another 2 studies comparing to a different 
topical CHM combined with WM (Table 4-5). 
Three studies utilised a combination of oral CHM, topical CHM and WM as the experimental 
trial intervention, one of which utilised the same topical CHM with WM as control 
intervention; another utilised a combination of the same WM alone; while another utilised a 
different WM alone (Table 4-6). 
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Table 4-3: Studies comparing oral CHM VS control intervention 
Author 
(Date) 
Experimental trial intervention Control intervention Treatment 
duration 
Other concurrent treatment (for all 
groups) 
Oral CHM VS Placebo 
Cheng, H. 
M. et al. 
(2011) 
Xiao Feng San granules Placebo 8 weeks treatment; 
4 weeks follow-up 
Maintain previous dermatological 
treatments 
Fung, A. Y. 
P. et al. 
(1999) 
Zemaphyte decoction Placebo 8 weeks treatment 
(4 weeks washout 
between crossover) 
Continue previous topical 
corticosteroid treatment without 
increasing frequency or potency 
Hon, K. L. E. 
et al. 
(2007)  
Pentaherbs capsules Placebo 2 weeks run-in; 12 
weeks treatment; 4 
weeks follow-up 
Routine medications, which principally 
included emollients, bath oils, soap 
substitutes, topical corticosteroids and 
oral systemic antihistamine 
Kobayashi, 
H. et al. 
(2010) 
Hochu-ekki-to granules Placebo 6 months Maintain previous treatments such as 
topical steroids (other than the 
strongest class), topical tacrolimus, 
emollients or oral antihistamines 
Sheehan, 
M. P. & 
Atherton, 
D. J. (1992) 
Zemaphyte decoction Placebo 4 weeks run-in; 8 
weeks treatment (4 
weeks washout 
between crossover) 
Corticosteroids and systemic 
antibiotics were not allowed 
Sheehan, 
M. P. et al. 
(1992) 
Zemaphyte decoction Placebo 8 weeks treatment 
(4 weeks washout 
between crossover) 
Maintain previous dermatological 
treatments 
Oral CHM VS WM 
Cai, X. 
(2012) 
Modified Shen Ling Bai Zhu San 
decoction  
Oral antihistamine (Loratadine)  28 days Topical corticosteroid (Triamcinolone 
acetonide) + Vitamin E cream 
Cao, M. 
(2009) 
Jian Pi Hua Shi Fang granules  Oral antihistamine (Cetirizine 
hydrochloride drops) 
1-4 weeks Pi Yan Xi Ji wash + Topical Huang Qin 
Gao  
Chen, Y. et 
al. (2006) 
Zi Yin Xi Feng Tang decoction  Oral corticosteroid (Prednisone) 4 weeks Not stated 
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Author 
(Date) 
Experimental trial intervention Control intervention Treatment 
duration 
Other concurrent treatment (for all 
groups) 
Cheng, X & 
Yue, D. 
(2012) 
Ping Wei Bao He Wan granules  Oral antihistamine 
(Chlorpheniramine) + vitamin C + 
other Western medication to stop 
itching 
1 week Topical corticosteroid (Hydrocortisone 
butyrate) 
Gong, X. et 
al (2010) 
Liang Xue Xiao Feng Fang 
decoction  
Oral antihistamine (Desloratadine 
suspension) 
28 days treatment; 
3 months follow-up 
Topical San Huang Xi Ji  
Guan, L. & 
Li, Q. 
(2006) 
Huo Xue Qu Feng decoction  Western medication such as 
antihistamines, corticosteroids, 
immunosuppressants, antibiotics  
1-2 months Not stated 
Huang, W. 
(2001) 
Xiao Feng Qu Zhen Tang decoction  Oral antihistamine (0.2% 
Diphenhydramine hydrochloride 
syrup) + Vitamin C + calcium lactate   
5 days treatment; 2 
months follow-up 
Not stated 
Li, X. (2004) Modified Bu Sheng Yang Xue Jian Ji 
decoction 
Oral antihistamine 
(Chlorpheniramine) + Vitamin C + 
transfer factor oral solution 
1 month Not stated 
Liao, X. 
(2012) 
CHM granules of Bai Zhu, Zhi Zi, Yi 
Yi Ren, Lai Fu Zi, Zhi Zi, Ma Ya, Bai 
Xian Pi, Shen Qu, Shan Zha, Sheng 
Di, Ze Xie, Che Qian Zi 
Topical anti-inflammatory agent 
(Bufexamac) 
3 days treatment; 1 
week follow-up 
Not stated 
Liu, J. & 
Ma, J. 
(2008) 
Modified Jian Pi Xiao Feng Tang 
decoction  
Oral antihistamine (Loratadine) 4 weeks treatment; 
3 months follow-up 
For obvious exudation, apply Ma Chi 
Xian decoction as a wet wrap; for dry 
skin, apply topical silicone oil 
Lu, H. & 
Zhao, Y. 
(2010) 
Modified Yin Qiao San Fang 
decoction  
Vitamin C + Oral antihistamine 
(Chlorpheniramine) 
7 days Not stated 
Qu, P. et al. 
(2010) 
Qing Re Qu Feng Tang decoction Oral antihistamine 
(Chlorpheniramine) + Vitamin C  
20 days treatment; 
3 months follow-up  
Not stated 
Shi, J. et al 
(2012) 
CHM formula decoction (Sha Shen, 
Huang Qi, Fang Feng, Bai Zhu, Yi Yi 
Ren, Fu Ling, Gan Cao)  
Oral antihistamine (Cetirizine)  3 weeks Not stated 
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Author 
(Date) 
Experimental trial intervention Control intervention Treatment 
duration 
Other concurrent treatment (for all 
groups) 
Song, X. 
(2008)  
Xiao Er Hua Shi Tang decoction  Oral antihistamine (Loratadine)  4 weeks Xiao Fan San wet wrap + topical 
Paeonol cream 
Sun, J. & 
Xu, C. 
(2006) 
Zi Yin Chu Shi Fang decoction  Oral antihistamine  (Cetirizine)  2 months 
treatment; 1 year 
follow-up 
For exudative cases, apply wet wrap 
with normal saline; for non-exudative 
cases, apply topical Qing Dai Gao 
Weng, S. 
(2013) 
CHM formula decoction to tonify 
Spleen, clear dampness, expel wind 
and stop itching (Dang Shen, Fu 
Ling, Bai Zhu, Gan Cao, Mai Ya, Gu 
Ya, Ma Ti Jin, Cang Er Zi, Di Fu Zi, 
Fang Feng)  
Oral antihistamine (Cetirizine drops)  30 days CHM external wash (Ji Li, Cang Er Zi, Di 
Fu Zi, Fang Feng, Lu Cha)  
Xie, Y. & 
Sun, Z. 
(2013) 
CHM formula decoction (Sha Shen, 
Huang Qi, Fang Feng, Bai Zhu, Yi Yi 
Ren, Fu Ling, Gan Cao)  
Oral antihistamine (Cetirizine)  Not stated Not stated 
Zheng, Y. et 
al. (2012) 
Bu Pi Qu Feng Fang granules  Oral antihistamine (Loratadine)  4 weeks Topical Fu Fang Dang Gui Bo He Gao  
Zhong, W. 
(2002) 
Modified Chu Shi Wei Ling Tang 
decoction for acute phase/wind 
damp (Jin Yin Hua, Ze Xie, Bai Xian 
Pi, Huo Xiang, Hua Shi, Fu Ling, 
Fang Feng, Huang Lian, Mu Tong, Yi 
Yi Ren)  
OR 
CHM formula decoction for 
remission phase/blood deficient 
and wind dryness (Sheng Di Huang, 
Xuan Shen, Fu Ling, Ze Xie, Bai Xian 
Pi, He Shou Wu, Dang Gui, Chuan 
Xiong, She Chuang Zi)  
Oral antihistamine (Cyproheptadine) 
+ Vitamin C  
30 days Not stated 
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Author 
(Date) 
Experimental trial intervention Control intervention Treatment 
duration 
Other concurrent treatment (for all 
groups) 
Zhou, F. 
(2012) 
Modified Kang Min Yi Hao Fang 
decoction 
Oral antihistamine (Loratadine) 
1/day 
4 weeks Topical Zhang Nao Shuang 
Oral CHM 1 VS Oral CHM 2 
Choi, I. H. 
et al. 
(2012) 
TJ-15 (Huang Lian Jie Du Tang) + TJ-
17 (Wu Ling San) 
TJ-15 (Huang Lian Jie Du Tang)  4 weeks Emollients, lotions and ointments that 
do not contain steroid 
Huang, H. 
& Wang, Z. 
(2009)  
Xiao Gan Hua Shi San granules  Shen Ling Bai Zhu San  ~ 4 weeks 
treatment 
(Continue herbs for 
2 weeks after 
symptoms 
disappear); 3 
months follow-up 
For acute phase, apply topical 
corticosteroid (Hydrocortisone 
butyrate) 
Zhou, H. 
(2000) 
CHM formula decoction for damp 
heat stagnation (Cang Zhu, Yi Mi, 
Ma Chi Xian, Di Fu Zi, Dong Gua Pi, 
Huang Qin, Fang Feng, Jiao San 
Xian, Lai Fu Zi, Gan Cao) 
CHM formula decoction to tonify 
Spleen and nourish blood (Bai Zhu, 
Hou Po, Dang Gui, Sheng Di, Mai 
Dong, Chi Shao, Bai Xian Pi, Fu Ling, 
Ze Xie, Gan Cao) 
1 month 
treatment; 6 
months follow-up  
Participants were not allowed to use 
any other medication 
Oral CHM VS WM VS No Treatment 
Zhang, Q. 
(2005) 
Jian Pi Hua Shi Fang granules  1. Oral antihistamine 
(Chlorpheniramine)  
2. No treatment 
3 months Pi Yan Xi Ji wash + Topical Huang Qin 
Gao 
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Table 4-4: Studies comparing combined oral CHM and WM VS control intervention 
Author 
(Date) 
Experimental trial intervention Control intervention Treatment 
duration 
Other concurrent 
treatment (for all groups) 
Oral CHM + WM VS WM 
Bao, L. 
(2009) 
Run Fu Zhi Yang Tang + WM (same as control 
intervention) 
Oral antihistamine (Desloratadine tablets OR 
suspension) + Topical corticosteroid 
(Budesonide)  
4 weeks 
treatment but 
stop using 
Budesonide 
when rash 
disappears 
Not stated 
Chen, B. & 
Zhang, Y. 
(2011) 
Jian Pi Li Shi Tang decoction + WM (same as 
control intervention) 
Oral antihistamine (Cetirizine & Loratadine)  4 weeks Not stated 
Chen, H. S. 
(2008)  
Xiao Er Qi Xing Cha granules + WM (same as 
control intervention) 
Not specific – mainly antihistamines and 
sedative hypnotics; for acute phase, take 
Vitamin C, calcium supplements and may 
also take corticosteroids (for short term); 
topical application of Hydrocortisone and 
calamine lotion 
Not stated Not stated 
Huang, Y. 
et al. 
(2004) 
Jian Pi Shen Shi granules + WM (same as 
control intervention) 
Oral antihistamine (Cyproheptadine tablets) 
+ Topical Triamcinolone and urea cream 
4 weeks Not stated 
Lin, H. 
(2006) 
Jian Pi Li Shi Tang decoction + WM (same as 
control intervention) 
Oral antihistamine (Cetirizine hydrochloride 
drops) + topical corticosteroid 
(Hydrocortisone butyrate) 
21 days 
treatment; 6 
months 
follow-up  
Not stated 
Lin, S. 
(2011) 
Jian Pi Zhi Yang Tang decoction WM (same 
as control intervention) 
Oral antihistamine (Loratadine)  4 weeks Topical Fu Fang Dang Gui 
Bo He Gao  
Ou, B. et al. 
(2006) 
Modified Si Wan Feng Tang decoction + WM 
(same as control intervention) 
Oral antihistamine  (Loratadine) + topical 
corticosteroid (Mometasone furoate) 
4 weeks Not stated 
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Author 
(Date) 
Experimental trial intervention Control intervention Treatment 
duration 
Other concurrent 
treatment (for all groups) 
Sheng, H. & 
He, Q. 
(1996) 
Modified Qu Shi Tang decoction + WM 
(same as control intervention) 
Oral antihistamine (Chlorpheniramine) + 
Topical Di Lu Gan You (combination of 
Dexamethasone, chloromycetin/linomycin 
and glycerin oil) 
14 days Not stated 
Shi, Y. J. et 
al. (2008) 
Modified Dang Gui Yin decoction + WM 
(same as control intervention) 
Oral antihistamine (Loratadine) + Topical 
corticosteroid (Hydrocortisone butyrate) 
4 weeks Not stated 
Wang, L. & 
Zhou, L. 
(2002) 
Qing Re Li Shi He Ji liquid solution + WM 
(same as control intervention) 
Oral antihistamine (Loratadine) + Topical 
corticosteroid (Hydrocortisone butyrate) 
4 weeks 
treatment; 6 
weeks follow-
up 
Not stated 
Zhang, N. 
(2012) 
Xing Pi Yang Er granules + WM (same as 
control intervention)  
Oral Glycyrrhizin tablets  Not stated Topical moisturisers 
Zhang, T. 
(2013) 
Modified Si Chong Xiao Feng San + WM 
(same as control intervention) 
Oral antihistamine (Chlorpheniramine) + 
Topical corticosteroid (Mometasone 
furoate); if infection present, apply 
erythromycin ointment until infection clears 
1 month Not stated 
Zhang, Y. 
(2013) 
 
 
 
 
 
 
 
 
 
 
 
 
Gui Di Qu Feng Tang decoction + WM (same 
as control intervention) 
Oral antihistamine (Ebastine) + Topical 
corticosteroid (Budesonide) 
4 weeks 
treatment; 2 
weeks follow-
up 
Not stated 
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Author 
(Date) 
Experimental trial intervention Control intervention Treatment 
duration 
Other concurrent 
treatment (for all groups) 
Oral CHM + WM 1 VS WM 2 
Fan, P. 
(2012) 
Jing Fu Zhi Yang granules +  Week 1 WM: 
Topical Neomycin hydrocortisone ointment 
(morning & night) + Paeonol ointment 
(afternoon); Week 2 WM: Paeonol ointment  
(morning & night) + Neomycin 
hydrocortisone (afternoon); Week 3 WM: 
Paeonol ointment (morning & night) 
Week 1 & 2: Topical Neomycin 
hydrocortisone ointment (twice/day)  
Week 3: Topical Neomycin hydrocortisone 
ointment (once/day)  
 
3 weeks 
treatment; 4 
weeks follow-
up 
Not stated 
Liu, N. & 
Zhang, X. 
(2012) 
Hua Shi Tang decoction + Ku Shen Pian + 
Topical compound boric acid and zinc oxide 
ointment 
Oral antihistamine (Loratadine) + Topical 
compound boric acid and zinc oxide 
ointment 
4 weeks Not stated 
Lu, H. 
(2002) 
Dang Gui Sheng Di Huang Fang  decoction + 
Topical Heparin ointment 
Oral antihistamine (Triprolidine 
hydrochloride capsules) + Vitamin C + 
Topical Heparin ointment 
30 days Not stated 
Peng, Y. et 
al. (2013) 
Jian Pi Qu Feng Fang decoction + Topical 
urea cream  
Oral antihistamine (Cetirizine) + Topical urea 
cream 
4 weeks Not stated 
Oral CHM + WM VS Oral CHM VS WM 
Zhao, Z. et 
al. (2010) 
Modified Jian Pi Xiao Dao Tang decoction + 
Oral antihistamine (Loratadine) + Vitamin C  
1. Modified Jian Pi Xiao Dao Tang decoction 
2. Oral antihistamine (Loratadine) + Vitamin 
C 
6 weeks For acute stages, wash or 
wet wrap with CHM 
formula (Jin Yin Hua, Di 
Fu Zi, She Chuang Zi, San 
Ya Ku, Di Dan Tou, Hei 
Mian Shen) 
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Table 4-5: Studies comparing combined oral and topical CHM VS control intervention 
Author 
(Date) 
Experimental trial intervention Control intervention Treatment 
duration 
Other concurrent 
treatment (for all groups) 
Oral CHM + Topical CHM VS WM 
Bu, J. & Li, 
B. (2003) 
Oral CHM: Modified Si Wu Tang decoction + 
Topical CHM (wash): Bai Xian Pi, Tao Ren, 
Fang Feng, Shuang Hua, Ku Shen, Di Fu Zi, Ye 
Jiao Teng  
Oral antihistamine (Chlorpheniramine) + 
Topical Pi Kang Shuang (Triamcinolone 
acetonide acetate and Miconazole nitrate 
cream) 
3-5 weeks Not stated 
Chi, H. 
(2012) 
Oral and Topical (wet wrap) CHM: Long Mu 
Tang Fang decoction  
Oral antihistamine (Loratadine) + Topical 
corticosteroid (0.1% Hydrocortisone 
butyrate) 
8 weeks Not stated 
Dai, G. & 
Wang, C. 
(2007) 
Oral CHM: Modified Shen Ling Bai Zhu San 
decoction + Topical CHM (wash): Bing Pian, 
Ku Shen, Zi Cao, She Chuang Zi, Chan Yi, Che 
Qian Zi 
Oral antihistamine (Cetirizine drops) + 
Topical corticosteroid (Pevisone) 
20 days Not stated 
Fu, H. & Xu, 
L. (2000) 
Oral CHM: Pi Yan Yi Hao or Pi Yan Er Hao 
granules + Topical CHM: Shi Fu Fang wet 
wrap OR Huang Fu Shuang cream 
2% boric acid wet wrap 
OR 
Topical corticosteroid (0.025% 
dexamethasone) 
15 days Not stated 
Lang, N. 
(2011) 
Oral and Topical (wet wrap) CHM: Long Mu 
Tang decoction  
Oral antihistamine (Loratadine) + Topical 
corticosteroid (0.1% Hydrocortisone 
butyrate) 
8 weeks Not stated 
Li, H. 
(2010) 
Oral CHM: Modified Qu Shi Tang decoction + 
Topical CHM (bath): Ma Chi Xian, Huang Bai 
Oral antihistamine (Chlorpheniramine) + 
Topical corticosteroid (0.1% Hydrocortisone 
butyrate) + Topical zinc oxide cream; for 
severe exudation, apply 2% boric acid wet 
wrap before applying hydrocortisone  
2 weeks Not stated 
Liu, H. 
(2006)  
Oral CHM: Modified Cang Yi Tang decoction 
+ Topical CHM: Qing Dai You Gao; for 
exudative cases, also apply CHM wet wrap: 
Huang Bai, Jin Yin Hua) 
Oral antihistamine (Terfenadine) + Topical 
corticosteroid (Dexamethasone) 
2 months Not stated 
 
113 
 
Author 
(Date) 
Experimental trial intervention Control intervention Treatment 
duration 
Other concurrent 
treatment (for all groups) 
Ma, Y. et al. 
(2010) 
Oral CHM: Modified Jian Pi Run Fu Tang 
decoction + Topical CHM: Gan Cao You 
Antihistamine (oral) (Loratadine) 10mg 
1/day (5mg for 14 years and under) + Topical 
Non-steroidal anti-inflammatory drug 
(Flufenamic acid ointment) 
4 weeks Not stated 
Tian, Y. 
(2011) 
Oral and Topical (wash) CHM: Modified Qu 
Shi Tang decoction  
Oral antihistamine (Chlorpheniramine) + 
Topical corticosteroid (0.1% hydrocortisone 
butyrate) + other WM (including 
Diphenhydramine hydrochloride syrup, 
Vitamin B supplements, Vitamin C 
supplements et cetera) + Antibiotics if 
infection present 
4 weeks Not stated 
Wang, J. 
(2004) 
Oral CHM: CHM formula decoction according 
to syndrome differentiation (Yin Chen, Fu 
Ling Pi, Shan Yao, Yi Yi Ren, Cang Zhu, Huang 
Bai, Wu Mei, Hua Jiao, Huang Lian, Hua Shi, 
Pu Gong Ying, Jin Yin Hua, Chan Tui, Lian 
Qiao, Zhu Ye, Deng Xin Cao) + Topical CHM 
(powder) for cases with severe 
ulceration/exudation: Cang Zhu, Huang Bai, 
Shan Yao, Da Zao, Bing Pian  
Oral antihistamines such as 
Diphenhydramine hydrochloride syrup or 
tablets + Topical zinc oxide cream OR Topical 
zinc oxide cream with added prednisone 
2 weeks Not stated 
Xiao, M. 
(2008) 
Oral and Topical (wet wrap) CHM: Ma Chi 
Xian Tang decoction 
Oral antihistamine (Chlorpheniramine) + 3% 
boric acid wet wrap 
2 months 
treatment; 3 
months 
follow-up 
For dryness, apply 
sesame oil; participants 
were not allowed to use 
any medication which 
may interfere with the 
study 
Yang, Y. et 
al. (2007) 
Oral CHM: Jian Pi Zhi Yang granules + Topical 
CHM: Xiao Yan Xuan Shi ointment 
Oral antihistamine (Loratadine) + Topical 
corticosteroid (1% Hydrocortisone butyrate) 
4 weeks Not stated 
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(Date) 
Experimental trial intervention Control intervention Treatment 
duration 
Other concurrent 
treatment (for all groups) 
Zhang, Y. et 
al. (2010) 
Oral CHM: Modified Qu Shi Tang decoction + 
Topical CHM (bath): Huang Bai, Ma Chi Xian, 
Bai Fan 
Oral antihistamine (Chlorpheniramine) + 
Topical CHM: Pi Fu Kang cream; for acute 
phase with ulceration, apply Berberine 
solution  
4 weeks Not stated 
Zhao, Y. 
(2011) 
Oral and Topical (wet wrap) CHM: Long Mu 
Tang Yi Hao Fang decoction OR Long Mu 
Tang Er Hao Fang decoction  
Oral antihistamine (Cetirizine) + Topical 
corticosteroid (0.1% Hydrocortisone 
butyrate) 
8 weeks Not stated 
Zhao, Y. 
(2013) 
Oral and Topical (wet wrap) CHM: Zhen Xin 
An Shen Fang Yi Hao decoction OR Zhen Xin 
An Shen Fang Er Hao decoction 
Oral antihistamine (Loratadine) + Topical 
corticosteroid (0.1% Hydrocortisone 
butyrate); for severe exudation, apply 
normal saline wet wrap 
8 weeks 
treatment; 24 
weeks follow-
up  
Not stated 
Zheng, L. et 
al. (2010) 
Oral and Topical (wet wrap) CHM: Modified 
Qu Feng Zao Shi Tang decoction  
Topical corticosteroid (Hydrocortisone 
butyrate) 
4 weeks Not stated 
Oral CHM + Topical CHM VS Oral CHM 
Chu, Q. 
(2005) 
Oral CHM: CHM formula decoction (Tu Fu 
Ling, Huang Qin, Bai Xian Pi, Yin Chen, Sheng 
Yi Yi Ren, Shan Zhi, Ku Shen, Chan Yi, Zi Cao, 
Sheng Shi Gao) + Topical CHM (wash/bath): 
Wai Xi Fang (Bai Fan, Ma Chi Xian, Tu Fu Ling, 
Di Fu Zi, Ku Shen, She Chuang Zi)  
Oral CHM: CHM formula decoction (Tu Fu 
Ling, Huang Qin, Bai Xian Pi, Yin Chen, Sheng 
Yi Yi Ren, Shan Zhi, Ku Shen, Chan Yi, Zi Cao, 
Sheng Shi Gao) 
2 weeks Not stated 
Zhang, X. 
(2010) 
Oral CHM: Modified Zhi Zi Qin Lian Tang 
granules + Topical CHM: Qi Shen Lian Ruan 
Gao  
 
 
 
 
 
 
 
Oral CHM: Modified Zhi Zi Qin Lian Tang 
granules 
Not stated Not stated 
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Author 
(Date) 
Experimental trial intervention Control intervention Treatment 
duration 
Other concurrent 
treatment (for all groups) 
Oral CHM + Topical CHM VS Topical CHM 
He, Y. & 
Wang, B. 
(2009) 
Oral CHM: Jiao Zhi Zi, Dan Pi, Zi Cao, Cao He 
Che, Yin Hua, Lian Qiao, Cang Zhu, Ku Shen, 
Jing Jie, Bai Xian Pi, Fu Ling Pi, Ze Xie, Gan 
Cao, Yi Yi Ren + Topical CHM: Lu Gan Shi, Wu 
Zei Gu, Mi Tuo Zeng, Hua Shi, Huang Bai, 
Bing Pian, Qing Dai 
Topical CHM formula: Lu Gan Shi, Wu Zei Gu, 
Mi Tuo Zeng, Hua Shi, Huang Bai, Bing Pian, 
Qing Dai 
1 month Not stated 
Zhou, M. et 
al. (2012) 
Oral CHM: Modified Sheng Jiang San 
decoction (given to breastfeeding mothers 
of infant participants) + Topical CHM: Lian 
Bai Yang Xin Gao  
Topical CHM: Lian Bai Yang Xin Gao  10 days Not stated 
Oral CHM + Topical CHM 1 VS Topical CHM 2 + WM 
Fu, Z. 
(2013) 
Oral CHM: Modified Qu Shi Tang decoction + 
Topical CHM (bath): Huang Bai, Ma Chi Xian, 
Bai Fan 
Oral antihistamine (Chlorpheniramine) + 
Topical CHM (Pi Fu Kang cream); for acute 
phase with ulceration, apply Berberine 
solution  
28 days Not stated 
Li, C. (2012) Oral CHM: Qu Shi Tang decoction + Topical 
CHM (bath): CHM formula for acute phase to 
clear heat, dry damp, nourish blood and 
expel wind (Dang Gui, Sheng Di, Chi Shao, 
Fang Feng, He Shou Wu, She Chuang Zi, Yu 
Zhu, Guan Zhong, Bing Lang, Tu Fu Ling) OR 
CHM for chronic phase to transform damp, 
clear heat, disperse wind and stop itching 
(Fu Ping, Zi Su Ye, Qing Dai, Zi Cao, He Ye, Bai 
Jiang Cao, Di Fu Zi, Sheng Di, Gan Cao) 
Oral antihistamine (Chlorpheniramine) + 
topical CHM: Kang Fu Shuang cream; for 
acute phase with ulceration and exudation, 
apply Berberine solution 
4 weeks Not stated 
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Table 4-6: Studies comparing combined oral CHM, topical CHM and WM VS control intervention 
Author 
(Date) 
Experimental trial intervention Control intervention Treatment 
duration 
Other concurrent 
treatment (for all groups) 
Oral CHM + Topical CHM + WM VS Topical CHM + WM  
An, J. et al. 
(1996) 
Oral and Topical CHM according to 
syndrome differentiation: 
1) For damp-heat: Oral CHM: Bai Zhu, Zhi Ke, 
Yi Mi, Jiao Bing Lang, Jiao Zhi Zi, Chao Lai 
Fu Zi, Huang Qin, Da Qing Ye, Ma Chi Xian, 
Bai Xian Pi, Dong Gua Pi + Topical CHM 
(wet wrap): Ma Chi Xian, Huang Bai; for 
skin damage, apply topical CHM: Gan Cao 
You + Qu Shi San; for non-exudative 
erythematous papules, apply Topical CHM 
Chu Fei Fen OR Huang Lian Gao + Topical 
WM (Triamcinolone cream) 
2) For Spleen deficiency: Oral CHM: Chao Bai 
Zhu, Chao Zhi Zi, Chao Yi Mi, Chao Lai Fu 
Zi, Hou Po, Bai Xian Pi, Shou Wu Teng, 
Dang Gui, Ku Shen, Chi Bai Shao, Sheng Di 
+ Topical CHM: Huang Lian Gao + Topical 
corticosteroid (Triamcinolone cream) + 
Oral antihistamine (Chlorpheniramine or 
Diphenhydramine hydrochloride) 
 
 
 
 
 
 
 
 
Antihistamines (not specified) + Topical CHM 
and WM (same as treatment group) 
1 month Adjuvant treatments such 
as Vitamin B6 and 
multivitamin 
supplements 
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Author 
(Date) 
Experimental trial intervention Control intervention Treatment 
duration 
Other concurrent 
treatment (for all groups) 
Oral CHM + Topical CHM + WM VS WM 
Zhang, J. 
(2012) 
Oral CHM: CHM formula decoction according 
to syndrome differentiation (for foetal heat: 
Shu Feng Dao Chi San decoction; for Spleen 
dampness: Chu Shi Wei Ling Tang decoction; 
for Yin deficiency and blood dryness: 
Modified Dang Gui Yin Zi) + Topical CHM: Shi 
Zhen San + WM (same as control 
intervention) 
Oral antihistamine (Ranitidine + 
Diphenhydramine hydrochloride syrup 
1 month Not stated 
Oral CHM + Topical CHM + WM 1 VS WM 2 
Zhu, Z. 
(2008) 
Oral and Topical (wash) CHM: Modified CHM 
formula decoction (Sheng Shi Gao Fen, Bo 
He, Hua Shi Fen, Bai Zhi, Ku Shen, Lu Gen, 
Huang Qin, Mu Dan Pi, Huang Bai, Sheng Gan 
Cao, Bai Xian Pi, Di Fu Zi + Topical urea 
cream  
Oral antihistamine (Ketotifen) + Topical 
corticosteroid (Hydrocortisone butyrate) + 
Topical urea cream 
4 weeks 
treatment; 1 
year follow-up 
Not stated 
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Sixty-five studies used topical CHM alone as the experimental trial intervention; topical CHM 
included CHM which was applied as creams, ointments, pastes, sprays, washes or baths, or 
via fumigation or wet wraps. Fifty-nine studies compared topical CHM to WM; 1 study 
compared to a different topical CHM alone; 1 study compared to a different topical CHM 
combined with WM; 1 study compared topical CHM to saline wash; 1 study compared to 
water bath; 1 study was a three-armed trial which compared topical CHM to 1) WM 1 and 2) 
WM 2; and 1 study was a four-armed trial which compared topical CHM to 1) the same 
topical CHM of a different concentration, 2) WM and 3) vehicle (Table 4-7). 
Thirty-four studies evaluated the combination treatment with topical CHM and WM, out of 
which 15 compared to the same WM alone; 12 compared to different WM; 1 compared to 
the same topical CHM alone; 2 compared with different topical CHM; 1 compared to a 
different combination of topical CHM and WM; 3 were three-armed trials which compared 
to 1) the same topical CHM alone and 2) the same WM alone (Table 4-8). 
Nine studies utilised a combination treatment of topical CHM and other therapies, which 
included acupressure, Tuina, swimming therapy, semiconductor laser, emollients and normal 
saline wet wrap. Among the 9 studies, 4 utilised WM as control intervention; 1 compared to 
the same topical CHM alone; 2 compared to a different topical CHM; 2 were three-armed 
studies: 1 which compared to 1) the same topical CHM alone and 2) the same other therapy 
alone, while the other study compared to 1) the same topical CHM alone and 2) WM (Table 
4-9). 
Only 1 study utilised CHM as an enema compared to WM (Z. Gong & Zhou, 2007). The 
formula applied consisted of Jin Yin Hua, Huai Hua, Di Fu Zi, Huang Lian and Lian Qiao while 
the WM intervention consisted of the oral antihistamine, chlorpheniramine, and the TCS, 
hydrocortisone butyrate. 
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Table 4-7: Studies comparing topical CHM VS control intervention 
Author 
(Date) 
Experimental trial intervention Control intervention Treatment 
duration 
Other concurrent 
treatment (for all groups) 
Topical CHM VS WM  
Cai, X. 
(2011a) 
Fu Fang Ku Shen Xi Ji lotion Topical calamine lotion  1 week Not stated 
Cai, X. 
(2011b) 
Bai Bei Shi Zhen San powder Topical calamine lotion + Topical 
corticosteroid (Fluocinonide) 
10 days For skin damage of large 
surface areas, take oral 
antihistamine 
(Chlorpheniramine) + 
Vitamin C; if infection 
present, take oral 
antibiotics 
Chen, G. 
(2013) 
Fu Ning lotion Topical corticosteroid (Hydrocortisone 
butyrate) 
Not stated Not stated 
Chen, J. & 
Zhang, Z. 
(2010) 
Shi Yang Ye solution + Shi Yang Gao cream  Conventional treatment (no details 
provided) 
Not stated Not stated 
Chen, L. 
(2008) 
CHM formula (fumigation): Jin Yin Hua, Bai 
Xian Pi, Wan Can Sha, Chan Yi, Ye Ju Hua, 
Pu Gong Ying, Lian Qiao, Fu Ling, Fang Feng 
Topical corticosteroid (0.1% 
Hydrocortisone butyrate) + Oral 
antihistamine (Loratadine syrup)  
Not stated Not stated 
Deng, L. & 
Mao X. 
(2012) 
Shi Zhen Gao cream  Topical corticosteroid (0.025% 
Fluocinonide ointment); if severe, take 
oral antibiotics and antihistamine 
(Chlorpheniramine) as appropriate 
7 days Not stated 
Fu, M. & 
Zhang, S. 
(2005) 
Suan Ma Gao cream  Topical corticosteroid: 999 Ping Yan Ping 
(Dexamethasone acetate cream)  
2 weeks for 
acute and 
subacute cases; 
4 weeks for 
chronic cases 
Participants were not 
allowed to use any other 
medication 
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Author 
(Date) 
Experimental trial intervention Control intervention Treatment 
duration 
Other concurrent 
treatment (for all groups) 
Gan, J. & 
Gong, L. 
(2011) 
Qing Ge San powder mixed with sesame oil Topical zinc oxide cream 2 weeks Not stated 
Gao, Y. 
(2006) 
Xiao Yan Xuan Shi Yao Gao cream Topical Qu Mi Xin Ruan Gao 
(Triamcinolone Acetonide Acetate and 
Miconazole Nitrate and Neomycin Sulfate 
Cream)  
2 weeks If more than 3 body areas 
affected, take oral 
antihistamine 
(Chlorpheniramine) 
Gong, J. et al. 
(2012) 
CHM wash: Ye Ju Hua, Bai Xian Pi, Qian Li 
Guang, Pu Gong Ying, An Ye, Ku Shen, Er 
Cha; for exudative cases, apply formula as 
wet wrap 
Topical corticosteroid (Hydrocortisone 
butyrate) 
2 weeks Not stated 
Guan, J. & 
Dong, X. 
(2009) 
Xiao Yan Zhi Yang Xi Ji fumigation and 
wash 
Xin Fu Song Ruan Gao cream (contains 
antibiotics + corticosteroids)  
6 weeks Not stated 
Guan, X. 
(2009) 
Fu Fang Huang Bai Ye as wet wrap 3% boric acid wet wrap 9 days Oral antihistamine 
(Chlorpheniramine) 
Guo, Y. & Ye, 
J. (2011) 
Run Fu Zhi Yang San wet wrap  Topical Kenacomb ointment (contains 
Triamcinolone acetonide, nystatin, 
gramicidin and neomycin)  
3 weeks  Participants were not 
allowed to consume 
systemic corticosteroids, 
antibiotics or antifungals 
Han, X. 
(2011) 
Chuan Bai Zhi Yang Xi Ji lotion Topical corticosteroids (not specified) + 
Oral antihistamines (as required) 
7 days Not stated 
He, Y. et al. 
(2000) 
Shuang Shen Long Pen Wu Ji spray Topical calamine lotion 6 days Not stated 
Huang, J. et 
al. (2011) 
Da Huang Gao cream (contains CHM and 
WM) 
Topical corticosteroid (Fluocinonide) 3-9 days Not stated 
Huang, S. 
(2010) 
CHM wash or wet wrap (Ku Shen, Huang 
Bai, Di Yu, Yin Hua, Di Fu Zi, She Chuang Zi, 
Bai Xian Pi, Huang Qin, Ye Ju Hua; For 
exudative cases,  add Cang Zhu or Ku Fan 
Topical antibiotic: Bai Duo Bang 
(Mupirocin cream) 
1 week Not stated 
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Author 
(Date) 
Experimental trial intervention Control intervention Treatment 
duration 
Other concurrent 
treatment (for all groups) 
Huang, X. 
(2011) 
She Fu Wai Xi Fang wash/bath Topical corticosteroid: Pi Yan Ping Shuang 
(Dexamethasone acetate cream) 
7 days Not stated 
Huang, X. & 
Deng, L. 
(2010) 
Bao Er Gao cream Topical corticosteroid (0.025% 
fluocinonide); if condition is severe, take 
oral antibiotics and antihistamine 
(chlorpheniramine) as appropriate 
7 days Not stated 
Huang, Z. et 
al. (2010) 
Chu Shi Zhi Yang Ruan Gao ointment Topical corticosteroid (Clobetasol 
propionate) 
2 weeks Oral antihistamine 
(Promethazine syrup; for 
acute and subacute cases, 
use 3% boric acid wet wrap 
+ infrared radiation 
Jiang, L. 
(1998) 
CHM wash (Ma Chi Xian, Jin Yin Hua, Pu 
Gong Ying, Ye Ju Hua, Di Fu Zi)  
Oral antihistamine (chlorpheniramine), + 
Vitamin C + calcium supplements + 
Topical calamine lotion + Oral or topical 
antibiotics as required 
3 days Not stated 
Jiang, N. 
(2008) 
Zhong Yao Xi Ye lotion; for exudative cases, 
apply formula as wet wrap  
Topical corticosteroid (Hydrocortisone 
butyrate) 
7 days Not stated 
Lan, Z. 
(2013) 
Bing Huang Fu Le Ruan Gao ointment For exudative cases, apply 3% boric acid 
wet wrap; for non-exudative cases, apply 
calamine lotion and topical corticosteroid 
(Fluocinonide) 
7 days 
treatment; 7 
days follow-up 
Oral antihistamine 
(Promethazine); if white 
blood cell count is high, 
take oral antibiotics 
(Amoxicillin granules) for 3 
days 
Li, H. (2005) Erfukang liniment or wet wrap Topical corticosteroid (Pevisone) 1 week Not stated 
Li, H. et al. 
(2007) 
Ku Shen Qu Shi Xi Ji scrub  Conventional treatment (no details 
provided) 
Not stated Not stated 
Lin, T. & Xu, 
J. (2003) 
San Qi Fang Ji topical application or wet 
wrap  
Topical corticosteroid (Triamcinolone 
acetonide) 
4 weeks Moisturisers; participants 
were not allowed to use 
any other medication 
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Author 
(Date) 
Experimental trial intervention Control intervention Treatment 
duration 
Other concurrent 
treatment (for all groups) 
Liu, W. 
(2002) 
Modified San Huang Tang wet wrap  Conventional treatment  with 
antihistamine and calcium supplement  
10 days 
treatment; 3 
months follow-
up 
Not stated 
Liu, R. et al. 
(2005) 
Chu Shi Yi Hao Xi Ji wet wrap Topical corticosteroid (Hydrocortisone 
butyrate); for severe ulceration and 
exudation, apply 3% boric acid wet wrap  
7 days Not stated 
Luo, W. 
(2010) 
Chu Shi Zhi Yang Ruan Gao ointment Topical corticosteroid (Hydrocortisone 
butyrate) 
4 weeks  Oral antihistamine 
(Mizolastine) 
Lu, H. (2011) Fu Fang Ma Chi Xian Xi Ji wet wrap Topical corticosteroid (Hydrocortisone 
butyrate) 
7 days 
treatment; 7 
days follow-up 
Not stated 
Qian, J. 
(2006) 
Topical Erfukang liniment Topical corticosteroid (Hydrocortisone 
butyrate) 
1 week 
treatment; 2 
weeks follow-up 
Not stated 
Qian, X. et al. 
(2005) 
Topical Erfukang liniment; if large surface 
area is affected, dilute liniment to use as 
wash; for exudative cases, apply as wet 
wrap 
Topical corticosteroid (Dexamethasone) 5 days Oral antihistamine 
(Promethazine) 
Ren, Y. & Lu, 
X. (2002) 
Qing Re Shou Lian Tang wet wrap  Boric acid wet wrap  7 days Oral antihistamine 
(Chlorpheniramine) + 
Vitamin C 
Shao, M. & 
Niu, H. 
(2004) 
Qu Shi Zhi Yang San wet wrap Topical corticosteroid (Halcinonide) 9 days Not stated 
Tan, L. 
(2011) 
Topical Qu Shi Fang  Topical Calamine lotion 2 weeks 
treatment; 2 
weeks follow-up 
Basic treatment (mainly 
antihistamines + sedative 
hypnotics; for acute 
phases, take Vitamin C and 
calcium supplements) 
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Author 
(Date) 
Experimental trial intervention Control intervention Treatment 
duration 
Other concurrent 
treatment (for all groups) 
Tan, S. et al. 
(2008)  
Huang You Gao cream  Topical corticosteroid (0.025% 
Fluocinonide); if severe, take oral 
antibiotics and antihistamine 
(Chlorpheniramine) as appropriate 
7 days Not stated 
Tian, J. 
(2002) 
Topical Zi Huang You Gao cream  Topical Ben Yang Gao (combination of 
Diphenhydramine hydrochloride + zinc 
oxide) 
Not stated For exudative cases, apply 
Yin Hua Tang wet wrap; for 
dryness, wash with Yin Hua 
Tang 
Wang, H. et 
al. (2008)  
Shi Zhen San /Gao; for acute phase or 
severe skin damage, apply as powder; for 
subacute or chronic phase, mix formula 
with sesame oil to apply as paste  
Conventional treatment: For localised 
ulceration/exudation, apply wet wrap 
using 2% boric acid or normal saline + 
Topical 40% zinc oxide ointment + Topical 
corticosteroid (not specified) for 
subacute cases 
Not stated  Not stated 
Wang, P. et 
al. (2008) 
Chu Shi Zhi Yang Ruan Gao ointment Topical Vitamin B6  1 week Not stated 
Wang, Q. 
(2010) 
Chu Shi Hu Ji paste Topical corticosteroid (Hydrocortisone 
butyrate) 
~20 days For exudative cases, apply 
3% boric acid wet wrap; 
participants were not 
allowed to use any 
systemic medication, and 
soaps or cleansers which 
may cause irritation  
Wei, H. & 
Liu, J. (2011) 
Fu Fang Huang Bai Ye wet wrap 2% boric acid wet wrap 7 days Not stated 
Wu, Z. 
(2013) 
Topical CHM powder (Qing Dai, Huang Bai, 
Hua Shi, Gan Cao) 
Topical Calamine lotion  7-14 days Not stated 
Wu, Z. & Li, 
W. (2010) 
CHM wet wrap (Ma Chi Xian, Huang Bai, Ku 
Shen, Huang Lian, Zi Hua Di Ding, Sheng 
Gan Cao) 
3% boric acid wet wrap 7 days Not stated 
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Author 
(Date) 
Experimental trial intervention Control intervention Treatment 
duration 
Other concurrent 
treatment (for all groups) 
Xiao, C. et al. 
(2013) 
Topical CHM formula (Liu Huang, Da Feng 
Zi Ren, Zhang Nao, Sheng Xing Ren, Qing 
Fen, Cang Zhu, Zhu You (Lard)) 
Topical corticosteroid (Fluocinonide) Not stated Not stated 
Xiao, H. 
(1996) 
CHM wet wrap (Jing Jie, Fang Feng, She 
Chuang Zi, Wei Ling Xian)  
For exudative cases, apply 3% boric acid 
wet wrap + Topical corticosteroid 
(Fluocinonide) 
5 days Not stated 
Xu, X. (2012) Topical Kou Qiang Xiao Yan San Topical corticosteroid (Triamcinolone 
acetonide) 
2 weeks Not stated 
Yang, S. 
(2007) 
Topical CHM powder (Qing Dai, Shi Gao, 
Hua Shi, Huang Bai, Ku Shen, Lu Gan Shi) 
Antihistamines + Vitamin B + Vitamin C + 
calcium supplements as appropriate; for 
poor digestion, take probiotics and 
multivitamins  
Not stated Not stated 
Yang, S. & 
Yan, J. (2012) 
Shi Run Shao Shang Gao cream Topical zinc oxide  1 month Not stated 
Ye, Q. (2006)  CHM wash (Jin Yin Hua, Huang Lian, Di Yu, 
Da Huang, Zi Cao, Wu Bei Zi, Gan Cao, Ma 
Chi Xian, Er Cha)  
Topical corticosteroid (Hydrocortisone 
butyrate) 
1 week Not stated 
Yu, H. et al. 
(2007) 
Ma Chi Xian decoction wet wrap Boric acid wet wrap 10 days Not stated 
Yuan, S. 
(2008) 
Shi Zhen Xi Ji wash or wet wrap  Topical corticosteroid (0.1% 
Hydrocortisone butyrate); for exudative 
cases, apply 1.5% boric acid wet wrap  
7 days Not stated 
Zhang, H. 
(2010) 
Sheng Bai Bu Xi Ji bath  Topical Chloramphenicol/ 
Dexamethasone cream 
1 week Not stated 
Zhang, J. et 
al. (2010) 
Wu Dai Ruan Gao cream Topical antihistamine (Diphenhydramine 
hydrochloride) 
2 weeks Not stated 
Zhang, W. & 
Luo, X. 
(2012) 
Topical CHM powder (Huang Bai, Qing Dai, 
Hua Shi, Gan Cao)  
Topical Calamine lotion  7-14 days Not stated 
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Author 
(Date) 
Experimental trial intervention Control intervention Treatment 
duration 
Other concurrent 
treatment (for all groups) 
Zhang, X. et 
al. (2012) 
Qi Wei Jie Du Huo Xue Gao cream Topical corticosteroid (Hydrocortisone 
butyrate) 
7 days Not stated 
Zhang, X. & 
Zhang, W. 
(1994) 
Fu Fang Wu Bei Zi Gao cream  Topical corticosteroid (Fluocinonide) Not stated Participants were asked to 
stop all other medication 
Zhang, Y. & 
Li, N. (2009) 
Pu Ding Xi Ji lotion; for widespread cases, 
use formula as bath; for severe skin 
damage/ulceration, mix Si Gua leaf juice 
with Ru Yi Jin Huang San to apply as a 
paste 
Oral antihistamine (Cetirizine) 7 days 
treatment; 2 
weeks follow-up 
Not stated 
Zhou, Y. 
(2011) 
Cang Er Ku Shen Xi Ji scrub; for 
ulcerative/exudative cases, apply formula 
as wet wrap 
Topical Calamine lotion  2 weeks 
treatment; half 
year follow-up 
Not stated 
Zou, G. & 
Xie, B. (2011) 
Fu Fang San Huang Xi Ji wet wrap + Fu 
Fang San Huang Xi Ji powder mixed with 
sesame oil to apply as paste 
Topical 3% boric acid wet wrap + Topical 
zinc oxide 
14 days Not stated 
Topical CHM 1 VS Topical CHM 2 
Zhuo, Y. et 
al. (2010) 
Topical Kugan Decoction  Topical Erfukang liniment  15 days Not stated 
Topical CHM 1 VS Topical CHM 2 + WM 
Nie, Y. (2012) CHM wet wrap (Di Yu, Ma Chi Xian, Huang 
Lian, Huang Bai, Cang Zhu, Wu Bei Zi, He Zi, 
Ku Fan)  
Intramuscular Penicillin injection for 3 
days + Topical Wei Fu Gao (contains WM 
+ TCM) or Pi Kang Shuang (CHM) + Oral 
antihistamine (Chlorpheniramine) for 3 
days 
 
 
 
 
 
3-5 days Not stated 
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Author 
(Date) 
Experimental trial intervention Control intervention Treatment 
duration 
Other concurrent 
treatment (for all groups) 
Topical CHM VS Other therapy 
Guo, X. 
(2013) 
CHM wash/bath and wet wrap (Ku Shen, 
Jing Jie, Sheng Di Yu, Bai Xian Pi, Fang Feng, 
Huang Bai, Ma Chi Xian, She Chuang Zi) 
Water bath 2 weeks Not stated 
Lin, S. et al. 
(2002) 
Modified Bai Fan San wash/bath Saline wash/bath  7 days Not stated 
Topical CHM VS WM 1 VS WM 2 
Zhong, R. 
(2008) 
Bing Huang Fu Le Ruan Gao cream 1. Topical corticosteroid (Pevisone) 
2. Topical zinc oxide cream 
2-3 weeks For exudative cases, apply 
3% boric acid wet wrap  
Topical CHM 1 VS Topical CHM 2 VS WM VS Vehicle 
Chao, Q. 
(2003) 
5% Huang Bai Zi Cao Di Yu Shuang cream 1. 10% Huang Bai Zi Cao Di Yu Shuang  
cream 
2. Topical corticosteroid (Pevisone) 
3. Vehicle 
3 weeks 
treatment (stop 
treatment upon 
cure) 
For exudative lesions, apply 
3% Huang Bai Ye wet wrap 
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Table 4-8: Studies comparing topical CHM and WM VS control intervention 
Author 
(Date) 
Experimental trial intervention Control intervention Treatment 
duration 
Other concurrent 
treatment (for all groups) 
Topical CHM + WM VS WM 
Chen, J. 
(2012) 
Jin Yu Wai Xi Fang wet wrap + WM (same 
as control intervention)  
Oral antihistamine (Chlorpheniramine) 1 month Not stated 
Deng, C. 
(2009) 
Topical Chu Shi Zhi Yang Ruan Gao 
ointment + WM (same as control 
intervention) 
Topical corticosteroid (Hydrocortisone 
butyrate) 
2 weeks Participants were not 
allowed to use any other 
topical or systemic 
antihistamines and 
corticosteroids 
Du, D. (2012) CHM wash or wet wrap (Ma Chi Xian, Ku 
Shen, Sheng Di Yu, Huang Bai) + WM (same 
as control intervention) 
Topical zinc oxide cream Not stated Not stated 
Han, H. et al. 
(2013) 
CHM bath (Huang Bai, Dang Gui, Dan Shen, 
Fu Ling, Bai Zhu, Ma Chi Xian, Ji Xue Teng, 
Bai Xian Pi) + WM (same as control 
intervention) 
Topical calcineurin inhibitor (0.03% 
Tacrolimus ointment) 
4 weeks 
treatment; 3 
months follow-
up 
Not stated 
Ji, L. (2005) CHM wet wrap (Ma Chi Xian, Gan Cao, Ku 
Shen, Huang Bai, Bai Xian Pi, Di Yu, Sheng 
Di) + WM (same as control intervention) 
Topical Vitamin B6 cream Not stated For scabbing, apply topical 
zinc oxide ointment until 
scabs disappear 
Lei, S. (2005) CHM formula powder (Sheng Di, Mu Dan 
Pi, Niu Bang Zi, Bai Xian Pi, Jin Yin Hua, Bo 
He, Bai Mu Tong, Huang Lian, Gan Cao, Jing 
Jie, Rou Gui) applied as umbilical + WM 
(same as control intervention) 
Oral antihistamine (Chlorpheniramine) + 
Vitamin C + Topical anti-inflammatory 
agent (Bufexamac) 
7 days Not stated 
Li, Z. & Di, W. 
(2007) 
CHM bath (Formula I for severe itching: Bai 
Bu, Fang Feng, Ku Shen, Jin Yin Hua, She 
Chuang Zi, Gan Cao; Formula II for severe 
exudation: Qin Jiao, Ku Shen, Jin Yin Hua, 
She Chuang Zi, Gan Cao) + WM (same as 
control intervention) 
Johnson & Johnson body wash + Topical 
Calamine lotion + Topical Talcum powder; 
for scabbing, soak in paraffin oil for 5-10 
minutes 
3-7 days Not stated 
128 
 
Author 
(Date) 
Experimental trial intervention Control intervention Treatment 
duration 
Other concurrent 
treatment (for all groups) 
Liu, H. & Li, 
H. (2007)  
CHM wet wrap or bath + WM (same as 
control intervention) 
Topical corticosteroid (Hydrocortisone 
butyrate) 
Half a month 
treatment; 3 
months follow-
up 
Not stated 
Liu, G. & 
Zhang, L. 
(2004)  
CHM wet wrap or wash (Ma Chi Xian, Ku 
Shen, Sheng Di Yu, Huang Bai) + WM (same 
as control intervention) 
Topical Vitamin B6 cream Not stated For scabbing, apply topical 
zinc oxide ointment until 
scabs disappear 
Mo, J. (2007) Pi Fu Kang Xi Ye wet wrap + WM (same as 
control intervention) 
Topical corticosteroid (Hydrocortisone 
butyrate) 
7 days Not stated 
Tong, L. 
(2010)  
Er Shi Xi Ji wet wrap or bath + WM (same 
as control intervention)  
Topical Non-steroidal anti-inflammatory 
drug (Flufenamic acid ointment)  
2 weeks Not stated 
Xuan, Z. 
(2008) 
Yi Yi Fu Zi Bai Jiang San wash + WM (same 
as control intervention) 
Topical corticosteroid (Hydrocortisone 
butyrate) 
Not stated Not stated 
Xue, L. 
(2010) 
Topical CHM granules (Huang Bai, Ku Shen, 
Fang Feng, honey) applied as umbilical 
paste + WM (same as control intervention) 
Oral antihistamine (Cetirizine syrup) 1 week 
treatment; 6-12 
months follow-
up 
Not stated 
Zhang, X. 
&Li, Y. (2011) 
Chu Shi Zhi Yang Ruan Gao ointment + WM 
(same as control intervention)  
Topical corticosteroid (Budesonide 
cream) + Oral antihistamine 
(Desloratadine suspension) 
3 weeks Not stated 
Zheng, F. & 
Gu, L. (2013) 
CHM bath/wash (Lian Qiao, Ku Fan, Ye Ju 
Hua, Bai Bu, She Chuang Zi, Huang Bai, Ku 
Shen, Di Fu Zi, Bai Xian Pi) + WM (same as 
control intervention) 
 
 
 
 
 
 
Topical corticosteroid (Mometasone 
furoate) 
2 weeks Not stated 
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Author 
(Date) 
Experimental trial intervention Control intervention Treatment 
duration 
Other concurrent 
treatment (for all groups) 
Topical CHM + WM 1 VS WM 2 
Li, J. et al. 
(2013) 
CHM wash (Dang Gui, Di Fu Zi, Bai Xian Pi, 
She Chuang Zi, Ku Shen, Chuan Xin Lian, Ye 
Gan Ju) for 1 week + Topical corticosteroid 
(Budesonide) for 1 week + Topical Vitamin 
E and Allantoin cream for 4 weeks 
Topical corticosteroid (Budesonide) for 1 
week 
4 weeks Not stated 
Li, W. (2006) CHM formula (fumigation and wash) 
according to syndrome differentiation (She 
Chuang Zi, Di Fu Zi, Cang Er Zi, Bai Xian Pi, 
Jing Jie, Huang Bai, Ku Shen) + Oral 
antihistamine (Chlorpheniramine)  
Topical corticosteroid (Hydrocortisone 
butyrate) + Oral antihistamine 
(Chlorpheniramine) 
2 weeks Not stated 
Lin, K. (2006) Gan Cao Xi Ji lotion or wet wrap + Oral 
antihistamine  (Chlorpheniramine)  
For exudative cases, apply 3% boric acid 
wet wrap; for non-exudative cases, apply 
topical Calamine lotion or zinc oxide 
cream 
7 days 
treatment; 15 
days follow-up 
Not stated 
Qiao, S. 
(2008) 
Ma Chi Xian decoction wet wrap + Oral 
antihistamine (Triprolidine hydrochloride 
capsules) 
Boric acid wet wrap + Oral antihistamine 
(Triprolidine hydrochloride capsules) 
4 days Not stated 
Qin, S. et al. 
(2006) 
Topical Erfukang liniment + Oral 
antihistamine (0.1% Diphenhydramine 
hydrochloride syrup) 
Topical Calamine lotion + Oral 
antihistamine (0.1% Diphenhydramine 
hydrochloride syrup) 
1 week Not stated 
Rao, X. et al. 
(2012) 
Topical Erfukang liniment + Topical 
corticosteroid (0.1% Hydrocortisone 
butyrate) 
Topical corticosteroid (0.1% 
Hydrocortisone butyrate) 
7 days Not stated 
Wang, S. et 
al. (2013) 
Topical Qi Wei Jie Du Huo Xue Gao cream 
(stop upon cure) + Oral probiotics: Si Lian 
Kang 
Topical corticosteroid (Pevisone) 1-2 weeks; 2 
months follow-
up 
Participants were not 
allowed to use any other 
medication 
Yang, L., 
Zhang, X. et 
al. (2012) 
CHM wash and wet wrap (Da Huang, Ma 
Chi Xian, Huo Xiang) + Topical Glycerin oil  
Topical corticosteroid (Hydrocortisone 
butyrate) + Topical Glycerin oil 
3 days Not stated 
130 
 
Author 
(Date) 
Experimental trial intervention Control intervention Treatment 
duration 
Other concurrent 
treatment (for all groups) 
Yao, C. et al. 
(2007) 
Topical Jin Huang Gao cream + Topical 
corticosteroid (Hydrocortisone butyrate) 
Topical antibiotic (Mupirocin) + Topical 
corticosteroid (Hydrocortisone butyrate) 
4 weeks Not stated 
Yin, H. (2005) CHM wet wrap (Tu Fu Ling, Bai Xian Pi, Ku 
Shen, Huang Bai, Jin Yin Hua, Qin Jiao, She 
Chuang Zi, Jing Jie, Gan Cao) + Topical 
corticosteroid (Hydrocortisone cream) 
3% boric acid wet wrap 10-20min + 
Topical corticosteroid (Hydrocortisone 
cream) 
7-21 days Participants were not 
allowed to consume any 
systemic medication 
Zhang, Y. 
(2013) 
Topical Qi Bai Xiao ointment + antibiotics 
(if infection present) 
Oral antihistamine (Chlorpheniramine + 
Cyproheptadine) + Oral or IV calcium 
supplements + vitamin supplements + 
corticosteroids  
For acute cases, 
3-7 days 
treatment; for 
subacute and 
chronic cases, 
10-15 days 
treatment  
Not stated 
Zhong, J. 
(2010) 
Zhuang Yao Kang Fu Wai Xi Fang wash + 
Topical corticosteroid (Hydrocortisone 
butyrate) on non-exudative areas 
Apply boric acid wet wrap on exudative 
areas and topical corticosteroid 
(Hydrocortisone butyrate) on non-
exudative areas 
10 days 
treatment; 2 
months follow-
up 
For cases of itching, take 
Oral antihistamine 
(Chlorpheniramine or 
Ketotifen)  
Topical CHM + WM VS Topical CHM 
Zhou, M. 
(2007) 
Shu Fu San fumigation and wash + topical 
Compound Econazole Nitrate Cream  
Shu Fu San fumigation and wash  4 weeks Not stated 
Topical CHM 1 + WM VS Topical CHM 2 
Qin, Q. & 
Zhang, L. 
(2011) 
Qing Re Zhi Yang Xi Ji wet wrap + topical 
corticosteroid (Halcinonide cream) 
Topical Yi Sao Guang ointment 5 days Not stated 
Zhao, Y. & 
Tang, J. 
(2002) 
Topical Hei You Gao cream (Zi Cao, Pu 
Gong Ying, Ye Ju Hua, Huang Bai, 
Erythromycin, Dimethyl sulfoxide) 
 
 
 
Topical Wei Fu Gao cream + Topical Hei 
Dou Liu You Ointment 
2 weeks Not stated 
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(Date) 
Experimental trial intervention Control intervention Treatment 
duration 
Other concurrent 
treatment (for all groups) 
Topical CHM 1 + WM VS Topical CHM 2 + WM 
Yang, L., 
Zheng, L. & 
Yang, L. 
(2012) 
CHM wash and wet wrap (formula not 
stated) + Topical Qi Wei Jie Du Huo Xue 
Gao cream + WM (same as control 
intervention)  
Topical Qi Wei Jie Du Huo Xue Gao cream 
+ Topical Glycerin oil + Oral antihistamine 
(Chlorpheniramine) 
3-5 days 
treatment 
Not stated 
Topical CHM + WM VS Topical CHM VS WM 
Tao, P. 
(2010) 
Zhong Yao Shi Fu Ji wet wrap + Topical 
corticosteroid (Hydrocortisone butyrate) 
1. Zhong Yao Shi Fu Ji wet wrap  
2. Topical corticosteroid (Hydrocortisone 
butyrate) 
7 days Not stated 
Zhou, X. et 
al. (2007) 
Topical Erfukang liniment + Topical 
corticosteroid (Hydrocortisone butyrate) 
1. Topical Erfukang liniment 
2. Topical corticosteroid (Hydrocortisone 
butyrate) 
1 week Not stated 
Zhu, X. 
(2013)  
Topical Chuan Bai Zhi Yang Xi Ji lotion, 
wash and bath for 10 days + Topical 
corticosteroid (Hydrocortisone butyrate) 
for 5 days 
1. Topical Chuan Bai Zhi Yang Xi Ji lotion, 
wash and bath for 10 days 
2. Topical corticosteroid (Hydrocortisone 
butyrate) for 5 days 
10 days Not stated 
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Table 4-9: Studies comparing topical CHM and other therapy VS control intervention 
Author 
(Date) 
Experimental trial intervention Control intervention Treatment 
duration 
Other concurrent 
treatment (for all groups) 
Topical CHM + Acupressure VS WM 
Zhang, A. 
(2006) 
Topical CHM or CHM wash and bath (Ku 
Shen, Ku Fan, She Chuang Zi, Ju Hua) + 
Acupressure (DU14, LI11, SP10, SP6, ST36, 
HT7, SP9)  
Topical corticosteroid (Mometasone 
furoate) 
 
Not stated Not stated 
Topical CHM + Acupressure VS Topical CHM VS WM 
Sun, S. 
(2009) 
CHM wash and soak/wet wrap (Ku Shen, 
She Chuang Zi, Ye Ju Hua) +  Acupressure 
(DU14, LI11, SP10, SP6, ST36, HT7, SP9) 
1. CHM wash and soak/wet wrap (Ku 
Shen, She Chuang Zi, Ye Ju Hua) 
2. Topical corticosteroid (Mometasone 
furoate)  
15 days Not stated 
Topical CHM + Tuina VS Topical CHM 
Huang, Y. & 
Song, Y. 
(2013) 
CHM wash and soak (Ku Shen, She Chuang 
Zi, Ye Ju Hua, Ma Chi Xian, Ku Fan) + Tuina 
(Xiao Tian Xin, He Gu, Wai Lao Gong)  
CHM wash and soak (Ku Shen, She 
Chuang Zi, Ye Ju Hua, Ma Chi Xian, Ku 
Fan) 
7 days Not stated 
Topical CHM + Tuina + Swimming Therapy VS WM 
Liu, C. et al. 
(2009)  
Modified Bai Bu He Ji bath (wet wrap for 
exudative cases) + Tuina (LI11, ST36, SP9, 
SP10, LI4, Spinal pinching) + Swimming 
therapy  
Oral antihistamine (Cyproheptadine); for 
exudative cases, apply 2% boric acid wet 
wrap; for non-exudative cases, apply 
topical corticosteroid (Hydrocortisone 
butyrate) + Topical zinc oxide cream 
15 days Participants were not 
allowed to use any other 
treatments or medication 
related to infantile eczema 
Topical CHM + Semiconductor laser VS WM 
Qie, D. et al. 
(2013) 
 
 
 
 
 
 
Fu Fang Huang Bai Ye wet wrap + 
semiconductor laser on lesions (for chronic 
cases, treat for 21 days) 
Topical Alpha-2b interferon for 8 weeks Not clearly 
stated 
Not stated 
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Author 
(Date) 
Experimental trial intervention Control intervention Treatment 
duration 
Other concurrent 
treatment (for all groups) 
Topical CHM 1 + Emollient VS Topical CHM 2 
Tang, L. & 
Zhu, Y. 
(2007) 
Topical Xiao Yan Xuan Shi Yao Gao cream + 
Topical Baby lotion 
Topical Zi Cao You  2 weeks Not stated 
Wang, H. et 
al. (2013) 
CHM wash (She Chuang Zi, Di Fu Zi, Huang 
Bai, Hua Jiao, Ku Shen, Ai Ye, Jin Yin Hua, 
Lian Qiao) + Topical Yumeijing children 
cream 
Topical Bing Huang Fu Le Ointment 3-6 days Not stated 
Topical CHM + Emollient VS Topical CHM VS Emollient 
Guan, X. 
(2010) 
Run Fu Zhi Yang Xi Ji wet wrap or bath + 
Topical Vaseline moisturising lotion 
1. Run Fu Zhi Yang Xi Ji wet wrap 
2. Topical Vaseline moisturising lotion 
4 weeks Not stated 
Topical CHM + Saline wet wrap VS WM 
Li, Z. (2010) Topical Bing Huang Fu Le ointment + 
Normal saline wet wrap  
Topical Calamine lotion  7 days Oral antihistamine (0.1% 
Diphenhydramine 
hydrochloride syrup); 
participants were not 
allowed to use any other 
topical or systemic 
medication 
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4.4.4.2 Acupuncture 
Three studies utilised acupuncture as the experimental trial intervention on AD (Table 4-10). 
One was a three-armed crossover study which compared 1 session of verum acupuncture to 
1) placebo-point acupuncture and 2) no treatment; 1 study compared acupuncture to no 
treatment over a period of 33 days; another study was a seven-armed crossover study 
comparing 1) verum abortive electro-acupuncture, 2) verum preventive electro-
acupuncture, 3) placebo abortive electro-acupuncture, 4) placebo preventive electro-
acupuncture, 5) oral antihistamine (Cetirizine), 6) placebo antihistamine and 7) no 
treatment. Abortive acupuncture referred to acupuncture which was applied after itch 
provocation (via allergen induction) to evaluate its direct effect on the condition, while 
preventive acupuncture refers to acupuncture which was applied before itch provocation to 
evaluate the preventive effect of acupuncture. A total of 6 acupuncture points were 
identified from the 3 studies: Hegu (LI4), Quchi (LI11), Liangqiu (ST34), Zusanli (ST36), Xuehai 
(SP10), Shaohai (HT3). However, only one common point, Quchi (LI11), was used in all 3 
studies. 
4.4.4.3 Acupressure 
Three studies involved acupressure as the experimental trial intervention, 2 of which were in 
combination with topical CHM and were included Table 4-9. The third study compared 
acupressure on Quchi (LI11) to no treatment. To enable a complete overview of the studies 
involving acupressure for the treatment of AD, the studies and interventions of all 3 studies, 
including the 2 overlapping studies, are summarised in Table 4-11. 
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Table 4-10: Studies comparing acupuncture VS control intervention 
Author 
(Date) 
Experimental trial intervention Control intervention Treatment 
duration 
Other concurrent treatment (for all 
groups) 
Pfab, F. et 
al. (2010) 
Verum acupuncture (LI11 & SP10) 
 
1. Placebo-point acupuncture 
2. No treatment 
 
1 treatment Not applicable (as the study focuses on 
one treatment and does not go on for a 
period of time) 
Pfab, F. et 
al. (2011) 
Acupuncture (LI4, LI11, ST36, SP10 
plus individualised points) 
 
No treatment 
Duration: 10 sessions (33 days) 
33 days Participants were allowed to continue 
previous topical therapy but potentially 
systemically active agents were 
prohibited 
Pfab, F. et 
al. (2012) 
1. Verum abortive electro-
acupuncture (LI11, HT3) 
2. Verum preventive electro-
acupuncture (LI11, HT3, ST34, 
SP10) 
 
1. Placebo abortive electro-
acupuncture  
2. Placebo preventive electro-
acupuncture Oral antihistamine 
(Cetirizine) 
3. Placebo antihistamine 
4. No treatment 
1 treatment Not applicable (as the study focuses on 
one treatment and does not go on for a 
period of time) 
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Table 4-11: Studies comparing acupressure (with or without other therapy) VS control 
intervention 
Author 
(Date) 
Experimental trial 
intervention 
Control intervention Treatment 
Duration 
Other concurrent 
treatment (for all 
groups) 
Acupressure VS  No Treatment 
Lee, K. 
C. et al. 
(2012) 
Acupressure on LI11 
using 1.2mm 
acupellets 
No treatment 4 weeks Participants were 
allowed to continue 
using any prescription 
or over-the-counter 
medications or lotions 
Topical CHM + Acupressure VS  WM 
Zhang, 
A. 
(2006) 
Topical CHM or CHM 
wash and bath (Ku 
Shen, Ku Fan, She 
Chuang Zi, Ju Hua) + 
Acupressure (DU14, 
LI11, SP10, SP6, ST36, 
HT7, SP9)  
Topical 
corticosteroid 
(Mometasone 
furoate) 
 
Not stated Not stated 
Topical CHM + Acupressure VS Topical CHM VS WM 
Sun, S. 
(2009) 
CHM wash and 
soak/wet wrap (Ku 
Shen, She Chuang Zi, 
Ye Ju Hua) +  
Acupressure (DU14, 
LI11, SP10, SP6, ST36, 
HT7, SP9) 
1. CHM wash and 
soak/wet wrap 
(Ku Shen, She 
Chuang Zi, Ye Ju 
Hua) 
2. Topical 
corticosteroid 
(Mometasone 
furoate)  
15 days Not stated 
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4.4.4.4 Tuina 
Four studies involved Tuina as the experimental trial intervention, 2 of which were in 
combination with topical CHM and were included in Table 4-9. Of the remaining 2 studies, 1 
compared Tuina to WM while the other study compared a combination of Tuina and WM to 
WM alone. The treatments used in all 4 studies are summarised in Table 4-12. 
4.4.4.5 Acupoint Injection 
Two studies involved acupoint injection as the treatment intervention compared to oral 
antihistamines (Table 4-13). One study utilised the injection of transfer factor into the 
acupoint Xuehai (SP10), while the other study injected glycyrrhizin compound into the 
acupoints Zusanli (ST36), Xuehai (SP10) and Shenmen (HT7).  
4.4.4.6 Bloodletting (via cupping and plum-blossom needling) 
Only 1 study utilised bloodletting via cupping and plum-blossom needling as the 
experimental trial intervention (Z. Fu & Fu, 2012). The treatment protocol was to apply 
plum-blossom needling on areas of skin damage and on the acupuncture points Dazhui 
(GV14), Feishu (BL13), Geshu (BL17), Xinshu (BL15), followed by cupping for 10 minutes, 
applied as soon as the areas turned red or presented with slight bleeding. The control 
intervention for this study was the oral antihistamine, Mizolastine slow release tablets. Both 
interventions were applied once a day for the treatment duration of 3 weeks.  
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Table 4-12: Studies comparing Tuina (with or without other therapy) VS control intervention 
Author 
(Date) 
Experimental trial intervention Control intervention Treatment 
duration 
Other concurrent treatment 
(for all groups) 
Tuina VS WM 
He, Y. et 
al.  (2009)  
Tuina (Pi Jing, Ba Gua, Si Heng Wen, Xiao Tian 
Xin, Wai Lao Gong, Yi Wo Feng, Tian He Shui, 
Liu Fu, Feng Shi) 
Oral antihistamine (Chlorpheniramine) + 
Vitamin C; for acute phase without or with 
little exudation, apply topical zinc oxide 
ointment; for exudative cases, apply boric 
acid wet wrap and change to topical 
corticosteroid (Hydrocortisone butyrate) 
upon improvement 
21 days 
treatment; 
3-6 months 
follow-up  
Not stated 
Tuina + WM VS WM 
Zhao, X. & 
Li, D. 
(2004) 
Tuina (Ba Gua, Pi Jing, Tian He Shui, Xiao Tian 
Xin, Wei Ling, Jing Ning, Wu Zhi Jie) + WM 
(Same as control intervention) 
Compound glycyrrhizic acid and 
monoamine injection and H1 receptor 
blocking agent (antihistamine) 
Not stated Not stated 
Topical TCM + Tuina VS Topical TCM 
Huang, Y. 
& Song, Y. 
(2013) 
CHM wash and soak (Ku Shen, She Chuang Zi, 
Ye Ju Hua, Ma Chi Xian, Ku Fan) + Tuina (Xiao 
Tian Xin, He Gu, Wai Lao Gong)  
CHM wash and soak (Ku Shen, She Chuang 
Zi, Ye Ju Hua, Ma Chi Xian, Ku Fan) 
7 days Not stated 
Topical TCM + Tuina + Swimming Therapy VS WM 
Liu, C. et 
al. (2009)  
Modified Bai Bu He Ji bath (wet wrap for 
exudative cases) + Tuina (LI11, ST36, SP9, 
SP10, LI4, Spinal pinching) + Swimming 
therapy  
Oral antihistamine (Cyproheptadine); for 
exudative cases, apply 2% boric acid wet 
wrap; for non-exudative cases, apply 
topical corticosteroid (Hydrocortisone 
butyrate) + Topical zinc oxide cream 
15 days Participants were not allowed 
to use any other treatments or 
medication related to infantile 
eczema 
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Table 4-13: Studies comparing acupoint injection VS WM 
Author 
(Date) 
Experimental trial 
intervention 
Control intervention Treatment 
Duration 
Other concurrent 
treatment (for all 
groups) 
Chen, K. 
(2004) 
Acupoint injection of 
compound glycyrrhizin 
(ST36, SP10, HT7)  
Pharmacotherapy 
such as Ketotifen, 
Chlorpheniramine et 
cetera, for 3 weeks 
Not clearly 
stated 
Not stated 
Xia, Z. 
(1995) 
Acupoint injection of 
transfer factor into 
SP10 
Oral antihistamine 
(Chlorpheniramine)  
4 weeks 
treatment; 
3 months 
follow-up 
Not stated 
 
4.4.5 Outcome Measures 
A number of different outcome measures were used among the 191 studies; these included 
disease/symptom severity scoring, QoL scoring, duration of treatment (till cure or 
improvement seen), reduction in concurrent medication, physiological/laboratory 
parameters, “self-defined global response” according to the rate of efficacy, and rate of 
recurrence. Many of the studies had more than 1 outcome measure. 
Seventy-seven studies utilised one or more disease/symptom severity scoring index. 
Eighteen used the Scoring Atopic Dermatitis (SCORAD) index, 9 used the Eczema Area and 
Severity Index, 8 used the Six Area, Six Sign Atopic Dermatitis, 5 utilised scoring systems used 
in previous studies, 5 utilised the Psoriasis Area and Severity Index (PASI), 4 used the Rajka 
and Langeland Scoring System, 3 used Pi Sun Yan Zhong Du Ji Fen (皮损严重度计分 [Skin 
Damage Severity Scoring], abbreviated as ADS in the studies), 1 used the scoring system by 
the Atopic Dermatitis Severity Evaluation Committee of Japanese Dermatological 
Association, 1 used the Investigator’s Global Assessment, 1 used the scoring system 
according to Zhong Yao Xin Yao Lin Chuang Yan Jiu Zhi Dao Yuan Ze (中药新药临床研究指导
原则 [Clinical Research Guidelines for Chinese Medicine and New Drugs]), 1 used the scoring 
system according to Zhong Yi Bing Zheng Zhen Duan Liao Xiao Biao Zhun (中医病症诊断疗
效标准 [Chinese Medicine Diagnosis and Treatment Efficacy Criteria of Diseases]), 11 utilised the 
itch intensity Visual Analogue Scale (VAS) and 21 used scoring systems which were 
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unidentified. Despite using scoring systems, 33 of the studies did not report the scores 
obtained from the studies, or had incomplete reporting. 
The “self-defined global response” was a term adapted from Wang (2008) and is an outcome 
measure which categorises participants into the groups “cured”, “marked improvement”, 
“improvement” and “no effect” based on the improvement in disease presentation or 
duration of treatment. However, the method of determining the categories of participants 
was inconsistent between studies. For instance, some studies categorised participants under 
the “cured” category only when there was 100% improvement while other studies might 
state that participants with at least 90%-95% improvement were under the “cured” 
category. In many studies, there was no description of how the percentage of improvement 
was determined. Furthermore, there were variations between the categorisation of 
participants, with some studies using only 2 or 3 categories.  
 
4.5 Discussion 
A total of 191 RCTs on the management of AD, eczema in the paediatric population, Si Wan 
Feng (四弯风) and/or Nai Xuan (奶癣) with TCM therapies were included in this 
comprehensive review.  
From the 12 included English studies, 11 were on AD and 1 was on infantile eczema; among 
the Chinese studies, 63 were on AD, 104 were on eczema, 1 was on Si Wan Feng (四弯风), 5 
were on Nai Xuan (奶癣), 3 were on both AD and Si Wan Feng (四弯风) and another 3 were 
on both AD and eczema. The use of Si Wan Feng (四弯风) and/or Nai Xuan (奶癣) among 
Chinese studies was possibly due to the fact that the studies were on TCM therapies, leading 
to the use of the TCM equivalent disease nomenclature of AD.  
The analysis of the diagnostic criteria for AD or eczema used in the included studies showed 
that out of the 80 studies on AD, 55 referenced validated diagnostic criteria; and out of all 
191 studies, 50 failed to report the diagnostic criteria used. Fourteen studies had more than 
one diagnostic criterion. However, the relevance of using multiple criteria was not 
elucidated. 
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From the evaluation of the experimental trial interventions, 105 studies utilised one TCM 
therapy, while the remaining 86 studies applied a combination of one or more TCM 
therapies with or without WM or other non-TCM therapies. Among all the TCM therapies 
used identified from the included studies, CHM, especially topical CHM, had been the most 
evaluated. Fewer than 5 RCTs evaluated acupuncture, acupressure, Tuina, acupoint injection 
and bloodletting in the management of AD, respectively. Despite the larger number of CHM 
studies, most studies evaluated different CHM formulae with variations in treatment 
protocol. The most frequently-used topical CHM treatment was the combination of oral Qu 
Shi Tang decoction plus CHM bath, which was used in 6 studies. Topical Erfukang liniment 
was also used in 6 studies as the experimental trial intervention, with 3 of them applying it in 
combination with topical hydrocortisone butyrate. Five studies used Chu Shi Zhi Yang Ruan 
Gao ointment, with 2 using a combined treatment with WM. The CHM formula Zemaphyte 
was the most frequently-used systemic CHM, identified in 3 studies.  
The control interventions included oral or topical CHM, WM, emollients, water bath, normal 
saline wet wrap, placebo or no treatment. There were 8 studies (6 on oral CHM; 2 on 
acupuncture), all from the English literature, which used placebo intervention as control 
intervention. Five studies (4 English and 1 Chinese), 3 of which were multiple-armed trials, 
used no treatment as control intervention. All Chinese studies had active control 
interventions. This might be related to the fact that all the Chinese studies were conducted 
in hospital settings and that trial participants were patients of the hospital. The most 
commonly-used active control intervention included oral antihistamines and TCS.  
When comparing treatment protocols and control interventions, the English studies seemed 
to suit the scientific method of conducting explanatory trials, whereby every step of the trial 
followed a standardised protocol. The Chinese studies, however, tended to be more 
pragmatic. For instance, approximately one-fifth of the studies modified the CHM treatment 
according to the disease presentation or syndrome differentiation. In addition, the 
experimental trial interventions and control interventions were not necessarily comparable, 
and many of them made participant blinding impossible. Furthermore, the treatment 
protocol was not always standardised between participants as there were several topical 
CHM formulae which could be applied either as wet wraps or washes. Several studies also 
allowed the use of additional adjuvant therapies, such as oral antibiotics, TCS or other 
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topical CHM, according to different disease presentation or severity. A small number of 
studies did not have fixed treatment durations, had unclear treatment durations or reported 
inconsistent treatment durations according to the treatment group or disease presentation.    
The most frequently-used outcome measure was the “self-defined global response”, which 
was used in 176 Chinese studies and in 1 English study (which was translated from a Chinese 
study). Seventy-seven studies used some form of disease/symptom severity scoring system, 
out of which 33 either failed to report the scores obtained from the study or had incomplete 
reporting. Forty-six studies used validated instruments, with the SCORAD index being the 
most frequently-used instrument. However, 5 studies used PASI, which is a validated 
instrument for the evaluation of psoriasis (Fredriksson & Pettersson, 1978), rather than AD. 
The use of PASI to evaluate AD severity has not been justified and therefore its suitability as 
an outcome measure in AD studies is questionable. Five studies evaluated QoL, using the 
validated instrument, Dermatology Life Quality Index or Children’s Dermatology Life Quality 
Index (CDLQI). 
Overall, this comprehensive review showed several limitations in the currently-available 
literature on AD management with TCM therapies. The small number of studies aside, the 
evaluation of the diagnostic criteria, trial interventions and outcome measures alone 
showed that there was a lack of standardisation, which might lead to heterogeneity and 
incomparability between studies. With regard to diagnostic criteria and outcome measures, 
use of validated instruments was greatly lacking. When considering the quality of reporting, 
many studies failed to provide details on randomisation, allocation concealment and 
blinding. As mentioned earlier, there was also a distinct difference between the 
methodologies of the English and the Chinese studies, with the English studies adopting 
explanatory trials while the Chinese studies adopted a more pragmatic attitude. While each 
has its own pros and cons, pragmatic trials generally call for larger sample sizes and would 
require previous explanatory trials to establish the efficacy of the experimental trial 
intervention in question when compared against placebo (MacPherson, 2004). However, 
Cardini et al. (2006) argued that pragmatic studies should be first approached when 
evaluating traditional medicine systems. 
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4.5.1 Strengths of this Review 
This comprehensive review encompassed the common TCM therapies to identify which ones 
have been evaluated in RCTs for the management of AD. No other reviews on TCM 
treatments of AD of such scale were identified from the database searches. This review 
outlined TCM therapies for AD that have been evaluated in RCTs. It also allowed the 
comparison with TCM therapies recorded in the TCM classical literature to help guide and 
improve clinical practice as well as identify what is lacking in the current literature. This 
comprehensive review is focused on identifying TCM treatments for AD which have been 
evaluated in RCTs. It also highlighted the methodologies used to ascertain what has been 
done and what is needed in future studies.  
4.5.2 Limitations of this Review 
There were 4 main limitations of this review. The first was the large scale of the review, as it 
included a total of 11 TCM treatment modalities. To prevent overly-complicated database 
searching which might have led to errors, it was decided that searches be conducted 
separately for each treatment modality. Not only was this a time-consuming process for 
both reviewers involved, but also there was a technical error with the English database, 
Embase, whereby the search syntax was not recognised, leading to a considerably larger 
number of hits (up to 8968 hits from Embase compared to 1552 hits from PubMed), most of 
which were irrelevant studies. To overcome this technical problem, assistance was sought 
from more experienced researchers, the librarian and Embase itself. However, there was no 
solution aside from changing the search terms for Embase. To avoid overlooking relevant 
RCTs, it was decided that the search strategies remain unchanged and the large number of 
hits be screened. 
The second limitation of this review was the lack of familiarity with the Chinese electronic 
database searching. The Chinese databases use a different method and syntax from the 
English databases to identify studies. Furthermore, there were also differences in syntax 
between each Chinese database. Three people who were experienced with Chinese 
database searching were consulted regarding this matter. However, it must be said that the 
Chinese database can be quite erratic, often producing inconsistent results within the same 
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searches. Consequently, this limitation might have led to certain studies being left out from 
this review.  
The third limitation was due to language barriers. This study accepted studies which were 
published in English, Chinese, Japanese, French and Spanish. However, it must be noted that 
the database search identified studies published in German, Italian, Russian and Mongolian 
that had to be excluded due to the lack of reviewers with adequate comprehension of the 
respective languages. Furthermore, database searching was limited to the English and 
Chinese databases, which might have prevented the complete identification of studies 
published in other languages.  
The fourth limitation was due to a lack of understanding of research and clinical practice and 
cultural differences between countries, which might have led to mistakes in interpretation 
and evaluation. For example, 3 obvious differences in the Chinese studies compared to the 
English studies were the use of diagnostic criteria which were unfamiliar to researchers of 
other countries, the application of TCM treatment according to syndrome differentiation 
rather than a standardised TCM treatment, and the use of the “self-defined global response” 
as an outcome measure. With the majority of the included studies in this review being from 
China, the variation in research methods compared to those of Western countries were 
easily identified but the rationale behind them remained obscure. There might be 
differences in the research methods or practice of TCM in other countries, such as Japan, 
Korea and Germany. For example, with regard to the practice of Japanese Kampo medicine 
(Japanese herbal medicine similar to CHM), Nishimura et al. (2009) emphasised that its 
application differed from that of TCM, despite their shared Chinese roots. However, such 
differences were not detected through this review due to insufficient data. 
4.5.3 Comparison with Classical Literature Review 
There were several TCM disease nomenclatures which were mentioned in the introduction 
or discussion of some of the Chinese studies which were included in this comprehensive 
review. However, only Si Wan Feng (四弯风) and Nai Xuan (奶癣) were considered 
synonymous with AD and infantile eczema, respectively, and used as a diagnosing condition. 
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This matched the findings of the classical literature review, which showed Si Wan Feng (四弯
风) having the closest matching description to AD. 
The classical literature review identified that CHM, moxibustion, and bloodletting were used 
for the treatment of AD-like conditions. Aside from acupoint injection which is a modern-day 
therapy, the modern literature did not identify studies using moxibustion for AD, but found 
studies using acupuncture, acupressure and Tuina. As seen in the classical literature review, 
the most commonly-used TCM therapy was CHM, with topical CHM more commonly used 
than oral CHM. Many of the topical CHM formulae had no names, as with the classical 
literature. Even among the named formulae, there were not many which overlapped 
between the classical and modern literature. In fact, most of the formulae used in the 
modern literature were newly-formulated CHM products of the respective hospitals. When 
comparing formula ingredients, it seemed that the actions of herbs used in the classical and 
modern literature were similar, consisting of herbs that expel external pathogenic factors 
and herbs that tonify underlying deficiencies commonly-seen in AD patients. 
 
4.6 Conclusion 
4.6.1 Implications for Research 
The limited number of studies on acupuncture, acupressure, Tuina, acupoint injection and 
bloodletting in the management of AD did not allow for concrete and valid conclusions, 
especially when the heterogeneity between studies was taken into account. However, this 
review showed that there is much room for research with regard to these therapies in the 
management of AD, with the main challenge being the difficulty in finding a suitable placebo 
intervention which enabled blinding or a comparable active intervention.  
With regard to topical and oral CHM, despite the larger number of studies, many would have 
been excluded when going through the rigorous study selection process for SRs. To date, the 
available SRs on CHM in the management of AD have yet to yield conclusive evidence, with 
the main reason being the low quality of available RCTs. 
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Researchers planning future studies need to consider if their research questions can be 
better-answered by either explanatory trials or pragmatic trials. Nevertheless, all future 
studies should apply validated diagnostic criteria and outcome measure instruments, as well 
as the use of comparable trial interventions with standardised treatment protocols. When 
publishing future studies, researchers should pay attention to the quality of reporting, 
especially with regard to the accuracy and comprehensiveness of data.  
4.6.2 Implications for Clinical Practice 
Considering the results from this comprehensive review and its comparison with the classical 
literature review, CHM is the most commonly-used TCM therapy in the management of AD. 
Many different CHM formulae were identified but their efficacy was not evaluated in this 
review to have their use recommended. Nevertheless, the choice of CHM formulae used in 
the studies, whether standardised between participants or not, was based on the TCM 
understanding and diagnosis of AD. While there is yet to be conclusive evidence of its 
efficacy, compared to other TCM therapies, CHM application according to syndrome 
differentiation has the most historical and empirical evidence to support its clinical use in 
the management of AD.  
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 Systematic Review of the Efficacy and Safety of Orally-Chapter 5
Administered Chinese Herbal Medicine in the Management of Atopic 
Dermatitis 
5.1 Introduction 
Previously, two SRs on oral CHM treatment of AD had been conducted (Armstrong & Ernst, 
1999; W. Zhang, Leonard, et al., 2010). However, both reviews had focused only on the 
clinical evidence for one herbal formula, Zemaphyte, which is no longer manufactured due 
to the failure in obtaining a licence (W. Zhang, Leonard, et al., 2010). Zhang, et al.’s Cochrane 
review (2010) had also recently been updated by Gu, et al (2013), and included both topical 
and oral forms of CHM treatment. The different pathways of medication administration 
affect treatment actions and indications; oral and topical CHM are therefore considered 
different interventions (Daukes, 1929). Therefore, the current state of evidence of oral CHM 
in the management of AD remains unknown. This SR aimed to evaluate the published RCTs 
on the efficacy and safety of orally-administered CHM in the management of AD when 
compared to placebo, pharmacotherapy or no treatment.  
 
5.2 Objectives 
The comprehensive review of TCM treatments of AD aimed to: 
1. Evaluate the efficacy and safety of oral CHM in the management of AD from the 
modern literature; 
2. Identify limitations of the currently available RCTs on oral CHM in the management 
of AD; 
3. Combine results of this SR with those of the classical literature review to assist in the 
formulation of new CHM formula for AD. 
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5.3 Methods 
This SR shared the same search strategy with comprehensive review (Chapter 4) but 
included only RCTs with oral CHM as the experimental trial intervention and employed a 
more rigorous set of inclusion/exclusion criteria with regard to the diagnostic criteria, 
interventions, and outcome measures. Therefore, the studies for this SR were identified 
through the screening of the 191 studies which were included in the comprehensive review. 
The methodology utilised for this SR is described in Chapter 2.3. 
 
5.4 Results 
5.4.1 Identification of Studies 
From the 191 studies identified through the comprehensive review in Chapter 4, 185 studies 
were excluded – 118 were not on oral CHM, 25 had topical CHM as a co-intervention, 10 had 
topical CHM as a concurrent treatment, 9 either failed to report outcome measure scores or 
reported scores incompletely, 6 did not mention the use of any diagnostic criteria, 6 did not 
utilise disease/symptom severity scoring or QoL as outcome measures, 4 had CHM as control 
intervention, another 4 did not use the same co-intervention in all groups, and 3 used PASI 
as outcome measures. A total of 6 studies were included for qualitative analysis. However, 
due to insufficient data in 1 study, only 5 out of the 6 studies were included in the meta-
analysis. The study selection process is illustrated in Figure 5-1. 
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Figure 5-1: Flow diagram illustrating the study selection process for the SR of oral CHM in 
the management of AD 
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5.4.2 Description of Studies 
All the 6 studies involved a total of 425 AD patients diagnosed with validated diagnostic 
criteria, but only 2 included TCM diagnosis. Of the 6 included studies, 1 was a single-blind 
RCT comparing WM with CHM (Jian Pi Shen Shi granules) with WM alone (Y. Huang et al., 
2004); 6 studies were placebo-controlled, double-blind RCTs – 1 utilised Xiao Feng San (H. M. 
Cheng et al., 2011); 2 utilised a formula named Zemaphyte which was created by a 
practitioner in the UK (Fung et al., 1999; Sheehan et al., 1992); 1 applied a five-herb formula 
named Pentaherb (Hon et al., 2007); and 1 used the Kampo formula, Hochu-ekki-to (Bu 
Zhong Yi Qi Tang) (H. Kobayashi et al., 2010). The ingredients of each formula are listed in 
Table 5-1.  
All studies reported disease/symptom severity scores but there were a few different 
instruments and methods of score presentation used. One study utilised SCORAD (Hon et al., 
2007), another used the scoring system by the Atopic Dermatitis Severity Evaluation 
Committee of Japanese Dermatological Association (H. Kobayashi et al., 2010), 1 study used 
the Rajka and Langeland scoring system (Y. Huang et al., 2004) and 4 utilised an unnamed 
standardised scoring system (H. M. Cheng et al., 2011; Fung et al., 1999; Sheehan et al., 
1992). One study evaluated QoL, 2 evaluated the use of concurrent treatments and all but 1 
study evaluated safety profiles and occurrence of adverse events. 
The characteristics of the included studies are summarised in Table 5-2; the diagnosis, 
interventions and outcome measures of the included studies are summarised in Table 5-3.  
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Table 5-1: Herbal ingredients of the CHM formulae of included studies in the SR of oral 
CHM for AD 
Zemaphyte Jian Pi Shen Shi 
Granules 
Pentaherb Hochu-ekki-to Xiao Feng San 
Glyzyrrhiza 
uralensis 
(Gan Cao) 
Wolfiporia 
extensa 
(Fu Ling) 
Herba menthae 
(Bo He) 
Glycyrrhizae radix 
(Gan Cao) 
Glycyrrhiza 
uralensis 
(Gan Cao) 
Ledebouriella 
seseloides  
(Fang Feng) 
Codonopsis 
pilosula  
(Dang Shen) 
Flos lonicerae  
(Jin Yin Hua) 
Ginseng radix  
(Ren Shen) 
Saposhnikovia 
divaricata  
(Fang Feng) 
Schizonepeta 
tenuifolia 
(Jing Jie) 
Atractylodes 
rhizoma 
(Bai Zhu) 
Cortex 
phellodendri 
(Huang Bai) 
Atractylodes 
rhizome 
(Bai Zhu) 
Schizonepeta 
tenuifolia 
(Jing Jie) 
Lophatherum 
gracile 
(Dan Zhu Ye) 
 
Aurantii nobilis 
Pericarpium 
(Chen Pi) 
Rhizoma 
atractylodis 
(Cang Zhu) 
Aurantii nobilis 
Pericarpium 
(Chen Pi) 
Atractylodes 
lancea 
(Cang Zhu) 
Paeonia lactiflora 
(Bai Shao) 
 
Semen coicis 
(Yi Yi Ren) 
Cortex moutan 
(Mu Dan Pi) 
Angelicae radix 
(Dang Gui) 
Angelica sinensis 
(Dang Gui) 
 
Rehmannia 
glutinosa 
(Sheng Di Huang) 
  Bupleuri radix 
(Chai Hu) 
 
Rehmannia 
glutinosa 
(Sheng Di Huang) 
Anebia clematidis 
(Chuan Mu Tong) 
  Zizyphi fructus 
(Da Zao) 
Clematis armandii 
(Chuan Mu Tong) 
Dictamnus 
dasycarpus 
(Bai Xian Pi) 
  Astragali radix 
(Huang Qi) 
Cryptotympana 
pustulata 
(Chan Tui) 
Tribulus terrestris  
(Ji Li) 
  Zingiberis rhizome 
(Gan Jiang) 
Linum 
usitatissimum 
(Hu Ma Ren) 
Potentilla chinensis 
(Wei Ling Cai) 
  Cimicifugae 
rhizome 
(Sheng Ma) 
Anemarrhena 
asphodeloides 
(Zhi Mu) 
    Gypsum fibrosum 
(Shi Gao) 
    Sophora 
flavescens 
(Ku Shen) 
    Articum lappa 
(Niu Bang Zi) 
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Table 5-2: Characteristics of studies included in the SR of oral CHM for AD 
Author 
(Date) 
Age group Study design Number of participants Drop out Run-in/Treatment/ Follow-
up/Wash-out period 
Cheng, et 
al. (2011) 
Age group 
not 
specified 
Double-blind RCT – 
Computer-generated 
randomisation list by an 
independent statistician 
TCM: 47; Placebo: 24 2 (dropped-out at 
baseline, not included 
in ITT) 
Run-in: not mentioned 
Treatment: 8 weeks 
Follow-up: 4 weeks 
Fung, et al. 
(1999) 
7-50 years Double-blind, crossover RCT TCM: 40; Placebo: 40 3 (ITT analysis not 
mentioned)  
Run-in: not mentioned 
Treatment: 8 weeks  
Follow-up: not mentioned 
Wash-out: 4 weeks 
Hon, et al. 
(2007) 
5-21 years Double-blind RCT – 
Computer generated 
randomisation code 
TCM: 42; Placebo: 43 ITT analysis to include 
all participants 
Run-in: 2 weeks  
Treatment:12 weeks  
Follow-up: 4 weeks 
Huang, et 
al. (2004) 
3-11 years Single blind RCT – Simple 
randomisation method 
(ratio 1:1) 
TCM+WM: 49; WM: 49 6 (ITT analysis used to 
analyse overall 
treatment effect) 
Run-in: not mentioned 
Treatment: 4 weeks 
Follow-up: 3 months 
Kobayashi, 
et al. (2010) 
20-40 
years 
Double-blind RCT – Block 
randomisation 
TCM: 43; Placebo: 48 7 (excluded from 
analysis) 
Run-in: not mentioned 
Treatment: 24 weeks 
Follow-up: not mentioned 
Sheehan, et 
al. (1992) 
16-65 
years 
Double-blind, crossover RCT TCM: 40; Placebo: 40 9 (excluded from 
analysis) 
Run-in: not mentioned 
Treatment: 8 weeks  
Follow-up: not mentioned 
Wash-out: 4 weeks 
RCT: Randomised, controlled trial; TCM: Traditional Chinese medicine; WM: Western Medicine; ITT analysis: Intention-to-treat analysis 
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Table 5-3: Diagnosis, interventions and outcome measures of studies included in the SR of oral CHM for AD 
Author 
(Date) 
WM/TCM Diagnosis Severity Treatment Intervention Control Intervention Outcome measures 
Cheng, et 
al. (2011) 
AD - Hanifin & Rajka 
Diagnostic Criteria 
Extensive AD 
(> 20% body 
surface area 
involved) 
Xiao Feng San granules 
3-7 years: 3g t.i.d.; 8-12 years: 
6g t.i.d; >13 years: 9g t.i.d. 
Placebo Total clinical lesion; erythema 
score; surface damage score; 
pruritus score; sleep score 
Fung, et 
al. (1999) 
AD - Hanifin & Rajka 
Diagnostic Criteria 
Moderate to 
severe AD 
Zemaphyte decoction 
7-13 years: 2 large + 2 small 
sachets of herbs per day; >14 
years: 3 large + 3 small sachets 
Placebo Clinical scores for erythema, 
surface damage, lichenification 
and scaling 
Hon, et al. 
(2007) 
AD - Hanifin & Rajka 
Diagnostic Criteria 
Moderate to 
severe AD 
(objective 
SCORAD >15) 
Pentaherb capsule  
3 capsules b.i.d. 
Placebo SCORAD; CDLQI; allergic rhinitis 
symptoms; concurrent 
treatment 
Huang, et 
al. (2004) 
AD - UK Diagnostic 
Criteria / Spleen 
deficiency 
Moderate AD Jian Pi Shen Shi granules 
3-5 years: 5g t.i.d; 6-11 years: 
10g t.i.d. + WM (same as control 
intervention) 
Oral antihistamine 
(Cyproheptadine tablets) 
0.25mg/kg/day t.i.d.; 
Triamcinolone Urea Cream 
Rajka and Langeland scoring; 
overall treatment effect; Total 
IgE; rate of recurrence 3 months 
post trial 
Kobayashi
, et al. 
(2010) 
AD - Japanese 
Dermatology 
Association Criteria / 
Kikyo Constitution (Qi 
Deficiency) 
Not specified Hochu-ekki-to granules 
3.25g b.i.d. 
Placebo Skin severity score; dosage of 
topical steroids/tacrolimus 
used; prominent efficacy rate; 
aggravated rate 
Sheehan, 
et al. 
(1992) 
AD - Hanifin & Rajka 
Diagnostic Criteria 
Extensive AD 
(> 20% body 
surface area 
involved) 
Zemaphyte decoction 
4 large + 4 small sachets (200ml 
decoction/day) 
Placebo Erythema score; surface 
damage score; improvement in 
itching, sleep and asthma; 
preference of treatment 
AD: atopic dermatitis; SCORAD: Scoring Atopic Dermatitis; CDLQI: Children’s Dermatology Life Quality Index; t.i.d.: three times a day; b.i.d.: 
twice a day  
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5.4.3 Risk of Bias Assessment 
The risk of bias assessment of this study is illustrated in Figure 5-2. 
The random sequence generation was adequately described in 3 RCTs (H. M. Cheng et al., 
2011; Hon et al., 2007; H. Kobayashi et al., 2010) and considered “low risk” for that domain 
of bias assessment while it was “unclear” in the other 3 studies (Fung et al., 1999; Y. Huang 
et al., 2004; Sheehan et al., 1992). Allocation concealment was “low risk” in 2 studies (H. M. 
Cheng et al., 2011; H. Kobayashi et al., 2010) and “unclear” in the others. All included studies 
had “low risk” for the blinding of participants and personnel, and the blinding of outcome 
assessment. However, the single-blind RCT (Y. Huang et al., 2004) was judged “high risk” for 
both domains. Intention-to-treat (ITT) analysis was applied in only 2 trials (H. M. Cheng et al., 
2011; Hon et al., 2007) which were judged “low risk” in the incomplete outcome data 
category; 3 studies (Y. Huang et al., 2004; H. Kobayashi et al., 2010; Sheehan et al., 1992) 
were judged “high risk” for excluding drop-outs possibly related to the intervention; 1 study 
(Fung et al., 1999) was “unclear” as reasons were not provided for all exclusions. Two studies 
(Fung et al., 1999; Sheehan et al., 1992) were judged “high risk” in selective reporting as they 
reported results which were not previously mentioned; the other studies were judged “low 
risk”.  
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Figure 5-2: Summary of risk of bias assessment of studies included in the SR of oral CHM 
for AD 
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5.4.4 Quality of Reporting – CONSORT 2010 Statement with Extension for Herbal Medicinal 
Interventions 
The overall quality of reporting of the included studies was fairly poor, satisfying 
approximately half or fewer of the items on the checklist (Table 5-4). A number of items 
were only partially reported by the studies, such as the names of the herbal intervention 
whereby some studies reported the Latin binomial without the common or the family name 
of the herbs. 
Two out of the 6 studies applied classical CHM formulae – Xiao Feng San (H. M. Cheng et al., 
2011) and Hochu-ekki-to (Bu Zhong Yi Qi Tang) (H. Kobayashi et al., 2010). However, only the 
latter study applied syndrome differentiation to include only patients with Kikyo (Qi 
deficient) constitution. One study applied Jian Pi Shen Shi granules which was an empirical 
formula produced by the dermatology department of the Guangdong Provincial Hospital of 
Traditional Chinese Medicine (Y. Huang et al., 2004). While this was not a traditional TCM 
formula, it was formulated and modified according to TCM theories and the study included 
only AD patients with the TCM syndrome of Spleen Qi deficiency. The remaining 3 studies 
utilised non-traditional CHM formulae and did not apply TCM syndrome differentiation or 
evaluation in the studies. 
When reporting about the experimental trial interventions, only Zemaphyte was, at the 
time, licensed in the UK where Sheehan et al.’s study (1992) took place. Another study from 
Hong Kong, which used the same formula, did not state if the formula was licensed or 
authorised in Hong Kong. Information on product licensing was not found in any of the 
studies from China, Hong Kong, Taiwan and Japan. However, these countries have 
regulations regarding the use of Chinese herbal products (T. P. Fan et al., 2012) and may not 
require licensing for CHM formulae made of already-approved herbs. None of the studies 
reported the actual part of the herbal plant used for extraction. This might be due to the fact 
that the specific part of the plant that makes up each herb is clearly stated in the Materia 
Medica (Bensky et al., 2004). The 4 studies which used CHM extracts lacked information on 
the extraction methods while all the studies lacked reporting on items 4C and 4D for dosage 
regimen, quantitative description and qualitative testing. Three studies tested for 
contaminants and 1 study stated that the product was manufactured by a Good 
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Manufacturing Practice (GMP)-certified company. The rationale for the dosage regimen was 
not mentioned in 4 of the studies and none of the studies provided practitioner description.  
With regard to trial protocol, only 2 studies reported sample size calculation. Random 
sequence generation and allocation concealment reporting was lacking in 2 and 4 studies, 
respectively. With regard to blinding, 5 studies clearly reported blinding, but did not test for 
the success of blinding.  
When reporting the results, studies failed to report clearly concomitant medications used 
during the study and there was no mention of ancillary analysis. There seemed to be little or 
no discussion regarding study limitations and comparison to trials of other products.
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Table 5-4: CONSORT 2010 checklist with extension for herbal medicinal interventions 
Paper Section 
and Topic  
Item No. Descriptor  Reported;  not reported;  partially reported;  
N/A not applicable 
Studies: 
Cheng 
2011 
Fung 
1999 
Hon 
2007 
Huang 
2004 
Kobayashi 
2010 
Sheehan 
1992 
Title and abstract 
 1 How participants were allocated to interventions (e.g., 
“random allocation”,•”randomised”•or “randomly 
assigned”). 
 
Either the title or abstract, or both, should state the 
herbal medicinal product’s Latin binomial, the part of 
the plant used, and the type of preparation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
Background 2 Scientific background and explanation of rationale. 
Including a brief statement of reasons for the trial with 
reference to the specific herbal medicinal product being 
tested and, if applicable, whether new or traditional 
indications are being investigated. 
      
Methods 
Participants   
 
3 Eligibility criteria for participants and the settings and 
locations where the data were collected. 
 
If a traditional indication is being tested, a description 
of how the traditional theories and concepts were 
maintained. For example, participant inclusion criteria 
should reflect the theories and concepts underlying the 
traditional indication. 
 
 
 
 
 
 
 
 
 
 
 
N/A 
 
 
 
 
 
N/A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N/A 
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Paper Section 
and Topic  
Item No. Descriptor  Reported;  not reported;  partially reported;  
N/A not applicable 
Studies: 
Cheng 
2011 
Fung 
1999 
Hon 
2007 
Huang 
2004 
Kobayashi 
2010 
Sheehan 
1992 
Interventions   4 Precise details of the interventions intended for each 
group and how and when they were actually 
administered. 
      
 4A: Herbal 
medicinal 
product name 
 
1. The Latin binomial name and the botanical authority 
and family name for each herbal ingredient; 
common name(s) should also be included. 
 
2. The proprietary product name (i.e., brand name) or 
the extract name (e.g., EGb-761) and the name of 
the manufacturer of the product. 
 
3. Whether the product used is authorised (licensed, 
registered) in the country in which the study was 
conducted. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4B: 
Characteristics 
of 
the herbal 
product 
 
1. The part(s) of plant used to produce the product or 
extract. 
 
2. The type of product used (e.g., raw [fresh or dry], 
extract). 
 
3. The type and concentration of extraction solvent 
used (e.g., 80% ethanol, 100% H2O, 90% glycerine, 
etc.) and the ratio of herbal drug to extract (e.g., 2 
to 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N/A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N/A 
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Paper Section 
and Topic  
Item No. Descriptor  Reported;  not reported;  partially reported;  
N/A not applicable 
Studies: 
Cheng 
2011 
Fung 
1999 
Hon 
2007 
Huang 
2004 
Kobayashi 
2010 
Sheehan 
1992 
4. The method of authentication of raw material (i.e., 
how done and by whom) and the lot number of the 
raw material. State if a voucher specimen (i.e., 
retention sample) was retained and, if so, where it is 
kept or deposited, and the reference number. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4C: Dosage 
regimen 
and 
quantitative 
description 
 
1. The dosage of the product, the duration of 
administration, and how these were determined. 
 
2. The content (e.g., as weight, concentration; may be 
given as range where appropriate) of all quantified 
herbal product constituents, both native and added, 
per dosage unit form. Added materials, such as 
binders, fillers, and other excipients (e.g., 17% 
maltodextrin, 3% silicon dioxide per capsule), should 
also be listed). 
 
3. For standardised products, the quantity of 
active/marker constituents per dosage unit form. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4D: Qualitative 
testing 
1. Product’s chemical fingerprint and methods used 
(equipment and chemical reference standards) and 
who performed the chemical analysis (e.g., the 
name of the laboratory used). Whether a sample of 
the product (i.e., retention sample) was retained 
and if so, where it is kept or deposited. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
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Paper Section 
and Topic  
Item No. Descriptor  Reported;  not reported;  partially reported;  
N/A not applicable 
Studies: 
Cheng 
2011 
Fung 
1999 
Hon 
2007 
Huang 
2004 
Kobayashi 
2010 
Sheehan 
1992 
2. Description of any special testing/purity testing 
(e.g., heavy metal or other contaminant testing) 
undertaken; which unwanted components were 
removed and how (i.e., methods). 
 
3. Standardisation: what to standardise (e.g., which 
chemical components of the product) and how (e.g., 
chemical processes, or biological/functional 
measures of activity). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4E: Placebo/ 
control group 
The rationale for the type of control or placebo used. 
      
 4F: 
Practitioner 
A description of the practitioners (e.g., training and 
practice experience) who are a part of the intervention. 
      
Objectives  5 Specific objectives and hypotheses.       
Outcomes 6 Clearly defined primary and secondary outcome 
measures and, when applicable, any methods used to 
enhance the quality of measurements (e.g., multiple 
observations, training of assessors). 
 
Outcome measures should reflect the intervention and 
indications tested considering, where applicable, 
underlying theories and concepts. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample size 7 How sample size was determined and, when applicable, 
explanation of any interim analyses and stopping rules. 
      
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Paper Section 
and Topic  
Item No. Descriptor  Reported;  not reported;  partially reported;  
N/A not applicable 
Studies: 
Cheng 
2011 
Fung 
1999 
Hon 
2007 
Huang 
2004 
Kobayashi 
2010 
Sheehan 
1992 
Randomisation 
Sequence 
allocation 
8 Method used to generate the random allocation 
sequence, including details of any restriction (e.g., 
blocking, stratification). 
      
Allocation 
concealment 
 
9 Method used to implement the random allocation 
sequence (e.g., numbered containers or central 
telephone), clarifying whether the sequence was 
concealed until interventions were assigned. 
      
Implementation 10 Who generated the allocation sequence, who enrolled 
participants, and who assigned participants to their 
groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Blinding 
(masking) 
11 Whether or not participants, those administering the 
interventions, and those assessing the outcomes were 
blinded to group assignment. If done, how the success 
of blinding was evaluated. 
 
      
Statistical 
methods 
 
 
 
 
 
 
 
12 Statistical methods used to compare groups for primary 
outcome(s); methods for additional analyses, such as 
subgroup analyses and adjusted analyses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
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Paper Section 
and Topic  
Item No. Descriptor  Reported;  not reported;  partially reported;  
N/A not applicable 
Studies: 
Cheng 
2011 
Fung 
1999 
Hon 
2007 
Huang 
2004 
Kobayashi 
2010 
Sheehan 
1992 
Results 
Participant flow 13 Flow of participants through each stage (a diagram is 
strongly recommended). Specifically, for each group, 
report the numbers of participants randomly assigned, 
receiving intended treatment, completing the study 
protocol, and analysed for the primary outcome. 
Describe protocol deviations from study as planned, 
together with reasons. 
      
Recruitment  14 Dates defining the periods of recruitment and follow-
up. 
      
Baseline data 15 Baseline demographic and clinical characteristics of 
each group. 
 
Including concomitant medications, herbal and 
complementary medicine use. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Numbers 
analysed 
16 Number of participants (denominator) in each group 
included in each analysis and whether the analysis was 
by “intention-to-treat”. State the results in absolute 
numbers when feasible (e.g., 10/20, not 50%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Outcomes and 
estimation 
 
17 For each primary and secondary outcome, a summary 
of results for each group, and the estimated effect size 
and its precision (e.g., 95% confidence interval). 
      
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Paper Section 
and Topic  
Item No. Descriptor  Reported;  not reported;  partially reported;  
N/A not applicable 
Studies: 
Cheng 
2011 
Fung 
1999 
Hon 
2007 
Huang 
2004 
Kobayashi 
2010 
Sheehan 
1992 
Ancillary 
analyses 
18 Address multiplicity by reporting any other analyses 
performed, including subgroup analyses and adjusted 
analyses, indicating those pre-specified and those 
exploratory. 
      
Adverse events   
 
19 All important adverse events or side effects in each 
intervention group. 
      
Discussion 
Interpretation 20 Interpretation of the results, taking into account study 
hypotheses, sources of potential bias or imprecision, 
and the dangers associated with multiplicity of analyses 
and outcomes. 
 
Interpretation of the results in light of the product and 
dosage regimen used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Generalisability 21 Generalisability (external validity) of the trial findings. 
Where possible, discuss how the herbal product and 
dosage regimen used relate to what is used in self-care 
and/or practice. 
      
Overall 
evidence  
 
22 General interpretation of the results in the context of 
current evidence. 
 
Discussion of the trial results in relation to trials of 
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5.5 Data Analysis 
5.5.1 TCM + WM VS WM 
Only 1 study compared the effects of a combination of WM and CHM treatment to WM 
alone (Y. Huang et al., 2004). 
5.5.1.1 Disease Severity Scoring – Overall Clinical Score 
The study used the Rajka and Langeland scoring system whereby the overall clinical score 
was calculated by summing the severity score (0-3) of each symptom (itch, erythema, 
papules, exudation, erosion, infiltration, lichenification, dryness). Significant difference was 
shown in the end score (MD -2.56, 95% Confidence Interval (CI) -3.46 to -1.66) favouring the 
combination treatment (Figure 5-3). 
 
 
Figure 5-3: Meta-analysis of overall clinical scores of the study comparing TCM + WM VS 
WM 
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5.5.2 TCM VS Placebo 
Five studies compared CHM with placebo – two compared Zemaphyte to a placebo of inert 
plant materials with similar appearance, taste and smell, but without known benefits to AD 
(Fung et al., 1999; Sheehan et al., 1992); 1 compared Pentaherb to an identical-looking 
placebo capsule containing corn starch and caramel (Hon et al., 2007); 1 compared Xiao 
Feng San granules to a placebo made of caramel, lactose and starch (H. M. Cheng et al., 
2011); and 1 compared Hochu-ekki-to granules to placebo, with no details regarding the 
placebo (H. Kobayashi et al., 2010).  
The authors of the Pentaherb trial (Hon et al., 2007) provided raw data of their study. The 
Hochu-ekki-to trial (H. Kobayashi et al., 2010) presented results in graphs only and raw data 
was not provided by the authors; consequently estimated figures based on the graphs were 
used in analysis. Due to insufficient data in the Hong Kong Zemaphyte study (Fung et al., 
1999), it was excluded from the meta-analysis. 
5.5.2.1 Disease Severity Scoring – Overall Clinical Score 
SCORAD 
Only 1 study utilised SCORAD as the overall clinical score, with the results presented as mean 
and standard deviation (SD). However, the SCORAD results of the study showed no 
significant difference between the CHM Pentaherb and the placebo (MD 2.80, 95% CI -6.13 
to 11.73) (Figure 5-4). 
 
 
Figure 5-4: Meta-analysis of SCORAD of a study comparing TCM VS Placebo 
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Scoring system by the Atopic Dermatitis Severity Evaluation Committee of the Japanese 
Dermatological Association 
The study by Kobayashi et al. (2010) used the scoring system designed by the Atopic 
Dermatitis Severity Evaluation Committee of the Japanese Dermatological Association as the 
overall clinical score to evaluate treatment effect. The results showed that there was no 
significant difference between the Kampo Hochu-ekki-to and the placebo (MD 1.80, 95% CI    
-2.15 to 5.75) (Figure 5-5). 
 
 
Figure 5-5: Meta-analysis of Japanese Dermatological Association overall clinical score of a 
study comparing TCM VS Placebo 
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Unnamed standardised scoring system 
One study (H. M. Cheng et al., 2011) utilised an unnamed standardised scoring system as the 
overall clinical score. There was significant difference between the overall clinical score, 
favouring CHM over placebo (MD -65.60, 95% CI -84.16 to -47.04) (Figure 5-6).  
 
 
Figure 5-6: Meta-analysis of overall clinical scores of a study comparing TCM VS Placebo 
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5.5.2.2 Symptom Severity Scoring – Erythema, Surface Damage, Pruritus, Sleep 
Unnamed standardised scoring system 
Two studies which were included in the meta-analysis utilised the same standardised scoring 
system (Figure 5-7) to evaluate erythema and surface damage scores (H. M. Cheng et al., 
2011; Sheehan et al., 1992). 
 
 
Figure 5-7: Standardised scoring system used in Cheng et al. (2011) and Sheehan et al. 
(1992) 
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The meta-analysis showed significant difference in both erythema (SMD -0.84, 95% CI -1.21 
to -0.48) (Figure 5-8) and surface damage scores (SMD -1.14, 95% CI -2.06 to -0.22) (Figure 
5-9), favouring CHM when compared to placebo. However, there was high heterogeneity 
detected in the meta-analysis of surface damage scores (I2=82%). This might be due to the 
fact that Cheng et al.’s study reported results as least-squares means while Sheehan et al.’s 
study reported scores as geometric means. 
 
 
Figure 5-8: Meta-analysis of erythema scores of studies comparing TCM VS Placebo 
 
 
Figure 5-9: Meta-analysis of surface damage scores of studies comparing TCM VS Placebo 
 
  
171 
 
Cheng et al.’s study evaluated pruritus and sleep scores, all of which showed significant 
difference in favour of CHM compared to placebo (Figure 5-10 & Figure 5-11). 
 
 
Figure 5-10: Meta-analysis of pruritus scores of studies comparing TCM VS Placebo 
 
 
Figure 5-11: Meta-analysis of sleep scores of studies comparing TCM VS Placebo 
 
Sheehan’s study also evaluated improvement in pruritus and sleep, but without using a 
scoring system. Out of 31 participants, 14 reported improvement in itching and 15 
experienced improved sleep during CHM treatment; while 1 reported improvement in 
itching and 6 experienced improved sleep during placebo phase. 
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5.5.2.3 Quality of Life 
Only 1 study measured QoL using the CDLQI (Hon et al., 2007). The meta-analysis showed 
that CHM treatment significantly improved the in CDLQI compared to placebo (MD -2.50, 
95% CI -4.77 to -0.23) (Figure 5-12). 
 
 
Figure 5-12: Meta-analysis of CDLQI of a study comparing TCM VS Placebo 
 
5.5.2.4 Concurrent treatment 
Kobayashi et al. (2010) measured the effects of CHM on the amount of concurrent topical 
treatments used by participants during the trial. At the end of the study, the total equivalent 
amount (TEA) of topical agents used was significantly lower in the CHM group compared to 
the placebo group (MD -24.50, 95% CI -27.92 to -21.08) (Figure 5-13).  
 
 
Figure 5-13: Meta-analysis of TEA of topical agents of a study comparing TCM VS Placebo 
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In the study by Hon, it was reported that the amount of topical mometasone furoate used at 
the end of the trial was significantly lower in the CHM group (P=0.024); furthermore, there 
were significant reductions in the number of days of corticosteroid use (P=0.042) and total 
amount of topical mometasone furoate used (P=0.020) in the CHM group at the end of the 
trial when compared with baseline (Hon et al., 2007). 
5.5.2.5 Safety Profile and Occurrence of Adverse Events 
No significant difference in safety profiles was reported between CHM and placebo groups in 
all 4 studies. However, there was 1 case of transient elevation in aspartate aminotransferase 
which was reversed within 8 weeks of treatment cessation (H. M. Cheng et al., 2011).  
One study reported 2 cases of mild transient gastrointestinal upsets during CHM treatment 
(H. M. Cheng et al., 2011); 3 studies reported the occurrence of mild/moderate side-effects, 
such as gastrointestinal upsets, various dermatoses (including “new rash”, hives, acne 
pustulosa, facial herpes), and dizziness, with no significant difference between treatment 
and control groups (Hon et al., 2007; H. Kobayashi et al., 2010; Sheehan et al., 1992).  
 
5.6 Discussion 
Results from the meta-analysis showed significant improvement in disease severity scores by 
the combination treatment of CHM and WM compared to WM only (P<0.00001). When 
compared to placebo, CHM showed significant improvement in erythema (P<0.00001), 
surface damage (P<0.01), pruritus (P<0.0001) and sleep scores (P<0.00001), as well as in QoL 
(P<0.05). CHM also significantly reduced the need for concurrent pharmacotherapy 
(P<0.00001).  
The overall risk of bias assessment showed that the quality of included studies was poor. 
Therefore the results from the meta-analysis had to be translated with caution. Only 1 study 
was judged “low risk” in all domains (H. M. Cheng et al., 2011), while the other studies had 
“unclear” or “high risk” judgements in one or more domains (Fung et al., 1999; Hon et al., 
2007; Y. Huang et al., 2004; H. Kobayashi et al., 2010; Sheehan et al., 1992). In the study 
comparing CHM and WM with WM alone, despite being labelled as a “single-blind” trial, the 
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nature of the compared interventions did not seem to enable blinding and there were no 
details on how blinding was achieved. Aside from selective reporting and the lack of details 
on random sequence generation and allocation concealment, the main flaw of the included 
studies was the lack of ITT analysis, leading to incomplete outcome data. ITT analysis 
stresses that any exclusions from analysis would affect the comparability generated through 
randomisation between groups (Newell, 1992). Furthermore, drop-outs might reflect a flaw 
of the intervention (Montori & Guyatt, 2001). The 3 studies with “high risk” in this domain 
had exclusions likely to be related to the intervention, such as side-effects, non-compliance 
and use of prescribed drugs (Y. Huang et al., 2004; H. Kobayashi et al., 2010; Sheehan et al., 
1992). One study which excluded 2 participants at baseline due to family objections was 
wrongly claimed to have applied ITT analysis (H. M. Cheng et al., 2011), but it was considered 
“low risk” as the withdrawals were not related to the intervention.  
The overall quality of reporting, when assessed by the CONSORT 2010 statement with 
extension for herbal medicinal interventions’ checklist, was poor, with studies satisfying 
about half or fewer of the items on the checklist. Lack of reporting regarding the details of 
trial protocol, details of trial interventions and details of practitioners involved led to unclear 
and high risk of bias and poor reporting. The included studies did not discuss their limitations 
or comparison with other studies on similar products. 
From the meta-analysis of the 4 placebo-controlled trials, 2 studies favoured CHM compared 
to placebo; 1 was the Zemaphyte study from the UK while the other study utilised a 
traditional CHM formula commonly used for AD, Xiao Feng San. Zemaphyte also showed 
positive results in children in another RCT in the UK (Sheehan & Atherton, 1992) (the study 
excluded for not mentioning the use of diagnostic criteria) but when tested in a similar RCT 
in Hong Kong, the same positive results were not reproduced (Fung et al., 1999). W. Zhang et 
al. (2010) deduced that the difference could be due to variance in dosage, drop-out rates or 
racial variability in drug responsiveness. Furthermore, there were no details on chemical 
properties of the placebo; its similar smell and taste to the active treatment indicated a 
possibility of containing similar chemical properties and subsequently, similar or other 
pharmacological actions. With Cheng et al.’s study (2011), participants were given CHM 
granules with daily dosages of 9g to patients aged 3-7 years; 18g to patients aged 8-12 years; 
and 27g to patients aged above 13 years, which were significantly higher dosages compared 
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to the recommended daily dosage of 6-12g for adults (Scheid, Bensky, Ellis, & Barolet, 2009). 
Also, the placebo which was composed of caramel, lactose and starch could be a risk to the 
lactose intolerant individuals. Furthermore, according to Chinese medicine theory, sweet 
foods such as caramel could worsen symptoms of skin conditions (R. Yuan & Lin, 2000). 
Therefore, the data from the study needed to be interpreted with caution.  
In contrast, there were 2 trials which showed no significant difference in clinical scores. The 
lack of efficacy in the study by Hon et al. (2007) might have been due an inadequate dosage 
of CHM (T. F. Leung et al., 2008). Although the calculation of dosage in capsule form was not 
clearly stated, the Pentaherb formulation consisted of 9g of raw herbs and the same dosage 
was given to patients from 5 to 21 years old (Hon et al., 2007). Despite the lack of efficacy, 
significant improvement in CDLQI, as well as decrease in days of corticosteroid use and in 
amount of mometasone furoate needed, was seen in the CHM group when compared to the 
placebo group. However, it was unclear if the “days of corticosteroid use” comprised 
corticosteroids other than mometasone furoate, including those of higher potencies. In the 
trial by Kobayashi (2010), only patients with Kikyo (Qi deficiency) constitution were included 
for treatment with Hochu-ekki-to or placebo. This treatment strategy might have suited the 
Kampo diagnosis (sho) but it did not address the AD condition as per Chinese medicine 
theory. This might have contributed to the lack of treatment efficacy. Nevertheless, there 
was a significant decrease in TEA of topical agents used by the CHM group when compared 
to the placebo group. While these 2 trials were unable to support the claims of CHM as an 
effective treatment, they indicated that CHM might function as an adjunct treatment for AD.  
There had been reports of liver damage and kidney failure associated with CHM treatment 
(Ernst, 2000). However, these adverse events were said to be related to 
adulterated/contaminated herbs, herb misidentification and usage of herbs with known 
toxicity (Blackwell, 1996). The CHM in 3 of the studies underwent quality checking for 
potential contaminants (including steroids) (H. M. Cheng et al., 2011; Hon et al., 2007; 
Sheehan et al., 1992), while the Hochu-ekki-to was manufactured by a GMP-certified 
company (H. Kobayashi et al., 2010). Two of the 5 studies which had adverse events 
reported non-significant differences between both groups (H. Kobayashi et al., 2010; 
Sheehan et al., 1992). However, the Pentaherb group in Hon et al.’s study (2007) had 
significantly more general practitioner (GP) visits. The study did not provide further 
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explanations, making it difficult to determine whether it was related to Pentaherb. Other 
adverse events recorded were mild or moderate symptoms such as gastrointestinal 
discomfort, dizziness, lethargy or skin eruptions (H. M. Cheng et al., 2011; Fung et al., 1999; 
Hon et al., 2007; H. Kobayashi et al., 2010; Sheehan et al., 1992). There was 1 case of 
transient elevation of aspartate amino transferase which was reversed within 8 weeks of 
treatment cessation (H. M. Cheng et al., 2011). Elevated aspartate amino transferase could 
be due to many reasons, including alcohol abuse, medications such as antihistamines or non-
steroidal anti-inflammatory drugs, and certain herbs (Giboney, 2005). However, the Chinese 
herbs used in Xiao Feng San of the respective study were not among the listed herbs. The 
authors did not provide further details to evaluate the possible relation between the 
elevation and the trial intervention. The studies from this review showed that there were no 
significant safety concerns of CHM for AD. However, this data needed to be translated with 
caution. In these studies, CHM was administered for only 4-24 weeks in controlled 
conditions – strict quality control of interventions and treatment was given to only patients 
who suited the pre-set criteria.  
The sample sizes of each study were relatively small (n<100). Furthermore, calculation of 
sample size was mentioned in only 2 studies (H. M. Cheng et al., 2011; Hon et al., 2007). The 
sample populations of each study, in terms of age range, were heterogenic. All included 
studies were on AD patients who were diagnosed according to validated criteria. Method of 
medication delivery differed as well: 1 study used capsules (Hon et al., 2007); 3 used 
granules (H. M. Cheng et al., 2011; Y. Huang et al., 2004; H. Kobayashi et al., 2010); and  2 
used raw herb decoctions (Fung et al., 1999; Sheehan et al., 1992). In TCM practice, 
decoctions are the most common form of CHM, while granules and capsules are modern 
forms aimed to be more convenient and palatable (H. Luo, Li, Flower, Lewith, & Liu, 2012). It 
still remains unclear if the different methods of CHM delivery influence its treatment effect. 
A SR comparing the efficacy and safety between decoctions and granules suggested that 
there were no differences in treatment effect (H. Luo et al., 2012). On the other hand, a 
study on the chemical profiling of a CHM formula in its decoction and granule form showed 
that there were significant chemical differences (S. L. Li, Song, Qiao, Zhou, & Xu, 2010). In 
this review, there was insufficient evidence to compare the relation between methods of 
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delivery and treatment effect. However, studies which showed significantly better outcomes 
utilised a higher treatment dosage, regardless of method of delivery. 
As mentioned in Chapter 1.6, according to TCM diagnosis, AD patients have a congenitally 
weak constitution, resulting in a predisposition towards “atopic” diseases (D. Chen & Lu, 
2007) and susceptibility towards the attack of external pathogenic factors, such as wind, 
dampness and heat. AD can also be due to internal pathogenic factors – such as wind and 
heat generated by emotional disturbances; damp and heat due to irregular diet or Spleen 
and Stomach deficiency – being lodged in the skin. The recurrent and chronic nature of the 
disease can injure Yin and Blood; and generate wind and dryness (D. Chen & Lu, 2007). 
However, these diagnoses are not specific to AD and there are other dermatological 
conditions, such as psoriasis, which may share the same TCM diagnosis. This is because TCM 
diagnosis is based on the individual presentation of a disease and the same diagnosis may 
not require the same treatment, and the same condition may be due to different TCM 
syndromes. None of the included studies personalised the CHM formula for its participants, 
which would likely impact upon their treatment outcomes. 
Among the 6 included studies, only 2 attempted to treat AD according to TCM syndrome 
differentiation by including only patients with Spleen or Qi deficiency. Despite attempts of 
employing TCM syndrome differentiation, there were still issues with study design. For 
instance, all participants were given the same CHM formula without modification to suit 
individual presentation, particularly with the Hochu-ekki-to study, where the formula only 
tonified the underlying deficiencies without addressing the potential presence of pathogenic 
factors. This is not in line with normal TCM clinical practice and may lead to incorrect 
treatment and impact on treatment outcomes. The other 4 studies used a standardised CHM 
formula for AD treatment, which was also not consistent with TCM practice of individualised 
treatment. The Pentaherb study explained that the formula was based on the TCM 
syndromes of “wind”, “dampness” and “heat” pathogenic factors (Hon et al., 2004), while 
the Xiao Feng San and Zemaphyte studies justified the use of their use based on empirical 
evidence (Atherton et al., 1990; H. M. Cheng et al., 2011). However, neither of these studies 
included inclusion/exclusion criteria related to TCM syndrome differentiation, nor conducted 
any form of TCM syndrome differentiation evaluation during the study to allow further 
analysis. Despite the lack of difference between studies which attempted TCM syndrome 
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differentiation and those that did not, each formula applied in the studies consisted of herbs 
that addressed the common TCM syndrome of AD and was able to reduce AD symptom 
severity, improve QoL, and/or reduce the need for TCS. This implied that there were clinical 
benefits of CHM treatment for AD, and better treatment efficacy might be seen with 
treatment according to TCM syndrome differentiation as in real clinical practice. 
Five CHM formulae were included in this review: Jian Pi Shen Shi granules, Xiao Feng San, 
Pentaherb, Hochu-ekki-to, and Zemaphyte. In vitro studies had shown that the Pentaherb 
formula suppressed the production of AD-related inflammatory mediators such as brain-
derived neurotrophic factor, thymus and activation-regulated chemokine, IFN-γ and tumour 
necrosis factor-alpha (TNF-α) (T. F. Leung et al., 2008). Pentaherb also decreased histamine 
release and prostaglandin D2 synthesis in mast cells (Chan et al., 2008). In vitro studies of 
Zemaphyte showed that it could reduce the over-expression of CD23 receptors on 
monocytes and Langerhans cells in AD patients (Latchman et al., 2002). This reduction was 
due to the induction of IL-10 and TNF-α by the formula. The formula also inhibited 
lymphocyte IL-4 production and histamine release (Latchman et al., 2002). There were no 
studies on the range of concentrations of CHM in relation to the therapeutic levels as 
defined by WM. 
The individual herbal ingredients of these formulae exhibited pharmacological and Chinese 
medicine actions relevant to the treatment of AD. However, the pharmacokinetics and 
pharmacodynamics of the formulae might differ from those of individual herbs (R. Yuan & 
Lin, 2000). Furthermore, there were no details regarding the specific source location and 
active compounds of the raw herbal ingredients. A study from Japan identifying 
pharmacologically-active compounds of a CHM formula detected only 3 major compounds, 
which were found in only 2 out of the 10 herbal ingredients of the formula. It found no 
traces of compounds of the other 8 herbs (Homma et al., 1992). Furthermore, Yuan and Lin 
(2000) pointed out that in vitro data my not reflect in vivo treatment effects. A CHM formula 
presented anti-viral properties when given to mice infected with the influenza virus, despite 
the lack of effect when applied to Madin-Darby canine kidney cells in vitro (M. Kobayashi, 
Davis, Utsunomiya, Pollard, & Suzuki, 1999). The in vivo metabolism of the CHM formula 
might have resulted in the development of anti-viral compound(s) (R. Yuan & Lin, 2000). The 
absence of in vitro and in vivo pharmacological data of a CHM formula deters the full 
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understanding of the drug mechanism of a herbal formula. In order to provide strong 
evidence of the efficacy and safety of CHM treatment for AD, aside from rigorous RCTs, 
further laboratory studies on the pharmacokinetics and pharmacodynamics of each formula 
should be carried out.  
5.6.1 Strengths of this Review 
This review is the most updated one on the use of orally-administered CHM in the 
management of AD. All the studies included in the previous reviews utilised the same 
formula, Zemaphyte; whereas there were 5 different CHM formulae in the 6 included studies 
of this review. The criteria of this review excluded any study which had topical or other 
forms of TCM treatment in the experimental trial group. This was to focus solely on the 
efficacy and safety of oral CHM alone or in combination with WM. Although valid 
conclusions could not be made due to the poor quality and heterogeneity of studies, several 
potential benefits of oral CHM in the management of AD, such as the improvement of QoL or 
reduced need for TCS, were identified through this review and could guide the direction of 
future studies. The data from this review also outlined certain methodological 
improvements for future studies to provide stronger evidence.    
5.6.2 Limitations of this Review 
This SR, being a branch of the comprehensive review in Chapter 4, shares the limitations of 
language barriers, a lack of understanding of TCM practice and cultural difference between 
different countries and a lack of familiarity with the Chinese electronic database searching.  
In the updated Cochrane SR (Gu et al., 2013), 6 studies using oral CHM as the experimental 
trial intervention were not identified through the database search for this review (Jin, Ye, & 
Shen, 2007; F. Luo, 2010a; X. Sun, 2009; X. Yang, Ye, & Li, 2009; T. Yu & Zhu, 1999; C. Zhang, 
2011). Out of these 6 studies, 4 suited the inclusion criteria for this SR – 1 being a placebo-
controlled RCT (X. Sun, 2009) and 3 being studies comparing oral CHM to WM (Jin et al., 
2007; F. Luo, 2010a; C. Zhang, 2011). As these studies were all Chinese studies, it was most 
probably due to differences in search strategies and syntax when conducting searches in the 
Chinese electronic databases that led to the omission of these studies. This also outlined 
another limitation in the search strategy of the protocol for this SR, whereby only electronic 
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searches were conducted and other resources, such as conference proceedings and 
reference lists of reviews, were overlooked. 
5.6.3 Comparison with Other Systematic Reviews 
As mentioned in the introduction of this chapter, two SRs evaluating oral CHM for AD had 
been previously conducted (Armstrong & Ernst, 1999; W. Zhang, Leonard, et al., 2010), with 
the latter recently updated to include both topical and oral CHM (Gu et al., 2013). The first 
SRs on oral CHM included 2 studies while the second included 2 additional studies. Both 
reviews focused on the clinical evidence of Zemaphyte. The present review included 2 out of 
the 4 studies (Fung et al., 1999; Sheehan et al., 1992). The other 2 studies were excluded – 1 
due to the lack of diagnostic criteria (Sheehan & Atherton, 1992) and 1 due to the control 
intervention being the same CHM formula as the experimental trial intervention but was 
administered differently (Henderson, Morris, Wilson, & Llchyshyn, 2000).  
The updated Cochrane SR included both oral and topical CHM interventions. As mentioned 
in the introduction of this chapter, the different pathways of medication administration may 
affect treatment actions and indications. Oral and topical CHM are therefore considered 
different interventions and their effects should be separately evaluated. The updated 
Cochrane SR identified 3 studies comparing oral CHM to placebo and 5 studies comparing 
oral CHM to WM. As mentioned in the limitations of this review, 6 of these studies (4 of 
which could have been included in this review) were not identified through the database 
searching. The updated Cochrane review also opted to exclude all Zemaphyte studies due to 
the product being withdrawn from the market since 2004. The authors believed that the 
inclusion of those studies would skew the significance of systematically produced evidence-
based medicine. However, this study chose to include the Zemaphyte studies, should they 
satisfy the pre-determined criteria for this review, to provide a comprehensive, unbiased 
evaluation of oral CHM in the management of AD. Although Zemaphyte is no longer 
available in the market as a patented product, it consisted of 10 common Chinese herbal 
ingredients which could be prescribed by any registered TCM practitioner in clinical practice.  
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Another difference was that the updated Cochrane SR did not evaluate oral CHM as an 
adjunct treatment to WM, which was evaluated in this review. However, only 1 study of that 
category was included in this review, resulting in insufficient evidence to support the use of 
oral CHM as an adjunct treatment to WM in the management of AD.  
5.6.4 Impact on Conclusion 
The differences between Gu et al.’s review and this one, especially with regard to the 
missing studies, may have led to variation in conclusion. For one, the state of evidence of 
oral CHM in comparison to WM was not known from this SR as there were no such studies 
identified and included. Furthermore, individually, the missing studies reported positive 
outcomes by CHM compared to placebo or WM, which might have led to stronger evidence 
of the efficacy or effectiveness of oral CHM if their data was added to the meta-analysis of 
this SR. Despite these differences, Gu et al.’s review shared the conclusion of this SR, that 
conclusive evidence of the benefit of CHM in the management of AD could not be 
established due to the poor quality of and low level of evidence.   
5.7 Conclusion 
5.7.1 Implications for Research 
There was insufficient data to show that oral CHM treatment in combination with WM was 
more effective than WM treatment alone and there was a lack of well-designed RCTs 
comparing oral CHM and WM in the treatment of AD. The meta-analysis in this SR showed 
significant improvement in symptom (erythema, surface damage, pruritus and sleep 
disturbance) severity by oral CHM compared to placebo. Oral CHM was also reported as 
well-tolerated in all the studies and there were no reports of severe adverse events. 
However, the small number of and poor quality of included studies and differences in 
protocol and outcome measures of the individual studies did not allow for valid conclusions. 
More rigorous RCTs and research on pharmacological studies of CHM formulae are needed 
to provide stronger evidence regarding the efficacy and safety of CHM treatment outside 
clinical trial settings. Future studies should also be designed to allow the incorporation and 
evaluation of treatment according to TCM syndrome differentiation to better reflect and 
support the use of TCM as seen in clinical practice.  
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5.7.2 Implications for Clinical Practice 
While only 2 studies applied TCM syndrome differentiation, each of the oral CHM formulae 
consisted of herbs that addressed the common TCM syndrome of AD and were able to 
reduce AD symptom severity, improve QoL, and/or reduce need for TCS. This implied that 
there were clinical benefits of CHM treatment for AD, and better treatment efficacy might 
be seen with treatment according to TCM syndrome differentiation as in real clinical practice 
While valid conclusions of the efficacy of oral CHM in the management of AD could not be 
established, oral CHM seemed to be well-tolerated and there seemed to be budding signs of 
the potential of oral CHM as an adjuvant therapy to WM in the management of AD. 
Although only 1 included study compared combined oral CHM with WM to WM alone, from 
2 of the placebo-controlled RCTs, it was shown that there was potential in oral CHM when 
used alone to improve AD patients’ QoL and reduce the need for TCS. This is especially useful 
for patients or parents who are concerned regarding the overuse of TCS.  
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 Systematic Review of the Efficacy and Safety of Acupuncture in Chapter 6
the Management of Atopic Dermatitis 
6.1 Introduction 
Aside from CHM, there is yet to be a SR of other TCM treatments in the management of AD. 
Acupuncture is one of the commonly-used TCM treatments. From the comprehensive review 
in Chapter 4, 3 RCTs which evaluated acupuncture in the management of AD itch were 
identified. As the current state of evidence of acupuncture in the management of AD 
remains unknown, this SR aimed to evaluate the published RCTs on the efficacy and safety of 
acupuncture in the management of AD when compared to placebo acupuncture, 
pharmacotherapy or no treatment. 
 
6.2 Objectives 
This SR of acupuncture for the management of AD aimed to: 
1. Evaluate the efficacy and safety of acupuncture in the management of AD from the 
modern literature; 
2. Identify limitations of the currently-available RCTs of acupuncture in the 
management of AD. 
 
6.3 Methods 
This SR shared the same search strategy with comprehensive review (Chapter 4) but 
included only RCTs with acupuncture as the experimental trial intervention. It employed a 
more rigorous set of inclusion/exclusion criteria with regard to the diagnostic criteria, 
interventions, and outcome measures. Therefore, the studies for this SR were identified 
through the screening of the 191 studies which were included in the comprehensive review. 
The methodology utilised for this SR is described in Chapter 2.3. 
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6.4 Results 
6.4.1 Identification of Studies 
From the 191 studies identified through the comprehensive review, 188 studies were 
excluded for not being RCTs on acupuncture. A total of 3 studies were included for 
qualitative and quantitative analysis. The study selection process is illustrated in Figure 6-1. 
6.4.2 Description of Studies 
Three studies were included in this review for quality evaluation and meta-analysis. There 
were a total of 60 AD patients from the 3 studies. Two out of the 3 studies were crossover 
trials, making the total population between the 3 studies 240 participants. 
All 3 included studies were conducted in Germany by the same group of authors; 1 was a 
single-blind trial (Pfab et al., 2011) and 2 were double-blind studies (three-armed and seven-
armed crossover studies, respectively) (Pfab et al., 2010; Pfab et al., 2012). Both double-
blind studies involved itch provocation by exposure to a known allergen and the evaluation 
of the direct and preventive effects of a one-session acupuncture treatment on AD itch.  
All 3 studies evaluated itch intensity using VAS, with a scale ranging from 0 to 100, whereby 
0 represented “no itch” and 100 represented “maximum itch". The single-blind study 
evaluated disease severity using the SCORAD index and both crossover studies evaluated 
itch perception using the Eppendorf Itch Questionnaire (EIQ) as well as wheal and flare sizes. 
The EIQ is a validated instrument for the qualitative and quantitative evaluation of itch 
perception and can be separated into descriptive and emotional ratings (Darsow et al., 
2001). The measurements of wheal and flare sizes of lesions differed between the 2 studies 
– the three-armed trial measured the averages of four perpendicular diameters of the lesion 
and presented as square millimetres (mm2) and square centimetres (cm2), respectively (Pfab 
et al., 2010); while the seven-armed study measured the averages of four perpendicular radii 
centred at the skin prick site and presented as millimetres (mm) and centimetres (cm), 
respectively (Pfab et al., 2012). None of the studies evaluated safety profile or the 
occurrence of adverse events. The characteristics of the included studies are summarised in 
Table 6-1.  
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Figure 6-1: Flow diagram illustrating the study selection process for the SR of acupuncture 
for AD 
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Table 6-1: Characteristics of studies included in the SR of acupuncture for AD 
Author 
(Date) 
Study Design Age Group Inclusion Criteria Number of 
Participants 
Treatment 
Intervention 
Control Intervention Outcome 
Measure 
Pfab et 
al. 
(2010) 
Double-
blind, 
randomised, 
prospective, 
three-armed 
crossover 
trial 
18-50 years 
(mean age: 
28.6 ± 2.1) 
SCORAD>18; type 1 
sensitivity to  grass 
pollen or 
Dermatophagoides 
pteronyssinus; cease 
medication 10 days 
prior to study 
30 (1 
excluded due 
to lack of 
itch 
response) 
Verum acupuncture 
(LI11 & SP10) (n=29) 
Duration: 1 session 
 
Placebo-point 
acupuncture (n=29); No 
intervention (n=29) 
Duration: 1 session 
Primary: Itch 
intensity VAS; 
wheal and flare 
size 
Secondary: 
Regional blood 
flow; EIQ 
Pfab et 
al. 
(2011) 
Single-blind, 
randomised, 
prospective, 
clinical pilot 
trial 
23-43 years 
(mean age: 
25.2±4.5) 
SCORAD>20; duration of 
condition >10 years; has 
allergic rhinitis with 
sensitisation to Phleum 
pratense or 
Dermatophagoides 
pteronyssinus; cease 
therapies containing 
potentially 
systematically active 
agents 10 days prior to 
study 
10 Acupuncture (LI4, 
LI11, ST36, SP10 plus 
individual points) 
(n=5) 
Duration: 10 sessions 
(33 days)  
No intervention (n=5) 
Duration: 10 sessions 
(33 days) 
Itch intensity VAS; 
SCORAD; Basophil 
Activation Test 
Pfab et 
al. 
(2012) 
Double-
blind, 
randomised, 
prospective, 
seven-armed 
crossover 
trial 
18-50 years  
(mean age: 
23.3±1.7) 
SCORAD>20; type I 
sensitivity to grass or 
birch pollen, cat or dog 
dander, 
Dermatophagoides 
farinae or 
pteronyssinus; cease 
medication 10 days 
prior to study 
20 (1 
excluded due 
to lack of 
itch 
response) 
Verum acupuncture 
(direct effect) 
(n=19); Verum 
acupuncture 
(preventive effect) 
(n=19) 
Duration: 1 session 
Placebo acupuncture 
(direct effect) (n=19); 
Placebo acupuncture 
(preventive effect) 
(n=19); Verum cetirizine 
(n=19); Placebo 
cetirizine (n=19); No 
intervention (n=19) 
Duration: 1 session 
Primary: Itch 
intensity Visual 
Analogue Scale; 
Secondary: Wheal 
and Flare Size; 
EIQ; d2 Test of 
Attention 
SCORAD, Scoring Atopic Dermatitis; VAS, visual analogue scale; EIQ, Eppendorf Itch Questionnaire 
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6.4.3 Risk of Bias Assessment 
All 3 studies failed to elaborate on randomisation or allocation concealment; random 
sequence generation and allocation concealment and risk of bias assessment for those 
domains were therefore “unclear”. The single-blind study compared acupuncture with no 
treatment and was rated “high risk” of bias with regard to the blinding of participants and 
the blinding of personnel. This is because participants were able to differentiate between 
acupuncture intervention from non-acupuncture and no treatment (Pfab et al., 2011); the 
other 2 were rated “low-risk” as there were corresponding placebo interventions for both 
acupuncture and/or medication. Also, evaluation of blinding showed that participants were 
successfully blinded (Pfab et al., 2010; Pfab et al., 2012). All 3 studies were scored “low risk” 
in the domain for outcome assessment blinding as it was reported that the acupuncturist 
and assessor were different individuals. All 3 studies were rated “low risk” of attrition bias as 
any exclusion from analysis was due to the lack of itch response to stimuli, therefore 
preventing the relevant participants from moving on with the study. There was also low risk 
of reporting bias as outcome measures were reported as described in the methods section 
of each paper. Figure 6-2 summarises the risk of bias assessment for all 3 studies. 
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Figure 6-2: Summary of risk of bias assessment of studies included in the SR of 
acupuncture for AD 
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6.4.4 Quality of Reporting – CONSORT and STRICTA 2010 
When evaluated with the CONSORT 2010 checklist (Table 6-2), none of the studies reported 
on sample size calculation and randomisation methods aside from the mention of “block 
randomisation” in the single-blind study (Pfab et al., 2011). There were no reports on dates 
of recruitment either. None of the studies involved follow-up periods, mentioned the use of 
ancillary analyses, or evaluated the occurrence of adverse events. Only the single-blind trial 
discussed the limitations of the study (Pfab et al., 2011). None of the studies reported on the 
trial registration details or the availability of their study protocol.  
With the STRICTA extension checklist (Table 6-3), none of the studies mentioned the style of 
acupuncture, needling response sought and details of acupuncturists. In the single-blind trial 
(Pfab et al., 2011), partially individualised acupuncture treatment was provided but there 
was a lack of information regarding the number of needle insertions, names of individualised 
points used and application of stimulation. The three-armed crossover trial and the single-
blind trial did not provide instructions to practitioners or patients (Pfab et al., 2011; Pfab et 
al., 2010). With regard to the reasoning of treatment provided, only the 2 crossover studies 
provided treatment rationale (Pfab et al., 2010; Pfab et al., 2012). However, the rationale for 
the points chosen was that they were “points referenced in standard acupuncture textbooks, 
as being important for treating cutaneous pruritus”, with no elaboration with regard to TCM 
theory or scientific evidence.  
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Table 6-2: CONSORT 2010 checklist with additional items from the non-pharmacological trials extension 
Section/Topic Item 
# 
CONSORT 2010 Statement checklist item Additional items from the Non-
pharmacological Trials Extension to 
CONSORT 
 Reported;  not 
reported;  
partially reported; 
N/A not applicable 
Studies: Pfab 
2010 
Pfab 
2011 
Pfab 
2012 
TITLE AND ABSTRACT 
 1.a Identification as a randomised trial in the title In the abstract, description of the 
experimental treatment, comparator, care 
providers, centres and blinding status.  
   
1.b Structured summary of trial design, methods, results, 
and conclusions 
 
   
INTRODUCTION 
Background and 
objectives 
2.a Scientific background and explanation of rationale     
2.b Specific objectives or hypotheses     
METHODS 
 Trial design 3.a Description of trial design (e.g., parallel, factorial) 
including allocation ratio 
 
   
3.b Important changes to methods after trial 
commencement (e.g. eligibility criteria), with reasons 
 
N/A N/A N/A 
 Participants 4.a Eligibility criteria for participants When applicable, eligibility criteria for 
centres and those performing the 
interventions. 
   
4.b Settings and locations where the data were collected     
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Section/Topic Item 
# 
CONSORT 2010 Statement checklist item Additional items from the Non-
pharmacological Trials Extension to 
CONSORT 
 Reported;  not 
reported;  
partially reported; 
N/A not applicable 
Studies: Pfab 
2010 
Pfab 
2011 
Pfab 
2012 
Interventions 5 The interventions for each group with sufficient 
details to allow replication, including how and when 
they were actually administered 
Precise details of both the experimental 
treatment and comparator – Refer to Table 
6-3 
Refer to Table 6-3 
 Outcomes 6.a Completely defined pre-specified primary and 
secondary outcome measures, including how and 
when they were assessed 
 
   
 6.b Any changes to trial outcomes after the trial 
commenced with reasons 
 
N/A N/A N/A 
Sample size 7.a How sample size was determined When applicable, details of whether and 
how the clustering by care providers or 
centres was addressed.  
   
7.b When applicable, explanation of any interim analyses 
and stopping guidelines 
 
   
Randomisation 
Sequence 
generation 
8.a Method used to generate the random allocation 
sequence 
When applicable, how care providers were 
allocated to each trial group.  
   
8.b Type of randomisation; details of any restriction (e.g., 
blocking and block size) 
 
   
Allocation 
concealment 
9 Mechanism used to implement the random 
allocation sequence (e.g., sequentially numbered 
containers), describing any steps taken to conceal the 
sequence until interventions were assigned 
 
   
192 
 
Section/Topic Item 
# 
CONSORT 2010 Statement checklist item Additional items from the Non-
pharmacological Trials Extension to 
CONSORT 
 Reported;  not 
reported;  
partially reported; 
N/A not applicable 
Studies: Pfab 
2010 
Pfab 
2011 
Pfab 
2012 
Implementation 10 Who generated the random allocation sequence, 
who enrolled participants, and who assigned 
participants to interventions 
 
   
Blinding 11.a If done, who was blinded after assignment to 
interventions (e.g. participants, care providers, those 
assessing outcomes) and how  
Whether or not those administering co-
interventions were blinded to group 
assignment. If blinded, method of blinding 
and description of the similarity of 
interventions. 
   
11.b If relevant, description of the similarity of 
interventions 
 
 N/A  
Statistical 
methods 
12.a Statistical methods used to compare groups for 
primary and secondary outcomes  
When applicable, details of whether and 
how the clustering by care providers or 
centres was addressed.  
   
12.b Methods for additional analyses, such as subgroup 
analyses and adjusted analyses 
 
   
RESULTS 
Participant flow 
(A diagram is 
strongly 
recommended) 
13.a For each group, the numbers of participants who 
were randomly assigned, received intended 
treatment, and were analysed for the primary 
outcome  
The number of care providers or centres 
performing the intervention in each group 
and the number of patients treated by each 
care provider or in each centre. 
   
13.b For each group, losses and exclusions after 
randomisation, together with reasons 
 
   
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Section/Topic Item 
# 
CONSORT 2010 Statement checklist item Additional items from the Non-
pharmacological Trials Extension to 
CONSORT 
 Reported;  not 
reported;  
partially reported; 
N/A not applicable 
Studies: Pfab 
2010 
Pfab 
2011 
Pfab 
2012 
Implementation of intervention Details of the experimental treatment and 
comparator as they were implemented.  
   
Recruitment 14.a Dates defining the periods of recruitment and follow-
up 
 
   
14.b Why the trial ended or was stopped  N/A N/A N/A 
Baseline data 15 A table showing baseline demographic and clinical 
characteristics for each group 
 
When applicable, a description of care 
providers (case volume, qualification, 
expertise, etc.) and centres (volume) in each 
group.  
N/A  N/A 
Numbers 
analysed 
16 For each group, number of participants 
(denominator) included in each analysis and whether 
the analysis was by original assigned groups 
 
   
Outcomes and 
estimation 
17.a For each primary and secondary outcome, results for 
each group, and the estimated effect size and its 
precision (e.g., 95% confidence interval) 
 
   
17.b For binary outcomes, presentation of both absolute 
and relative effect sizes is recommended 
 
 N/A  
Ancillary analyses 18 Results of any other analyses performed, including 
subgroup analyses and adjusted analyses, 
distinguishing pre-specified from exploratory 
 
   
Harms 19 All important harms or unintended effects in each 
group 
  
 
 
 
 
 
194 
 
Section/Topic Item 
# 
CONSORT 2010 Statement checklist item Additional items from the Non-
pharmacological Trials Extension to 
CONSORT 
 Reported;  not 
reported;  
partially reported; 
N/A not applicable 
Studies: Pfab 
2010 
Pfab 
2011 
Pfab 
2012 
DISCUSSION 
Limitations 20 Trial limitations, addressing sources of potential bias, 
imprecision, and, if relevant, multiplicity of analyses 
 
   
Generalizability 21 Generalizability (external validity, applicability) of the 
trial findings 
Generalizability (external validity) of the 
trial findings according to the intervention, 
comparators, patients and care providers 
and centres involved in the trial. 
   
Interpretation 22 Interpretation consistent with results, balancing 
benefits and harms, and considering other relevant 
evidence 
In addition, take into account the choice of 
the comparator, lack of or partial blinding, 
unequal expertise of care providers or 
centres in each group. 
   
OTHER INFORMATION 
Registration 23 Registration number and name of trial registry     
Protocol 24 Where the full trial protocol can be accessed, if 
available 
 
   
Funding 25 Sources of funding and other support (e.g., supply of 
drugs); role of funders 
 
   
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Table 6-3: STRICTA 2010 checklist 
Item Detail  Reported;  not reported; 
 partially reported; N/A not 
applicable 
Studies: Pfab 
2010 
Pfab 
2011 
Pfab 
2012 
1. Acupuncture 
rationale 
1a) Style of acupuncture (e.g. Traditional Chinese Medicine, Japanese, Korean, Western medical, 
Five Element, ear acupuncture, etc.) 
   
1b) Reasoning for treatment provided, based on historical context, literature sources, and/or 
consensus methods, with references where appropriate 
   
1c) Extent to which treatment was varied     
2. Details of 
needling 
2a) Number of needle insertions per subject per session (mean and range where relevant)    
2b) Names (or location if no standard name) of points used (uni/bilateral)    
2c) Depth of insertion, based on a specified unit of measurement, or on a particular tissue level    
2d) Response sought (e.g. de qi or muscle twitch response)    
2e) Needle stimulation (e.g. manual, electrical)    
2f) Needle retention time    
2g) Needle type (diameter, length, and manufacturer or material)    
3. Treatment 
regimen 
3a) Number of treatment sessions    
3b) Frequency and duration of treatment sessions    
4. Other 
components of 
treatment 
4a) Details of other interventions administered to the acupuncture group (e.g. moxibustion, 
cupping, herbs, exercises, lifestyle advice) 
N/A N/A N/A 
4b) Setting and context of treatment, including instructions to practitioners, and information and 
explanations to patients 
   
5. Practitioner 
background 
5) Description of participating acupuncturists (qualification or professional affiliation, years in 
acupuncture practice, other relevant experience) 
   
6. Control or 
comparator 
interventions 
6a) Rationale for the control or comparator in the context of the research question, with sources 
that justify this choice 
   
6b) Precise description of the control or comparator. If sham acupuncture or any other type of 
acupuncture-like control is used, provide details as for Items 1 to 3 above. 
   
196 
 
6.4.5 Quality of Acupuncture Administered – An Instrument Developed via the Delphi 
Consensus Process 
When the quality of acupuncture administered was evaluated using Smith et al.’s instrument 
(Table 6-4) (Smith et al., 2011), it was shown that all 3 trials did not justify the diagnostic 
process linking to the treatment paradigm or clinical reasoning. Furthermore, it was unclear 
if crossover designs were suitable for acupuncture trials as acupuncture effects could persist 
up to 6 months (Carlsson, 2002; Carlsson & Sjolund, 1994). None of the studies mentioned 
treatment related to TCM differential diagnosis; for the single-blind trial (Pfab et al., 2011), 
treatment was semi-individualised according to participants conditions, but it was unclear as 
to how individualised acupoints were chosen. It was also unclear if the applied acupoints in 
the 3 studies were supported by the literature. As mentioned earlier, the 2 crossover studies 
mentioned that chosen points were from the same standard textbook and were “important 
in treating cutaneous pruritus”, without further elaboration.  
The single-blind study did not report on acupoint locations, whether bilateral or unilateral 
points were needled or whether needle manipulations were conducted (Pfab et al., 2011). 
The 2 crossover studies needled acupoints unilaterally but did not provide justification (Pfab 
et al., 2010; Pfab et al., 2012). Furthermore, the insertion depth of 2-3 cm for Hegu (LI4) was 
questionable, as textbooks usually indicate an insertion depth of 0.5-1 cun (Quirico & 
Pedrali, 2007). 
Only the seven-armed crossover study applied electro-acupuncture, but did not mention if 
the machine complied with the countries’ standards (Pfab et al., 2012). All 3 studies failed to 
mention acupuncturist details, trial personnel training and monitoring of acupuncture 
administration.  
  
197 
 
Table 6-4: Quality of acupuncture administered 
Domain Statement 
number 
Item  Yes;  No; ? unclear; 
N/A not applicable 
Studies: Pfab 
2010 
Pfab 
2011 
Pfab 
2012 
1 1 The research question of the study is clearly 
described in terms of population 
   
2 The research question of the study is clearly 
described in terms of intervention 
   
3 The research question of the study is clearly 
described in terms of comparator 
   
4 The research question of the study is clearly 
described in terms of outcome 
   
2 5 The study design is appropriate for the 
research question 
?  ? 
3 6 The active intervention is justified by a 
description of the diagnosis and treatment as 
per the stated acupuncture paradigm 
   
4 7 The acupuncture intervention is designed to 
address the research question 
   
5 8 Justification of the diagnostic process is 
provided by evidence linking to the treatment 
paradigm 
   
9 Justification of the diagnostic process is 
provided by evidence linking to clinical 
reasoning 
   
6 10 Acupuncture points needled consistent with 
the differential diagnosis 
 ?  
11 Acupuncture points needled consistent with 
treatment paradigm 
 ?  
12 Acupuncture points needled consistent with 
literature review or other evidence 
? ? ? 
7 13 Needle brand and gauge is used consistently 
across all participants and sessions 
   
8 14 Point location: Published standard 
acupuncture location text are used as 
reference or location described in anatomical 
terms 
   
15 Point location: An accurate proportional 
method for locating acupoints used where 
appropriate 
   
9 16 Symmetrical or asymmetrical needling sites 
are justified according to the clinical condition 
   
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Domain Statement 
number 
Item  Yes;  No; ? unclear; 
N/A not applicable 
Studies: Pfab 
2010 
Pfab 
2011 
Pfab 
2012 
10 17 Depth of needle insertion expressed in 
millimetres as a range and is justified or 
referenced to a standard text 
   
11 18 Number of treatments: If a chronic condition a 
minimum of six treatments are administered, 
if fewer treatments are delivered appropriate 
justification is documented 
   
19 Number of treatments: If an acute or subacute 
condition no minimum of treatments are 
specified, but appropriate justification is to be 
provided 
   
12 20 Needle manipulation must be standardised 
and/or applied at least once during the 
treatment session. Manipulation should be 
expressed in terms of the number of times the 
needle was manipulated and applied 
 ?  
21 In the absence of needle manipulation, 
justification is provided of the decision not to 
undertake needle manipulation 
N/A ?  
13 22 Electro-acupuncture machine should 
demonstrate approval status and compliance 
for the country where study is being 
undertaken 
N/A N/A  
14 23 The acupuncturist administering intervention 
is registered with a regularity authority, or 
meets at least the minimum WHO standard 
(WHO 1999) 
? ? ? 
24 When a traditional diagnosis is undertaken, 
evidence is provided that the practitioner has 
undertaken a full training course as per WHO 
guideline (WHO 1999) 
N/A N/A N/A 
25 Evidence is provided of prior clinical training 
by study personnel relevant to the 
acupuncture intervention and health 
condition 
   
26 Evidence is provided of monitoring the 
administration of acupuncture in the clinical 
trial setting 
   
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6.5 Data Analysis  
Analysis was conducted to compare verum acupuncture to each of the control intervention 
groups as well as to a combined control intervention group. In the latter, all types of control 
interventions (placebo acupuncture, no treatment and pharmacotherapy) were combined to 
create a single pair-wise comparison. 
6.5.1 Preventive Effect of Interventions 
Both crossover studies evaluated the preventive effects of verum acupuncture compared to 
placebo acupuncture and no treatment. The seven-armed study also compared verum 
acupuncture to the antihistamine, cetirizine.  
6.5.1.1 Verum Acupuncture VS Placebo Acupuncture 
Itch Intensity VAS 
The meta-analysis of preventive effect on itch intensity VAS was significantly better by 
verum acupuncture when compared to placebo acupuncture [MD -2.64, 95% CI -4.39 to         
-0.89] (Figure 6-3). 
 
 
Figure 6-3: Meta-analysis of preventive effect on itch intensity VAS of studies comparing 
verum acupuncture VS placebo acupuncture 
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EIQ 
Despite significant difference in itch intensity VAS, when itch perception was evaluated with 
the EIQ in both double-blind studies, there was significant difference by verum acupuncture 
only in the descriptive ratings [MD -0.05, 95% CI -0.10 to 0.00] (Figure 6-4), but not the 
emotional ratings [MD -4.23, 95% CI -13.97 to 5.51] (Figure 6-5).  
 
 
Figure 6-4: Meta-analysis of preventive effect on EIQ descriptive ratings of studies 
comparing verum acupuncture VS placebo acupuncture 
 
 
Figure 6-5: Meta-analysis of preventive effect on EIQ emotional ratings of studies 
comparing verum acupuncture VS placebo acupuncture 
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Wheal and Flare Sizes 
There was significant difference in the preventive effect on wheal size by verum acupuncture 
compared to placebo acupuncture [SMD -1.06, 95% CI -1.50 to -0.63] (Figure 6-6), but no 
significant difference in flare size [SMD -0.90, 95% CI -3.42 to 1.62] (Figure 6-7).  
 
 
Figure 6-6: Meta-analysis of preventive effect on wheal size of studies comparing verum 
acupuncture VS placebo acupuncture 
 
 
Figure 6-7: Meta-analysis of preventive effect on flare size of studies comparing verum 
acupuncture VS placebo acupuncture 
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6.5.1.2 Verum Acupuncture VS No Treatment 
Itch Intensity VAS 
The meta-analysis of preventive effect on itch intensity VAS was significantly better by 
verum acupuncture when compared to no treatment [MD -8.77, 95% CI -10.66 to -6.88] 
(Figure 6-8). 
 
 
Figure 6-8: Meta-analysis of preventive effect on itch intensity VAS of studies comparing 
verum acupuncture VS no treatment 
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EIQ 
There was no significant difference between the verum acupuncture and no treatment in 
EIQ descriptive ratings [MD -2.30, 95% CI -8.11 to 3.50] (Figure 6-9), nor the emotional 
ratings [MD -8.26, 95% CI -25.05 to 8.53] (Figure 6-10).  
 
 
Figure 6-9: Meta-analysis of preventive effect on EIQ descriptive ratings of studies 
comparing verum acupuncture VS no treatment 
 
 
Figure 6-10: Meta-analysis of preventive effect on EIQ emotional ratings of studies 
comparing verum acupuncture VS no treatment 
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Wheal and Flare Sizes 
There was significant difference in the preventive effect on wheal size by verum acupuncture 
when compared to no treatment [SMD -1.36, 95% CI -1.81 to -0.91] (Figure 6-11) but no 
significant difference in flare size (Figure 6-12). 
 
 
Figure 6-11: Meta-analysis of preventive effect on wheal size of studies comparing verum 
acupuncture VS no treatment 
 
 
Figure 6-12: Meta-analysis of preventive effect on flare size of studies comparing verum 
acupuncture VS no treatment 
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6.5.1.3 Verum Acupuncture VS Cetirizine 
Itch Intensity VAS 
There was no significant difference in preventive effect on itch intensity VAS between verum 
acupuncture and cetirizine (Figure 6-13). 
 
 
Figure 6-13: Meta-analysis of preventive effect on itch intensity VAS of studies comparing 
verum acupuncture VS cetirizine 
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EIQ 
There was no significant difference between the verum acupuncture and cetirizine in EIQ 
descriptive ratings (Figure 6-14), nor emotional ratings (Figure 6-14).  
 
 
Figure 6-14: Meta-analysis of preventive effect on EIQ descriptive ratings of studies 
comparing verum acupuncture VS cetirizine 
 
 
Figure 6-15: Meta-analysis of preventive effect on EIQ emotional ratings of studies 
comparing verum acupuncture VS cetirizine 
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Wheal and Flare Sizes 
There was no significant difference in preventive effect on wheal or flare size by verum 
acupuncture when compared to cetirizine (Figure 6-16 and Figure 6-17). 
 
 
Figure 6-16: Meta-analysis of preventive effect on wheal size of studies comparing verum 
acupuncture VS cetirizine 
 
 
Figure 6-17: Meta-analysis of preventive effect on flare size of studies comparing verum 
acupuncture VS cetirizine 
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6.5.1.4 Verum Acupuncture VS Combined Control Interventions 
Itch Intensity VAS 
When comparing the preventive effect of verum acupuncture to combined control 
interventions of placebo acupuncture and no treatment, there was significant difference in 
itch intensity VAS, favouring verum acupuncture [MD -4.85, 95% CI -8.46 to -1.25] (Figure 
6-18). 
 
 
Figure 6-18: Meta-analysis of preventive effect on itch intensity VAS of studies comparing 
verum acupuncture VS combined control interventions 
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EIQ 
There was significant difference in preventive effect on EIQ descriptive ratings, favouring 
verum acupuncture when compared to combined control interventions [MD -0.11, 95% CI     
-0.16 to -0.06] (Figure 6-19). However, no significant difference in emotional ratings was 
detected (Figure 6-20).  
 
 
Figure 6-19: Meta-analysis of preventive effect on EIQ descriptive ratings of studies 
comparing verum acupuncture VS combined control interventions 
 
 
Figure 6-20: Meta-analysis of preventive effect on EIQ emotional ratings of studies 
comparing verum acupuncture VS combined control interventions 
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Wheal and Flare Sizes 
There was significant difference in preventive effect on wheal size by verum acupuncture 
when compared to combined control interventions [SMD -0.94, 95% CI -1.53 to -0.35] 
(Figure 6-21), but no significant difference in flare size (Figure 6-22).  
 
 
Figure 6-21: Meta-analysis of preventive effect on wheal size of studies comparing verum 
acupuncture VS combined control interventions 
 
 
Figure 6-22: Meta-analysis of preventive effect on flare size of studies comparing verum 
acupuncture VS combined control interventions 
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6.5.2 Direct Effect of Interventions 
The effects of acupuncture from the single-blind trial were analysed as a direct effect. All 3 
studies evaluated the direct effect of acupuncture compared to no treatment, while the 
seven-armed trial also evaluated the direct effect of acupuncture compared to cetirizine. 
6.5.2.1 Verum Acupuncture VS Placebo Acupuncture 
Itch Intensity VAS 
The meta-analysis of direct effect on itch intensity VAS was significantly better by verum 
acupuncture when compared to the combined control interventions [MD -4.56, 95% CI -6.28 
to -2.84] (Figure 6-23). 
 
 
Figure 6-23: Meta-analysis of direct effect on itch intensity VAS of studies comparing 
verum acupuncture VS placebo acupuncture 
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EIQ 
There was significant difference in direct effect on descriptive ratings [MD -0.07, 95% CI -
0.12 to -0.02] (Figure 6-24) and emotional ratings [MD -0.14, 95% CI -0.19 to -0.09] (Figure 
6-25) of the EIQ, favouring verum acupuncture compared to placebo acupuncture. 
 
 
Figure 6-24: Meta-analysis of direct effect in EIQ descriptive ratings of studies comparing 
verum acupuncture VS placebo acupuncture 
 
 
Figure 6-25: Meta-analysis of direct effect EIQ emotional ratings of studies comparing 
verum acupuncture VS placebo acupuncture 
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Wheal and Flare Sizes 
There was no significant difference seen in direct effect on wheal or flare sizes between 
verum and placebo acupuncture (Figure 6-26 and Figure 6-27).  
 
 
Figure 6-26: Meta-analysis of direct effect in wheal size of studies comparing verum 
acupuncture VS placebo acupuncture 
 
 
Figure 6-27: Meta-analysis of direct effect in flare size of studies comparing verum 
acupuncture VS placebo acupuncture 
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6.5.2.2 Verum Acupuncture VS No Treatment 
SCORAD 
Only the single-blind study evaluated disease severity using the SCORAD index. However, 
there was no significant difference in SCORAD between verum acupuncture and no 
treatment (Figure 6-28).  
 
 
Figure 6-28: Meta-analysis of SCORAD in a study comparing verum acupuncture VS no 
treatment 
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Itch Intensity VAS 
The meta-analysis of direct effect on itch intensity VAS was significantly better by verum 
acupuncture when compared to no treatment [MD -12.85, 95% CI -14.68 to -11.02] (Figure 
6-29). 
 
 
Figure 6-29: Meta-analysis of direct effect on itch intensity VAS of studies comparing 
verum acupuncture VS no treatment 
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EIQ 
There was no significant difference between the direct effect of verum acupuncture and no 
treatment in EIQ descriptive ratings (Figure 6-30), or emotional ratings (Figure 6-31).  
 
 
Figure 6-30: Meta-analysis of direct effect on EIQ descriptive ratings of studies comparing 
verum acupuncture VS no treatment 
 
 
Figure 6-31: Meta-analysis of direct effect on EIQ emotional ratings of studies comparing 
verum acupuncture VS no treatment 
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Wheal and Flare Sizes 
There was significant difference in the direct effect on wheal size [SMD -1.12, 95% CI -1.55 to 
-0.69] (Figure 6-32) as well as flare size [SMD -0.92, 95% CI -1.35 to -0.50] (Figure 6-33) by 
verum acupuncture when compared to no treatment. 
 
 
Figure 6-32: Meta-analysis of direct effect on wheal size of studies comparing verum 
acupuncture VS no treatment 
 
 
Figure 6-33: Meta-analysis of direct effect on flare size of studies comparing verum 
acupuncture VS no treatment 
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6.5.2.3 Verum Acupuncture VS Cetirizine 
Itch Intensity VAS 
There was significant difference in direct effect on itch intensity VAS by verum acupuncture 
when compared to cetirizine [MD -4.90, 95% CI -6.86 to -2.94] (Figure 6-34). 
 
 
Figure 6-34: Meta-analysis of direct effect on itch intensity VAS of studies comparing 
verum acupuncture VS cetirizine 
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EIQ 
There was no significant difference between the direct effect of verum acupuncture and 
cetirizine in EIQ descriptive ratings (Figure 6-35), nor emotional ratings (Figure 6-36).  
 
 
Figure 6-35: Meta-analysis of direct effect on EIQ descriptive ratings of studies comparing 
verum acupuncture VS cetirizine 
 
 
Figure 6-36: Meta-analysis of direct effect on EIQ emotional ratings of studies comparing 
verum acupuncture VS cetirizine 
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Wheal and Flare Sizes 
There was no significant difference in the direct effect on wheal or flare size by verum 
acupuncture when compared to Cetirizine (Figure 6-37 and Figure 6-38). 
 
 
Figure 6-37: Meta-analysis of direct effect on wheal size of studies comparing verum 
acupuncture VS cetirizine 
 
 
Figure 6-38: Meta-analysis of direct effect on flare size of studies comparing verum 
acupuncture VS cetirizine 
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6.5.2.4 Verum Acupuncture VS Combined Control Interventions 
Itch Intensity VAS 
When comparing the direct effect of verum acupuncture to combined control interventions 
of placebo acupuncture and no treatment, there was significant difference in itch intensity 
VAS, favouring verum acupuncture [MD -7.63, 95% CI -9.28 to -5.98] (Figure 6-39). 
 
 
Figure 6-39: Meta-analysis of direct effect on itch intensity VAS of studies comparing 
verum acupuncture VS combined control interventions 
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EIQ 
There was no significant difference of direct effect in EIQ descriptive ratings (Figure 6-40) or 
emotional ratings (Figure 6-41) by verum acupuncture or control intervention. 
 
 
Figure 6-40: Meta-analysis of direct effect on EIQ descriptive ratings of studies comparing 
verum acupuncture VS combined control interventions 
 
 
Figure 6-41: Meta-analysis of direct effect on EIQ emotional ratings of studies comparing 
verum acupuncture VS combined control interventions 
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Wheal and Flare Sizes 
There was significant difference of direct effect of verum acupuncture on wheal size when 
compared to combined control interventions [SMD -0.81, 95% CI -1.44 to -0.17] (Figure 
6-42), but no significant difference in flare size (Figure 6-43).  
 
 
Figure 6-42: Meta-analysis of direct effect on wheal size of studies comparing verum 
acupuncture VS combined control interventions 
 
 
Figure 6-43: Meta-analysis of direct effect on flare size of studies comparing verum 
acupuncture VS combined control interventions 
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6.6 Discussion 
This review included 3 studies: 2 double-blind crossover studies and 1 single-blind pilot trial. 
The studies focused mainly on the anti-pruritic effect of acupuncture in AD. None of the 
studies mentioned the occurrence of adverse events or evaluation of safety profiles. The 
results of the crossover studies were published as means and SDs of each intervention, with 
no distinction between the phases of crossover. It was assumed that the reported values 
were combined results of all phases of each arm and were used in the meta-analysis 
accordingly.  
The meta-analyses showed that there were significant preventive and direct effects in itch 
intensity VAS by verum acupuncture when compared to placebo acupuncture or no 
treatment. However, there was no significant difference when compared to cetirizine, but 
the authors reported less cognitive impairment in the acupuncture group (Pfab et al., 2012). 
There was only significant difference in preventive effects by verum acupuncture in EIQ 
descriptive ratings when compared to the combined control interventions, although no 
significant difference was seen in EIQ descriptive or emotional ratings when verum 
acupuncture was compared against the control interventions individually. Significant 
difference in direct effects in EIQ descriptive and emotional ratings was also observed when 
verum acupuncture was compared against placebo acupuncture. There was significant 
difference in preventive effects in wheal size, favouring acupuncture when compared to 
placebo acupuncture, no treatment or combined control interventions, but not when 
compared to cetirizine. With direct effect in wheal size, significant difference was seen only 
when verum acupuncture compared to no treatment or combined control interventions. 
With regard to flare size, significant difference was seen only in the direct effects by verum 
acupuncture when compared to no treatment. While there was also significant difference in 
SCORAD by verum acupuncture, only 1 study was included in the meta-analysis, which did 
not allow for a valid conclusion.  
While there was significant improvement in itch intensity by verum acupuncture when 
compared to placebo acupuncture, no treatment, pharmacotherapy or combined control 
interventions, there was no significant improvement in EIQ ratings. This implied that the 
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reduction in itch did not mean an improvement in the perception of itch characteristics or its 
psychosocial significance in patients’ lives.  
It should be noted that there was high heterogeneity detected in many of the meta-
analyses. This might be due to the variation in trial designs, statistical analysis and units of 
measurement between the 3 included studies.  All 3 trials were conducted by the same 
group of authors; therefore, results had to be translated with caution. 
The 3 studies had a small number of participants (n=10-30); however, crossover trial designs 
were applied in 2 of the 3 studies, increasing the total population to 240 participants. The 
participants of all studies were said to have AD or AE, with the mention of a SCORAD index of 
more than 18 (Pfab et al., 2010) or 20 (Pfab et al., 2011; Pfab et al., 2012). The SCORAD index 
is a validated outcome measure for AD but not a validated instrument for AD diagnosis. 
Furthermore, there was no rationale for the cut-off points of 18-20 points; SCORAD classifies 
mild, moderate and severe AD according to indices of <25, 25-50, >50, respectively (Oranje, 
Glazenburg, Wolkerstorfer, & De Waard-van der Spek, 2007). The use of SCORAD to guide 
AD diagnosis might be an error in reporting or trial design. However, all 3 studies required 
that participants show type I sensitivity to specific allergens, which was a commonly-seen 
characteristic in AD. The single-blind study also required that participants have a history of 
AD for more than 10 years as well as allergic rhinitis; while the seven-armed crossover trial 
recruited participants from an outpatient clinic and had “AD diagnosis” as an inclusion 
criterion, which might imply that participants had to be clinically diagnosed. 
The overall risk of bias assessment showed that the studies lacked details on random 
sequence generation and allocation concealment. In the single-blind trial, the lack of patient 
blinding might affect trial outcomes of itch intensity and disease severity; however, basophil 
activation test, which was unlikely to be affected by the lack of blinding, showed that 
acupuncture improved AD by reducing basophil activation. In the double-blind studies, the 
crossover methods were not clearly explained. As mentioned earlier, there also was the 
question of the suitability of crossover-designed RCTs to evaluate acupuncture effects. 
Previous studies have shown acupuncture effects to persist for up to 6 months (Carlsson, 
2002; Carlsson & Sjolund, 1994). This suggested the possibility of participants, who were in 
the verum acupuncture intervention groups in the earlier phases of the crossover, reporting 
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better results in subsequent intervention groups due to the carry-over effects. Furthermore, 
in the three-armed crossover trial, there was no mention of wash-out periods between 
interventions, while the seven-armed trial had “at least 1 week” in between interventions.  
The acupuncture points Quchi (LI11), Xuehai (SP10), Shaohai (HT3) and Liangqiu (ST34) were 
chosen in the double-blind trials as they were recorded in “standard acupuncture textbooks” 
as important points for treating cutaneous pruritus, with no elaboration or reference to TCM 
theory and differential diagnosis. No rationale was provided for the point-selection in the 
single-blind trial.  
Nevertheless, the improvement in itch intensity by acupuncture showed this review was in 
agreement with previous studies on the anti-pruritic effects of acupuncture (Brinkhaus et al., 
2006; Ikoma, Steinhoff, Ständer, Yosipovitch, & Schmelz, 2006; Lundeberg et al., 1987).  
Itching is a complex, aversive sensation which can be reduced by pain stimuli (Ikoma et al., 
2006). Therefore, theoretically, analgesic agents enhance itching. However, acupuncture, 
which have been widely studied for its analgesic effects (Brinkhaus et al., 2006; Jena, Witt, 
Brinkhaus, Wegscheider, & Willich, 2008; Kawakita et al., 2006; Linde et al., 2005; Witt et al., 
2006), seemed to reduce itching as well. Ikoma et al.(2006) explained that inflammatory 
mediators such as bradykinin, serotonin and prostaglandins activated both itch and pain 
receptors. Both pain and pruritic lesions share peripheral sensitisation pathways and can 
increase nerve growth factor (NGF), which has been shown to play a role in the pathogenesis 
and severity of AD (Ikoma et al., 2006; Toyoda et al., 2002). Studies have shown that 
acupuncture effects might be mediated by various neurotrophins in the brain, including NGF 
(Manni, Albanesi, Guaragna, Barbaro Paparo, & Aloe, 2010).  
The anti-pruritic effect of acupuncture might also be related to the induction of vasodilation 
by needle insertion, stimulation of inflammatory cell mediators and depletion of 
neurotransmitters through the activation of C fibres (Carlsson & Wallengren, 2010). 
Following functional magnetic resonance imaging in AD patients, Napadow et al. (2012) 
found that acupuncture reduced the itch-evoked activation of parts of the brain related to 
itch perception, namely the insula, putamen as well as the premotor and prefrontal cortical 
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areas; neither antihistamine nor placebo acupuncture was able to alter itch sensation or 
itch-evoked brain activity.  
The therapeutic effects of acupuncture in AD were not limited to its anti-pruritic effects. The 
single-blind study in this review found that basophil activation, which played a part in the 
allergic response in AD, was significantly reduced, showing that acupuncture had an 
allergen-independent mechanism of action. Furthermore, previous studies have shown that 
acupuncture had beneficial effects in treating allergic rhinitis, which is an atopic disease 
closely related to AD. In 1 study, acupuncture significantly improved nasal and non-nasal 
symptoms in allergic rhinitis when compared to sham acupuncture or no active treatment (S. 
M. Choi et al., 2013). Another study showed that acupuncture significantly improved QoL 
and decreased antihistamine use when compared to sham acupuncture or rescue 
medication (Brinkhaus et al., 2013).  
Studies on acupuncture mechanism seemed to suggest that acupuncture effects were due to 
physiological response and nervous activation by needle insertion (and electric stimulation, 
in the case of electro-acupuncture). There was no mention of whether the use of different 
acupuncture points or de qi sensation would alter the effects of acupuncture physiologically 
(Manni et al., 2010). While no substantial evidence has been discovered as yet, a review 
characterising acupuncture stimuli using brain imaging found that the brain maps generated 
by different acupuncture points differed considerably, supporting the notion of acupuncture 
point specificity (W. Huang et al., 2012). Park et al. (2013) reported that stimulation of local 
points around AD lesions inhibited cutaneous hyperplasia and serum IgE but was ineffective 
in the regulation of pro-inflammatory cytokines; stimulation of the acupuncture point Quchi 
(LI11) in AD rats, however, not only inhibited cutaneous hyperplasia and reduced serum IgE 
to a greater extent but also reduced pro-inflammatory cytokines and proteins.  
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6.6.1 Strengths of this Review 
It goes on record that there has yet to be a SR evaluating acupuncture treatment in the 
management of AD. Although only 3 studies, all by the same group of authors, were 
included, the meta-analyses showed that acupuncture had the potential to reduce itch 
intensity. This finding is in agreement with previous studies in the literature. This SR 
provided a stand of the current evidence of acupuncture for the management of AD. It 
outlined what RCTs on acupuncture for AD had been conducted and what can be improved 
in future studies to build on the existing evidence.  
6.6.2 Limitations of this Review 
This SR shared the limitations that were mentioned in Chapters 4 and 5; these included 
language barriers that prevented the evaluation of all identified studies, lack of 
understanding of TCM practice and cultural difference between different countries and lack 
of familiarity with the Chinese electronic database searching.  
Aside from that, one main limitation of this SR was the fact that there were only 3 studies, all 
by the same group of authors, which were included. This posed a possible bias towards the 
results achieved from this study. In 2 of the studies, acupuncture effects were evaluated 
based on 1 acupuncture session, raising questions of duration/frequency of treatment and 
effects and how that translated in a clinical setting. Furthermore, the overall quality of 
studies, including the reporting and acupuncture administration, was poor and there were 
several questions regarding the study design and suitability of the design for acupuncture 
studies. Future studies need to ensure that these questions are addressed and reporting of 
studies should be consistent with the CONSORT and STRICTA 2010 checklists.  
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6.7 Conclusion 
6.7.1 Implications for Research 
This SR showed that there is potential for the use of acupuncture in the management of AD, 
especially with regard to the reduction of AD itch intensities. While results of this SR need to 
be interpreted with caution due to the fact that all 3 studies were by the same authors, the 
effects of acupuncture in reducing itch supported the existing literature on the anti-pruritic 
effects of acupuncture. This study also showed that acupuncture might possibly have a 
preventive effect on AD itch as well. However, more studies on the preventive effects of 
acupuncture are required to support this statement. Further studies need to focus on 
overcoming the flaws in study design and reporting identified in this SR and focus on the 
safety and beneficial effects of acupuncture on AD as a disease, including its effects on 
patients’ QoL, and not just as an anti-pruritic therapy. The 3 studies in this SR focused on 
acupuncture in itch-induced AD with outcome measures for itch intensity, itch perception 
and lesion wheal and flare severity. Only 1 study provided semi-individualised treatment 
with acupuncture. Future studies should also consider incorporating TCM differential 
diagnosis and treatment principles and evaluating disease severity, QoL, safety profiles and 
occurrence of adverse events. 
6.7.2 Implications for Clinical Practice 
While valid conclusions on the therapeutic effects of acupuncture in the management of AD 
could not be deduced, this SR supported the use of acupuncture as an anti-pruritic therapy. 
As itch is the main symptom that affects and debilitates AD patients and current anti-pruritic 
therapies are limited, this SR showed that acupuncture could act as an alternative form of 
management of AD itch. 
Although there was insufficient evidence, 1 study showed the potential of acupuncture to 
improve the SCORAD index, and the meta-analysis showed that acupuncture had the 
potential in reducing wheal size of AD lesions. This preliminary data presented the clinical 
prospects of acupuncture in the management of AD.   
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 Preparation for a Randomised Controlled Clinical Trial using Chapter 7
Orally-Administered Chinese Herbal Medicine (RCM-106) in the 
Management of Atopic Dermatitis in Children – Study Protocol 
7.1 Introduction 
This chapter elaborates on the protocol for a randomised, double-blind, placebo-controlled 
clinical trial using a newly-formulated Chinese herbal formula – RMIT Chinese Medicine-106 
(RCM-106) – in the management of AD in the paediatric population. The design of this study 
and the formula, RCM-106, was guided by the data collected from the reviews in Chapters 3, 
4, 5, and 6 to ensure a high-quality, rigorous study.  This protocol has been approved and 
finalised and the RCT will be conducted in the near future. 
 
7.2 Objectives 
This protocol aims to: 
1. Incorporate data from previous reviews to prepare a rigorously designed randomised 
controlled clinical trial using orally-administered CHM (RCM-106) for the 
management of AD in the paediatric population; 
2. Highlight what is involved in the preparation of a rigorous RCT evaluating the efficacy 
and safety of a CHM formula in the management of AD in the paediatric population 
to function as a guide for future studies. 
This protocol is for a RCT which aims to find a better form of management of AD using a new 
Chinese herbal formula – RCM-106. This trial will evaluate the efficacy and safety of RCM-
106 in the management of AD in children in a randomised, double-blind, placebo-controlled 
trial. Besides the efficacy and safety of RCM-106, this trial will also evaluate the effects of 
RCM-106 in improving the QoL of children affected by AD. 
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7.3 Trial Registration and Compliance 
This protocol complies with the principles of the Declaration of Helsinki and Good Clinical 
Practice guidelines, which include the following: 
 CPMP/ICH, Note for Guidance on Good Clinical Practice – Annotated with 
Therapeutic Goods Administration (TGA) comments (CPMP/ICH/135/95); 
 CPMP/ICH, General Considerations for Clinical Trial (CPMP/ICH/291/95); 
 CPMP/ICH, Statistical Principles for Clinical Trial (CPMP/ICH/363/96); 
 NH&MRC, National Statement on Ethical Conduct in Research Involving Humans; 
 NH&MRC, Guidelines Under Section 95 of the Privacy Act 1988, March 2000. 
This protocol is developed in line with the Standard Protocol Items: Recommendations for 
Interventional Trials (SPIRIT) 2013 statement: defining standard protocol items for clinical 
trials (Chan et al., 2013). The tables of registry data and protocol versions/amendments are 
found in Appendix 4. This protocol has received human ethics approval from the Human 
Research Ethics Committee (HREC) of RMIT University, Melbourne, Australia (Project 
Number 15/12). The study is also registered with the Australia and New Zealand Clinical 
Trials Register (ANZCTR) (Reference number ACTRN12612001181897) and with the 
Therapeutic Goods Administration (TGA) of Australia, under the Clinical Trial Notification 
(CTN) Scheme (Trial number 2012/0713; Protocol number 15/12). 
 
7.4 Participants 
This study is targeted at children aged 6-18 years old, as AD is more prevalent in children 
(Bieber, 2008). Children of both genders diagnosed with AD according to the UK diagnostic 
criteria (Williams et al., 1994) will be recruited according to the inclusion/exclusion criteria 
listed below. Participants will be randomly assigned into either treatment or placebo groups. 
Informed consent will be acquired in the form of written consent from the participant’s 
parent/legal guardian and from participants with sufficient language fluency; verbal assent in 
the presence of a witness who is not involved in the trial will be sought from the participants 
who are unable to read and write.  
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7.4.1 Inclusion Criteria 
Participants of the study will be required to meet the following criteria: 
 Diagnosed with AD according to the UK Diagnostic Criteria; 
 Have moderate-to-severe AD (SCORAD≥25); 
 Aged between 6 to 18 years old; 
 Agree to abstain from alcohol during the period of the trial; 
 Not be involved in other clinical trials; 
 Agree to avail themselves for the period of the study; 
 Provide written consent for participation from parent or legal guardian and verbal 
assent from the participant ; 
 Pass the “swallow-test” (able to swallow an empty size #1 capsule) during initial 
assessment or willing to undergo “capsule-swallowing training programme”. 
7.4.2 Exclusion Criteria 
Volunteers with 1 or more of the following conditions will be excluded from study: 
 Presence of overt bacterial infection/concurrent systemic disease (except asthma and 
allergic rhinitis); 
 Pregnant/intention to get pregnant/breastfeeding/females of childbearing age 
refusing contraception; 
 Unable to swallow size #1 capsules (approximately 19.4mm in length and 6.91mm in 
diameter) and refuse to undergo the “capsule-swallowing training programme; 
 Have history of sensitivity towards CHM; 
 Have abnormal full blood count (with the exception of parameters related to AD, 
such as eosinophil count and total IgE), renal or liver function tests; 
 Use of Chinese herbs, systemic steroids, antibiotics, phototherapy or any immuno-
modulating drugs 4 weeks prior to the study;  
 Currently using other therapies, including supplements and other complementary 
medicines (except for the use of topical, non-TCM therapies when necessary);  
 Unable to understand English. 
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7.4.3 Sample Size Calculation 
The sample size calculation for this study was based on the effect size calculations from the 
severity scores of 2 studies – 1 from Taiwan using a similar Chinese herbal formula for AD (H. 
M. Cheng et al., 2011); and another comparing prebiotic and symbiotic treatment (K. G. Wu, 
Li, & Peng, 2012). With the effect size estimate of 1.76 calculated from the Taiwan study, to 
achieve 95% power with a significance level of 5%, only 10 participants per group would be 
required. Based on the end SCORAD in Wu’s study, an effect size estimate of 0.64 was 
calculated. To achieve 85% power with a significance level of 5% with the effect size 
estimate of 0.64, 45 participants per group would be required. Considering that the former 
study had some methodological differences towards this study and used a much larger 
treatment dose, while the latter used a similar methodology but a different form of 
intervention, a sample size of 90 participants, inclusive of 20% drop-out compensation, will 
be applied in this study.  
 
7.5 Procedure of Recruitment 
7.5.1 Setting and participant source 
The RCT will be conducted in the RMIT Traditional and Complementary Medicine Research 
Group Clinical Trial Clinic, RMIT University, Bundoora West Campus and RMIT University City 
Campus, in Melbourne, Australia. Participants will be recruited from surrounding Melbourne 
suburbs. 
7.5.2 Advertising 
Participants of the trial will be recruited via advertising on the internet (AD or AE online 
communities; association websites; Facebook/Twitter; RMIT website). Advertising in the 
form of posters or flyers will be made available in RMIT University (Bundoora and City 
campuses), children’s hospital or paediatric wards of hospitals, medical centres, clinics of 
dermatologists and Chinese medicine practitioners, primary and secondary schools, and 
community libraries of surrounding suburbs in Melbourne. Advertising via other forms of 
media (radio, newspaper, television) may be used if necessary.  
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7.5.3 Screening  
Interested participants or their parent(s)/legal guardian(s) may make enquiries via email or 
telephone. Participant information and consent forms will be sent out to potential 
participants prior to the telephone interview and scheduling of the first visit. Potential 
participants will undergo preliminary screening for eligibility during Visit 1 by investigators, 
which will include a registered medical practitioner. As mentioned in the inclusion/exclusion 
criteria for this study, potential participants will be required to pass a swallow-test or have 
the option to undergo a capsule-swallowing training programme. 
7.5.3.1 Swallow-Test 
As the trial intervention will be herbal extracts or placebo encapsulated in size #1 capsules, 
this protocol included a “swallow-test” during participant screening as a safety precaution. 
The swallow-test is to confirm the participants’ ability to swallow capsules and therefore 
eligible to participate in the study. The swallow-test will require potential participants to 
swallow an empty, size #1, vegetarian capsule. Water will be supplied during the test and 
participants will not be allowed to use other drinks to complete the test. Participants who 
are unable to swallow the capsule will be given the option of either undertaking the 
“capsule-swallowing training programme” or being excluded from the study.  
7.5.3.2 Capsule-swallowing Training Programme 
Potential participants who fulfil the inclusion criteria but are unable to swallow size #1 
capsules, either self-reported or during the swallow-test, may choose to undergo a “capsule-
swallowing training programme”, if they are still keen to participate in the study. Studies 
have shown that various forms of training programmes have been successful in teaching 
children to swallow pills (Beck, Cataldo, Slifer, Pulbrook, & Guhman, 2005; Garvie, Lensing, & 
Rai, 2007; Kaplan et al., 2010). Parents of participants will be given training guidelines 
(Appendix 5) and a supply of empty capsules of various sizes for the training. The guidelines 
for the “capsule-swallowing training programme” were modified from the “Teach Children 
How to Swallow Tablets and Capsules” guidelines by the Royal Children’s Hospital (The Royal 
Children's Hospital Melbourne, 2013). Should participants succeed in swallowing size #1 
capsules after the training, they will be eligible to participate in the study. 
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7.5.4 Informed Consent 
Informed consent will be sought during the initial assessment at the clinic prior to the run-in 
period and randomisation process. Written information and verbal explanation concerning 
the study will be provided. Full explanation will be given to any questions that arise prior to 
the signing of the participant information and consent form. Written consent will be 
required from the parent(s)/legal guardian(s) and participants with adequate fluency in 
English; verbal assent in the presence of a witness will be sought from participants who are 
unable to read and write. The witness will be someone who is not involved in the clinical trial 
and whose signature will be required as evidence of witnessing the informed consent 
process. The responsible investigator will record the date, time, and location of the provision 
of Informed Consent. 
 
7.6 Trial Design 
7.6.1 Randomisation 
Randomisation will be carried out after the run-in period using block randomised sequences 
generated by computer. Each participant will be assigned an ID code. An independent 
statistician will be responsible for the stratified randomisation to ensure the balance in 
gender and disease severity of both groups. According to the SCORAD classification of 
severity, a SCORAD index of 25-50 is considered moderate AD and an index above 50 is 
considered severe AD (Oranje et al., 2007). 
7.6.2 Blinding 
Blinding will be done using treatment codes and pre-packing of placebo and RCM-106 
capsules, which are identical in appearance, taste and scent. The codes and labelling will be 
recorded in a password-protected computer program. Participants, investigators and 
outcome assessors will remain blinded to the treatment allocation until after the study has 
been completed. 
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7.6.3 Participant Withdrawal/Drop-outs 
A participant may be withdrawn from the trial by the investigator if a serious adverse event 
(SAE) occurs. Participants are also permitted to withdraw at will at any time during the trial. 
All withdrawn cases who have received the intervention will be contacted 4 weeks following 
withdrawal, as the follow-up period, to obtain information with regard to their condition 
using the self-reported outcomes using the Patient-oriented Scoring Atopic Dermatitis (PO-
SCORAD) and CDLQI instruments. 
 
7.7 Trial Interventions 
The treatment interventions are RCM-106 herbal extract capsules and matching placebo 
capsules, which are identical in appearance, taste and odour. The capsules will be dispensed 
as size #1, vegetarian capsules containing 500mg of RCM-106 extracts or placebo (herbal 
starch) and packed in sealed bottles containing a 2 week dose of capsules. Participants aged 
6-11 years will be required to take 3 capsules while participants aged 12-18 will be required 
to take 6 capsules, at each dosing period, twice daily, for the treatment period of 8 weeks.  
The capsules will be produced by a manufacturer that holds a TGA-approved GMP 
certificate. Quality control checks on the packaging and contents of the treatment 
interventions, including checks for potential contaminants such as heavy metal or steroids, 
will be undertaken by the manufacturers to ensure their stability and quality. 
7.7.1 RCM-106 Capsules 
The SR of classical literature in Chapter 3 showed that among the systemic CHM treatments 
for AD-like conditions, Xiao Feng San was one of the frequently-used formulae containing 5 
of the frequently-used individual herbs in the management of AD-like conditions. From the 
results of the SR of oral CHM for AD in Chapter 5, the study which utilised Xiao Feng San was 
reported to be of higher quality (low risk of bias) compared to the other studies, with 
positive efficacy outcomes when compared to the placebo.  
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Incorporating the data collected from the reviews, RCM-106 was formulated based on the 
classical formula, Xiao Feng San. The formulation was sent to experts in China and RMIT 
University for comments and advice before it was finalised.  
Each RCM-106 capsule will consist of the herbal granule extracts of 7 plant herbal substances 
(Table 7-1), all of which are listed as approved substances for human consumption by the 
TGA (2007). The dosage of each raw herbal ingredient is within the dose range as recorded 
in the Pharmacopoeia of the People’s Republic of China (The State Pharmacopoeia 
Commission of The People's Republic of China, 2000).  
The herbal extracts will be of a concentration ratio of 7:1. The dosage of RCM-106 for 
children was determined by taking into consideration the age-to-dose guidelines published 
by the Nanjing College of Traditional Chinese Medicine (J. K. Chen & Chen, 2009) and the 
conversion table of Von Harnack (Ministry of Health Labour and Welfare, 2010).  
 
Table 7-1: Herbal ingredients of RCM-106 
Chinese name of  
herbal ingredient 
Species 
Dosage of raw 
herbs (g) – 
adult dose 
Daily dose of 
extract per 
capsule (mg) – 
adult dose 
Fang Feng 
Saposhnikovia divaricata (TURCZ.) 
SCHISCHK. 
9 75.0 
Chao Bai Zhu 
Atractylodes macrocephala KOIDZ. 
(Dry Fried) 
9 75.0 
Ku Shen Sophora flavescens AIT. 9 75.0 
Sheng Di Huang Rehmannia glutinosa LIBOSCH. 12 100.0 
Bai Shao Paeonia lactiflora PALL. 6 50.0 
Gan Cao Glycyrrhiza uralensis FISCH. 6 50.0 
Bai Xian Pi Dictamnus dasycarpus TURCZ. 9 75.0 
Total 60 500.0 
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7.7.2 Placebo Capsules 
The placebo capsules will consist of herbal starch, which is starch made from the herbal 
dregs of the active intervention after extraction and therefore will have a similar 
appearance, smell and taste to RCM-106 extracts. However, they contain no active 
constituents. This method of placebo had been shown to be successful in a previous study 
(Lenon et al., 2012). 
 
7.8 Trial Procedure 
After initial screening, eligible participants will undergo initial assessments for baseline data 
collection, which includes the SCORAD, PO-SCORAD, CDLQI, a Chinese Medicine 
Questionnaire, measurement of vital signs (temperature, blood pressure and heart rate), full 
blood count, total IgE, eosinophil count, kidney function test and liver function test, and be 
given their daily diary.  
After the run-in period, participants will be randomly assigned to either the treatment (RCM-
106) group or the control (placebo) group and the treatment period will commence. During 
the fortnightly clinic visits, participants will be given 2 weeks’ worth of RCM-106 or placebo 
capsules and daily diary. Vital signs, SCORAD, PO-SCORAD and CDLQI will be assessed as well. 
Participants will be asked to return their medication bottles to enable the counting of left-
over capsules for participant adherence monitoring.   
Throughout the treatment period, participants will not be permitted to use any systemic 
treatments, including supplements and complementary medicines. The use of other topical, 
non-Chinese medicine therapies, such as TCS, are not encouraged but will be allowed on an 
“as needed” basis. To assist the monitoring of patient compliance and intervention 
acceptability, participants will be required to record their trial medication compliance, usage 
of any other therapies and occurrence of adverse events in the daily diary.  
After the treatment period, participants will be given the PO-SCORAD, CDLQI and a pre-paid 
envelope and be asked to return the completed outcome assessment instruments via post at 
the end of the follow-up period. The outline of trial procedures is illustrated in Figure 7-1. 
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Figure 7-1: Outline of trial procedure 
Advertising 
Parent/legal guardian 
of potential participant 
or potential participant 
(PP) contacts Principal 
Investigator (PI) 
Information 
package sent 
out 
Telephone interview 
with parent/legal 
guardian of PP or PP (if 
PP 18 years old) 
Eligible PP and parent/legal 
guardian invited to attend 
initial assessment 
(appointment made over the 
phone) 
Initial Assessment at Research Clinic (Visit 1) 
• Explanation of trial; Informed Consent; CM Questionnaire; 
baseline data collection: SCORAD; PO-SCORAD and CDLQI; safety 
assessments: laboratory data 
2-week run-in period 
• Daily diary provided to participants 
Randomisation 
• Control group (Placebo) 
• Treatment group (RCM-106) 
Treatment period (8 weeks) 
• Participants of each group will be required to come in for 5 fortnightly 
visits (from week 1 to week 9) 
• Visit 2-5 (Week 1, 3, 5, 7) will include patient evaluation (SCORAD, PO-
SCORAD, CDLQI); review of daily diary; record participant vital signs; and 
provision of 2-week's supply of placebo/RCM-106 
• Visit 6 (Week 9) will consist of a CM Questionnaire; patient evaluation 
(SCORAD, PO-SCORAD, CDLQI); safety assessments (lab tests) and 
review of daily diary 
Follow-up period (week 13) 
• Follow-up assessment (participants to return PO-SCORAD, CDLQI 
via post) 
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7.8.1 Early termination of the trial 
According to the TGA (2006), SAEs are defined as “Any untoward medical occurrence that at 
any dose: results in death, is life-threatening, requires inpatient hospitalisation or 
prolongation of existing hospitalisation, results in persistent or significant 
disability/incapacity, is a congenital anomaly/birth defect, or is a medically-important event 
or reaction”. All ingredients of RCM-106 are used in daily practice; if it becomes apparent 
that there are associated SAEs, the trial will be discontinued. 
7.8.2 Procedures for breaking codes 
Emergency 24-hour access to the participant ID and treatment codes will be made available 
to authorised personnel at the study site. Should the need to unmask the treatment code 
arise, the authorised personnel will have access to the treatment code upon request of the 
investigator and 1 of the supervisors. The details of adverse events and the unmasking of the 
treatment code will be documented by the investigator with endorsement from 1 of the 
supervisors. 
 
7.9 Assessments and Outcome Measures 
7.9.1 Chinese medicine diagnosis and syndrome differentiation 
Participants will be asked to complete a Chinese Medicine Questionnaire (Appendix 6) upon 
recruitment and at the end of the treatment period. This questionnaire is developed based 
on the State Administration of Traditional Chinese Medicine’s Criteria of Diagnosis and 
Therapeutic Effect of Disease and Syndromes in Traditional Chinese Medicine (The State 
Administration of Traditional Chinese Medicine of the People's Republic of China, 1994). The 
questionnaire is used to assist the TCM diagnosis and syndrome differentiation of AD and 
will be administered by a registered Chinese medicine practitioner. While RCM-106 does not 
target a specific syndrome, this questionnaire will allow comparison in treatment effects of 
the different TCM syndromes. This information is invaluable as it may help bridge the gap 
between TCM and WM when coupled with pharmacological studies of the formula.  
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7.9.2 Safety monitoring 
Participants’ detailed medical history and current condition will be collected. A registered 
medical practitioner, Dr. Marc Cohen, will be present to assist with participant evaluation 
and monitoring. Participants who present with contraindications towards the intervention or 
who show abnormal lab test results will be excluded from the trial. Participants’ condition 
will also be closely monitored throughout the trial to ensure their well-being is protected.  
Participants will be given a daily diary to record the occurrence and details of any adverse 
events. During the fortnightly clinic visits, participants’ daily diaries will be reviewed and vital 
signs (temperature, blood pressure, and heart rate) will be recorded. In the event where 
abnormalities of vital signs or unresolved adverse events occur, the medical practitioner will 
be consulted. The contact number of the investigators, which will be made available 24 
hours a day, will be given to participants to contact in cases of emergencies or adverse 
events.  
During the study, participants and their parent(s)/legal guardian(s) will be informed of any 
new findings with regard to the ingredients of RCM-106. Participants, with the help of their 
parent(s)/legal guardian(s), will be asked to record any experience of reactions in the daily 
diary. All SAEs will be recorded and immediately reported to the RMIT University HREC, 
followed by a detailed written report. Participants will be identified by their ID codes to 
maintain confidentiality. All adverse events will be followed-up from the date it is brought to 
the investigator’s attention to the date the adverse event is resolved. 
For safety assessments, full blood count, renal and liver function tests will be carried out by 
pathology laboratories during the initial assessment and at the end of the treatment period. 
In cases of abnormal blood (excluding parameters related to AD, such as eosinophil count 
and total IgE), liver and/or kidney function test results during the initial assessment prior to 
the trial commencement, the investigators will inform the respective participant’s doctors, 
with the consent of the participant’s legal guardian, for appropriate measures to be taken. 
The respective participants will be followed-up via telephone 1 week later to ensure that 
there are no further issues. As stated in the International Conference on Harmonisation of 
Technical Requirements for Registration of Pharmaceuticals for Human Use Guidelines for 
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clinical safety data management, in cases of fatalities, the investigator will supply RMIT HREC 
or Independent Ethics Committee with the cause of death and a statement of its likelihood 
of being related to the intervention and any information which might be relevant to the 
assessment of the case, such as autopsy reports, post-mortem findings or medical history, if 
available.  
7.9.3 Primary Outcome Measures 
Two instruments, the SCORAD and the PO-SCORAD, are used as primary outcome measures 
to evaluate the efficacy of RCM-106. Both these instruments were created by the European 
Task Force on Atopic Dermatitis (ETFAD) and their scores co-relate well to each other 
(Stalder et al., 2011). The instruments are available publicly from the Foundation of Atopic 
Dermatitis website (http://www.fondation-dermatite-atopique.org/en/healthcare-
professionals-space/therapeutic-education/scorad-and-po-scorad). Formal permission for 
the use of the SCORAD and PO-SCORAD instruments in this study has been obtained from 
the authors via email. 
7.9.3.1 Scoring Atopic Dermatitis (SCORAD)  
The SCORAD is a validated instrument that uses a scoring system to assess disease severity 
and extent by a third-party assessor(ETFAD, 1993) (Appendix 7). The calculation of the score 
is based on a severity grading (0-3) of erythema, oedema/papulation, oozing/crusting, 
excoriation, lichenification and dryness of uninvolved skin; percentage of surface area 
involvement and evaluation of subjective symptoms such as sleep loss and pruritus using a 
VAS from 0-10 respectively. The total score is then calculated using a formula to determine 
the severity of the condition. A higher score represents a more severe condition, with the 
maximum score being 103. The severity of AD can be classified into mild, moderate or severe 
according to a SCORAD index of below 25, 25-50 and above 50, respectively (Oranje et al., 
2007).  
7.9.3.2 Participant-oriented Scoring Atopic Dermatitis (PO-SCORAD) 
The PO-SCORAD is a validated instrument that the patient uses to assess the extent and 
severity of AD (Vourc'h-Jourdain et al., 2009) (Appendix 8). The assessment of the extent is 
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by shading the affected parts on a body sketch and by giving a description of how many of 
the patient’s hands are required to cover up all areas affected by AD. The assessment of 
severity is made by answering questions to grade (0-3) the severity of dryness, redness, 
swelling, crusting/oozing, scratching, thickening, bleeding, fissuring and scaling. Itching and 
sleep disturbance is graded the same way, using a VAS scale of 1-10.  
7.9.4 Secondary Outcome Measures 
Secondary outcome measures include the evaluation of QoL using the validated CDLQI, 
occurrence of adverse events and usage of other therapies as recorded in the daily diary, 
and safety components which include full blood count, eosinophil count, total IgE, renal 
function and liver function tests. The CDLQI is part of the assessment of efficacy of RCM-106, 
while the occurrence of adverse events, usage of concurrent therapies and safety profile are 
part of the assessment of safety and tolerability of RCM-106. 
7.9.4.1 Children’s Dermatology Life Quality Index (CDLQI) 
The CDLQI consists of 10 questions to determine the impact of dermatological conditions 
upon the QoL of affected children (Lewis-Jones & Finlay, 1995). Each question can be given a 
score of 0-3, with a total score of 30. A higher score represents a lower QoL or a higher 
impact of the disease towards a person’s QoL. The CDLQI is a validated instrument that is 
copyrighted world-wide. Formal permission for the use of the CDLQI (English text and English 
cartoon version) in this study has been obtained from the authors via email. Although the 
CDLQI was intended for children up to the age of 16 years (Lewis-Jones & Finlay, 1995), it has 
been shown to be applicable to children up to the age of 21 years (Hon et al., 2007). For this 
trial, the CDLQI will be used for children up to 18 years old. Participants aged 6-11 years will 
be given the English cartoon version of the instrument (Appendix 9); while participants aged 
12-18 years will be given the English text version (Appendix 10). 
7.9.4.2 Amount of Concurrent Therapies 
Participants are required to maintain a daily diary to record the amount of other concurrent 
topical therapies (including emollients) used during the period of the study. This is to 
monitor if treatment with RCM-106 can reduce the need for other therapies.  
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7.9.4.3 Adverse Events 
All reactions, including adverse events, will be recorded by participants in the daily diary. The 
record of adverse events aims to evaluate the safety or tolerability of RCM-106 in AD 
patients.  
7.9.4.4 Laboratory Tests 
There is a relation between increased eosinophil count and elevated serum IgE in AD 
patients (D. Y. M. Leung, 1997; Möhrenschlager et al., 2006; Schmid, Simon, Simon, Akdis, & 
Wüthrich, 2001). Therefore, these laboratory parameters will be measured at baseline and 
after treatment period. This outcome will evaluate if RCM-106 has an effect on eosinophil 
count or serum IgE in AD patients, regardless of whether clinical improvement is observed.  
Full blood count, renal function and liver function tests will be conducted as part of safety 
profile evaluation of RCM-106. 
 
7.10 Data Collection and Analysis 
7.10.1 Data Collection  
All data will be entered in the Case Report Form (CRF) by authorised personnel of this 
project. Training sessions for data entry will be provided to all personnel prior to the study 
commencement. All data entry will be personally initialled and dated by the responsible 
personnel. Assessors or data collectors will be blinded to the treatment assignment until the 
study is completed. Standard operation procedures for data entry in the CRF will be 
developed as a guide to all personnel and will be used as a training tool. Any correction or 
changes of data will be documented. Data entry into the database will be performed 
continuously throughout the study. Double-checking will be performed to ensure accuracy 
of data. Descriptive statistics to detect doubtful data will be performed on each significant 
variable in the database without unmasking the codes. Treatment codes will be broken only 
when the data validation and editing processes are completed for each individual using a 
code in the database. 
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7.10.2 Access to Source Data and Documents 
Investigators, supervisors and consultants will have access to the source data and outcomes 
of analysis of the data. Upon request of regulatory authority or RMIT HREC, the investigator 
will make available direct access to the source data and other trial-related records. 
7.10.3 Data Quality Control and Quality Assurance 
Quality control will be applied to each stage of data handling to ensure reliability and 
accuracy. Any corrections to the data will be documented and the database will be updated 
throughout the study. Double-checking will be performed to ensure accuracy of the data. 
Descriptive statistics to detect doubtful data will be performed on each significant variable in 
the database without unmasking the codes. 
The investigator will be available for agreed visits upon request of regulatory authority or 
RMIT HREC during the study for quality assurance. 
7.10.4 Data Handling and Record Keeping 
All information of the participants, including the administration of RCM-106, outcome 
measures (SCORAD, PO-SCORAD, CDLQI scores), adverse events, laboratory values and other 
relevant data will be recorded in or attached to the CRF, signed and dated by the 
investigator and stored in a secure place. All corrections made to the CRF must be personally 
signed and dated by the person responsible. In all CRFs, participants will be identified only by 
their ID code. In the event of the need to unmask the treatment code, such as in the 
occurrence of a severe adverse event, the investigator will have access to the treatment 
codes with the approval of the medical doctor. The details of the adverse events and the 
unmasking of the treatment code will be documented by the investigator with endorsement 
from 1 of the supervisors. 
7.10.5 Data Analysis 
The trial data will be processed and analysed by an independent statistician, who will be 
blinded to subject allocation, under the supervision of the School of Mathematical and 
Geospatial Sciences at RMIT University. ITT analysis will be applied to include all randomised 
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participants. Data will be summarised as means and SDs and analysed using the SPSS 
software, Windows Version 21.0. The statistical procedure to be employed is repeated 
measures analysis of variance utilising the General Linear Model. Data from non-repeated 
measures will be analysed by t-tests. Outcome measures with categorical responses will be 
analysed using 2 and Fisher exact tests. All P values will be 2-tailed and at α=0.05. To assist 
safety monitoring, interim analysis will be conducted. 
 
7.11 Discussion  
This protocol aims to produce a high-quality RCT evaluating the efficacy and safety of the 
oral CHM formula, RCM-106, in the management of AD in children. The protocol also aims to 
act as a guide to improve the quality of future RCTs on oral CHM.  
Previous SRs on CHM for AD concluded that the quality of trials was poor, and therefore did 
not allow for valid conclusions. This conclusion was in accordance with the SR conducted in 
Chapter 5 of this thesis. The reviews in Chapters 4, 5 and 6 highlighted several 
methodological and reporting aspects to be improved upon in future studies and these have 
been incorporated in this clinical trial protocol. These include, but are not limited to, the use 
of the most extensively-validated diagnostic criteria, the UK diagnostic criteria 
(Brenninkmeijer, Schram, et al., 2008), and validated outcome measure instruments to 
evaluate disease severity (SCORAD, PO-SCORAD) as well as QoL (CDLQI); the use of capsules 
to improve compliance; and dosage determination based on the Pharmacopoeia of the 
People’s Republic of China (The State Pharmacopoeia Commission of The People's Republic 
of China, 2000). Furthermore, this protocol conforms with the principles of the Declaration 
of Helsinki and Good Clinical Practice guidelines, as well as relevant guidelines by the WHO, 
TGA and FDA with regard to conducting clinical trials with traditional medicine. Upon 
completion of this RCT, the reporting of the trial will abide by the relevant CONSORT 
guidelines (Gagnier et al., 2006).  
This protocol was designed for a RCT to suit the paediatric population. It conforms to 
guidelines for safe dosages of Chinese herbs for the paediatric population. Furthermore, 
verbal assent from the child participants in addition to written consent from their 
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parent(s)/legal guardian(s) will be sought. This protocol has a unique feature with the 
inclusion of the swallow-test during screening and optional capsule-swallowing training 
programme. This inclusion not only acts as a safety precaution, but also prevents 
unnecessary loss in potential participants.  
The formulation of the active intervention, RCM-106, is supported by historical evidence 
from the classical literature, as well as modern-day clinical application of Chinese herbs. The 
formula, RCM-106, is based on the classical formula, Xiao Feng San; Xiao Feng San and its 
ingredients were identified among the most commonly-used systemic CHM in the 
management of AD-like conditions recorded in the classical literature (Chapter 3). In the SR 
of oral CHM for AD (Chapter 5), the study which utilised Xiao Feng San was of high quality 
and had low risk of bias; the study achieved significant improvement in disease severity and 
showed that the formula was well-tolerated by AD patients.  
Xiao Feng San is a key-base CHM formula for dermatological conditions (Scheid et al., 2009). 
According to TCM theory, it has the actions of dispelling wind and damp, clearing heat and 
cooling the blood. It is indicated for various rash and itch-related conditions involving the 
invasion of wind-heat or wind-damp, such as those seen in AD patients. There are 
components in the formula that affect the blood as the disease can progress to the blood 
vessels. Furthermore, treating the blood can help eliminate wind (Scheid et al., 2009).  
While the pharmacokinetics and pharmacodynamics of Xiao Feng San has yet to be 
investigated, there has been a report on the biomedical functions of some of the ingredients 
in the formula. The pharmacological properties of each individual herb of the formula have 
been studied on different levels. It is shown that many of the herbs possessed properties 
that could target certain pathologies seen in AD. Cheng (2011) cited reports regarding the 
anti-inflammatory effects of Saposhnikovia divaricata (Fang Feng); the inhibition of skin 
allergic reaction by Rehmannia glutinosa (Sheng Di Huang); and immuno-modulating 
functions of Angelica sinensis (Dang Gui) and Glycyrrhiza uralensis (Gan Cao).  
Studies on the pharmacological effects of other herbal ingredients of Xiao Feng San have 
shown that they could be beneficial in the treatment of AD. Articum lappa (Niu Bang Zi) 
showed positive results in its anti-allergic and anti-inflammatory effects in the treatment of 
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AD (Sohn et al., 2011). Cryptotympana atrata (Chan Tui) is shown to have anti-allergic 
actions by suppressing IgE antibody-mediated reactions and degranulation of mast cells in 
mice (S. P. Ma, Qu, & Hang, 1989). In the case of Sophora flavescens (Ku Shen), not only did 
its root show anti-inflammatory functions; when used in combination with Angelica sinensis 
(Dang Gui), a commonly-used herb pairing for eczema and pimples, it is also shown to have 
anti-microbial and a stronger anti-inflammatory effect (C. Han & Guo, 2011). Furthermore, it 
was stated that Ku Shen was superior to Dictamnus dasycarpus (Bai Xian Pi) in treating skin 
itching (Bensky et al., 2004). Other than that, 2 studies have respectively shown that Linum 
usitatissimum (Hu Ma Ren) possess anti-inflammatory and anti-microbial functions 
(Kaithwas & Majumdar, 2010; Kaithwas, Mukerjee, Kumar, & Majumdar, 2011).  
When compared to Xiao Feng San, the herb Mu Tong, which could refer to several herbs 
including Caulis akebiae or Clematis armandii, was omitted from the RCM-106. Both Caulis 
akebiae and Clematis armandii are listed as a botanical which might contain aristolochic acid 
according to the (TGA, 2001). When discussed with the expert panel, it was agreed that in 
the case of AD from a TCM point-of-view, many patients present with the syndrome of 
Spleen Deficiency. Subsequently, having too many wind-damp dispelling or cool herbs would 
not be suitable. Therefore, Schizonepeta tenuifolia (Jing Jie), Articum lappa (Niu Bang Zi), 
Periostracum cicadae (Chan Tui), Gypsum fibrosum (Shi Gao), Amenarrhenae asphodeloides 
(Zhi Mu) and Linum usitatissimum (Hu Ma Ren) were omitted from the formula. With regard 
to Periostracum cicadae (Chan Tui), it was omitted due to risks of being a potential allergen 
as well. It was also agreed that Angelica sinensis (Dang Gui) be replaced with Paeonia 
lactiflora (Bai Shao), as the former is warm in nature and may be too drying while the latter 
has the additional function to stop itching.  
Further modifications included the addition of Dictamnus dasycarpus (Bai Xian Pi) and the 
replacement of Atractylodis lancea (Cang Zhu) with Atractylodis macrocephala (Bai Zhu). 
These modifications were made to enhance the formula’s therapeutic effect in the 
treatment of AD. According to TCM, Dictamnus dasycarpus (Bai Xian Pi) has the function to 
clear wind-damp-heat and is indicated for eczema and other skin diseases as it can alleviate 
itching, and has detoxifying and disinfecting functions (Hempen & Fischer, 2009). A study in 
Japan using Dictamnus dasycarpus (Bai Xian Pi) on allergic models in mice showed that it has 
anti-allergic effects (S. Jiang, Nakano, Rahman, Yatsuzuka, & Kamei, 2008). Another study 
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showed that Dictamnus dasycarpus (Bai Xian Pi) possess immuno-suppressive effects by 
inhibiting T-cell proliferation in-vitro (Chang, Xuan, Xu, & Zhang, 2002). The replacement of 
Atractylodis lancea (Cang Zhu) with Atractylodis macrocephala (Bai Zhu) was due to the 
latter’s stronger Qi tonifying effects. The target participants in this RCT will be children aged 
6-18 years old, most of whom would have had AD since young and possessed underlying Qi 
deficiency. Pharmacologically, Atractylodis macrocephala (Bai Zhu) has fewer essential oils 
than Cang Zhu but contains a component known as atractylenolide (Dharmananda, 2003). 
Atractylenolide has an inhibitory effect on TNF-α (C. Li, He, & Jin, 2007) which can be useful 
in the treatment of inflammatory disease with overproduction of TNF-α, such as AD 
(Sumimoto, Kawai, Kasajima, & Hamamoto, 1992). 
When comparing study protocols, the Xiao Feng San study by Cheng, et al. (2011) was 
assessed as a high-quality trial according to the risk of bias assessment in the SR in Chapter 
5. However, there were reservations regarding the protocol of the study by Cheng et al. 
(2011) despite the positive results achieved with regard to the efficacy and safety of Xiao 
Feng San. Firstly, the formula Xiao Feng San that was used in the trial contained Clematis 
armandii (Chuan Mu Tong) which, as mentioned earlier, might contain aristolochic acid 
(TGA, 2001). Secondly, the Xiao Feng San used in Cheng’s study was not modified according 
to TCM theories to address the underlying Spleen deficiency that is often seen in AD 
patients. Thirdly, participants were given the herbal formula in granule form with dosages of 
3g, 3 times a day to patients aged 3-7 years; 6g, 3 times a day to patients aged 8-12 years; 
and 9g, 3 times a day to patients aged above 13 years, which were significantly higher 
dosages when compared to the recommended daily dosage of 6-12g for adults (Scheid et al., 
2009). Furthermore, the placebo used composed of caramel, lactose and starch which can 
be a risk to the lactose-intolerant individuals. Moreover, sweet foods such as caramel can 
generate damp and phlegm, according to Chinese medicine theories (C. S. Yuan, Bieber, & 
Brent, 2011) which can worsen symptoms of skin conditions. Therefore, the data from 
Cheng’s study might not reflect the true efficacy of the treatment. Lastly, the method of 
assessment of AD severity was through a standardised scoring system used in previous trials, 
rather than a validated assessment instrument of AD severity. 
Several improvements have been introduced in this protocol to address the above-
mentioned deficiencies. Clematis armandii (Chuan Mu Tong) has been omitted from the 
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formula, RCM-106, to comply with TGA regulations. The formula has also been modified to 
address the underlying Spleen deficiency that is often seen in AD patients. The concept of 
tonifying the Spleen in AD patients has been researched by a team in Japan through a clinical 
trial using Hochu-ekki-to to treat AD patients diagnosed with Kikyo (Qi deficient) constitution 
(H. Kobayashi et al., 2010). Although the trial did not yield significant difference in efficacy 
(skin severity scores) when compared with placebo, the authors argued that the treatment 
group had a significantly better prominent efficacy rate (the percentage of patients whose 
severity score = 0 at the end of the trial period) of 19% compared to the 5% in the control 
group. The authors concluded that Hochu-ekki-to is a useful adjunct to conventional 
treatments of AD that reduces need for topical steroids/tacrolimus (calcineurin inhibitors) 
without aggravating the disease. Therefore, in RCM-106, there is a component of Spleen 
tonification but it is not the only focus of the formula. 
With regard to the dosing of RCM-106, it has been adjusted to be within the recommended 
daily dose of 6g/day (3g, twice a day). For better blinding and medication compliance, 
treatment will be given in capsule form. A herbal starch placebo containing non-active 
ingredients will be used instead of a placebo containing sweet-natured ingredients so as not 
to affect the participants’ condition. With regard to the outcome measure assessment, this 
study will be using the SCORAD index (ETFAD, 1993), one of the most adequately-validated 
AD assessment instruments, to evaluate the severity of the patients’ condition.  
There are existing limitations to this study protocol. These include a lack of pharmacological 
data of RCM-106, minimal laboratory parameters and lack of application of TCM syndrome 
differentiation. While RCM-106 is a modified version of Xiao Feng San to balance out the 
formula actions of dispelling wind, dampness and heat pathogenic factors, cooling the blood 
and tonifying the Spleen, as these were identified as the common TCM syndromes involved 
in AD, the protocol of this study does not limit the type of participants according to TCM 
syndrome differentiation. As with most studies identified in the SR of oral CHM (Chapter 5), 
this study protocol also gives a standardised RCM-106 formula to all participants without 
modifications. Although it has been identified that this is not in agreement with the clinical 
practice of TCM, it is acknowledged that this would be the preliminary study for RCM-106, 
designed in a more “Western” setting. Furthermore, the study involves too small a sample 
size to enable proper analysis involving TCM syndrome differentiation. However, the design 
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of this study protocol will provide results to evaluate the generalisability of efficacy and 
safety of RCM-106 in the treatment of AD in children in a WM perspective and allow for 
future pharmacological studies of RCM-106 and its individual ingredients. In addition, the 
protocol involves the evaluation of TCM syndrome differentiation of participants before and 
after the trial, which will enable to analysis of the effects of RCM-106 on the various TCM 
syndromes of AD and work as the basis for future, larger-scaled, more pragmatic RCTs of 
RCM-106 involving TCM syndrome differentiation and more laboratory parameters as well.   
Overall, this protocol will lead to a high-quality RCT and act as a guide for future oral CHM 
studies. The results of this RCT will provide clinical data on the efficacy and safety of RCM-
106 in reducing the severity of AD and improving the QoL of AD patients. Positive results 
from the RCT can lead to a better management of AD to help patients. This RCT will also 
contribute to the understanding and treatment of AD from Chinese medicine perspectives. 
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 Challenges of Conducting Clinical Trials of Chinese Medicine with Chapter 8
the Paediatric Population 
8.1 Introduction 
The World Health Organisation (WHO) defined a clinical trial as “any research study that 
prospectively assigns human participants or groups of humans to one or more health-related 
interventions to evaluate the effects on health outcomes” (WHO, 2012). During the 
preparation of any clinical trial, it is incumbent to select and justify methodologies that are 
suitable and feasible to achieve the aim of the study. Furthermore, the overall safety and 
ethical issues such as informed consent should also be addressed. Depending on the type of 
studies, there would be additional considerations with regard to particular target age group, 
disease and/or trial interventions. 
The general challenges of conducting a clinical trial include calculating an adequate sample 
size, justifying the trial treatment regime (dose, timing, frequency, duration of treatment), 
finding a suitable control intervention, ensuring that the overall protocol includes 
appropriate randomisation, blinding, methods of managing confounding factors such as diet 
and lifestyle of participants during the study, outcome measures and data analysis and 
adequate safety monitoring. Ethical issues that need to be addressed involve the justification 
of conducting the study, ensuring that informed consent be obtained, and the fact that the 
safety measures to protect participants are in place. 
However, when clinical trials involve a non-conventional therapy with little scientific 
evidence such as CHM, and a particular target population which may be more vulnerable 
such as the paediatric population, there will be additional issues that need to be addressed. 
Furthermore, some of the general challenges mentioned previously need to be handled 
differently to suit the intervention and specific target population as well. With traditional 
medicine, there is also the challenge of translating traditional medicine concepts of 
treatment so that it can be accepted by the scientific community who are unfamiliar with 
the theories of traditional medicine. 
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During the preparation of the protocol for an RCT to evaluate the efficacy and safety of RCM-
106 in the management of AD in the paediatric population (Chapter 7), several of these 
challenges were encountered and had to be resolved prior to achieving human ethics 
approval. This chapter will highlight the challenges encountered and how they were 
overcome. 
 
8.2 Challenge 1: Starting with Phase II Clinical Study for RCM-106  
The first challenge encountered was the request that a Phase I study of RCM-106 be 
conducted prior to this Phase II. Phase I clinical trials involve the first-time administration of 
an intervention, usually to a small number of healthy volunteers. The purpose of Phase I 
studies is used to determine the pharmacological actions, pharmacokinetics and safety of 
the intervention when given to humans. Phase I trials are also carried out to determine the 
appropriate doses and route of administration of the intervention. Participants of Phase I 
trials are closely monitored during the period of intervention administration and follow-up. 
Therefore, Phase I trials are usually conducted in centres which have the equipment and 
ability to support specialised monitoring and close surveillance of participants of the trial 
(TGA, 2004).  
It is the usual practice for clinical studies on new medicinals to be conducted in sequence 
starting from Phase I to Phase IV (Figure 8-1) as the information from one phase enables the 
next phase to be conducted. However, this requirement is not valid when the active 
intervention in question is a form of traditional herbal medicine. Traditional herbal medicine, 
including CHM, has a long history of its use based on traditional knowledge. Therefore, the 
development process, known as reverse pharmacology, works backwards (Figure 8-2), that 
is, establishing clinical or actual use before scientific or laboratory validation (Arun & 
Chandra, 2012).  
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Figure 8-1: Sequence of Clinical Trial Phases I-IV for new medicinals 
 
 
Figure 8-2: Sequence of Clinical Trial Phases of reverse pharmacology for traditional 
medicine (Adapted from Arun & Chandra, 2012) 
 
Due to the long history of traditional use and clinical practice of herbal treatment, the FDA is 
fairly lenient with regard to the requirements for Phase I and II trials (H. Yuan, Yang, & 
Huang, 2011). According to the Guidance for Industry for Botanical Drug Products by the 
FDA, clinical trials involving a botanical drug registration can start on a Phase III in the United 
States (FDA, 2004; H. Yuan, Yang, et al., 2011).  
Phase I 
Phase 
II 
Phase 
III 
Phase 
IV 
Scientific validation 
(Phase I & IIa) 
Establish clinical 
use (Phase IIb & III) 
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The WHO Operational Guidance for Information Needed to Support Clinical Trials of Herbal 
Products stated that Phase I studies are normally unnecessary for traditional herbal 
medicines (WHO Special Programme for Research and Training in Tropical Diseases, 2005). 
The safety of the traditional dose regimens of such remedies is fairly established through 
prior substantial human use and therefore considered safe for administration to small 
numbers of carefully-monitored participants of Phase II trials. For example, the basis of 
safety of TCM, which has a history of several thousands of years, is due to the relatively rare 
clinically-associated toxicity despite the various ingredients used in Chinese herbal formulae. 
Therefore, when considering the ethics of short-term trials, along with the historical 
evidence of TCM practice, the clinical experience of the practitioners could add on to the 
basis for safety evidence, provided certain groups of “at-risk” patients (e.g. pregnant 
women) are excluded (Critchley, Zhang, Suthisisang, Chan, & Tomlinson, 2000).  
Clinical trials using CHM, whether with traditional formulae or new formulae, have been 
commonly carried out.  As far as it is known, to date, only 1 trial, which involved 
individualised herbal treatment compared with placebo for the treatment of endometriosis 
in the UK, mentioned regulatory obstacles from the Medicines and Healthcare products 
Regulatory Agency (MHRA) and their local Ethics committee (Flower, Lewith, & Little, 2011). 
Flower, et al. (2011) overcame this by providing the available pharmacology data on the 70 
herbs that were most likely to be used in their trial. MHRA and ethical approval was 
facilitated by the fact that the trial method of providing individualised Chinese herbal 
formula to participants was in accordance with current clinical practice and therefore was 
considered a Phase IV, rather than a Phase III trial, which reduced costs and regulatory 
requirements.  
With the clinical trial involving RCM-106, although treatment will not be individualised, RCM-
106 is a herbal formula which might be prescribed by current TCM practitioners in Australia 
as all herbal ingredients are on the list of TGA-approved substances (TGA, 2007) and are 
commercially available from Chinese herbal shops or Asian grocers. The formulation of RCM-
106 is in accordance with the standard practice of TCM, with support from reviews of the 
classical and modern literature. Existing pharmacological and toxicology data was compiled 
in the Investigator’s Brochure for evaluation by the HREC of RMIT University. The safety of 
the formula is as established as any Chinese herbal formula, traditional or individualised, 
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that is currently available either commercially or from TCM practitioners. Furthermore, 
RCM-106 will be produced by a manufacturer that holds a TGA-approved GMP certificate. 
The manufacturer will therefore comply with the GMP guidelines and will be able to provide 
data on raw herbal ingredients used, identification tests and assays, tests for contaminants 
and adulterants, processing instructions, sampling and quality control of the end product to 
ensure the safety of RCM-106. Carrying out a Phase II trial involving RCM-106 with the 
proper precautions and protocol for safety monitoring would also reduce cost and 
regulatory requirement as was the case with the trial by Flower, et al (2011).  
 
8.3 Challenge 2: Justification of Dosing Regimen 
The second challenge encountered was the justification of the proposed dosing regimen. 
From a scientific perspective, the pharmacological effect of a medicinal product is based on 
its active constituents; and its dosing determines its effects or lack thereof (Rang, Dale, 
Ritter, Flower, & Henderson, 2011). The dosing of CHM is highly based on historical and 
empirical experience, which is also used as evidence of the safety of the herbs. The study of 
the pharmacology of CHM had been introduced since the 1920s (Y. Liu, Xu, & Wang, 2003); 
however, it still remains a fairly-new area of study with insufficient data to fully support its 
effects from a scientific point-of-view. 
Despite the lack of pharmacological information of CHM, aside from empirical evidence, the 
application of CHM includes safeguards according to TCM theories to ensure safe herbal 
prescriptions. In the Material Medica, herbs with known precautions and toxicities have 
been noted, as well as any methods of processing to reduce toxicity or increase efficacy 
(Bensky et al., 2004). Each herb’s nature according to TCM theory has also been recorded 
and these act as a guide for practitioners as certain herbal properties are either suitable or 
contraindicated in particular TCM syndrome differentiations (Y. Liu et al., 2003). For 
instance, during the formulation of RCM-106, herbs which were of dry or cool properties 
were closely controlled so as not to worsen the TCM syndrome of Spleen deficiency in AD 
patients. The compatibilities and incompatibilities between herbs according to empirical 
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evidence are also listed in the Materia Medica, as well as any particular information related 
to dosing and administration of the herbs (Bensky et al., 2004).  
The data from the Materia Medica, when combined with TCM theory and application, is 
assumed to be sufficient to ensure the safety of the CHM application. As mentioned earlier, 
the WHO Operation Guidelines stated that the dosing regimen for herbal clinical studies can 
be deduced from traditional methodology rather than animal pharmacokinetics (WHO 
Special Programme for Research and Training in Tropical Diseases, 2005).  
With RCM-106, the dosage of each raw herbal ingredient was determined according to the 
safe dose ranges listed in the Pharmacopoeia of the People’s Republic of China (The State 
Pharmacopoeia Commission of The People's Republic of China, 2000). A recent study found 
that the recommended dose ranges in the Chinese Pharmacopoeia were much narrower 
than the doses found in classical prescriptions and clinical application (H. Y. Ji, Chen, Jiao, & 
Tong, 2013). The dose for RCM-106 is therefore considered fairly conservative.  
As RCM-106 is to be administered as capsules (containing extract of RCM-106), the 
conversion of doses of raw herbs to extracts needs to be considered and justified. With 
herbal extracts, dosing differs between manufacturers based on methods of extraction, 
extraction ratio of herbs and the use of buffers in the extracts. According to Scheid, Bensky, 
Ellis, & Barolet (2009), the standard recommended adult dosage of herbal extracts with 
concentration ratios between 2.5:1 and 5:1 in Japan is 6g per day, while it is 10-12g per day 
in Taiwan. However, Brand (2008) stated that in Taiwan, concentration ratios usually range 
between 4:1 and 6:1, and it is common practice to prescribe extracts based on an average 
concentration ratio of 5:1, with the prescribed daily dose being approximately 18g (6g, 3 
times per day), in accordance with Taiwan’s national health insurance cover. The use of 
herbal extracts in granule form was first introduced in Japan (Brand, 2008), and the 
recommended effective dose from Japan was also the lowest. Therefore, it was decided that 
the herbal extract dose for RCM-106 would not veer too far from 6g per day. As it has been 
noted that the dosing of extracts differs according to manufacturers and their extraction 
methods and procedures, the manufacturers of RCM-106 were consulted with regard to 
their recommended daily dose based on their extraction methods. Water and alcohol 
extraction methods would be used for the production of RCM-106, with a concentration 
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ratio of 7:1. The recommended effective daily dose for adults based on these conditions was 
6g per day, which is in accordance with the recommended dose used in Japan.  
The dosing regimen of RCM-106 during the RCT, including dosing frequency, and duration of 
run-in, treatment and follow-up periods, was determined with reference to previous studies 
as identified from the SR in Chapter 5, with consideration of the acceptability and ease of 
administration of RCM-106. 
8.3.1 Dosages of RCM-106 in Children 
As the proposed RCT for RCM-106 targets the paediatric population aged 6-18, there were 
uncertainties with regard to the suitability and safety of the dosing regimen in children. It is 
a known fact that the pharmacodynamics and pharmacokinetics of a substance differs when 
it is administered in children compared to when it is administered in adults (Rang et al., 
2011). Suitably effective and safe dose in children will, therefore, differ with adult dosage.  
However, even among WM, many approved drugs have been tested in only adults (Thaul, 
2012) with a lack of proper dosing guidelines for children (Cella, Knibbe, Danhof, & Della 
Pasqua, 2010). Calculations for paediatric medicines may be in relation to either the child’s 
body weight or age, or by scaling from the adult dose, with existing arguments of the pros 
and cons of each method.  
Recently, some English CHM books (J. K. Chen & Chen, 2009; Flaws, 1997) have adopted the 
WM calculation for paediatric dosing according to body weight, Clark’s Rule (Figure 8-3) 
(Ansel & Prince, 2004).  
 
Paediatric dose      = 
Body weight (in lbs.) x Adult dose 
150 
Figure 8-3: Clark's Rule to calculate paediatric dosing based on body weight (Ansel & 
Prince, 2004) 
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However, in so far as we know, Chinese CHM textbooks and older CHM books usually utilised 
age-to-dose dosing guidelines, which might have slight variations from one another. One of 
the commonly-used age-to-dose guidelines (Table 8-1) was published by the Nanjing College 
of Traditional Chinese Medicine in Zhong Yao Cao (中药草) [Chinese Herbal Medicine] (J. K. 
Chen & Chen, 2009).  
 
Table 8-1: Age-to-dose paediatric dosing guideline for CHM (J. K. Chen & Chen, 2009) 
Age Recommended Daily Dosage 
0-1 month 1/18 – 1/14 of adult dose 
1-6 months 1/14 – 1/7 of adult dose 
6-12 months 1/7 – 1/5 of adult dose 
1-2 years 1/5 – 1/4 of adult dose 
2-4 years 1/4 – 1/3 of adult dose 
4-6 years 1/3 – 2/5 of adult dose 
6-9 years 2/5 – 1/2 of adult dose 
9-14 years 1/2 – 2/3 of adult dose 
14-18 years 2/3 – full adult dose 
18-60 years Adult dose 
60 years and over 3/4 or less of adult dose 
 
In Japan, however, the Ministry of Health, Labour and Welfare (2010) recommended the use 
of the Conversion Table of Von Harnack (Table 8-2) in the dosage determination for children 
and infants for all medicinals, including CHM. 
 
Table 8-2: Conversion Table of Von Harnack (Ministry of Health, Labour and Welfare, 2010) 
Age 6 months 1 year  3 years  5 years  7 years 10 years  12 years  Adult 
Dosage 1/5 1/4 1/3 2/5 1/2 2/3 3/4 1 
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The weight-to-dose guideline gauges the concentration of CHM on a per pound basis and is 
especially useful for patients whose weight falls beyond the normal range; while the age-to-
dose guideline considers the maturity of the internal organs to absorb, utilise and eliminate 
the herbs. As the dose of RCM-106 during the clinical trial needed to be standardised to 
reflect the general dose required in paediatric AD patients, it was decided that both the age-
to-dose guidelines be taken into consideration to determine the paediatric dose of RCM-106.  
The RCT involving RCM-106 targets children from the ages of 6 to 18. According to the 
CPMP/ICH guidelines on age classifications, those aged between 2 to 11 are considered 
“children” while those aged between 12 to 17 are considered adolescence (EMA, 2006a). 
The pharmacokinetics of drugs in adolescents are said to be similar to those in adults. 
Therefore, for the RCT, participants aged 12 and above will be given adult doses of RCM-106. 
With reference to the age-to-dose guidelines, participants of the younger age group of 6-11 
will be given half the total adult dose. 
 
8.4 Challenge 3: Suitable Method of Administration for Children in Clinical Trials 
The third challenge was with regard to the method of oral administration of RCM-106. Its 
administration had to be suitable for children while maintaining the integrity of the study by 
supporting blinding, participant recruitment and retention rate and medication compliance. 
Issues that needed to be taken into consideration included the smell, taste, appearance and 
ease of administration of RCM-106 and the ability to produce an identical placebo. The 4 
most common forms of oral administration include decoction, granules, capsules, and syrup. 
To facilitate blinding, ease of drug dosing, medication compliance and to reduce drop-outs 
due to unpalatability, capsules were considered the most suitable form of administration for 
RCM-106. Capsules would allow identical taste and appearance between RCM-106 and 
placebo interventions; the use of herbal starch in placebo capsules would ensure similar 
scent and prevent the identification between active intervention and placebo, should 
participants open to examine the capsule contents.  
Previously, there have been many studies which used capsules in children from as young as 2 
months to 2 years old (Chernyshov, 2009; M. M. Rahman et al., 2002; Ramírez-Bosca et al., 
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2012; Takwale et al., 2003; K. G. Wu et al., 2012). This reflected that it is a feasible method of 
administration in children. However, there were several concerns, such as participants’ 
inability to swallow capsules and the capsules being choking hazards. To overcome these 
issues, the size and number of capsules had to remain as minimal as possible. Previous 
studies were sought as references for suitable capsule size and number for children; 
however, the reporting of such details was lacking in published studies. One study reported 
providing 12 capsules per day to children with bipolar disorder aged 6-17 years old (Gracious 
et al., 2010); with regard to capsule size, 1 study provided size #0 capsules (approximately 
21.7mm in length and 7.65mm in diameter) to children aged 6-12 years old (Swanson et al., 
2004).  
The manufacturers of RCM-106 advised that the formulation be made into small, size #1 
capsules (approximately 19.4mm in length and 6.91mm in diameter), with a dose of 3 
capsules, twice a day for participants aged 6-11; and 6 capsules, twice a day for those aged 
12 and above.  
As extra precautions, the inability to swallow size #1 capsules was included in the exclusion 
criteria. Upon advice from, Dr. Dean Tey, a paediatric allergist from the Royal Children’s 
Hospital, as a safety measure against false reports of the ability to swallow capsules by eager 
participants or their parent(s)/legal guardian(s), the protocol included a “swallow-test” 
during participant screening to ensure that included participants were indeed able to 
swallow capsules without difficulty.  The protocol also offered an optional “capsule-
swallowing training programme” for potential participants who were unable to swallow 
capsules upon screening but were still keen to participate in the study. Participation, 
however, would be dependent on the successful completion of training, success being 
defined as being able to swallow size #1 capsules. Anecdotal evidence suggested that 
children aged 6 years or younger would be able to take solid dosage forms with adequate 
support and training (EMA, 2006b). Furthermore, studies on various methods of pill-
swallowing training had shown them to be successful (Beck et al., 2005; Garvie et al., 2007; 
Kaplan et al., 2010). The introduction of the training programme prevented the excess loss in 
participant number due to the inability to swallow capsules.  
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8.5 Challenge 4: Informed Consent (Assent) with the Paediatric Population 
The fourth challenge was related to informed consent with the paediatric population. 
Informed consent from participants is required for every clinical study; however, before 
reaching the legal age, which varies depending on the country, children are unable to 
provide legal consent and therefore, consent must be sought from their legal representative 
(EMA, 2008).  
It has been estimated that children around the age of 14 have the capability of making their 
own decisions and therefore capable of providing assent, that is, the presumed will to 
participate (Wendler, 2006); the European Medicines Agency (2008) stated that the 
participants’’ development stages, intellectual capacities and life experiences should be 
taken into consideration as studies on cognition have shown that children from the age of 3 
are able to provide assent. For the purposes of clinical studies involving children, whenever 
possible, the child participants’ assent should also be obtained, preferably in writing, when 
the child is of “school age” (6 or 7 years old). Regardless of the ability to provide assent, age- 
and maturity-appropriate information is still required. 
For this study, written informed consent will be sought from participants aged 18. For 
participants below the age of 18, written informed consent from the parent(s)/legal 
guardian(s) and written assent will be sought from participants in the presence of a witness 
who is not involved in the study. Should the participant be deemed incapable of English 
comprehension or writing, verbal rather than written assent will be sought.  
A research assent form written in simple English suitable for the targeted paediatric age 
group has been prepared for the study (Appendix 11). The assent from was adapted from 
the assent form templates used by Seattle Children’s Hospital, Research and Foundation 
(Seattle Children's Hospital, 2013), The Ohio State University (2005) and Stanford University 
(2013) and includes all the details of the study. The form clearly states that the child has the 
right to say ‘no’ or stop at any time of the study.  
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8.6 Challenge 5: Additional Safety Precautions 
Aside from a rigorous design and stringent inclusion/exclusion criteria, the RCT on RCM-106 
also highly regards safety monitoring and precautions. Safety monitoring and precautions 
are clearly detailed in Chapter 7.9.2. 
 
8.7 Discussion  
The current literature is greatly lacking in the field of paediatric medicine (EMA, 2011). Apart 
from unknown paediatric doses, there is also a lack of an “ideal formulation” for the 
administration of medication for children. The WHO has recently launched a campaign 
entitled “Make Medicine Child Size” in efforts of overcoming this issue.  
As mentioned previously, many drugs which are being prescribed to children have been 
tested and approved for use in only adults (Thaul, 2012). It has long been noted that the 
pharmacokinetics and pharmacodynamics of a drug varies when applied in adults compared 
to when applied in children (Rang et al., 2011). Results from efficacy and safety studies of 
drugs in adults cannot, therefore, be directly extrapolated to the paediatric population. 
Specific adverse effects of an intervention may be seen in only children due to the difference 
in pharmacology. It has been recognised that clinical studies involving children are therefore 
required to ensure the safety of and improve the treatments available to them (EMA, 2008). 
This is especially true with regard to therapies for paediatric diseases, such as AD.  
While promoting RCTs in children, the fact that they are a vulnerable population has not 
been neglected. Clinical trials in children need to be conducted while providing adequate 
protection for their well-being throughout the entire study (EMA, 2008). 
The protocol of the RCT for RCM-106 for the management of AD attempts to address these 
issues while maintaining a rigorous design. The protocol preparations were done with 
reference to the literature such as clinical trial guidelines, Chinese medicine regulations, 
pharmacology and toxicology of herbs, traditional and modern application and dosage of 
herbs and previous clinical or laboratory studies of herbs. Extensive research has been done 
to formulate RCM-106, with the literature supporting the determination of dosing and 
264 
 
method of administration. Safety measures, such as the swallow-test and monitoring of vital 
signs, kidney and liver function, have been included to reduce risks related to the method of 
capsule administration of CHM. Furthermore, informed consent from parent(s)/legal 
guardian(s) as well as written or verbal assent from all participants will be obtained prior to 
the commencement of the study and participants are made aware that they can withdraw at 
any time.  
Clinical trials involving the use of CHM with the paediatric population will face more 
challenges due to the lack of scientific validation of the intervention and the vulnerability of 
the target population. While each step of this RCT has been justified in terms of application 
and safety, there are still many uncertainties and there is lack of concrete evidence, 
especially from a scientific point-of-view with regard to the pharmacology of RCM-106. It is 
anticipated that the results from this study will contribute to the existing literature, whether 
in terms of efficacy and safety of AD treatment with CHM, in terms of rigorous RCT 
methodology, or in terms of paediatric medicine. Future studies should continue efforts of 
better understanding the pharmacology of herbs, the pharmacokinetics in the paediatric 
population and also suitable methods for paediatric drug administration. 
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 General Discussion and Future Direction Chapter 9
9.1 Introduction 
This thesis aimed to provide a comprehensive understanding of TCM management of AD 
from the classical and current literature, including the evaluation of the efficacy and safety 
of TCM management of AD, via comprehensive review and SRs; to evaluate the evidence and 
identify what is lacking in the current literature; and to develop a protocol of a rigorous RCT 
incorporating the obtained data to address identified limitations and challenges.  
 
9.2 Summary 
There was no disease in the TCM classical literature that fully matched the description of AD. 
Si Wan Feng (四弯风) had the most similar description to AD as it was often described as an 
itchy and chronic or recurrent rash that occurred in the knee and ankle joints. The term Nai 
Xuan (奶癣) also had a fairly close description as AD and was described as an itchy rash that 
occurred during childhood, but certain descriptions mentioned accompanying scaling, which 
is not characteristic of AD. When compared to the modern literature, both these TCM 
diagnoses were occasionally used in studies involving AD or paediatric eczema.  
There were 191 identified RCTs evaluating TCM treatments, alone or in combination, in 
comparison to placebo, no treatment or non-TCM treatments. Both the classical and modern 
literature showed that, among TCM treatments, topical CHM, followed by systemic CHM, 
were the most commonly-used for AD or AD-like diseases; with very little on other TCM 
therapies. This meant that there was little evidence of TCM therapies, other than CHM, for 
the management of AD.  
Among the CHM therapies, the types and commonly-used herbs reflected the modern-day 
clinical practice of TCM in the management of AD, whereby topical CHM usually contains 
herbs that clear external pathogens and are more likely to contain toxic herbs, while 
systemic herbs usually include tonics. However, in the modern literature, many CHM 
formulae were newly-formulated despite maintaining the same treatment principles and 
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commonly-used herbs. In the classical literature, it was common to see a combination 
treatment with topical and systemic CHM; in the modern literature, out of the 87 studies 
which utilised TCM treatments in combination with one or more other therapies, 22 used 
combined topical and systemic CHM, with the majority of the remaining studies utilising 
CHM in combination with WM or other therapies. This shows that in the current clinical 
practice of TCM, researchers and practitioners are making an effort to integrate TCM 
therapies with the current lifestyle and healthcare system.  
When evaluating the characteristics of the 191 RCTs, there was a fairly distinct difference 
between studies conducted in China compared to English studies. The studies from China 
tended to be more pragmatic in design, whereby the treatment might be modified according 
to the condition and an active intervention was usually used as the control intervention. 
When considering the diagnostic criteria and outcome measures, English studies were more 
likely to refer to validated instruments while Chinese studies often referenced Chinese texts 
which were not easily accessed by those outside of China. This variation impeded evaluation 
and increased heterogeneity between studies. Furthermore, the standard of reporting was 
lacking among the Chinese studies, with many studies failing to report the diagnostic criteria 
applied, final outcome measures, random sequence generation and blinding procedures.  
Due to the identified limitations, when conducting the SR of oral CHM for the management 
of AD, only 6 studies were included – 5 comparing oral CHM to placebo and 1 comparing 
combined oral CHM and WM to WM alone. The overall risk of bias assessment of the 6 
studies was poor, with only 1 study rated low risk in all domains. The evaluation of reporting 
against the CONSORT checklist also showed that there was incomplete reporting of a 
number of items, particularly with respect to the intervention details. The meta-analysis of 
outcome measures showed that combined oral CHM and WM significantly improved disease 
severity when compared to WM alone; while there was conflicting evidence with regard to 
the efficacy of oral CHM compared to placebo. With regard to safety, none of the studies 
reported any SAEs and presented that oral CHM was well tolerated. Nevertheless, the low 
number and low quality of studies did not allow for valid conclusions. When compared to 
the most recent Cochrane SR, despite differences in SR protocol and included studies, both 
SRs shared the conclusion that there was insufficient evidence to support the efficacy and 
safety of CHM for the management of AD.  
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There were 3 studies which evaluated the efficacy of acupuncture in the management of AD. 
Two out of the 3 studies evaluated the preventive and direct effect of acupuncture on itch-
induced AD in multiple-armed trials. The meta-analysis showed that there were significant 
preventive and direct effects in the reduction of itch intensity VAS by verum acupuncture 
when compared to placebo acupuncture or no treatment, but not when compared to 
pharmacotherapy, cetirizine. However, verum acupuncture did not achieve the same results 
with regard to itch perception by EIQ or wheal and flare size. The heterogeneity between the 
3 studies was high due to differences in protocol and outcome measures. The evaluation of 
risk of bias and quality of reporting showed that the overall quality of studies was poor. 
Furthermore, the results of the studies had to be interpreted with caution as all 3 studies 
were by the same team of authors. 
From the comprehensive review and SRs, Xiao Feng San was identified as one of the most 
commonly-used classical CHM formulae which also achieved positive results in an RCT. Using 
the details of CHM from the reviews, in combination with advice from an expert panel from 
RMIT University and China, Xiao Feng San was modified into RCM-106, a new CHM formulae 
for the management of AD.  
A new protocol for a double-blind, placebo-controlled RCT to evaluate the efficacy and 
safety of RCM-106 was finalised, incorporating methodological improvements of the 
limitations of existing studies which were identified from the reviews. The study was also 
designed specifically for RCTs involving the paediatric population. The protocol is now 
registered with the ANZCTR and under the CTN scheme with the TGA and carries human 
ethics approval from the HREC of RMIT University. 
During the preparation of the protocol, there were several challenges which needed to be 
addressed before human ethics approval. These included the justification of conducting a 
Phase II trial without existing pre-clinical or Phase I studies; the justification of dosing 
regimen, especially with regard to paediatric dosing; choosing a suitable form of 
administration of RCM-106; issues relating to informed consent and assent; and additional 
safety precautions for studies involving the more vulnerable paediatric population. To 
overcome these challenges, evidence from the existing literature and broad comprehension 
of related guidelines was necessary to rationalise every significant detail of the study 
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protocol, especially with regard to ensuring the harmlessness of the intervention and the 
safety of the target population.  
The reviews of classical and modern literature, as well as the clinical trial guidelines and TCM 
regulations, provided sufficient justification to conduct a Phase II study based on reverse 
pharmacology methods for traditional medicine. There was justification as well to support 
the dosing regimens, safety precautions and procedures for informed consent and assent of 
the study protocol. However, it was noted that these were not fully competent in justifying 
the dosing and method of administration in the paediatric population. Further studies, with 
regard to paediatric and CHM pharmacology and proper forms of administration of 
paediatric medication, are still warranted to provide more substantial evidence. 
 
9.3 Strengths of this Project 
This project included a SR of the TCM classical literature of AD-like conditions and 
treatments, a comprehensive review of RCTs involving TCM treatments in the management 
of AD and a SR of acupuncture treatment of AD. It also included the most updated SR of oral 
CHM in the management of AD. Through these reviews, the project provided a complete 
overview and understanding from the classical and modern literature of the current state of 
evidence on the TCM treatments in the management of AD. Through the comparison of the 
classical and modern literature, it is shown that the TCM principles and methods for the 
management of AD had remained on the same track, with CHM being the most used form of 
TCM treatment in the management of AD.  
Despite the lack of conclusive evidence from the SRs with regard to the efficacy and safety of 
oral CHM and acupuncture in the management of AD, the reviews have outlined the level of 
evidence available. They have also identified limitations in methodology and reporting which 
could be improved on in future studies to produce rigorous studies of higher quality to 
provide more substantial conclusions. 
This project compiled the data from the reviews and advice from experts to formulate RCM-
106 for the management of AD. The study protocol to evaluate this new CHM formula 
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incorporated methodological improvements of the identified limitations of current studies. 
In time, its reporting will be guided by the CONSORT statement with its relevant herbal 
extension. As mentioned previously, the overall quality of RCTs and their reporting had been 
poor and more rigorous studies are warranted. The RCT protocol for RCM-106 aims to be 
one of such rigorous studies needed and act as a guide for future studies as well.  
Aside from preparing a rigorous RCT design for CHM studies, the protocol was also designed 
specifically for the paediatric population, integrating safety precautions suited to the target 
population. Due to the vulnerability of the paediatric population, there was a lack of RCTs for 
paediatric conditions and medications. It had also been noted that the difference in 
paediatric pharmacology did not allow for results from adult studies to be directly 
transposed to the paediatric population. Therefore, the current state of evidence of efficacy 
and safety of paediatric medicine and information of suitable forms of paediatric medication 
remains unknown. RCTs designed to suit the paediatric population are required to ensure 
the efficacy and safety of treatments for paediatric conditions, such as AD. The RCT protocol 
for RCM-106 had undergone strict evaluation by the HREC of RMIT University to incorporate 
adequate protection of the well-being of the paediatric participants throughout the study. 
The protocol and methodology of the study is supported by the literature such as clinical 
trial guidelines, Chinese medicine regulations, pharmacology and toxicology of herbs, 
traditional and modern application and dosage of herbs and previous clinical or laboratory 
studies of herbs. Safety measures and monitoring, such as the swallow-test and 
measurement of vital signs, kidney function and liver function, have been included where 
possible. The protocol also considered issues related to participant compliance, such as 
palatability and method of administration of intervention. Furthermore, the protocol 
required that verbal assent from all participants be obtained in addition to written informed 
consent from their parent(s)/legal guardian(s) and that participants be made aware that they 
can withdraw at any time.  
It is believed that this protocol will act as an important guide for future RCTs, especially RCTs 
involving the paediatric population, and assist in the development of future research related 
to paediatric medicine and traditional medicine.  
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9.4 Limitations of this Project 
As mentioned in Chapters 3 to 7, the main limitations of the reviews included the technical 
errors experienced with database searching, lack of familiarity with the Chinese database 
searching, language barriers and lack of familiarity with the difference in culture and 
research or clinical practice of TCM in different countries. Furthermore, due to limitations in 
accessibility, databases of other countries or languages, such as the Japanese and Korean 
databases, were not included in the search strategies. These limitations could have led to 
incomplete searching of the English and Chinese databases as well as misinterpretation of 
data, and subsequently impacted the conclusion of the studies. With regard to the studies 
evaluated in the reviews, there was an overall high heterogeneity and low quality of studies, 
impeding valid conclusions to be made.  
On the protocol of the RCT, the current limitations include the lack of pharmacological data 
on RCM-106 and lack of laboratory parameters as outcome measures.  
The lack of pharmacological data of RCM-106 and the lack of laboratory parameters as 
outcome measures deter the complete understanding of the efficacy and safety of the 
intervention and justification of its dosing regimen in the study. This may lead to an over- or 
under-estimation of treatment doses and their relative effects and safety. As the current 
protocol is based on the reverse pharmacology paradigm for traditional medicine, the safety 
of RCM-106 and its dosing regimen is based on empirical evidence and existing TCM 
guidelines. However, as mentioned in Chapter 7, this protocol is for a preliminary clinical 
study of RCM-106; its results, when combined with further pharmacological studies, can lead 
to RCTs of a larger scale to build on existing evidence of its efficacy and safety. 
 
9.5 Implications for Further Studies 
From the reviews conducted in this project, there is an overall need for more rigorous RCTs 
and improved quality of reporting. In particular, future studies should focus on addressing 
the following aspects – efficacy and safety studies of individual TCM therapies when 
compared to placebo, pragmatic studies involving integrated TCM and WM treatments as 
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seen in real clinical practice compared to conventional treatments alone, and studies of 
pharmacology and underlying mechanisms of action of TCM treatments.  
Although the reverse pharmacology paradigm is accepted for clinical research of traditional 
medicine, there is no clear guideline stating if the paradigm should begin either with 
pragmatic (Phase III) studies which evaluate the effectiveness of the traditional medical 
system as seen in real practice, or explanatory (Phase II) studies which evaluate individual 
treatments against placebo. It is argued that interventions of traditional and complementary 
medicine were already widely used and research should therefore be focused on its 
effectiveness in real-life clinical settings (Cardini et al., 2006; MacPherson, 2004). While it is 
an ongoing debate on whether efficacy or effectiveness should first be established, both 
research questions regarding efficacy and effectiveness need to be addressed with 
adequately-designed studies. At present, there is a lack of placebo-controlled studies and 
well-designed pragmatic studies. Researchers need to consider future clinical study designs 
which are suitable for the specific research question.  
From a scientific and WM perspective, pharmacology studies and other studies evaluating 
the mechanism of action of various TCM treatments will increase its acceptability within the 
healthcare system and by the public. Previous studies had established that CHM possess 
pharmacological actions such as anti-inflammatory, anti-bacterial, anti-fungal, and immuno-
suppressive functions (Bedi & Shenefelt, 2002), while acupuncture produced anti-pruritic 
effects by causing vasodilation, and by stimulating inflammatory cell mediators and 
neurotrophins (Belgrade et al., 1984; Carlsson et al., 2006; Kesting et al., 2006; Lundeberg et 
al., 1987), which might support the use of these treatments in the management of AD. 
However, the complete mechanism of TCM treatments has yet to be elucidated, especially 
with regard to the pharmacological action of different herbal combinations in CHM formulae 
as is used in clinical practice. Furthermore, the difference in effects and safety, when applied 
to different target populations with AD, such as in the elderly, adults or children, is also an 
area for future studies to explore. The understanding of the mechanisms of action of TCM 
treatments will allow a more targeted treatment of AD from both WM and TCM 
perspectives. 
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9.6 Implications for Clinical Practice 
From the comprehensive review, it was shown that TCM treatments, especially CHM, can be 
integrated with conventional treatments to assist in the management of AD; treatment 
effects may be seen within 2 weeks but longer treatment may be required to prevent 
recurrence. Treatment effects may be defined as an improvement in disease symptom, 
reduction in medication usage or improved QoL. The comprehensive review showed that the 
treatment duration of TCM treatments in RCTs were rarely longer than 8-12 weeks; its long-
term effects or harm remains uncertain and therefore, long-term use of such treatments is 
not recommended.  
The two SRs did not provide valid conclusions to recommend CHM or acupuncture 
treatment in the management of AD. However, they do provide preliminary evidence of the 
potential of CHM in reducing symptom/disease severity, reducing use of concurrent 
medication and/or improving QoL; and the potential of acupuncture in preventing or 
reducing itch intensity. Practitioners may explain this to patients and provide the option to 
try TCM treatments for AD.  
From the preparation of the RCT protocol, it is shown that the pharmacology of TCM 
treatments and the pharmacology of these treatments in the paediatric population play an 
important part in determining the efficacy and safety of treatments. As the pharmacology of 
TCM treatments remains unclear, practitioners need to be familiar with patients’ medical 
history and existing medications. Practitioners have to ensure the quality of the CHM that is 
provided to patients and closely monitor the liver and kidney functions in patients with 
existing systemic diseases or who are taking multiple medications for long durations. 
Practitioners need to be up-to-date with the latest information regarding the pharmacology 
of TCM treatments and ensure that the clinical application of TCM treatments is in 
accordance with the historical and currently-available evidence to ensure the safety of 
patients, especially when treating the paediatric population. When treating the paediatric 
population, aside from the pharmacological aspects of WM and TCM treatments, 
practitioners should be aware of every treatment decision, from the palatability of 
medication to the method of administration and that of obtaining assent from the child 
patient.  
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Glossary of Chinese Terms* 
Chinese Terms (Pin Yin) English Translation/definition 
四弯风(Si Wan Feng) Literally translated as “four bend wind”. Noted to be 
synonymous with “eczema” or “atopic dermatitis” 
奶癣 (Nai Xuan) Literally translated as “milk tinea/ dry ulcer”. Noted to be 
synonymous with “infantile eczema”; may refer to nipple 
dermatitis 
中华医典 (Zhong Hua Yi 
Dian) 
Encyclopedia  of Traditional Chinese Medicine – A TCM classical 
literature database software 
说文解字(Shuo Wen Jie 
Zi) 
Explaining Simple and Analysing Compound Characters – A 
Chinese language dictionary) 
辞海 (Ci Hai) Encyclopaedia Dictionary – A Chinese language dictionary) 
中医字典 (Zhong Yi Zi 
Dian) 
Chinese Medical Dictionary  
中医大辞典 (Zhong Yi Da 
Ci Dian) 
Comprehensive Chinese Medical Dictionary  
湿疹 (Shi Zhen) Literally translated as “damp papule”. Current Chinese term 
equivalent to “eczema” 
浸淫疮 (Jin Yin Chuang) Literally translated as “immersed sore”. Noted to be 
synonymous with “eczema” 
湿疮 (Shi Chuang) Literally translated as “damp sore. Noted to be synonymous 
with “eczema” 
特应性皮炎 (Te Ying Xing 
Pi Yan) 
Current Chinese term for “atopic dermatitis” 
特应性湿疹 (Te Ying Xing 
Shi Zhen) 
Current Chinese term for “atopic eczema” 
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湿毒疮 (Shi Du Chuang) Literally translated as “damp toxin sore”. Noted to be 
synonymous with “eczema (on the lower limbs)” 
湿气疮 (Shi Qi Chuang) Literally translated as “damp Qi sore”. Noted to be synonymous 
with “eczema (on the lower limbs)” 
胎敛疮 (Tai Lian Chuang) Literally translated as “foetal accumulation sore”. Synonym of 
Nai Xuan (奶癣)  
湿敛 (Shi Lian) Literally translated as “damp accumulation”. May refer to a 
syndrome differentiation of Nai Xuan (奶癣); may also be 
synonymous with Tai Lian Chuang (胎敛疮) 
干敛 (Gan Lian) Literally translated as “dry accumulation”. May refer to a 
syndrome differentiation of Nai Xuan (奶癣); may also be 
synonymous with Tai Lian Chuang (胎敛疮) 
溼疹 (Shi Zhen) Literally translated as “damp papule”. Same as Shi Zhen (湿疹) 
(in traditional Chinese characters) 
湿癣 (Shi Xuan) Literally translated as “damp tinea/dry ulcer”. Noted to be 
synonymous with “acute eczema” 
胎癣 (Tai Xuan) Literally translated as “foetal tinea/dry ulcer”. Noted to be 
synonymous with Nai Xuan (奶癣) or “infantile eczema” 
乳癣 (Ru Xuan) Literally translated as “milk/nipple tinea/dry ulcer”. Noted to be 
synonymous with Nai Xuan (奶癣) or “infantile eczema”; may 
refer to nipple dermatitis 
干癣 (Gan Xuan) Literally translated as “dry tinea/dry ulcer”. Noted to be 
synonymous with “chronic eczema” or “neurodermatitis”; 
current Chinese term equivalent to “psoriasis” or “tinea” 
梅毒 (Mei Du) Noted to be synonymous with “syphilis” 
湿 (Shi) Dampness  
疳湿疮 (Gan Shi Chuang) Literally translated as “malnutrition damp sores”. Noted as 
rashes related to weakness and parasites in the 
stomach/intestines 
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下注疮 (Xia Zhu Chuang) Noted as chronic and exudative lesions that occur around the 
knee creases or lesions that are caused by damp toxins that 
occurs around the shin, heel, ankle and feet. 
风寒湿气疮 (Feng Han Shi 
Qi Chuang) 
Lesions due to wind-cold-damp invasion according to Chinese 
medicine theories 
湿奶癣 (Shi Nai Xuan) Literally translated as “damp milk tinea/dry ulcer” and 
described as a type of rash that is caused by the consumption 
of “damp milk” and can lead to parasitic growth in chronic 
phases. 
白壳疮 (Bai Ke Chuang) Literally translated as “white shelled ulcer” and is used to 
describe a type of rash 
湿奶 (Shi Nai) Literally translated as “damp milk”. Its consumption is said to 
be a cause of Shi Nai Xuan. 
癣 (Xuan) Noted to be synonymous with tinea or dry ulcers 
口齿疳疮 (Kou Chi Gan 
Chuang) 
Literally translated as “mouth and teeth malnutrition sores”. 
Possibly referring to Gan Chuang that occurs around the mouth 
and teeth 
小儿疳湿疮 (Xia Er Gan 
Shi Chuang) 
Literally translated as “paediatric malnutrition damp sores”. 
Noted as rashes related to weakness and parasites in the 
stomach/intestines in children  
寒湿疮毒 (Han Shi 
Chuang Du) 
Literally translated as cold-damp lesion toxins 
*Does not include titles of Chinese texts, diagnostic criteria or excerpts from classical 
literature
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Appendix 1: Data Scoring for Classical Literature Review 
Erythema 
Ranking Score Condition Decision Log 
0 No mention  
1 No 疹之所由，乃肺为热灼，故红点见于皮毛，与湿疹白色
而无红点者不同 (ID2)/ 乳癣便毒之不红肿焮热(ID322-
2)/ 根脚不红(ID464,472)/ 
2 Yes 疮赤痒痛 (ID 73)/ 或肿，或赤，或痛，或痒(ID115-7)/ 初
生赤小(ID128)/ 周郭中如虫行，浸淫赤湿，搔痒汁出是
也(ID252)/ 痒痛红肿 (ID305-1)/ 鼻下两傍湿疮赤痒
(ID363)/ 周身肉赤无皮，脓血淋漓 (ID425)/ 小儿脐久不
干出脓, 赤肿及清水出(ID430)/ 红紫流水奇痒(ID473)/ 红
晕成片(ID565-2,575-3,577-1)/ 浸淫赤湿痒(ID664)/郭中如
虫行。浸淫赤色。搔痒汁出者是也(ID691-6to20)/ 浸淫
赤湿(692)/ 赤(ID725,726-1,749-1,756-1to7,788-2~)/或赤
痒(ID922)/ 
3 Other 
discolouration 
或紫或黑(ID542)/ 
White/pale skin 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes 湿疹白色而无红点 (ID2)/ 则呈白色而有光泽之鳞片(ID 
887)/ 
Papules 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes 初如粉粟。渐大如豆(ID55-8)/ 如黍粟麻豆(ID128)/ 似疥
形(ID134)/ 初生如疥(ID141-1,141-2,921,934)/初起如粟米
(ID298)/ 如小豆脓窠状(ID547)/皮肤起粟(ID565, 567-
5,575,577-3)/ 斑疹(ID576,578)/ 肌肤起颗成片(ID958-4)/ 
Macules 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes 斑痕不退，宜翠云散点之(ID458)/ 斑疹(ID576,578)/ 
Distinct margin 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes 有边远之象(ID78)/ 周郭中如虫行，浸淫赤湿，搔痒汁出
是也(ID252)/ 但有周郭，皮枯瘙痒，搔之白屑起者是也
(ID252,691-4,691-5,691-8to20)/ 延生或如钱成圈晕，久
不效者(ID260)/ 有棱廓(ID664,692,847,858)/   
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Distinct margin (continued) 
Ranking Score Condition Decision Log 
2 Yes 郭中如虫行。浸淫赤色。搔痒汁出者是也(ID691-6to20)/ 
痒痛有棱廓(ID693)/ 有匡郭(ID725,726,749,756,758,868)/ 
有匡廓(ID729)/ 有匡栏(ID788)/ 
Blister 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes 火烙浆疱(ID55-8)/ 有水窠头，不烂而甚痒(ID294-2,294-
3,294-4,294-5)/ 
Lichenification/swelling/scabing 
Ranking Score Condition Decision Log 
0 No mention  
1 No 乳癣便毒之不红肿焮热(ID322-2)/ 
2 Yes 积年生痂(ID41-3,683-1,683-2,698-3，745-4， 745-5,749-
3,839,840, 841,842,843,846,847-8to13,858-8to11,910)/ 积
年生痂疕(ID109-5)/ 或肿，或赤，或痛，或痒(ID115-7)/
脓痂遍周(ID126-4,126-5)/ 积年痂厚(252-11,756-9,756-
10,758-8to10)/ 若肿而痛甚者(ID296,382,420,466-2)/ 痒痛
红肿 (ID305-1)/ 生茄擦之黄水出(337-2)/ 肿痛(ID 
358,922)/ 肿痛湿疮(ID359)/ 渐至蚀透(ID365)/ 小儿脐久
不干出脓, 赤肿及清水出(ID430)/ 浮肿溺赤(ID515-4)/ 皮
如甲错干燥(ID552-1,553-1,863-11)/ 皮如甲错，起干燥
(ID560-1)/ 脓痂过厚(ID565)/皮如甲错起。干燥
(ID665,826)/治积年疮癣生痂。搔之则水出。遇阴雨时
即痒。(ID691-7)/ 初起肿痛(ID784,794)/ 
Dry skin/scaling 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes, dry skin 皮如甲错干燥(ID552-1,553-1,863-11)/ 皮如甲错，起干燥
(ID560-1)/ 皮如甲错起。干燥(ID665,826)/ 枯索痒
(ID848)/燥痒(ID908)/ 
3 Yes, scaling 搔之则有白屑(ID104)/ 搔痒则起白屑(ID141-4,564-1,773-
2)/ 但有周郭，皮枯瘙痒，搔之白屑起者是也
(ID252,691-4,691-5,691-8to20)/ 湿奶白壳疮(ID484,574)/ 
痒起白屑(ID565,567-4,567-5,567-6,575,577)/ 搔出白屑
(ID676-1,690-1)/ 皮枯瘙痒(ID693-2)/ 皮枯索，痒，搔之
白屑出(ID726-2,749-2,749-3)/ 皮枯索，痒搔之白屑出
(ID756-8to 12,758-6to10,868)/ 搔之起屑(ID775-2)/ 搔则
出白屑(787-2,899-3,899-4,902-2,904-2)/ 搔之白屑起
(ID788-1)/ 皮枯痒。搔之白屑出(ID847,858)/则呈白色而
有光泽之鳞片(ID 887)/ 
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Itching 
Ranking Score Condition Decision Log 
0 No mention  
1 No 痛而不痒(ID183,294-7,301,336-1,391,941)/ 
2 
 
Yes 
 
痒浸淫，日瘙痒不可忍，搔之(ID41-2)/ 每逢阴雨即痒
(ID41-3, 109-5,337-2,683-1,683-2,698-3，745-4,745-5,749-
3,756-9,756-10,758-8to10,839,840, 841,842,843,846,847-
8to13,858-8to11,910)/搔之(ID41-3,111,252-11)/先痒后痛
(ID42，48,54-1,81,97，115,133,138)/ 痒痛汁出(ID45,55)/ 
有痒处即以手掌拂之(ID50-2)/或痒或痛(ID72,99,139)/ 疮
赤痒痛 (ID 73)/ 浅搔之蔓延长不止(ID81,111,140)/瘙痒者
初如疥(ID81,111,140)/搔之转生汁相连着是也
(ID81,111,140)/初生微痒(ID101)/ 搔之则有白屑(ID104-
2)/ 搔之则有汁出(ID104-3)/痒不可忍(ID106-2,252-
6,522,593,699,989)/ 搔之黄水出(ID109-5,252-11,683-
1,683-2,698-3，745-4，745-5,756-9,756-10,758-
8to10,910)/痛痒坼裂(ID111)/ 或肿，或赤，或痛，或痒
(ID115-7)/ 搔之黄汁出(ID117)/ 浸淫痛痒者(ID120-1)/ 痒
不止(ID134)/搔痒无时(ID 134,934)/ 瘙痒蔓延(ID141-
1,141-2)/搔痒则出粘汁(ID141-3,564-2,773-1)/搔痒则起白
屑(ID141-4,564-1,773-2)/ 热痒而痛
(ID146,150,180,208,212, 225,259,263,279-
2,284,347,385,396,400,479,502)/ 痒而痛(ID229，336-3)/ 
作风湿癣疮，瘙痒脓水 
(ID157,320,324,357,359,595,607,610,620,657,659)/风湿疮
痒脓水(ID157)/ 极痒有虫(ID189,331,362)/ 火衰风湿疮痒
(ID222)/ 身痒(ID223)/ 湿疮痒搔有黄水(ID231)/ 湿疮奇痒
者(ID241)/ 周郭中如虫行，浸淫赤湿，搔痒汁出是也
(ID252)/ 但有周郭，皮枯瘙痒，搔之白屑起者是也
(ID252,691-4,691-5,691-8to20)/治湿癣痒，搔之有黄水，
杀虫(ID252-3)/ 痒痛不可忍(ID252-19,252-24,664-1,664-
2,691-16,788-4,788-5)/ 下注阴湿疮痒(ID256,280)/ 治风热
湿疮痒痛(ID264-1)/ 治漏瘤疮湿癣痒，浸淫日广，痒不
可忍，搔之黄水出，瘥后复发(ID264-2,593)/ 浸淫日
广。痒不可堪。搔之黄水出。瘥后复发 (ID273)/ 经年抓
搔痒处成孔者 (ID275)/ 有痒处即以手掌摩之(ID276)/有
水窠头，不烂而甚痒(ID294-2,294-3,294-4,294-5)/ 时时
作痒(ID298)/ 湿水痒痛(ID303-1)/ 脂水痒痛(ID304)/ 痒痛
红肿 (ID305-1)/ 痛痒不休(ID307,314)/ 发痒湿疮(ID311)/ 
搔痒不休(ID329)/ 痒而出水(ID336-2)/ 湿疮虫痒(ID356)/
鼻下两傍湿疮赤痒(ID363)/ 疼痒(ID364,415)/ 风湿疮痒
(ID377-2,417-1)/痛痒(ID377-4,397)/ 浸淫日久，痒不可
忍，搔之黄水出，瘥后复发(ID402-1,481,605)/  浸淫日
广，痒不可堪，搔之黄汁出。    瘥后复发(ID405)/ 日痛
痒不可堪，搔之黄水汁出，瘥复发方(ID410-1)/ 搔痒成
疮(ID454)/ 时痛时痒(ID466-1)/ 痒如虫一般(ID470)/ 红紫
流水奇痒(ID473)/ 其痒无度(ID482,524,782)/淫痒滋延
(ID488)/ 痛痒不常(ID459)/ 瘙痒难忍(ID461)/ 痒者
(ID487)/ 疵湿疮痒(ID494,495)/  
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Itching (continued) 
Ranking Score Condition Decision Log 
2 Yes 痒定，黄赤水出，又痛不可耐(ID507-2)/ 每爬搔则黄水
出(ID507-3,738-2)/痒热而痛(ID518)/ 搔破成疮痒难堪
(ID521)/ 搔破成疮(ID522)/ 发痒(ID527,738-1，745-3)/ 痛
痒不禁(ID530)/两足湿毒疮痛痒(ID532)/ 初起而微痒
(ID537)/ 故初起之时微痒者(ID541)/ 腐溃流水痒痛
(ID545-2)/ 作痒蔓延(ID545-3)/ 滋水作痒(ID546)/ 夜睡肌
热且痒(ID547)/瘙痒不绝(ID556)/搔痒流脂成片(ID564-
3,564-4)/ 搔痒不绝(ID567-1,572)/ 痒起白屑(ID565,567-
4,567-5,567-6,575)/ 搔痒无度(ID567-5)/浸淫日广，痒不
可忍，愈后复发，出黄水(ID614)/风湿癣疥痒脓水
(ID643-1)/ 浸淫赤湿痒…搔之多汁(ID664)/ 搔出白屑
(ID676-1,690-1)/ 搔之多汁(ID676-2,690-2,725)/湿痒搔之
有黄水出(ID691-1,691-2)/ 郭中如虫行。浸淫赤色。搔痒
汁出者是也(ID691-6to20)/ 治积年疮癣生痂。搔之则水
出。遇阴雨时即痒。(ID691-7)/ 痒抓则痛。而久不瘥
者。(ID691-9,867)/ 痒痛不可忍者(ID691-13)/ 湿癣只干揩
贴之。并候黄水出。及数数痒痛(ID691-15)/ 瘙痒(ID691-
17,692)/ 痒痛有棱廓(ID693)/ 皮枯瘙痒(693-2)/搔之有汁
(ID693,726,749)/ 躁痒(ID718)/ 痒痛流黄水(ID722)/ 痒痛
不一(ID729)/ 发时极痒(ID734)/ 
 风湿癣疮，瘙痒，脓血水(ID732-1)/ 痒搔之(ID756-
1to7,758-1to5)/皮枯索，痒搔之白屑出(ID756-8to 
12,758-6to10,868)/ 搔之起屑者为干癣。有汁水者为湿
癣(ID775)/瘙之则有汁出(ID780)/ 搔则多汁(ID787-1,899-
1,899-2,902-1,904-1) 搔则出白屑(787-2,899-3,899-4,902-
2,904-2)/ 搔之白屑起(ID788-1)/ 遇痒搔之多水成疮
(ID788-2~)/作痒流水(ID838)/ 皮枯痒。搔之白屑出
(ID847,858)/ 痒痛不止(ID847-4to6,858-5,858-6)/ 枯索痒
(ID848)/ 阴雨之时即痒痛(ID858-12)/ 暖则痒闷(ID863-
11)/瘙之生汁 (ID 921)/ 或赤痒(ID922)/浸淫作痒(ID957)/ 
Bleeding 
Ranking Score Condition Decision Log 
0 No mention  
1 No 无脓无血(ID459)/ 
2 Yes 抓破津血者(ID134-2,141-2,934-2)/脓血淋漓(ID307,314)/ 
周身肉赤无皮，脓血淋漓 (ID425)/风湿癣疮，瘙痒，脓
血水(ID732-1)/ 
Ulceration/Skin breakage 
Ranking Score Condition Decision Log 
0 No mention  
1 No 有水窠头，不烂而甚痒(ID294-2, 294-3,294-4, 
294-5)/ 
2 Yes 汁出侵溃肌肉(ID42,97)/湿烂肌肉(ID48,54-
1,133,137,138)/侵溃肌肉(ID81)/湿渍腐烂不已(ID91)/溃
烂成疮(ID92)/痛痒坼裂(ID111)/ 儿身体湿烂(ID120-1)/  
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Ulceration/Skin breakage (continued) 
Ranking Score Condition Decision Log 
2 Yes 抓破津血者(ID134-2,141-2,934-2)/ 脓汁所至辄皮破肉腐
(ID140-12)/ 破津黄水(ID134,141-1,141-2)/ 经年抓搔痒处
成孔者 (ID275)/ 破时作痛(ID298)/ 无皮红肉现露(ID308-
3)/ 湿疮无皮(ID324)/ 浸淫湿烂(ID336-2)/ 浓汁淋漓臭烂
(ID366,403,465)/ 周身肉赤无皮，脓血淋漓 (ID425)/ 湿疮
破者(ID440-1)/ 搔破津水(ID482,524,782)/搔破成疮痒难
堪(ID521)/ 搔破成疮(ID522)/ 止处即溃烂(ID542)/ 腐溃流
水(ID545-1)/ 腐溃流水痒痛(ID545-2)/ 浮腐流水(ID545-4)/
风湿癣疥湿烂(ID643-2)/ 抓溃黄水浸淫成片(ID934)/ 破碎
时流脂水(ID958-4)/ 
Exudation 
Ranking Score Condition Decision Log 
0 No mention  
1 No 无脓无血(ID459)/ 搔之无汁(ID693-2,848)/ 无汁(ID756-
8,758-6,758-7,847,858,868)/ 无水(ID788-1)/ 
2 Yes 浸淫疮转有汁(ID15,22,41-1)/ 有汁(ID16,17,23,24,922-2)/
浸淫疮出黄水(ID27,41-2,41-3)/ 汁出侵溃肌肉(ID42,97)/ 
后有脓汁(ID44,65,98,121,124,126-1,126-2,126-3)/ 痒痛汁
出(ID45,55)/ 汁出浸淫(ID48,54-1，115,133,137,138)/ 黄
水出(ID55-6,60,63-1,106-2,133-2)/ 转广有汁(ID55-
9,80,87,115-1,136)/ 习习然黄水出者(ID58-2)/ 如疮湿
(ID56,63-3,123, 325)/ 搔之即黄汁出(ID863-11)/ 脓汁浸淫
渐大(ID65-1,121-10)/ 浸微黄水(ID66)/出黄水
(ID70,103,402-2)/ 脓水不绝 (ID72,99,139,536)/ 湿即敷之
(ID72)/ 成疮汁出(ID81)/ 搔之转生汁相连着是也
(ID81,111)/ 湿渍腐烂不已(ID91)/ 湿渍之状，脓水流处
(ID92)/ 有水出(ID101)/ 搔之则有汁出(ID104-3)/ 搔之黄水
出(ID109-5,252-11,683-1,683-2,698-3，745-4,745-
5,839,840, 841,842,843,846,847-8to13,858-8to11)/疮汁所
着处即成疮(ID115-5)/ 搔之黄汁出(ID117)/ 儿身体湿烂
(ID120-1)/ 脓汁着处便生(ID126-1,126-2,126-3)/ 脓汁浸淫
而生(ID126-4,126-5)/ 长出脓汁成疮(ID128)/ 黄水浸淫
(ID134,298,565,575,577-3)/抓津黄水(ID134)/ 破津黄水
(ID141-1,141-2)/搔痒则出粘汁(ID141-3,564-2,773-1)/ 出
黄汁(ID146,150,180, 
188-2,208,212, 229,336-3,385,400,479,518,631)/黄水湿疮
(ID155,161,169,215,308-3,328-2,330-1)/ 
 作风湿癣疮，瘙痒脓水(ID157,320,324,357,359, 
595,607,610,620,657,659)/风湿疮痒脓水(ID157)/ 粘着衣
被(ID183,294-7,301,336-1)/ 湿疮痒搔有黄水(ID231)/ 湿疮
流水(ID242)/ 如湿疮即干敷 (ID251)/ 周郭中如虫行，浸
淫赤湿，搔痒汁出是也(ID252)/ 治湿癣痒，搔之有黄
水，杀虫(ID252-3)/ 治漏瘤疮湿癣痒，浸淫日广，痒不
可忍，搔之黄水出，瘥后复发(ID264-2)/ 浸淫日广。痒
不可堪。搔之黄水出。瘥后复发 (ID273)/ 次日再用手轻
轻拭出脓水(ID274)/ 
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Exudation (continued) 
Ranking Score Condition Decision Log 
2 Yes 黄水流注(ID279-1)/ 贴半日黄水流出(ID287)/ 若湿疮脓水
甚者(ID296,382,420,466-2)/ 湿水痒痛(ID303-1)/ 女子阴户
湿疮浸湿(ID303-3)/ 脂水痒痛(ID304)/ 脓血淋漓
(ID307,314)/ 出水不瘥(ID332,620-2)/ 痒而出水(ID336-2)/ 
生茄擦之黄水出(337-2)/ 脓水(ID358,360,370,389)/ 常出
汁水(ID359)/浓汁淋漓臭烂(ID366,403,465)/ 湿疮脓水
(ID370)/脓水流注(ID395)/ 浸淫日久，痒不可忍，搔之黄
水出，瘥后复发(ID402-1,481,605)/ 浸淫日广，痒不可
堪，搔之黄汁出。    瘥后复发(ID405)/ 日痛痒不可堪，
搔之黄水汁出，瘥复发方(ID410-1)/ 周身肉赤无皮，脓
血淋漓 (ID425)/ 小儿脐久不干出脓, 赤肿及清水出
(ID430)/ 耳流脓水湿疮生(ID443)/ 成片出水(ID466-1)/ 红
紫流水奇痒(ID473)/ 淫痒滋延(ID488)/  搔破津水
(ID482,524,782)/ 出脓水(ID500)/ 湿疮而出浓水流注
(ID504-1,504-2)/ 痒定，黄赤水出，又痛不可耐(ID507-
2)/ 每爬搔则黄水出(ID507-3,738-2)/ 湿疮滋水(ID515-5)/ 
搔破成疮痒难堪(ID521)/ 流水不止(ID530)/ 爬则水出
(ID537)/ 脚膝间脓水不绝(ID540)/ 生疮既久，流脓流水
(ID541)/ 脓水淋漓(ID542)/ 腐溃流水(ID545-1)/ 腐溃流水
痒痛(ID545-2)/ 浮腐流水(ID545-4)/ 滋水作痒(ID546)/ 黄
水出尽(ID560-17)/搔痒流脂成片(ID564-3,564-4)/ 流脂成
片(ID567-1,556,572)/ 黄水津淫(ID567-5)/ 黄水疮(ID568-
4to10)/浸淫日广，痒不可忍，愈后复发，出黄水
(ID614)/风湿癣疥痒脓水(ID643-1)/风湿癣疥湿烂(ID643-
2)/ 浸淫赤湿痒…搔之多汁(ID664)/ 搔之多汁(ID676-
2,690-2,692,725)/湿痒搔之有黄水出(ID691-1,691-2)/ 郭
中如虫行。浸淫赤色。搔痒汁出者是也(ID691-6to20)/ 
治积年疮癣生痂。搔之则水出。遇阴雨时即痒。(ID691-
7)/ 湿癣只干揩贴之。并候黄水出。及数数痒痛(ID691-
15)/ 搔之有汁(ID693)/ 延蔓津脂(ID718)/ 痒痛流黄水
(ID722)/ 搔痒出汁(ID729)/风湿癣疮，瘙痒，脓血水
(ID732-1)/ 黄赤水流(ID738-1，745-3)/ 多汁成疮(ID756-
1to7,758-1to5)/ 搔之起屑者为干癣。有汁水者为湿癣
(ID775-1)/ 瘙之则有汁出(ID780)/ 搔则多汁(ID787-1,899-
1,899-2,902-1,904-1)/ 遇痒搔之多水成疮(ID788-2~)/作痒
流水(ID838)/ 出黄水不止(ID858-12)/ 瘙之生汁 (ID 921)/ 
抓溃黄水浸淫成片(ID934)/ 黄水流注(ID939)/破碎时流脂
水(ID958-4)/ 
3 Yes, with 
pustules 
兼治下部脓窠湿疮(ID151,230)/ 如小豆脓窠状(ID547)/ 
Dry rash  
Ranking Score Condition Decision Log 
0 No mention  
1 No 小儿脐久不干出脓, 赤肿及清水出(ID430)/   
2 Yes 干者猪脂调(ID29)/ 如疮干(ID42,76)/ 干者，猪膏涂
(ID47)/ 干疮用乌臼油或酥或油腊调涂(50-2)/  
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Dry rash (continued) 
Ranking Score Condition Decision Log 
2 Yes 干疮麻油调(ID56-2)/如疮干燥痛(ID63-3)/ 干者以猪脂和
涂之(ID112,405-5)/ 如干癣以醋调涂(ID252-10)/ 干癣用生
油调涂(252-15)/ 如干疮(ID253)/ 干则香油调搽(ID258)/ 
湿疮干掺，干疮麻油调涂之(ID261)/ 干疮用乌桕油或酥
或油蜡调涂(ID276-1)/ 疮干油调搽。(ID276-2)/ 无汁。以
猪脂和涂之(ID281)/ 湿疮干敷。干疮油敷(ID288)/ 如干
疮即作膏。用猪脂调纸上贴 (ID291)/ 如干者
(ID296,382,420,466-2)/ 湿则干敷，干则用麻油调搽
(ID308-1)/ 干则麻油调搽(ID312)/ 如疮干痛痒 (ID325)/ 湿
疮干掺，干疮香油调敷(ID360)/ 如湿疮干掺，疮干油调
搽(ID365)/ 如燥痛(ID375-3)/ 湿疮干掺；干疮，公猪胆汁
调点(ID394)/ 湿疮干掺，燥用腊猪油熬化调敷(ID401)/ 
湿疮干贴，干疮津调贴 (ID416)/ 如干癣疮
(ID429,439,444,863-17)/ 燥疮用腊猪油熬化调敷(ID450)/ 
湿疮干撒，干疮以公猪胆汁调浓点之(ID458)/ 湿疮干
掺。干疮用公猪胆汁调点(ID464)/如疮干猪油调搽
(ID466-1)/燥疮熬猪油调搓(ID468)/ 湿疮干掺，干疮公猪
胆汁调点(ID469,472)/干用猪脂和(ID489)/干者以小油调
搽(ID691-8)/ 干癣用生油调涂(ID691-15)/ 湿癣干掺。干
者用指甲抓破 (ID714)/ 
Chronic/recurrent 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes 瘥后复发(ID41-2,106-2)/积年生痂(ID41-3,683-1,683-
2,698-3，745-4,745-5,749-
3,839,840,841,842,843,846,847-8to13,858-8to11,910)/渐
展不止(ID44,65-1,65-4,107-1,121-5,125-1,131-1)/ 久不治
者(ID54-2,54-3)/ 久不愈(ID55-6,60,63-1,133-2,140-
2,156,365,402-2)/久不瘥(ID552-2,671-1,671-2,672,863-
10,858-12)/ 浸淫不已(ID80,87,124)/ 留连不已也
(ID81,86)/浅搔之蔓延长不止(ID81,111,140)/ 反聚(ID83)/ 
留流不已(ID90)/ 浸淫日久(ID106-2)/ 多年湿癣(ID109-
4,252-4,692-15,700,745-2,788-10,788-11)/ 积年生痂疕
(ID109-5)/干癣不瘥(ID109-8,698-2)/随月生死(ID111)/ 春
夏秋冬随瘥剧者是也(ID111)/ 百疗不瘥，动经年月
(ID117)/ 疮再发(ID119)/ 作不解者(ID120-2)/荏苒不已
(ID128)/ 蔓延不止(ID134,934)/ 旧患发颐之处(ID140-12)/ 
久不瘥者 (ID158,560-17,726,749)/ 治下部湿疮不愈
(ID232)/ 治久患湿疮不瘥 (ID252-1)/ 积年痂厚(252-
11,756-9,756-10,758-8to10)/ 延生或如钱成圈晕，久不效
者(ID260)/ 治漏瘤疮湿癣痒，浸淫日广，痒不可忍，搔
之黄水出，瘥后复发(ID264-2)/ 远年不效(ID268)/ 浸淫日
广。痒不可堪。搔之黄水出。瘥后复发 (ID273)/ 经年抓
搔痒处成孔者 (ID275)/ 自少至长(ID279-4)/  
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Chronic/recurrent (continued) 
Ranking Score Condition Decision Log 
2 Yes 凡远年湿风疮痒甚，诸药不效者，必有虫在内(ID294-
2,294-3,294-4,294-5)/ 一切潮湿疮疖，缠绵不愈 (ID299)/ 
日久不愈(ID308-3)/ 连年不愈(ID323,536,540)/出水不瘥
(ID332,620-2)/ 发歇不定(ID336-2)/ 积年干癣(337-2)/ 浸
淫日久，痒不可忍，搔之黄水出，瘥后复发(ID402-
1,481,605)/ 浸淫日广，痒不可堪，搔之黄汁出。    瘥后
复发(ID405)/ 日痛痒不可堪，搔之黄水汁出，瘥复发方
(ID410-1)/小儿脐久不干出脓, 赤肿及清水出(ID430)/ 久
不得愈(ID473)/ 每月一发(ID482,524,782)/ 已年余(ID507-
3)/ 湿疮又发(ID515-7)/每月一发最缠绵(ID521)/  一月一
发(ID522)/ 久而不愈(ID537)/ 生疮既久，流脓流水
(ID541)/ 久而不敛(ID542)/ 蔓延半载(ID545-1)/ 作蔓延无
定，最淹缠也 (ID545-2)/ 屡痊屡发(ID545-4)/ 易于滋蔓，
最淹缠也(ID546,838)/缠绵不已(ID567-2,567-
3,825,987,988)/ 湿则干掺；干则香油调搓(ID568-
5,825,987,988)/ 浸淫日广…后复发(ID593,682-18)/浸淫日
广，痒不可忍，愈后复发，出黄水(ID614)/治积年疮癣
生痂。搔之则水出。遇阴雨时即痒。(ID691-7)/ 痒抓则
痛。而久不瘥者。(ID691-9)/ 新久干湿癣 (ID691-15)/ 不
瘥(ID692-13,692-14,858-7,871,899-4)/ 经久不瘥者
(ID693)/ 久久延及遍身(ID729)/ 已年矣(ID738-2)/ 久干癣
(ID848)/ 抱恙多年(ID958-4)/ 延今已久(ID957)/ 
Onset 
Ranking Score Condition Decision Log 
0 No mention  
1 No particular 
age of 
onset/both 
adult and 
childhood 
小儿、大人(ID560-16,560-18)/ 
2 Infancy/ 
Childhood 
小儿(ID14,19,29,43,44,46,50-1,51,52,64,65,66,76-
2,98,107-1,107-3,110,121,122,125-1，125-2,126-1,126-
2,126-3,131,173,185-2,199,200,250,253,289, 291,292-
2,339,340,341,404-1,404-2,411,421,425, 
427,430,432,552,553,554,556,560-1to3,560-5 to11,560-
13to15, 597,617,622,665,666,684-1, 
684-2,684-3,707,757,759,763,809,810,863,912,918, 
927,969,970,976)/胎癣毒肿 (ID120-3)/ 儿科(ID321)/小儿
乳癣(ID691-3,825,987,987,988)/ 乳癣便毒之不红肿焮热
(ID322-2)/ 婴儿(ID564-3,564-4)/ 小儿面上生癣谓之为乳
癣(ID759-3)/ 
3 Adulthood  
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Pain 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes 疼痛不可忍(ID14,19,52,65-10,121-4,684-2)/ 先痒后痛
(ID42，48,54-1,81,97，115,138)/ 痒痛汁出(ID45,55)/ 疼
痛动脏腑(ID55-7)/ 疼痛至甚(ID55-8)/ 如疮干燥痛(ID63-
3)/或痒或痛(ID72,99,139)/ 疮赤痒痛 (ID 73)/痛不可忍（
ID76-2,106-1,126-1,131-2,140-4to11,402-3,692-17,738-
1,788-12）/肤痛(ID81,83,94)/ 骨痛(ID94)/ 痛痒坼裂
(ID111)/ 或肿，或赤，或痛，或痒(ID115-7)/ 浸淫痛痒者
(ID120-1)/ 先疮后痛(ID137)/ 热痒而痛
(ID146,150,180,208,212, 225, 259,263,279-
2,284,347,385,396,400,479,502)/  
痛即止(ID171)/ 痛而不痒(ID183,294-7,301,336-
1,391,941)/ 痒而痛(ID229，336-3)/ 痒痛不可忍(ID252-
19,252-24,664-1,664-2,691-16,788-4,788-5)/ 治风热湿疮
痒痛(ID264-1)/ 破时作痛(ID298)/若肿而痛甚者
(ID296,382,420,466-2)/  
Pain (continued) 
Ranking Score Condition Decision Log 
2 Yes 湿水痒痛(ID303-1)/ 湿疮作痛(ID303-2)/ 脂水痒痛
(ID304)/ 痒痛红肿 (ID305-1)/ 痛痒不休(ID307,314)/ 痒痛
自止(ID329)/ 肿痛(ID 358,922)/ 肿痛湿疮(ID359)/ 疼痒
(ID364,415)/如燥痛(ID375-3)/ 痛痒(ID377-4,397)/ 日痛痒
不可堪，搔之黄水汁出，瘥复发方(ID410-1)/ 痛痒不常
(ID459)/时痛时痒(ID466-1)/ 作疼不可忍(ID470)/ 痒定，
黄赤水出，又痛不可耐(ID507-2)/痒热而痛(ID518)/ 痛痒
不禁(ID530)/ 两足湿毒疮痛痒(ID532)/ 腐溃流水痒痛
(ID545-2)/痒抓则痛。而久不瘥者。(ID691-9)/ 痒痛不可
忍者 (ID691-13)/ 湿癣只干揩贴之。并候黄水出。及数
数痒痛(ID691-15)/ 痒痛有棱廓(ID693)/ 痒痛流黄水
(ID722)/ 痒痛(ID726,749)/ 痒痛不一(ID729)/ 痒定极痛
(ID734)/ 初起肿痛(ID784,794)/ 痒痛不止(ID847-4to6,858-
5,858-6)/ 阴雨之时即痒痛(ID858-12)/ 痛不能睡卧
(ID946)/ 
Hot to touch 
Ranking Score Condition Decision Log 
0 No mention  
1 No 乳癣便毒之不红肿焮热(ID322-2)/ 
2 Yes 热痒而痛(ID146,150,180,208,212,225,259,263,279-
2,284,347,385,396,400,479,502)/ 痒热而痛(ID518)/ 夜睡
肌热且痒(ID547)/ 皮肤火热(ID565-2)/ 
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Symmetric 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes 常相对生(ID111)/ 
Spreading (Contagious) 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes 浸淫疮系传染之疾也(ID69)/ 浸淫犹渐染也(ID81)/ 疮汁
所着处即成疮(ID84，115-5)/ 脓汁着处便生(ID126-1,126-
2,126-3)/ 手爬处即延生(ID501-2)/ 易于滋蔓，最淹缠也
(ID546,838)/ 手爬处即延生(ID809,810) 
Fatal 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes 绕身至心者死(ID12,55-18)/ 续身周匝则杀人(ID15,41-1)/
周匝身则杀人(ID16,23,55-16)/ 周身则杀人
(ID17,22,24,922-2)/ 浸淫疮遍身至心者死(ID18,20)/ 不治
杀人(ID25-2)/ 周身杀人(ID30)/ 不早治则绕身周匝，能杀
人(ID45-5,61,140-3)/ 早不治则绕身周匝。能杀人(ID55-
9)/ 散周身则杀人(ID55-11)/ 至心者死(ID57)/不早治杀人
(ID73,167)/入里者。即死(ID80,85) /入里者即死
(ID82,87,89,91, 93,95,105)/ 绕身周匝则死(ID128-3)/ 
Insects/parasite 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes 蠼螋尿疮(ID58)/ 蠼螋疮(ID128)/有其虫(ID128)/ 极痒有虫
(ID189,331,362)/ 久则因风湿而变化生虫(ID252)/治湿癣
痒，搔之有黄水，杀虫(ID252-3)/ 凡远年湿风疮痒甚，
诸药不效者，必有虫在内(ID294-2,294-3,294-4,294-5)/ 
蠼螋伤(ID329)/ 湿疮虫痒(ID356)/ 内必生虫(ID541)/ 久则
有虫(ID574)/其里亦有虫生(ID664,692,725)/ 有虫
(ID693,726,749, 756,758,788-1)/ 中亦生虫(ID788-2~)/匡
内生虫(ID729)/ 其中亦生虫(ID847,858,868)/ 
Personal/family history of rash  
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes 病人本有疮(ID120-1)/相连胤生(ID 921)/ 
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Personal/family history of wheezing (哮喘 “xiao chuan”, 喘 “chuan”) 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes 素有哮症(ID513)/ 防其增喘(ID514,515-4)/ 
Cough (咳 “ke”) 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes 咳嗽(512,515-5,515-6) 
Personal/family history of nasal symptoms (runny/blocked nose, allergic rhinitis-like presentations) 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes  
Aggravated by gloomy/rainy weather 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes 每逢阴雨即痒(ID41-3,109-5,337-2,683-1,683-2,  
698-3,745-4,745-5,749-3,756-9,756-10,758-
8to10,839,840,841,842,843,846,847-8to13,858-
8to11,910)/ 遇阴雨即剧(ID252-11)/ 治积年疮癣生痂。搔
之则水出。遇阴雨时即痒。(ID691-7)/ 阴雨之时即痒痛
(ID858-12) 
Aggravated by sweating 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes  
Wool intolerance 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes  
Affected by Emotions 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes  
 
  
317 
 
Aggravated by food/food intolerance 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes 嗜酒，贪啖，喜鱼蟹发风等物(ID146,150,385,400,479)/
嗜酒食，喜鱼蟹发风等物(ID180,336-3)/嗜酒，喜食鱼、
虾发风之物(ID208,212,225)/ 嗜酒。喜食鱼蟹发风等物
(ID229)/多食鱼虾发风热物得之(ID259)/ 因食鱼虾发风热
物得之(ID279-2)/ 因多食鱼虾发风热物得之(ID284)/嗜酒
贪啖喜鱼鰕发风之物(ID518)/ 
Affected by cold 
Ranking Score Condition Decision Log 
0 No mention  
1 Cold worsens 
condition 
 
2 Cold improves 
condition 
得寒则稍减 (ID863-11)/ 
Heat 
Ranking Score Condition Decision Log 
0 No mention  
1 Heat worsens 
condition 
暖则痒闷(ID863-11)/ 
2 Heat improves 
condition 
 
3 Heat does not 
improve 
condition 
汤火俱不解(507-2,738-1, 
745-3,788-12)/ 
Facial pallor 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes  
Facial erythema 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes  
 
Hypopigmentation 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes  
 
  
318 
 
Infra-orbital darkening 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes  
Infra-orbital folds/wrinkles 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes  
Cheilitis 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes  
Recurrent conjunctivitis 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes  
Involvement of anterior neck folds 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes 满颊满项 (336-2) /颈项（ 66，302，512）/  
颈(577-1)/ 项上(903-2)/颈项间(109-2,109-3,144,147,188-
1,226,337-1,507-1,691-1,691-2,745-1) 
Ichthyosis 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes  
Hyperlinear palms 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes  
Keratosis pilaris 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes  
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Hand/foot dermatitis 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes 流散四肢者轻。若从四肢发生(ID54)/掌内湿癣(ID120-2)/ 
手足尤甚(ID183,294-7,301,336-1,941)/ 脚气湿疮
(ID189,331,362)/ 脚生湿疮(ID349)/足肿成疮(ID356)/两足
背风湿疮(377-4)/ 两脚背风湿疮(ID397,415)/手足(ID485)/ 
四弯风生腿脚弯(ID521,522,524)/两足湿毒疮(ID532)/ 二
足胫足踝足背足跟(ID537)/多生于两足，非在足胫，即
在足踝，非在足背，即在足跟(ID541)/ 左足内外湿毒疮
(ID545-1)/ 两足底湿毒疮(ID545-4)/ 初起手足(ID567-
2,567-3)/ 生两腿弯，及脚弯(ID782)/ 两脚阴面湿癣
(ID802-1)/先起手足(ID825,988)/ 起于手足(ID987) 
Nipple eczema 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes 妇人女子乳头生小浅热疮(ID117)/ 男女乳上湿疮
(ID307,314)/ 乳癣(ID802-2,823,831,834,838)/ 乳上湿疮
(ID936)/ 妇人乳癣 (ID989) 
White dermatographism 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes 湿疹白色而无红点 (ID2) 
Perifollicular accentuation 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes  
Chills & Fever 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes 发寒热(ID14,17,52,65-10，76-2,106-1,121-4,126-1,131-
2,140-4to11,402-3,684-2), 寒热(ID259,263,279-
2,284,347,396,435,514)/ 乍寒乍热(ID502)/ 寒热往来
(ID545-3)/ 
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Fever 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes 发寒热(ID14,17,52,65-10，76-2,106-1,121-4,126-1,131-
2,140-4to11,402-3,684-2), 寒热(ID259,263, 279-
2,284,347,396,435,514)/ 乍寒乍热(ID502)/ 寒热往来
(ID545-3)/身热（ID81,94,134,136, 140,  
141-1,141-2,451,934/晡热潮热(ID435)/ 
Sweating 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes 有汗(ID55-11,55-16,61)/ 每食则汗出成流(ID140-12)/ 汗
出(ID451,454)/出黄汗(ID647) 
Convulsions 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes 发搐(ID119)/ 
Irritability 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes 烦闷欲死(ID73)/ 烦毒欲死(ID115-7,922) 
Difficulty passing motion 
Ranking Score Condition Decision Log 
0 No mention  
1 No 大便行者(ID181-2)/ 
2 Yes 
(Constipation) 
大小便涩(ID146,150,180,229,259,263,279-2,284，336-
3,347,385,396,400,479,,502,518)/ 
二便涩(ID208,212,225) 
 
3 Loose stools 大便溏泄(ID513)/ 大便时溏(ID516)/ 
Reduced appetite 
Ranking Score Condition Decision Log 
0 No mention  
1 No 食饮不减(ID547)/ 
2 Yes 食亦减(ID146,150,180,229,259,263,279-2,284，336-
3,347,385,396,479,518)/ 食减(ID400)/ 饮食减少(ID502)/ 
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Oedema 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes 身面微肿(ID146,150,180,229,259,263,279-2,284，336-
3,347,396,400,502,518)/ 湿疮脚肿(ID181-1)/  
身面浮肿(ID385,479)/ 浮肿下体为甚(ID515-5)/ 
 
Mobility problems 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
2 Yes 行履难者(ID181-1)/ 有妨行步(ID279-1)/ 
Affects sleep 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
 
2 Yes 晓夕不得睡 (ID183,301,336-1,941)/ 日夜不得眠者(ID294-
7)/ 睡卧不安(ID567-1,556,572)/ 痛不能睡卧(ID946)/ 
Dizziness/Vertigo 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
 
2 Yes 耳鸣目眩(ID256,280)/ 
Tinnitus 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
 
2 Yes 耳鸣目眩(ID256,280)/ 
Anorexia 
Ranking Score Condition Decision Log 
0 No mention  
1 No  
 
2 Yes 疳气入腹(ID250)/ 毒入腹。渐渐羸瘦(ID289)/ 及疳气入
腹，渐渐羸瘦方(ID432)/ 
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Appendix 2: Comprehensive Review – PubMed Search Terms  
Acupressure Treatment for AD 
#1 “Eczema”[Mesh] 
#2 “Dermatitis”[Mesh] 
#3 “Dermatitis, Atopic”[Mesh] 
#4 “atopic eczema” 
#5 “infantile eczema” 
#6 “childhood eczema” 
#7 “Neurodermatitis”[Mesh] 
#8 “besnier’s prurigo” 
#9 #1 or #2 or #3 or #4 or #5 or #6 or#7 or #8 
#10 “Humans”[Mesh] 
#11 “In Vitro” [Publication Type] 
#12 #10 NOT #11 
#13 “Acupressure”[Mesh] 
#14 #9 and #12 and #13 
Acupuncture Treatment for AD 
#1 “Eczema”[Mesh] 
#2 “Dermatitis”[Mesh] 
#3 “Dermatitis, Atopic”[Mesh] 
#4 “atopic eczema” 
#5 “infantile eczema” 
#6 “childhood eczema” 
#7 “Neurodermatitis”[Mesh] 
#8 “besnier’s prurigo” 
#9 #1 or #2 or #3 or #4 or #5 or #6 or#7 or #8 
#10 “Humans”[Mesh] 
#11 “In Vitro” [Publication Type] 
#12 #10 NOT #11 
#13 “Acupuncture”[Mesh] 
#14 “Acupuncture Therapy”[Mesh] 
#15 “needling” 
#16 “Acupuncture, Ear”[Mesh] 
#17 “auricular acupuncture” 
#18 “Auriculotherapy”[Mesh] 
#19 “acupoints” 
#20 “Acupuncture Points”[Mesh] 
#21 “Electroacupuncture”[Mesh] 
#22 “electro-acupuncture” 
#23 “electro acupuncture” 
#24 “electro-stimulation” 
#25 “electrostimulation” 
#26 “Electric Stimulation”[Mesh]  
#27 “electrostimulation therapy” 
#28 “Electric Stimulation Therapy”[Mesh] 
#29 “laser acupuncture” 
#30 “scalp acupuncture” 
#31 “hydroacupuncture” 
#32 “hydro-acupuncture” 
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Acupuncture Treatment for AD (continued) 
#33 “hydro acupuncture” 
#34 “pharmacopuncture” 
#35 “point injection” 
#36 “acupoint injection” 
#37 “catgut embedding” 
#38 #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 
or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 
#39 #9 and #12 and #38 
Bloodletting Treatment for AD 
#1 “Eczema”[Mesh] 
#2 “Dermatitis”[Mesh] 
#3 “Dermatitis, Atopic”[Mesh] 
#4 “atopic eczema” 
#5 “infantile eczema” 
#6 “childhood eczema” 
#7 “Neurodermatitis”[Mesh] 
#8 “besnier’s prurigo” 
#9 #1 or #2 or #3 or #4 or #5 or #6 or#7 or #8 
#10 “Humans”[Mesh] 
#11 “In Vitro” [Publication Type] 
#12 #10 NOT #11 
#13 “Bloodletting”[Mesh] 
#14 “blood letting” 
#15 “Phlebotomy”[Mesh] 
#16 #13 or #14 or #15 
#17 #9 and #12 and #16 
Chinese Herbal Medicine Treatment for AD 
#1 “Eczema”[Mesh] 
#2 “Dermatitis”[Mesh] 
#3 “Dermatitis, Atopic”[Mesh] 
#4 “atopic eczema” 
#5 “infantile eczema” 
#6 “childhood eczema” 
#7 “Neurodermatitis”[Mesh] 
#8 “besnier’s prurigo” 
#9 #1 or #2 or #3 or #4 or #5 or #6 or#7 or #8 
#10 “Medicine, Chinese Traditional”[Mesh] 
#11 “Chinese medicine” 
#12 “Medicine, East Asian Traditional”[Mesh] 
#13 “east Asian medicine” 
#14 “traditional Korean medicine” 
#15 “Korean medicine” 
#16 “traditional oriental medicine” 
#17 “oriental medicine” 
#18 “kampo” 
#19 “Medicine, Kampo”[Mesh] 
#20 “alternative medicine” 
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Chinese Herbal Medicine Treatment for AD (continued) 
#21 “alternative therapies”  
#22 “complementary medicine” 
#23 “Complementary Therapies”[Mesh] 
#24 “Medicine, Traditional”[Mesh] 
#25 “Chinese herbal medicine” 
#26 “Chinese herbs” 
#27 “Herbal Medicine”[Mesh] 
#28 “herbalism” 
#29 “herbs” 
#30 “medicinal herbs” 
#31 “herbal drugs” 
#32 “Chinese herbal drugs” 
#33 “Chinese drugs” 
#34 “herbology” 
#35 “herbaceous agent” 
#36 “plant medicine” 
#37 “Plants, Medicinal”[Mesh] 
#38 “plant medicinal product”  
#39 “Plant Extracts”[Mesh] 
#40 “Plant Preparations”[Mesh] 
#41 “Ethnopharmacology”[Mesh] 
#42 “ethnomedicine” 
#43 “Ethnobotany”[Mesh] 
#44 “Phytotherapy”[Mesh] 
#45 “Materia Medica”[Mesh] 
#46 “Integrative Medicine”[Mesh] 
#47 #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 
or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or 
#35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 
#48 “Humans”[Mesh] 
#49 “In Vitro” [Publication Type] 
#50 #47 NOT #48 
#51 #9 and #46 and #49 
Chinese Medicine Diet Therapy for AD 
#1 “Eczema”[Mesh] 
#2 “Dermatitis”[Mesh] 
#3 “Dermatitis, Atopic”[Mesh] 
#4 “atopic eczema” 
#5 “infantile eczema” 
#6 “childhood eczema” 
#7 “Neurodermatitis”[Mesh] 
#8 “besnier’s prurigo” 
#9 #1 or #2 or #3 or #4 or #5 or #6 or#7 or #8 
#10 “Humans”[Mesh] 
#11 “In Vitro” [Publication Type] 
#12 #10 NOT #11 
#13 “chinese diet” 
#14 “chinese diet therapy” 
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Chinese Medicine Diet Therapy for AD (continued) 
#15 #13 or #14 
#16 #9 and #12 and #15 
Cutaneous Needling for AD 
#1 “Eczema”[Mesh] 
#2 “Dermatitis”[Mesh] 
#3 “Dermatitis, Atopic”[Mesh] 
#4 “atopic eczema” 
#5 “infantile eczema” 
#6 “childhood eczema” 
#7 “Neurodermatitis”[Mesh] 
#8 “besnier’s prurigo” 
#9 #1 or #2 or #3 or #4 or #5 or #6 or#7 or #8 
#10 “Humans”[Mesh] 
#11 “In Vitro” [Publication Type] 
#12 #10 NOT #11 
#13 “cutaneous needling” 
#14 “dermal needling” 
#15 “seven star needling” 
#16 “plum blossom needling” 
#17 #13 or #14 or #15 or #16 
#18 #9 and #12 and #17 
Cupping Treatment for AD 
#1 “Eczema”[Mesh] 
#2 “Dermatitis”[Mesh] 
#3 “Dermatitis, Atopic”[Mesh] 
#4 “atopic eczema” 
#5 “infantile eczema” 
#6 “childhood eczema” 
#7 “Neurodermatitis”[Mesh] 
#8 “besnier’s prurigo” 
#9 #1 or #2 or #3 or #4 or #5 or #6 or#7 or #8 
#10 “Humans”[Mesh] 
#11 “In Vitro” [Publication Type] 
#12 #10 NOT #11 
#13 “cupping” 
#14 #9 and #12 and #13 
Guasha Treatment for AD 
#1 “Eczema”[Mesh] 
#2 “Dermatitis”[Mesh] 
#3 “Dermatitis, Atopic”[Mesh] 
#4 “atopic eczema” 
#5 “infantile eczema” 
#6 “childhood eczema” 
#7 “Neurodermatitis”[Mesh] 
#8 “besnier’s prurigo” 
#9 #1 or #2 or #3 or #4 or #5 or #6 or#7 or #8 
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Guasha Treatment for AD (continued) 
#10 “Humans”[Mesh] 
#11 “In Vitro” [Publication Type] 
#12 #10 NOT #11 
#13 “guasha” 
#14 “gua sha” 
#15 “spooning” 
#16 “coining” 
#17 “scrapping” 
#18 #13 or #14 or #15 or #16 or #17 
#19 #9 and #12 and #18 
 
Moxibustion Treatment for AD 
#1 “Eczema”[Mesh] 
#2 “Dermatitis”[Mesh] 
#3 “Dermatitis, Atopic”[Mesh] 
#4 “atopic eczema” 
#5 “infantile eczema” 
#6 “childhood eczema” 
#7 “Neurodermatitis”[Mesh] 
#8 “besnier’s prurigo” 
#9 #1 or #2 or #3 or #4 or #5 or #6 or#7 or #8 
#10 “Humans”[Mesh] 
#11 “In Vitro” [Publication Type] 
#12 #10 NOT #11 
#13 “Moxibustion”[Mesh] 
#14 “moxa” 
#15 “mugwort” 
#16 “Artemisia vulgaris” 
#17 “Artemisia”[Mesh] 
#18 #13 or #14 or #15 or #16 or #17 
#19 #9 and #12 and #18 
Taiji for AD 
#1 “Eczema”[Mesh] 
#2 “Dermatitis”[Mesh] 
#3 “Dermatitis, Atopic”[Mesh] 
#4 “atopic eczema” 
#5 “infantile eczema” 
#6 “childhood eczema” 
#7 “Neurodermatitis”[Mesh] 
#8 “besnier’s prurigo” 
#9 #1 or #2 or #3 or #4 or #5 or #6 or#7 or #8 
#10 “Humans”[Mesh] 
#11 “In Vitro” [Publication Type] 
#12 #10 NOT #11 
#13 “taiji” 
#14 Tai Ji[Mesh] 
#15 “taijiquan” 
#16 “tai ji quan” 
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Taiji for AD (continued) 
#17 “tai chi chuan” 
#18 “taichi” 
#19 “tai chi” 
#20 “qigong” 
#21 “qi gong” 
#22 “chi kung” 
#23 “Breathing Exercises”[Mesh] 
#24 “Exercise Therapy”[Mesh] 
#25 “Exercise Movement Techniques”[Mesh] 
#26 “Meditation”[Mesh] 
#27 “Mind-Body Therapies”[Mesh] 
#28 “mind body medicine” 
#29 “mind body techniques” 
#30 “chinese exercise” 
#31 “therapeutic exercise” 
#32 #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 
or #26 or #27 or #28 or #29 or #30 or #31 
#33 #9 and #12 and #32 
Tuina Treatment for AD 
#1 “Eczema”[Mesh] 
#2 “Dermatitis”[Mesh] 
#3 “Dermatitis, Atopic”[Mesh] 
#4 “atopic eczema” 
#5 “infantile eczema” 
#6 “childhood eczema” 
#7 “Neurodermatitis”[Mesh] 
#8 “besnier’s prurigo” 
#9 #1 or #2 or #3 or #4 or #5 or #6 or#7 or #8 
#10 “Humans”[Mesh] 
#11 “In Vitro” [Publication Type] 
#12 #10 NOT #11 
#13 “tuina” 
#14 “tui na” 
#15 “anmo tuina” 
#16 “chinese massage” 
#17 “manipulation” 
#18 “manipulation therapy” 
#19 “manipulation treatment” 
#20 “manual therapy” 
#21 “manipulative medicine” 
#22 “manipulative therapies” 
#23 “manipulative treatment” 
#24 “Musculoskeletal Manipulations”[Mesh] 
#25 “massage therapy” 
#26 Massage[Mesh] 
#27 #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 
or #26 
#28 #9 and #12 and #27 
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Appendix 3: Comprehensive Review – Chinese Database Search Terms for All 
TCM treatments for AD 
Chinese Database Search Terms 
VIP Database for Chinese 
Technical Periodicals 
(CQVIP) 
T=(例+临床+观察+研究+分析+报告)*(皮炎+湿疹+特应性皮炎+特
应性湿疹+异位性皮炎+异位性湿疹+婴儿湿疹+儿童湿疹+幼儿湿
疹+小孩湿疹+浸淫疮+四弯风+奶癣+乳癣+胎癣)*(中医+中药+汉
方+针灸+电针+耳针+头针+埋线+穴位注射+激光针灸+梅花针+皮
针+七星针+镭射针灸+灸+艾灸+草药+拔罐+推拿+放血+穴位按摩+
按摩+整骨+刮痧+中医饮食疗法+方+剂+太极+气功+膏+汤+散) 
 
China National 
Knowledge Infrastructure  
(CNKI) 
TI=(例+临床+观察+研究+分析+报告)*(皮炎+湿疹+特应性皮炎+特
应性湿疹+异位性皮炎+异位性湿疹+婴儿湿疹+儿童湿疹+幼儿湿
疹+小孩湿疹+浸淫疮+四弯风+奶癣+乳癣+胎癣)*(中医+中药+汉
方+针灸+电针+耳针+头针+埋线+穴位注射+激光针灸+梅花针+皮
针+七星针+镭射针灸+灸+艾灸+草药+拔罐+推拿+放血+穴位按摩+
按摩+整骨+刮痧+中医饮食疗法+方+剂+太极+气功+膏+汤+散) 
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Appendix 4: Additional data as required by the SPIRIT 2013 checklist 
World Health Organization Trial Registration Data Set 
Data category Information 
Primary registry and 
trial identifying 
number 
Australia and New Zealand Clinical Trials Register (ANZCTR): 
ACTRN12612001181897 
Date of registration in 
primary registry 
22 October, 2012 
Secondary identifying 
numbers 
TGA CTN Scheme: Trial number 2012/0713; Protocol number 15/12 
Source(s) of monetary 
or material support 
- 
Primary sponsor RMIT University 
GPO Box 2476 
Melbourne VIC 3001 
Australia 
Secondary sponsor(s) - 
Contact for public 
queries 
Dr. George Lenon / Amy Tan 
School of Health Sciences  
RMIT University 
PO Box 71 
Bundoora VIC 3083 
 
Contact number: +61 3 9925 6587 or +61 3 9925 7177 
Fax number: +61 3 9925 7178 
Email address: george.lenon@rmit.edu.au / amy.tan@rmit.edu.au 
Contact for scientific 
queries 
Dr. George Lenon / Amy Tan 
School of Health Sciences  
RMIT University 
PO Box 71 
Bundoora VIC 3083 
 
Contact number: +61 3 9925 6587 or +61 3 9925 7177 
Fax number: +61 3 9925 7178 
Email address: george.lenon@rmit.edu.au / amy.tan@rmit.edu.au 
Public title Evaluation of the efficacy and safety of a Chinese herbal medicine formula 
in the management of eczema (atopic dermatitis) in children 
Scientific title Evaluation of the efficacy and safety of a Chinese herbal medicine formula 
(RCM-106) in the management of atopic dermatitis in children: A 
randomised placebo-controlled clinical trial 
Countries of 
recruitment 
Australia 
Health condition(s) or 
problem(s) studied 
Atopic dermatitis; skin; dermatological conditions; alternative and 
complementary medicine; herbal remedies 
Intervention(s) Active comparator: Chinese herbal formula, RCM-106 capsules (6 
capsules per day for participants aged 6-11 years old; 12 capsules per day 
for participants aged 12-18 years old) 
Placebo comparator: herbal starch placebo capsules (matching capsules 
containing no active ingredients) 
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Key inclusion and 
exclusion criteria 
 Diagnosed with atopic dermatitis according to the UK Diagnostic 
Criteria; 
 Has moderate-to-severe AD (SCORAD≥25) 
 Aged between 6 to 18 years old; 
 Agree to abstain from alcohol during the period of the trial; 
 Not involved in other clinical trials; 
 Agree to avail themselves for the period of the study; and 
 Provide written consent for participation from parent or legal 
guardian and verbal consent from the participant 
 Pass the “swallow-test” (able to swallow an empty size #1 capsule) 
during initial assessment or willing to undergo “capsule-swallowing 
training program” 
Study type Interventional 
Allocation: randomised 
Intervention model: parallel assignment 
Masking: double blind (subject, caregiver, investigator, outcomes assessor) 
Primary purpose: treatment 
Phase II 
Date of first 
enrolment 
TBA 
Target sample size 90 
Recruitment status Not yet recruiting 
Primary outcome(s) 
Primary Outcome 1: Severity and improvement of atopic dermatitis using 
the validated instrument – SCORing Atopic Dermatitis (SCORAD) 
Timepoint: at baseline (during initial assessment), after wash-out period 
prior to intervention commencement (week 1), weeks 3, 5, 7 and 9, and 
after 4 weeks follow-up period (week 13) 
Primary Outcome 2: mean Patient-oriented SCORAD (PO-SCORAD) 
Timepoint: at baseline (during initial assessment), after wash-out period 
prior to intervention commencement (week 1), weeks 3, 5, 7 and 9, and 
after 4 weeks follow-up period (week 13) 
Key secondary 
outcomes 
Secondary Outcome 1: Quality-of-life scoring using the Children’s 
Dermatology Life Quality Index (CLDQI) 
Timepoint: at baseline (during initial assessment), after wash-out period 
prior to intervention commencement (week 1), weeks 3, 5, 7 and 9, and 
after 4 weeks follow-up period (week 13) 
Secondary Outcome 2: Occurrence of adverse events – self-reported by 
participants using a daily diary 
Timepoint: Daily diary will be reviewed every 2 weeks from trial 
commencement. 
Secondary Outcome 3: Usage of other therapies during the duration of the 
trial – self-reported by participants using a daily diary 
Timepoint: Daily diary will be reviewed every 2 weeks from trial 
Secondary Outcome 4: Safety profiles – Blood tests (full blood count, 
eosinophil count, and total IgE), liver function test and kidney function test. 
Timepoint: at baseline and after treatment period (8 weeks) 
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Protocol version 
Issue Date: 4 April 2013 
Protocol Amendment Number: 06 
Author(s): H.Y.T; A.L.Z; C.C.X; D.C; C.D.C; G.B.L 
2012-May-4: Original 
2012-July-6: Amendment 01.: Primary reason for amendment: HREC concerns about dosage 
and safety of herbal ingredients 
Changes in dosage of herbal ingredients according to pharmacopoeia 
recommendations. 
2012-Sept-3: Amendment 02.: Primary reason for amendment: HREC concerns about age group 
involved 
Changes in target age group from 5-18 years old to 6-18 years old 
2012-Sept-10: Amendment 03.: Primary reason for amendment: HREC concerns about participant 
consent and procedures to identify and manage adverse events 
Clarified procedures in regard to participant consent – aside from written consent 
from parent/legal guardian of participants, written consent from participants who 
are able to read/write fluently or verbal assent from participants will be sought. 
Involved a registered medical practitioner to assist with the screening and 
monitoring of participants and clarified wording with regard to management of 
adverse events. 
2012-Sept-18: Amendment 04.: Primary reason for amendment: HREC requirement to change 
research assent form for participants 
Updated research assent form according to requirements 
2013-Feb-2: Amendment 05.: Primary reason for amendment: Trial intervention manufacturers 
input on RCM-106 capsules 
Changes in method of herbal extraction and dosage and size of capsules to be used 
in study; for safety precaution, an exclusion criteria of participants unable to 
swallow size #0 capsules was added in the protocol 
Other changes: interim analysis will be conducted to assist with safety monitoring; 
participants will not be required to attend clinic after follow-up period but will be 
required to return outcome measure instruments by post. 
2013-Apr-4: Amendment 06.: Primary reason for amendment: Manufacturer update on trial 
intervention and response to HREC concerns on giving capsules to children 
Updated protocol according to manufacturers’ ability to do 7:1 concentration ratio 
herbal extracts in vegetarian capsules, enabling the use of the smaller sized #1 
capsules. In response to HREC safety concerns, a paediatrician’s recommendations 
of including a “swallow-test” during screening and introducing an optional 
“capsule-swallowing training program” has been included in the protocol. 
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Appendix 5: Capsule-swallowing Training Programme Guidelines 
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Appendix 6: Chinese Medicine Questionnaire 
Key:   
0 = None (you do not have this symptom) 
1 = Mild (you only have the symptoms once in a while and it doesn’t affect you daily life) 
2 = Moderate (the symptoms can cause an inconvenience to your daily life) 
3 = Severe (the symptoms affect the performance of daily duties) 
4 = Very Severe (the symptoms severely affect the performance of daily duties) 
 
PATTERN DIFFERENTIATION 0 1 2 3 4 
Accumulation of 
damp and heat 
1. Sudden onset, lesions red and hot to touch, 
constantly itchy with exudation 
     
2. Feeling hot, irritable and thirsty      
3. Dry stools      
4. Burning pain and upset in the stomach      
5. Red tongue with thin white or yellow 
coating 
     
6. Slippery and rapid pulse.      
Spleen deficiency 
with damp 
retention 
1. Slower onset, lesions red and itching with 
erosion/exudation/scaling after 
scratching 
     
2. Mentally fatigued       
3. Impaired appetite      
4. Stomach bloating and loose stools      
5. Swollen pale tongue with white or greasy 
coating 
     
6. Slow and taut pulse      
Blood deficiency 
with wind 
dryness 
1. Dry and thickened skin      
2. Itching with scratch marks and scabs      
3. Bloating after meals      
4. Irregular bowel motion (constipation or 
loose stools) 
     
5. Swollen pale tongue with white coating      
6. Slippery pulse      
Ref. State Administration of TCM: Criteria of diagnosis and therapeutic effect of diseases and syndromes in TCM                 
ZY/T001.1~001.9-94 
FINAL IMPRESSION OF DIFFERENTIATION (by Chinese medicine practitioner)  
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________ 
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Appendix 7: Scoring Atopic Dermatitis (SCORAD) 
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Appendix 8: Patient-oriented Scoring Atopic Dermatitis (PO-SCORAD) 
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Appendix 9: Children’s Dermatology Life Quality Index (CDLQI) – Cartoon Version 
 
© Children's Dermatology Life Quality Index. M. S. Lewis-Jones, A. Y. Finlay, May 1993.
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Appendix 10: Children’s Dermatology Life Quality Index (CDLQI) – English Text 
Version 
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Appendix 11: Research Assent Form 
Project: Chinese herbal treatment for eczema rash 
My name is _______________. I am studying Chinese Medicine at RMIT University and I am doing a 
research project for my course. 
What is a research study? 
Research studies are done to help us find better ways to treat people or to understand things better. 
We can also learn new things from research.  
First, we ask a question. Then, we try to find the answer. 
You are being asked to be part of our research study. We will be telling you about our research and 
you can decide whether or not to take part. We would like you to ask us any questions you have. You 
can ask questions any time. 
Important things to know… 
 It is up to you whether you want to take part. 
 You can say “No” or you can say “Yes”. 
 No one will be upset if you say “No”. 
 If you say “Yes”, you can always say “No” later. 
 You can say “No” at any time. 
 We would still take good care of you no matter what you decide. 
Why are we doing this research? 
We are doing this research to find out a better way to help you and other children who have the 
same itchy rash as you. The rash is called eczema or atopic dermatitis. There is no cure for this rash 
now. We are trying to find a better treatment for this rash using Chinese herbal medicine. 
Chinese herbal medicine has been used for thousands of years and uses herbs (natural plant, animal 
and mineral materials) to treat people. For this research, we have come up with a combination of 7 
herbs (plant materials) to make a medicine for eczema. The medicine is then put in capsules. We 
want to know if these Chinese herbal medicine capsules can help to treat eczema. 
To test if these capsules work, we have to compare it with a placebo, which is a capsule that does 
nothing for eczema. If you decide to participate, you and 90 other participating children would be 
divided into two groups – one group will take the herbal capsules and the other group will take the 
placebo.  
If you decide to join, you have to: 
 Be between 6-18 years old 
 Have moderate-to-severe atopic dermatitis/eczema (we will rate your eczema for you) 
 Be able to swallow capsules 
 Understand English 
 Stop using other treatments (Chinese medicine, steroids, antibiotics, phototherapy, immuno-
modulating medicine) 4 weeks before the study 
 Stop using other treatments for the rash for 14 weeks, except for creams or moisturisers if 
rash is unbearable. 
 Not have other health problems (except hay fever or asthma) 
What would happen if I join this research? 
If you decided to be in the research, we would ask you to do the following: 
 Take capsules two times a day for 8 weeks. 
 Come in to the clinic every 2 weeks for 8 weeks, and then one more time 4 weeks later. 
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 With the help of your mom/dad/legal guardian (name)              , you would be asked to 
answer questions about your rash and how you feel, and write down how many capsules you 
have taken, what other treatments you used, and if you felt unwell after taking the capsules. 
 Blood draws: You may need a needle poke so we can test some of your blood. If possible, we 
will try to get blood without a new poke. 
 Questions: We would ask you to read questions on a piece a paper. Then, you would mark 
your answers on the paper. You can ask for help from your mom/dad/legal guardian (name).           
 Talking: A person on the research team would ask you some questions and you can tell us 
your answers. 
Could bad things happen if I join this research? 
Some of the tests might make you uncomfortable or the questions might be hard to answer. We will 
try to make sure that no bad things happen. 
Sometimes, after taking the herbal capsules, you may feel some stomach discomfort. Please tell your 
mom/dad/legal guardian (name) or one of the research team members if you feel 
sick/pain/uncomfortable. 
The poke to test your blood can hurt. Sometimes, the needle can leave a bruise on the skin. We can 
put a cream on your skin before we take blood. This cream would help so it won’t hurt as much. 
You can say “no” to what we ask you to do for the research at any time and we will stop. 
Could the research help me? 
We think being in this research may help you because we have studied this rash and possible ways to 
treat it and came up with this herbal capsules. We believe that this herbal capsules can help treat 
eczema.  
If the herbal capsules do help treat eczema but you were given the placebo during the study, you will 
be given the 8 weeks of herbal capsules after the study to help you with your eczema. 
What else should I know about this research? 
If you don’t want to be in this study, you don’t have to be, 
It is also OK to say yes and change your mind later. You can stop being in the research at any time. If 
you want to stop, please tell the one of us from the research team. 
You would not be paid to be in the study. 
You can ask questions any time. You can talk to          Amy Tan, George Lenon    . Ask us any questions 
you have. Take the time you need to make your choice. 
Is there anything else? 
If you want to join the research after we talk, please write your name below, or tell us “Yes”. We will 
write our name too and so will your ___mom/dad/legal guardian (name)              , and        (witness’s 
name)   . This shows we talked about the research and that you want to take part. 
Name of Participant: _________________________________ 
(To be written by participant, if he/she is able to) 
Printed Name of Researcher: __________________________________ 
Signature of Researcher: ___________________________________ 
Name of Parent/Legal Guardian of Participant: ____________________________ 
Signature of Parent/Legal Guardian of Participant: _________________________ 
Name of Witness: __________________________________ 
Signature of Witness: _____________________________________ 
Date: __________________   Time: ___________________ 
 
